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Schizophrenia, bipolar disorder and major depression are common, heritable 
neuropsychiatric conditions and yet the source of the inherited risk remains largely 
unknown. This thesis focuses on two complementary strategies for identifying and 
characterising the genetic component of these illnesses: homozygosity mapping in 
consanguineous pedigrees, and genetic and neurobiological investigations of candidate 
genes identified by the analysis of structural chromosomal abnormalities carried by 
patients with psychiatric diagnoses.  
 
In a family of a cousin marriage, five of six offspring presented with a rare combination 
of schizophrenia, sensori-neural hearing impairment and epilepsy. Two loci were located 
on chromosomes 22q13 and 2p24-25 where a series of markers were homozygous by 
descent (HBD). Five further HBD loci were identified in a second, related family where 
four of five offspring had hearing loss. However, there was no overlap of the HBD 
intervals in the two families, and sequencing coding regions of candidate genes failed to 
identify causative mutations.  
 
A second study investigated the candidate gene ABCA13 identified at a breakpoint 
region on chromosome 7 in a patient with schizophrenia who carried a complex 
chromosomal rearrangement. Re-sequencing exons encoding the highly conserved 
functional domains identified eight potentially pathogenic, rare coding variants. Case 
control association studies involving cohorts of schizophrenia, bipolar disorder and 
major depression revealed significant associations of these variants with all three clinical 
phenotypes, and follow-up in relatives displayed familial inheritance patterns. 
Disruption of ABCA13, expressed in human hippocampus and frontal cortex, implicates 
aberrant lipid biology as a pathological pathway in mental illness.   
 
A third study focused on GRIK4, a candidate gene previously reported disrupted in a 
patient with schizophrenia who carried a chromosome abnormality. A deletion in the 
 iv 
3’UTR of GRIK4, encoding the kainate receptor subunit KA1, was identified as a 
protective factor for bipolar disorder. Using post mortem human brain tissue from 
control subjects, KA1 protein expression patterns were characterized in the hippocampal 
formation, amygdala, frontal cortex and cerebellum. KA1 expression was found 
significantly increased in subjects with the protective allele, supporting the hypothesis 
that reduced glutamatergic neurotransmission is a risk factor in major psychiatric 
illnesses.  
 
Together, these novel discoveries define aspects of the genetic contribution to mental 
illness, implicate specific dysfunctional processes and suggest new directions for 
research in the quest to find rationally based treatments and preventative strategies for 




















PUBLICATIONS FROM THESIS 
 
Knight HM, Maclean A, Irfan M, Naeem F, Cass S, Pickard BS, Muir WJ, Blackwood 
DH, Ayub M (2008) Homozygosity mapping in a family presenting with 
schizophrenia, epilepsy and hearing impairment. Eur J Hum Genet 16:750-758. 
 
 
Pickard BS, Knight HM, Hamilton RS, Soares DC, Walker R, Boyd JK, Machell J, 
Maclean A, McGhee KA, Condie A, Porteous DJ, St Clair D, Davis I, 
Blackwood DH, Muir WJ (2008) A common variant in the 3'UTR of the GRIK4 
glutamate receptor gene affects transcript abundance and protects against bipolar 
disorder. Proc Natl Acad Sci U S A 105:14940-14945. 
 
 
The PDFs of these papers are attached in appendix 2. No explicit permission to include 
these papers is required as The European Journal of Human Genetics and Proceedings of 
the National Academy of Sciences (PNAS) both grant the noncommercial use of papers 






Knight HM, Ayub M, Maclean A, Pickard BS, Muir WJ, Blackwood DH (2006) 
Homozygosity mapping in a consanguineous family with schizophrenia co-
morbid with epilepsy and hearing impairment. XIVth World Congress on 
Psychiatric Genetics (ISPG). 
 
 
Knight HM, Walker R, Porteous DJ, Muir WJ, Blackwood DHR, Pickard BS. (2008) 
GRIK4/KA1 protein expression in human brain tissue and correlation with a 
genetic variant associated with bipolar disorder. The Federation of European 







Publications from thesis……………………………………………………………………..v 
Contents…………….………………………………………………………………………vi 
List of figures…………………………………………………………………………..….xiii 
List of tables……………………………………………………………………….……...xvii 
List of graphs………………………………………………………………………….....xviii 
Abbreviations…………………………………………………………………….….….....xix 
 
1 INTRODUCTION.............................................................................................. ..1 
          ACKNOWLEDGEMENTS FOR CHAPTER 1........................................................................ 2 
1.1     PSYCHIATRIC ILLNESS......................................................................................................... 3 
1.1.1 Schizophrenia .............................................................................................. 3 
1.1.2 Affective disorders....................................................................................... 4 
1.1.3 Epidemiological analysis of psychiatric disorders ......................................... 5 
1.1.4 Genetic models of psychiatric illnesses......................................................... 6 
1.1.5 What do we mean by genetic factor? ............................................................ 9 
1.2     MOLECULAR APPROACHES TO THE STUDY OF PSYCHIATRIC DISORDERS….....10 
1.2.1 Linkage analysis......................................................................................... 10 
1.2.2 Case-control association studies ................................................................. 11 
1.2.3 The study of chromosomal abnormalities.................................................... 14 
1.3     AETIOLOGICAL THEORIES OF PSYCHIATRIC ILLNESS……………………………..17 
1.3.1 Aberrant function of neurotransmitter systems............................................ 17 
1.3.2 Fatty acid hypothesis of schizophrenia.................................................... ....21 
1.4     INTRODUCTION TO PROJECTS …………………………..………………………..23 
1.4.1 Project 1: Homozygosity mapping in a consanguineous family................... 23 
1.4.1.1   Homozygosity mapping in consanguineous populations …………. .......... 23 
1.4.1.2   The Pedigree …………. .......................................................................... 24 
1.4.1.3   Hereditary hearing impairment, epilepsy and schizophrenia …………. ... 25 
 vii 
1.4.1.4   Results of a genome-wide scan using microsatellite markers ………….... 25 
1.4.1.5   A second related family …………............................................................ 26 
1.4.2 Project 2: Investigation of a complex chromosomal abnormality and  
      the disrupted break point gene ABCA13 ................................................. 28 
1.4.2.1   The mapping of breakpoints regions …………. ....................................... 28 
1.4.2.2   ABC proteins and disease …………. ....................................................... 31 
1.4.3 Project 3: GRIK4- a candidate breakpoint gene for psychiatric illness ......... 34 
1.4.3.1   GRIK4 disrupted in a chromosomal re-arrangement …………................ 34 
1.4.3.2   Case-control SNP-tag association & identification of a 3’UTR variant . . 34 
1.4.3.3   The role of kainate receptors in glutamatergic  neurotransmission …….. 36 
1.4.3.4   Alterations of kainate receptor subunit expression …………. .................. 37 
1.4.3.5   KA1 Expression …………. ...................................................................... 39 
1.5    AIMS……………………………….……………..…..………………………..………..…. ..41 
2 MATERIALS AND METHODS…….…………………………………...…43 
2.1     CLINICAL SAMPLES……………………..……...………………………………….……...44 
2.1.1 Case samples….………………………………………… …...……………..44 
2.1.2 Control cohort ............................................................................................ 45 
2.1.3 1936 Lothian birth cohort ........................................................................... 45 
2.1.4 Pakistan families ........................................................................................ 46 
2.1.5 Brain tissue samples................................................................................... 46 
2.2     MATERIALS………………………………..……...………………………………………..46 
2.2.1 Chemicals and biological products ............................................................. 46 
2.2.2 Kits ............................................................................................................ 47 
2.2.3 Solutions, buffers and loading dyes ............................................................ 48 
2.2.4 Antibodies.................................................................................................. 53 
2.2.5 Primers and microsatellite markers ............................................................. 54 
2.2.6 BAC and fosmid clones.............................................................................. 58 
2.2.7 DNA .......................................................................................................... 59 
2.2.8 Cell lines, lymphocytes and RNA blood ..................................................... 60 
2.2.9 Human brain tissue..................................................................................... 60 
2.3     GENERAL METHODS…………………….... …………………….…………………….....60 
2.3.1 FISH techniques......................................................................................... 60 
 viii 
2.3.1.1   Mini preparation of bacterial clone DNA …………................................. 60 
2.3.1.2   Nick translation …………....................................................................... 61 
2.3.1.3   Preparation of metaphase arrested chromosomes …………. ................... 61 
2.3.1.4   Hybridization …………........................................................................... 62 
2.3.2 Sequencing ................................................................................................ 63 
2.3.2.1   Polymerase chain reaction…………........................................................ 63 
2.3.2.2   Agrose gel electrophoresis …………....................................................... 64 
2.3.2.3   Exosapit clean up…………. .................................................................... 64 
2.3.2.4   Sequencing PCR …………...................................................................... 64 
2.3.2.5   Ethanol/EDTA precipitation and sequence analysis................................ 64 
2.3.2.6   Sequence analysis ………….................................................................... 65 
2.3.3 Confirmation of novel variants ................................................................... 65 
2.3.3.1   Restriction enzyme assay …………. ........................................................ 66 
2.3.3.2   Cloning of PCR products …………. ........................................................ 66 
2.3.4 TaqMan assays........................................................................................... 67 
2.3.5 Genotyping ................................................................................................ 67 
2.3.5.1   GRIK4 3’UTR variant ………….............................................................. 69 
2.3.5.2   Chromosome 7 microsatellites …………. ................................................ 69 
2.3.5.3   Whole genome SNP genotyping …………. .............................................. 69 
2.3.6 RT-PCR..................................................................................................... 70 
2.3.6.1   RNA preparation …………. .................................................................... 70 
2.3.6.2   cDNA synthesis …………........................................................................ 70 
2.3.6.3   RT PCR …………. .................................................................................. 71 
2.3.7 Immunohistochemistry............................................................................... 72 
2.3.7.1   Immunoperoxidase staining …………. .................................................... 72 
2.3.6 Antibody specicifity assays ........................................................................ 73 
2.3.6.1   Immunoblotting …………. ...................................................................... 73 
2.3.6.2   Pre-immune antisera assay …………...................................................... 74 
2.3.6.3   Peptide pre-absorption blocking assay …………..................................... 75 
2.4     IMAGE ANALYSIS……..…………………..…………..…...……………………………...75 
2.4.1 Image analysis............................................................................................ 75 
2.4.2 Image capture settings ................................................................................ 75 
2.5     DATA ANALYSIS…….…………………….... …………………….……………………...76 
 ix 
2.5.1 Chapter 3 ................................................................................................... 76 
2.5.1.1   Genome-wide analysis of autozygosity …………. .................................... 76 
2.5.1.2   Inbreeding coefficients ………. ............................................................... 76 
2.5.2 Chapter 4 ................................................................................................... 77 
2.5.2.1   Haplotype analysis …………. ................................................................. 77 
2.5.2.2   Amino acid conservation and splice site mutation prediction ………. ...... 77 
2.5.2.3   Linkage analysis ……........................................................................ 78 
2.5.3 Chapter 6 ................................................................................................... 79 
2.5.3.1   Testing for deviations from HWE …………. ............................................ 79 
2.5.4 Chapter 7 ................................................................................................... 79 
2.5.4.1   GRIK4 protein expression correlation analysis …………. ....................... 79 
2.6     GENE/PROTEIN NOTATION…………………….…….…………….…………..………...80 
2.7     PEDIGREE DRAWING…….…………………….... …………...….……………..………...82 
2.8     STATISTICAL ANALYSIS…………..…….... …………………….…………..………......82 
2.9     BIOINFORMATICS…….…………………….... ………………….…………………….....83 
3 HOMOZYGOSITY MAPPING IN A FAMILY PRESENTING WITH 
SCHIZOPHRENIA, EPILEPSY AND SENSORI-NEURAL HEARING LOSS .........84  
          ACKNOWLEDGEMENTS FOR CHAPTER 3...................................................................... 85 
3.1     PREFACE ................................................................................................................................ 86 
3.2     RESULTS………...…….…………………….... …………………….………………….…...86 
3.2.1 A high density genome-wide SNP scan for linkage..................................... 86 
3.2.2 Inbreeding coefficients and runs of homozygosity ...................................... 90 
3.2.3 A  genome-wide linkage scan performed on a second related sibship.......... 92 
3.3     DISCUSSION ...........................................................................................................................96 
4 INVESTIGATION OF A COMPLEX CHROMOSOMAL ABNORMALITY                   
AND THE DISRUPTED BREAK POINT GENE ABCA13 ............................................103  
          ACKNOWLEDGEMENTS FOR CHAPTER 4....................................................................104 
4.1     PREFACE ..............................................................................................................................105 
4.2     RESULTS……….. …….…………………….... …………………….……………………..105 
4.2.1     Fine mapping of breakpoint regions on chromosomes 8p and 7p............... 105 
 x 
4.2.2     Re-sequencing exons of the ABCA13 gene encoding functional domains in             
cases of schizophrenia and controls……..……………………………...…………..109 
4.2.2.1   Analysis of known SNPS …………. ....................................................... 112 
4.2.2.2   Novel intronic and synonymous variants…………................................. 112 
4.2.2.3   Novel non synonymous variants discounted as pathogenic …………. .... 113 
4.2.2.4   The detection of potentially pathogenic variants…………. .................... 113 
4.2.2.5   Further assessment of the pathogenic nature of identified variants. ...... 137 
4.2.2.6   Cases carrying multiple rare risk variants…………. ............................. 137 
4.2.2.7   Association  and Linkage analysis…..................................................... 139 
4.2.2.8   Exploring potential gender effects. ....................................................... 140 
4.2.3     The identification of a CNV within ABCA13 ............................................ 140 
4.2.4     An affected individual homozygous for rare alleles .................................. 143 
4.3     DISCUSSION ........................................................................................................................145 
4.3.1     Cytogenetics and the chromosome 7 region in disease .............................. 145 
4.3.2     Linking cytogenetics and rare variants: lessons from ASD........................ 147 
4.3.3     Rare variants in psychiatric illness............................................................ 148 
4.3.4     The nature of the ABCA13 rare varants discovered: penetrance issues, 
 variable expressivity, and mutation effects ........................................................... 151 
4.3.5     Interacting variants in psychiatric illness .................................................. 155 
4.3.6     Odds ratio estimates for common and rare variants ................................... 156 
4.3.7     How do the findings fit in with current models of complex genetic 
disease?................................................................................................................  157 
4.3.8     The function of ABCA13 and its potential involvement in biological 
processes………….…………………………………………………………………159 
5  ANALYSIS OF ABCA13 EXPRESSION………...…..............................................164 
         ACKNOWLEDGEMENTS FOR CHAPTER 5.....................................................................165 
5.1     PREFACE ..............................................................................................................................166 
5.2    RESULTS……………………………………………………….……………………...…….166 
5.2.1     RT- PCR of human ABCA13 in cell lines and brain tissue………………...166 
5.2.2 IHC analysis of ABCA13 in human post mortem brain tissue…………….168 
5.3     DISCUSSION .....................................................................................................................173 
5.3.1     ABCA13 expression in human and mouse tissues………..………………..174 
 xi 
5.3.2 Expression profile and function of other ABCA sub-family members…….176 
6  A CASE-CONTROL ASSOCIATION STUDY OF A VARIANT WITHIN                     
THE 3’UTR OF GRIK4 AND BIPOLAR DISORDER……………………………......180 
         ACKNOWLEDGEMENTS FOR CHAPTER 6.....................................................................181 
6.1     PREFACE ..............................................................................................................................182 
6.2    RESULTS…………...…….…………………….... …………………….….……………......182 
6.3     DISCUSSION .......................................................................................................................185 
7  THE CHARACTERISATION OF KA1 EXPRESSION IN HUMAN BRAIN...193  
          ACKNOWLEDGEMENTS FOR CHAPTER 7....................................................................194 
7.1     PREFACE ..............................................................................................................................195 
7.2     RESULTS………..…….…………………….... …………………….…………………...…195 
7.2.1 Antiserun specicity................................................................................... 195 
7.2.2 Frontal cortex........................................................................................... 197 
7.2.3 Cerebellum .............................................................................................. 199 
7.2.4 Amygdala ................................................................................................ 203 
7.2.5 The hippocampal formation................................................................... 203 
7.2.5.1   Hippocampus…………. ........................................................................ 203 
7.2.5.2   Parahippocampal regions. ................................................................... 213 
7.3     DISCUSSION ........................................................................................................................217 
7.3.1 Previous reports of KA1 expression in murine and human brain ............... 217 
7.3.1.1   Frontal cortex…………......................................................................... 219 
7.3.1.2   Cerebellum. ......................................................................................... 220 
7.3.1.3   Amygdala…………. .............................................................................. 222 
7.3.1.4   Hippocampus. ...................................................................................... 222 
7.3.1.5   Parahippocampal regions…………....................................................... 226 
7.3.2 Descrepancies between studies: advantages and disadvantages of IHC ..... 226 
7.3.3 Expression patterns of kainate receptor subunits in the brain .................... 227 






8  A GENOTYPE EXPRESSION CORRELATION STUDY OF KA1 IN  
          HUMAN  BRAIN……………………………………...……………………….......232 
          ACKNOWLEDGEMENTS FOR CHAPTER 8....................................................................233 
8.1     PREFACE ..............................................................................................................................234 
8.2    RESULTS………..…….…………………….... …………………….…………………...... 234 
8.2.1 Quantification of KA1 expression ............................................................ 234 
8.2.2 Genotype/protein correlation in the hippocampus ..................................... 236 
8.2.3 Genotype/protein correlation in the frontal cortex..................................... 243 
8.3     DISCUSSION ........................................................................................................................246 
8.3.1 Abnormalities in KAR subunit expression in individuals with psychiatric 
  illness ……………………………………………………………………………...249 
8.3.2 Genotype specific KA1 increases in neuronal cells, dendrites and 
neuropil……………………………………………………………………………...251  
8.3.3 Genotype/KA1 expression in DG and link to neurogenesis ....................... 253 
8.3.4 Stress, psychiatric illness and a role for KA1............................................ 254 
8.3.5 Differential KA1 expression and neural circuits........................................ 255 
9 GENERAL DISCUSSION ......................................................................................259 
9.1     REVIEW OF PROJECTS ......................................................................................................260 
9.2     WHAT DO THE FINDINGS TELL US ABOUT THE GENETIC ARCHITECTURE OF     
PSYCHIATRIC ILLNESS?............................................................................................................262 
9.3     FUTURE RESEARCH ..........................................................................................................266 
9.4     CONCLUDING REMARKS .................................................................................................268 
 BIBLIOGRAPHY....................................................................................................269 
 APPENDICES..........................................................................................................295 
          APPENDIX 1: CLINICAL DESCRIPTION OF THE CONSANGUINEOUS FAMILY ....295 
          APPENDIX 2: TABLE S1 ....................................................................................................297 
          APPENDIX 3: FIGURE S1 ..................................................................................................298 





LIST OF FIGURES 
 
Number  Page 
FIGURE   1.1 Diagram of consanguineous pedigree 24 
FIGURE   1.2 Constructed haplotypes of microsatellite markers on chromosome 22q13 27 
FIGURE   1.3 Pedigree of second family of the same kindred 27 
FIGURE   1.4 Schematic illustration of the complex chromosomal re-arrangement 
inv(7)(p12.3;q21.11), t(7;8)(p12.3;p23) 
29 
FIGURE   1.5 
 
Schematic illustration of the breakpoint regions on chromosomes 7p12.3, 
7q21.11 and 8p 
  
29 
FIGURE   1.6 Schematic illustration of the identified breakpoint region on chromosomes 
7q21.11 
30 
FIGURE   1.7 Diagrammatic representation of ABCA13 protein structure 30 
FIGURE   1.8 ABCA sub-family members 33 
FIGURE   1.9 Diagrammatic illustration of a complex chromosomal re-arrangement 
identified as disrupting GRIK4 
35 
FIGURE   1.10 Diagrammatic representation of GRIK4: showing the cytogenetic and 
association findings 
35 
FIGURE   2.1 Illustration of IHC image analyzed by a colour deconvolution technique in 
Image J 
81 
FIGURE   3.1 SNP and microsatellite data identifying locus on chromosome 22q12.3-
q13.3 
87 
FIGURE   3.2 SNP markers identifying HBD locus on chromosome 2p24.1-p25.3 89 
FIGURE   3.3 SNP markers identifying HBD loci on chromosome 7q21.11-q31.1 94 
FIGURE   3.4 SNP markers identifying HBD loci on chromosome 1p22.2-1q23.1 95 
FIGURE   4.1 The breakpoint fosmid G248P87290G10 on chromosome 8 106 
FIGURE   4.2 BACs and fosmids used to define the breakpoint on chromosome 8p23.1 106 
FIGURE   4.3 Breakpoint fosmid 188G7 on chromosome 7 107 
FIGURE   4.4 BACs and fosmids used to define the breakpoint on chromosome 7p12.3 108 
FIGURE   4.5 Flow chart of findings initiated from the screening of exons encoding the 
functional domains of ABCA13 
111 
 xiv 
FIGURE   4.6 Family pedigree carrying R4454C 114 
FIGURE   4.7 Sequence traces, amino acid position and conservation and family pedigree 
of the T4031A variant 
117 
FIGURE   4.8 The location of T4031 and ATP-binding site in a 3D-model 118 
FIGURE   4.9 Sequence trace, restriction digest, position and conservation of R4728X 120 
FIGURE   4.10 Co-segregation of R4728X with illness in four pedigrees 122 
FIGURE   4.11 Conserved background haplotypes carrying the R4728X or T4031A 
mutations 
123 
FIGURE   4.12 Sequence trace, amino acid position and conservation of R4843C 125 
FIGURE   4.13 Small families carrying the R4843C variant 125 
FIGURE   4.14 Sequence chromatogram, splice variant sequence, amino acid position, and 
conservation, and segregation, of S3704R with illness in a large pedigree 
127 
FIGURE   4.15 Sequence chromatogram, amino acid position and conservation of H3609P 
and R3604Q 
128 
FIGURE   4.16 Family pedigrees carrying H3609P 130 
FIGURE   4.17 Family pedigree carrying R3604Q 132 
FIGURE   4.18 Sequence chromatogram, amino acid position, AA conservation and 
segregation of T4550A 
133 
FIGURE   4.19 Sequence chromatogram, amino acid position and conservation of R4590W 135 
FIGURE   4.20 Sequence chromatogram, amino acid position and pedigree with H4262R 135 
FIGURE   4.21 Schematic representation of the functional domains within ABCA13 and the 
locations of the identified putative mutations 
136 
FIGURE   4.22 Pedigree of family carrying the 11 kb intronic CNV deletion 142 
FIGURE   4.23 Schematic illustration of fosmid clones used to investigate a possible 
deletion in an individual with schizophrenia 
142 
FIGURE   4.24 Interphase nuclei hybridized with fosmid and BAC DNA in an individual 
with schizophrenia and a potential deletion 
144 
FIGURE   4.25 Microsatellite marker genotyping on chromosome 7 in an individual with 
schizophrenia 
144 
FIGURE   5.1 Human ABCA13 expression in cell lines and human tissue 167 
FIGURE   5.2 ABCA13 870 antibody and corresponding pre-immune antiserum 
immunoreactivity in the medulla oblongata 
170 
 xv 
FIGURE   5.3 High magnification images of ABCA13 870 antibody reactivity in layers 2 
and 6 and the underlying white matter of the frontal cortex 
171 
FIGURE   5.4 High magnification images of ABCA13 870 antibody and corresponding 
pre-immune antiserum immunoreactivity in layer 3 of the frontal cortex 
171 
FIGURE   5.5 ABCA13 870 antibody and corresponding pre-immune antiserum 
immunoreactivity in the dentate gyrus and hilus of the hippocampus 
172 
FIGURE   6.1 Alignment of 3’UTR deletion/insertion in human, chimp, macaque and 
mouse 
186 
FIGURE   6.2 Relative expression levels of the deletion and insertion GRIK4 alleles as 
determined by a fluorescently labelled PCR reaction 
186 
FIGURE    6.3 Schematic representations of multiple positive associations of GRIK4 with 
antidepressant treatment and with schizophrenia and bipolar disorder 
190 
FIGURE   7.1 KA1 detection in cell lines and mouse 196 
FIGURE   7.2 KA1 protein expression in layer 1 of the frontal cortex 196 
FIGURE   7.3 KA1 protein immunoreactivity in layers 2 and 4 of the frontal cortex 198 
FIGURE   7.4 KA1 protein immunoreactivity in layers 3 and 5 of the frontal cortex 198 
FIGURE   7.5 KA1 protein immunoreactivity in layer 6 of the frontal cortex 200 
FIGURE   7.6 Protein immunoreactivity for KA1 and GFAP in the white matter 
underlying the neocortex 
200 
FIGURE   7.7 Protein immunoreactivity for KA1 in the cerebellar cortex 201 
FIGURE   7.8 High magnification images of KA1 protein immuno-reactivity in the 
cerebellum 
202 
FIGURE   7.9 Protein immunoreactivity for GFAP in the cerebellar cortex 204 
FIGURE   7.10 Protein KA1 immunoreactivity in cortical layers surrounding deeper nuclei 
of the amygdala 
204 
FIGURE   7.11 Schematic illustration of the hippocampal formation and major pathway 
circuitry 
206 
FIGURE   7.12 KA1 and GFAP protein immuno-reactivity in the molecular layer and GCL 
of the dentate gyrus 
207 
FIGURE   7.13 KA1 expression in the granular cell layer of the dentate gyrus 208 
FIGURE   7.14 KA1 expression in the DG hilus and CA4 region 210 
FIGURE   7.15 KA1 expression in the CA3 and CA2 fields  211 
FIGURE   7.16 KA1 immunoreactivity in the CA1 field 212 
 xvi 
FIGURE   7.17 KA1 immunoreactivity in the alveus of the hippocampus and subiculum. 214 
FIGURE   7.18 KA1 immunoreactivity in layers 1 and 2 of the entorhinal cortex 214 
FIGURE   7.19 KA1 immunoreactivity in layers 3 and 5 and 6 of the entorhinal cortex 216 
FIGURE   7.20 KA1 immunoreactivity in layers 1 and 2 of the perirhinal cortex 216 
FIGURE   7.21 KA1 immunoreactivity in layers 3, 4, 5 and 6 of the perirhinal cortex 218 
FIGURE   7.22 Schematic representation summarizing KAR subunit expression in the 
hippocampus and dentate gyrus 
229 
FIGURE   S1 Comparison of KA1 expression in the CA3 field of the hippocampus in a 

























LIST OF TABLES 
 
Number  Page 
TABLE   1.1 KA1 expression in brain 40 
TABLE   2.1 Chemical and biological products used for molecular biological techniques 47 
TABLE   2.2 Kits used for molecular biological techniques 48 
TABLE   2.3 Antibodies and pre-immune serum 53 
TABLE   2.4 Primers used for DNA PCR amplification and sequencing 
 
54 
TABLE   2.5 BAC and Fosmid clones used for cytogenetic analysis 58 
TABLE   2.6 Primers used for TaqMan assays 68 
TABLE   2.7 RT-PCR primers designed across exons encoding different parts of 
ABCA13 
71 
TABLE   3.1 Analysis of homozygosity tract lengths and inbreeding coefficients per 
individual 
91 
TABLE   3.2 HBD regions identified in the second related family 93 
TABLE   4.1 Summary of identified breakpoint BAC and fosmid clones 108 
TABLE   4.2 Novel variants identified from re-sequencing cases with schizophrenia and 
comparative controls 
110 
TABLE   4.3 The frequency of novel variants initially identified in cases, controls or both 
populations 
111 
TABLE   4.4 Known SNPs detected from the sequencing of case and control populations 114 
TABLE   4.5 Putative pathogenic variants identified from initially screening of the 
ABCA13 gene subsequent genotyped in larger cohorts of cases and controls 
116 
TABLE   4.6 In silico prediction of the functional/pathological consequences of all 13 
newly identified non-synonymous variants 
138 
TABLE   4.7 Affected individuals identified as being biallelic for risk variants 138 
TABLE   4.8 Comparison of percentage of males and females carrying risk variants  141 
TABLE   6.1 Insertion/deletion genotyping results from individuals diagnosed with 
bipolar disorder and controls in the original and replication studies 
184 
TABLE   6.2 The combined data set from the original and replication indel study 184 
 xviii 
TABLE   8.1 Details of individual samples used for the genotype correlation study 235 
TABLE   8.2 Genotype Group Demographics 235 
TABLE   8.3 Hippocampal cell counts and neuropil percentage means per individual 
sample 
237 
TABLE   8.4 Hippocampal cell count and neuropil percentage means per genotype group 238 
TABLE   8.5 P and F values associated with hippocampal cell counts and neuropil 
immunoreactivity percentages 
238 
TABLE   8.6 Percentage increase in KA1 expression calculated for the deletion groups 
relative to the insertion group per hippocampal region. 
241 
TABLE   8.7 Analysis of genotype, gender, age, PMI, pH and hippocampal counts 242 
TABLE   8.8 Frontal cortex cell count means per individual sample 244 
TABLE   8.9 Frontal cortex cell count means per genotype group 244 
TABLE   8.10 P and F values associated calculated for frontal cortex cell counts 245 
TABLE   8.11 Mean percentage increase in frontal cortex KA1 expression estimated for 
the deletion allele groups relative to the insertion group 
247 
TABLE   8.12 Analysis of genotype, gender, age, PMI, pH and frontal cortex cell counts 248 





LIST OF GRAPHS 
 
Number  Page 
GRAPH 3.1 Graph of homozygous tract lengths (ROHs) for each pedigree member 91 
GRAPH 8.1 Genotype effect on mean cell counts and neuropil abundance in the 
hippocampus 
239 
GRAPH 8.2 The deletion allele increases KA1 immunoreactivity in neuronal cells in 
the hippocampus 
241 
GRAPH 8.3 Genotype effect on mean cell counts in the frontal cortex 245 
GRAPH 8.4 The deletion allele increases KA1 immunoreactivity in neuronal cells in 






aa Amino acid 
AA Arachidonic acid 
ABC ATP binding cassette transporters 
ABCA ATP binding cassette transporter, subfamily A 
ABCA1 ATP binding cassette transporter A1 
ABCA4 ATP binding cassette transporter A4 
ABCA12 ATP binding cassette transporter A12 
ABCA13 ATP binding cassette transporter A13 
AMD Age-related macular degeneration 
AD Altheimer’s disease 
ADSL Adenylosuccinate lyase 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AREs AU-Rich elements 
ASD Autism Spectrum Disorder 
ATF4 Activating transcription factor 4 
ATP Adenosine triphosphate 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2. 
BAC Bacterial artificial chromosome 
BBS Bardet-Biedl syndrome 
BDNF Brain derived neurotrophic factor 
BLAST Basic local alignment search tool 
BLAT Basic local alignment tool 
bp Base pair 
BP Bipolar disorder 
BRCA1 Breast cancer 1 
BRCA2 Breast cancer 2 
BSA Bovine serum albumin 
°C Degrees centigrade 
CDCV Common disease – common variant hypothesis 
CDFE Cortical Dysplasia–Focal Epilepsy syndrome 
CDRV Common disease – rare variant hypothesis 
cDNA Complementary DNA 
CA Cornu ammonis 
CACNA1C Calcium channel, voltage-dependent, L type 
CACNG2 Voltage-dependent calcium channel gamma-2 
CAD Coronary artery disease 
cAMP Cyclic adenosine monophosphate 
CFTR Cystic fibrosis transmembrane conductance regulator 
CHB Chinese population 
CI Confidence interval 
 xx 
cM centiMorgans 
CNS Central Nervous System 
CNTNAP2 Contactin-associated protein-like 2 precursor 
CNTF Ciliary neurotrophic factor 
CNV Copy Number Variant 
CRC Colorectal cancer 
CRD3 Cone-rod dystrophy type 3 
CSF2RA Colony stimulating factor 2 receptor, alpha 




DAAO D-amino acid oxidase 
DAG Diacylglycerol 
D2 Dopamine type-2 receptors 
δ Delta 
DD Darier disease 
del Deletion 
DFNB Deafness, Neurosensory, Autosomal Recessive 
DFNB31 Autosomal recessive deafness type 31 protein 
DG Dentate gyrus 
DGKH Diacyl glycerol kinase 
dH2O Distilled water 
DISC1 Disrupted-In-Schizophrenia-1 
DMD Duchenne Muscular Dystrophy 
DZ Dizygotic 
DNA Deoxyribonucleic acid 
DNase A deoxyribonuclease 
dNTP Deoxyribonucleotide triphosphate 
DSM Diagnostic and Statistical Manual of Mental Disorders 
DTNBP1 Dysbindin 
DYNC1I1 Dynein, cytoplasmic 1, intermediate chain 1 
EC Entorhinal cortex 
E-Coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
EEG Electroencephalographic 
EFAs Essential fatty acids 
EGFR Epidermal growth factor receptor isoform b 
EM Electron microscopy 
EM Expectation Maximisation 
EPSCs Excitatory postsynaptic currents 
EPSCKA Excitatory postsynaptic currents kainate receptor 
ER Endoplasmic Reticulum 
 xxi 
F Inbreeding coefficient 
FISH Fluorescence in situ hybridization 
fMRI Functional Magnetic Resonance Imaging 
FPEVL Familial Partial Epilepsy syndrome with Variable Loci 
g Grams 
GABA Gamma-aminobutyric acid 
GAD Generalized anxiety disorder 
GAD67 Glutamate decarboxylase 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GC Glucocorticoids 
GCL Granular cell layer 
gDNA Genomic DNA 
GFAP Glial fibrillary acidic protein  
GFP Green fluorescent protein 
G6PD Glucose-6-phosphate dehydrogenase 
GPR24 G protein-coupled receptor 24 
GRIA1 Glutamate ionotrophic receptor, AMPA 1 
GRIA3 Glutamate ionotrophic receptor, AMPA 3 
GRID2 Ionotropic glutamate receptor, delta subunit 2 
GRIK1 Ionotropic glutamate receptor, kainate 1 (protein GLUR5) 
GRIK2 Ionotropic glutamate receptor, kainate 2 (protein GLUR6) 
GRIK3 Ionotropic glutamate receptor, kainate 3 (protein GLUR7) 
GRIK4 Ionotropic glutamate receptor, kainate 4 (protein KA1) 
GRIK4 Ionotropic glutamate receptor, kainate 5 (protein KA2) 
GRIM3 Metobotropic glutamate receptor 3 
GRIM4 Metobotropic glutamate receptor 4 
GRIN1 NMDA receptor 1  
GRIN2B NMDA receptor subunit 2B 
GWAS Genome-Wide Association Study 
h Hilus 
HBD Homozygous-by-descent 
HD Huntington’s disease 
H DAB Haematoxylin and DAB 
HDL High Density Lipoprotein 
HDR ATP binding cassette transporters 
HGU Human Genetics Unit 
HPA Hypothalamic-pituitary-adrenal axis 
HRP Hydrophobic dipping region 
5-HT 5-hydroxytryptamine /serotonin 
5-HT1 Serotonin type 1 receptor 
5-HT2 Serotonin type 2 receptor 
HTR2A 5-hydroxytryptamine (serotonin) receptor 2A 
HTT Huntingtin protein 
HWE Hardy–Weinberg equilibrium 
 xxii 
IBD Identity By Descent 






iml Inner molecular layer 
IP3 Inositol-1, 4,5-triphosphate 
IPSC Inhibitory post synaptic currents 
IPTG Isopropyl β-D-thiogalactopyranoside 
IREs Iron-responsive elements 
IRPs Iron regulatory proteins 
JAM3 Junctional adhesion molecule 3 precursor 
JPT Japanese population 
KAR Kainate receptor 
kb Kilobase 
KCNB1 Potassium voltage-gated channel, subfamily G 
KCND3 Potassium voltage-gated channel, Shal-related 
KCNF1 Potassium voltage-gated channel, subfamily F 
kDA Kilo Daltons 
Kir Inward rectifying potassium channel 
KO Knock out 
KRIT1 Krev interaction trapped protein 1 
l Stratum lucidum 
LB Luria-Bertani 
LD Linkage disequilibrium 
LOD Logarithm of odds 
LSD Lysergic acid diethylamide 
LTP Long term potentiation 




m Stratum lucunosum moleculare 
M Molar 
MAF Minor allele frequency 
Mb Megabase 
MCHR1 Melanin-concentrating hormone receptor 1 
MDD Major Depressive Disorder 
MELAS Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like 
episodes 
MeOH Methanol 
MERRF Myoclonic Epilepsy with Ragged Red Fibers 
 xxiii 
MF-CA3 Mossy fibre-CA3 
mg Milligrams 
MgCl2 Magnesium chloride 
mGluR Metobotropic glutamate receptor 




MR Mental retardation 
MRC Medical Research Council 
mRNA Messenger RNA 
MYLC2PL Myosin light chain 2 
MYO5B Myosin VB 
MZ Monozygotic  
nACh Nicotinic acetylcholine 
NaCl Sodium chloride 
NAD Non affected with psychiatric illness 
NaOH Sodium hydroxide 
NBD Nucleotide binding domain 
NCBI National Center for Biotechnology Information 
NLGN3 Neuroligin 3 
NLGN4 X-linked neuroligin 4 
ng Nanograms 
NMDA N-methyl-D-aspartic acid 
NMR Nuclear magnetic resonance 
NPL Non parametric linkage analysis 
NPAS3 Neuronal PAS domain-containing protein 3  
NRG1 Neuregulin 
NXN Nucleoredoxin 
o Stratum oriens 
OD Optical density 
oml Outer molecular layer 
OR Odds ratio 
p stratum pyramidal 
PAR Population Attributable Risk 
PBS Phosphate buffered saline 
PCM1 Pericentriolar material 1 protein 
PCP Phencyclidine 
PCR Polymerase chain reaction 
PDE4D Phosphodiesterase 4d 
PDE4 Phosphodiesterase 4 
PET Positron emission tomography 
pH Power of Hydrogen 
PI Phosphoinositide 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
 xxiv 
PKC Protein kinase C 
PLA2 Phospholipase A2 
PLA2G6 Phospholipase A2, group VI 
PPF Paired pulse facilitation 
PMI Post mortem interval 
PPP1R9A Protein phosphatase 1, regulatory (inhibitor) subunit 
PPP1R3B Protein phosphatase 1, regulatory (inhibitor)subunit 
PrS Presubiculum 
PTSD Post traumatic stress disorder 
qs quantum sufficiat /quantity sufficient 
QTL Quantitative trait loci 
r Stratum radiatum 
RGS4 Regulator of G-protein signaling 4 
RIN RNA Integrity Number 
RNA Ribonucleic acid 
RNaseA Ribonuclease A 
RNS Reactive nitrogen species 
ROHs Runs of Homozygosity 
ROS Reactive oxygen species 
RP19 Retinitis pigmentosa type 19 
rpm Revolutions per minute of rotor 
RTA Road traffic accident 
RT-PCR Reverse transcription - PCR 
s Subiculum 
SADS-L Schedule for Affective Disorders and Schizophrenia-Lifetime 
SCZ Schizophrenia 
SDS Sodium dodecyl sulphate 
SDSC San Diego Super Computer 
SDS-PAGE SDS-polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SEMA3A Semaphorin 3E 
SGZ Subgranular zone 
SHANK3 Proline-rich synapse-associated protein 2 
SLC26A4 Pendrin 
SLC26A5 Prestin isoform d 
SLC6A4 Solute carrier family 6 member 4 / serotonin transporter gene 
SORCS2 Sortilin-related VPS10 domain containing receptor 2 
SNHL Sensori-neural hearing loss 
SNP Single nucleotide polymorphism 
SOX2 Sry-related HMG box transcription factor 
SSC Standard saline citrate 
SSRI Specific serotonin re-uptake inhibitor 
STAR*D Sequenced Treatment Alternatives to Relieve Depression 
STGD Stargardt disease 
TAC1 Tachykinin 1 isoform 
 xxv 
Taq thermus aquaticus 
TBE Tris-Borate-EDTA 
TBlast Translated sequence database 
TD Tangier disease 
TE Tris-EDTA 
THEX1 Three prime histone mRNA exonuclease 1 
TMDs Transmembrane cluster domains 
TPH2 Tryptophan hydroxylase 2 
TRIOBP TRIO and F-actin binding protein 
TSPAN8 Transmembrane 4 superfamily member 3 
Tween 20 Poly(oxyethylene) sorbitan monolaurate 
TX-100 Triton-X-100 
U units 
UCSC University of California Santa Cruz  
UPD Uniparental disomy 
USS Upstream sequence 
dUTP 2'-Deoxyuridine 5'-Triphosphate 
UTR Untranslated region 
3’UTR 3 prime untranslated region 
5’UTR 5 prime untranslated region 
UV Ultraviolet 
VGCNL1 Voltage gated channel like 1 
VEGF Vascular endothelial growth factor 
WFS1 Wolfram syndrome 
WGH Western General Hospital, Edinburgh 
WHO World Health Organization 
WS Wolfram syndrome 
WTCCC Welcome Trust Case Control Consortium  
WT-CRF Welcome Trust Clinical Research Facility 
xg Measure of relative centrifugal force 
YAC Yeast artificial chromosome 































ACKNOWLEDGEMENTS FOR CHAPTER 1 
 
The clinical data relating to the consanguineous families were collected by Dr M. Ayub, 
Dr M. Irfan and Dr F. Naeem.  The clinical description of the family members was 
written jointly by Dr Mohammed Ayub and Professor Douglas Blackwood. 
Microsatellite genotyping was initially performed by me assisted by Alan Maclean.  
 
The initial mapping of chromosomal breakpoints disrupted in the complex chromosomal 
re-arrangement inv(7)(p12.3;q21.11), t(7;8)(p12.3;p23) was performed by Pat Malloy, 






















1.  INTRODUCTION 
 




Schizophrenia is a leading cause of morbidity, incurs high public health costs and has a 
devastating impact on the lives of patients, their families, and on societies as a whole in 
populations world-wide. It is a debilitating, progressive neuropsychiatric disease 
characterized by alterations in mood, beliefs, perceptions and psychomotor behaviour - 
frequently accompanied by cognitive impairment. The lifetime morbid risk to the 
general population, as surveyed in developed countries, is close to 1%. The incidence of 
schizophrenia shows relatively little variation across a variety of different populations, 
suggesting culture and ethnicity are not important biological factors (Owen et al., 2002). 
Age of onset is usually in adolescence or early adult life with the mean age of onset later 
in women than for men (American Psychiatric Association, 2004). The illness typically 
follows a course of acute episodes which may then develop into a chronic form of the 
disease. Life expectancy is generally reduced and self-harming and suicide are relatively 
frequent and tragic consequences of the disease.  
 
Traditionally the characteristic features of schizophrenia have been divided into two 
clusters of symptoms; positive symptoms (delusions, hallucinations and formal thought 
disorder), and negative symptoms (affective flattening, apathy, poverty of speech and 
psychological deficits in executive function and episodic memory). In turn, studies of 
symptomatology have shown that these positive and negative symptoms segregate into 
three distinguishable subgroups termed psychomotor poverty (primarily negative 
symptoms) disorganization (disorder of the form of thought and inappropriate effect) 
and reality distortion (delusions and hallucinations) (Liddle, 1987). Clinical diagnosis is 
based upon international definitions published in The International Classification of 
Disease ICD-10 (WHO 2003) and Diagnostic and Statistical Manual of Mental 
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Disorders DSM-IV (American Psychiatric Association, 2004). Both nosological manuals 
recognize sub-varieties or sub-categories of schizophrenia. For example, DSM-IV 
defines five sub-types, i.e. hebephrenic, catatonic, paranoid, simple and residual; and the 
ICD-10 a further two (post-schizophrenic depression and undifferentiated 
schizophrenia). However, there is no consistent evidence of differential prognosis or 
response to treatment between these types, and the manifestation of the characteristic 
symptoms of these sub-varieties may change with the course of a patient’s illness. 
Likewise, family studies do not provide convincing evidence supporting these 
subdivisions. Indeed, psychiatric conditions such as schizotypal personality disorder 
categorized as “part of the genetic spectrum” of schizophrenia (Kendler et al., 1991) and 
schizoaffective and bipolar disorder, both classified separately, are relatively common in 
close relatives of schizophrenics (Craddock et al., 2005). This raises interesting 
questions about the aetiological relationship between schizophrenia and other psychiatric 
illnesses which, as yet, cannot be answered. It is clear that the standard definitions of 
psychiatric disease will inevitably evolve as neurobiological findings are reported and in 
a reciprocal manner, the interpretation and the direction of research will change with 
new models of psychiatric disease.  
 
1.1.2 Affective disorders 
 
‘Affective disorders’ include a wide variety of complex conditions that have as a core 
feature a pathological disturbance of mood. A fundamental clinical distinction in 
classification of these disorders is between mania and depression. Bipolar disorder 
(formerly known as manic depressive psychosis) is characterized by two or more manic 
episodes lasting at least one week and usually accompanied, at other times in a patient’s 
history, by major depressive episodes. Symptoms of mania, as outlined in DSM-IV, 
include: inflated self-esteem, decreased need for sleep, elevated and irritable mood, 
distractibility, increased goal-directed activity and psychomotor agitation. Symptoms for 
depressive episodes include depressed mood, reduced energy and decreased activity, 
ideas of self-harming, reduced self-esteem and confidence, and pessimistic thoughts 
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(WHO, 2003). It is not uncommon for mania and depressive symptoms to occur 
simultaneously and to be accompanied by psychotic features and/or cognitive 
impairment. Furthermore, bipolar disorder itself is highly co-morbid with other 
conditions such as anxiety and substance abuse (Gelder et al., 2006). Lifetime 
prevalence is estimated between 0.5-1.5 per cent with similar rates in males and females.  
Mean age of onset is around 17 to 21, but symptoms may first appear at any stage in life 
(Smith and Weissman, 1992) (Kessler et al., 1997). 
 
Major depressive disorder (MDD), formerly called endogenous depression or 
melancholia is now often termed unipolar disorder or recurrent depressive disorder. It is 
characterized by one or more depressive episodes lasting at least two weeks without 
other episodes of mania or hypomania. Lifetime population risk is higher than bipolar 
disorder although reported estimates differ between studies, ranging from 4 to 17% 
(Kessler et al., 1994; Weissman et al., 1998). Moreover, lifetime prevalence is twice as 
great in women as men in developed countries (Kessler et al., 1994; Weissman et al., 
1998; Alonso et al., 2004) Age of onset varies widely, however, with the mean age 
generally reported to be mid-20s and to be similar for both males and females. Like 
schizophrenia, the pathogenesis of these affective disorders is not well understood and 
there are no biological diagnostic markers. Yet these disorders are associated with high 
mortality, high levels of heath service utilization, and they are estimated to be second 
only to ischaemic heart disease as a cause of global health burden in 2020 (Murray and 
Lopez, 1996).   
 
1.1.3 Epidemiological analysis of psychiatric disorders 
 
Epidemiological analysis of psychiatric illness involving family, twin and adoption 
studies provides strong evidence for the vertical transmission of genetic factors 
contributing to the expression of schizophrenia, bipolar and major depressive disorder. 
Extensive family studies, reviewed by Gottesman (1991), indicate the lifetime risk for 
first degree relatives of schizophrenics is approximately ten times greater (10%) than for 
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the general population (1%) (Gottesman, 1991). The risk increases to between 40 and 
50% when both parents are affected and declines to about 3% for second degree 
relatives (Kendler, 2000). The lifetime risk for first degree relatives of bipolar 
individuals is similar to that of schizophrenia (5-10 %) but relative risk is estimated to be 
lower (2%) for MDD (Craddock and Jones, 2001).  Furthermore, relatives of bipolar 
probands are also at increased risk of other affective disorders including major 
depressive disorder. 
 
Adoption studies have consistently shown increased incidence of schizophrenia in 
biological relatives of schizophrenic adoptees but not in control adoptees or adoptive 
relatives. This implicates shared genetic rather than environmental influences (McGuffin 
et al., 1995). Moreover, based upon data from five recent twin studies, proband-wise 
concordance rates for MZ twins are between 41 and 65% as compared with 0-28% for 
DZ twin pairs. Consequently, heritability has been estimated at approximately 80-85% 
(Cardno and Gottesman, 2000). Likewise, concordance rates for bipolar MZ twins (50-
60%) and major depressive disorder monozygotic (MZ) twins (46%) are higher than for 
dizygotic (DZ) twin pairs (20%) - with heritability rates for bipolar disorder calculated 
to be similar to schizophrenia (>80%) and lower for MDD (70%) (Kendler et al., 1993; 
McGuffin et al., 1996). From these findings it is clear that both the environment and 
genetics are aetiological factors and that genotype confers a predisposition or liability to 
develop the disease.  
 
1.1.4 Genetic models of psychiatric illnesses 
 
The study of psychiatric genetics is complicated by a number of issues, for example, 
phenotypic heterogeneity, incomplete disease penetrance and uncertainties concerning 
mode of inheritance. Nevertheless, three models hypothesized to explain the underlying 
genetics of complex traits have influenced how investigators approach and interpret 
genetic research. The first model, the quantitative trait loci (QTL) hypothesis, assumes 
that the genetic contribution to a disorder involves the additive and/or epistatic 
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interaction of several (oligogenic inheritance) or many (polygenic inheritance) genes of 
small effect. Under this model, also termed the ‘common disease – common variant 
hypothesis’ (CDCV), disease is postulated to stem from multiple common factors each 
with a small impact on disease risk (Chakravarti, 1999). In contrast, the single gene 
defect model, the ‘common disease – rare variant’ hypothesis (CDRV), proposes that a 
single gene can have a major effect on risk of disease and that these rare mutations are 
highly penetrant (i.e. most carriers express the disease phenotype). However, the term 
‘rare variant’ has been used to describe two types of risk factor. Firstly, it is applied to 
severely deleterious mutations (of the type causing monogenic diseases) which are 
highly penetrant and individually rare, even specific to single patients or families hence 
showing familial segregation with a minor allele frequency (MAF) of <0.1%. Secondly, 
there are risk variants that are more common than deleterious mutations but rarer than 
polymorphisms (>1% in population) and are of moderate risk (i.e. have moderate odds 
ratios OR) and penetrance so that familial concentration may not appear to follow 
standard Mendelian segregation. Moreover, in the CDRV model different affected 
individuals may harbour both types of rare variant in the same or different ‘high risk’ 
gene, but each individual carries only one or two mutations (McClellan et al., 2007; 
Bodmer and Bonilla, 2008). 
 
The third model, the mixed model of inheritance, suggests that a gene of major effect 
might act in combination with a background of polygenes. However, the testing of this 
model has yielded inconclusive results (McGuffin et al., 1995). Nevertheless, population 
genetics equilibrium models and empirical studies support a role for both rare and 
common variants. The genetic architecture of other common genetically complex 
chronic diseases such as colorectal cancer (CRC), breast cancer and Alzheimer’s disease 
provide evidence that a significant proportion of the inherited susceptibility may be due 
to moderate to high penetrant rare mutations and common mulitfactorial variants (Di 




1.1.5 What do we mean by a genetic factor? 
 
From the preceding discussions it is clear that genetic factors predispose individuals to 
psychiatric illness and that multiple models exist to explain the underlying genetics of 
common complex disease. This leads to the next pertinent question: what exactly is 
meant by a genetic factor or variant? Traditionally, chromosomal abnormalities resulting 
in a loss, gain, inversion or disruption of genomic material, together with large-scale 
deletions or duplications of genomic sequence, are known to give rise to clinical 
disorders and syndromes. These lesions may result in the disruption of transcription of 
one or more genes and consequently may affect gene product dosage.  
 
Similarly, small-scale deletions, insertions and duplications as well as point mutations 
within a gene are known to cause simple Mendelian diseases. Point mutations, the 
substitution of one nucleotide base for another, can be further classified into the 
subgroups, null mutations, missense mutations and silent mutations.  Nonsense 
mutations, frameshift and cryptic splice variants (generally termed loss-of-function or 
null mutations) commonly result in a premature stop codon, truncated transcription 
products and reduced or no protein product as a consequence of mRNA products being 
broken down by nonsense mediated decay processes. Missense or non-synonymous 
mutations are the exchange of one nucleotide for another, causing substitution of a 
different amino acid in the peptide sequence. This may alter protein structure and 
activity by either reducing the efficacy of normal protein function or causing new and 
abnormal gain of functions. Silent mutations which can occur within exons 
(synonymous variants) or non-coding regions are base changes that do not change the 
protein sequence but may affect splicing, or transcription control. It is this class of 
mutation which is more likely to be neutral, i.e. it confers no change to protein function, 
and constitutes the majority of common single nucleotide polymorphisms (SNPs) in the 
human genome.  
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For simple Mendelian diseases, hundreds of different null mutations and missense 
mutations have been identified and consequently shown to have a significant effect on 
the function of a specific disease causing protein. For example, over 1600 mutations 
have been found in the CFTR gene which causes cystic fibrosis, with over 600 being 
missense and 500 nonsense, frameshift or splice mutations (Cystic Fibrosis Mutation 
Database 2008, http://www3.genet.sickkids.on.ca/cftr/). What is evident from the 
genetic research of simple Mendelian diseases, and more recently of common complex 
diseases such as breast cancer and colorectal cancer, is that these disorders are 
characterized by high alleleic heterogeneity (sets of multiple mutations in the same 
gene) particularly for rare causal mutations (McClellan et al., 2007). Disease causing 
sets of rare point mutations have already been identified in different genes known to 
underlie Autistic Spectrum Disorders (ASD) (Jamain et al., 2003; Laumonnier et al., 
2004; Durand et al., 2007; Bakkaloglu et al., 2008).  Moreover, putatively pathological 
ultra-rare variants have been reported in DISC1 (a schizophrenia candidate gene 
discussed in section 1.2.3); and in genes known to cause Wolfram syndrome (WS) and 
Darier disease (DD), two diseases frequently co-morbid with mood disorders (Kato, 
2001; Song et al., 2008).  
 
Common disease variants are candidates for susceptibility if there is a significant 
difference in the frequency of alleles between diseased and control groups. A group of 
susceptibility variants may be in the same gene or indeed a set of different genes with 
related functions indicating disruption of a biological pathway. Variants are assessed for 
their potential effect on protein function by a number of criteria including: occurrence in 
conserved functional regions of the protein; species and protein family amino acid 
conservation; charge and amino acid structural changes likely to affect protein folding 
and structure; variant segregation in affected members of families; and biochemical and 
functional assays.  Furthermore, altered expression of the gene product assessed by 




Owing to advancements in chip array technologies, another type of structural variant, 
copy number variants (CNVs), have grown in prominence in recent years. Copy number 
variants are submicroscopic DNA segments ranging from kilobases to megabases, 
variable in copy number compared to a reference genome. CNVs are classified into 
types according to their complexity and include deletions, duplications, multi allelic loci, 
and more complex loci (e.g. inversions) (Redon et al., 2006). In a seminal paper, Redon 
and colleagues estimate that over 360 megabases of DNA are covered with CNVs, 
which is approximate to 12% of the human genome. This is more nucleotide content per 
genome than [as yet known] single nucleotide polymorphisms (SNPs). Thus CNVs are 
likely to have a major effect on genetic diversity and evolution. Although many CNVs 
are postulated to be neutral polymorphisms there is emerging evidence that rare, 
inheritied and de novo, CNVs give rise to psychiatric disorders and other diseases (ISC, 
2008; Stefansson et al., 2008; Walsh et al., 2008). 
 
1.2   Molecular approaches to the study of psychiatric disorders 
 
Molecular genetic research currently employs three main strategies to detect candidate 
genes: linkage analysis, case-control association studies, and investigation of cytogenetic 
abnormalities.  
 
1.2.1. Linkage analysis 
 
In families with multiple affected members, linkage techniques assess the co-inheritance 
of DNA marker alleles (microsatellite or single nucleotide polymorphisms SNPs) with a 
disease state. This approach has been highly successful in identifying susceptibility 
regions and genes for other complex disorders such as early-onset Alzheimer’s disease. 
However, the genomic regions so mapped tend to be large, the technique has limited 
power to detect susceptibility genes of small effect and diagnosis of family members 
may change with time. Linkage studies of schizophrenia pedigrees have found evidence 
for linkage at genome-wide significance levels, although many positive findings have 
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failed to be subsequently confirmed. Two meta-analyses of schizophrenia linkage 
studies have been reported with some overlap in results. Badner and Gershon found 
support for the existence of susceptibility genes on chromosome 8p, 13q and 22q whilst 
Lewis and colleagues for chromosome 1q, 3p, 5q, 6p, 8p, 11q, 14p, 20q and 22q (Badner 
and Gershon, 2002; Lewis et al., 2003). Thus two regions, 8p and 22q were supported by 
both meta-analyses, but these loci are large and harbour hundreds of genes. 
 
Genome-wide linkage scans have also provided some support for loci of large/moderate 
effect in multiplex pedigrees affected by bipolar and major depressive disorder. Again, 
there has been a lack of replicable findings and identification of causal factors or 
variants. The most consistent and replicated findings for bipolar disorder have been 
chromosome 4p16, 6q16-25, 11p15, 12q23-24, 18p11, 21q22 and 22q12 and for MDD 
2q33, 3p12, 8p22, 12q22-23, 15q13, 18q21 (Camp et al., 2005; Levinson, 2006; Serretti 
and Mandelli, 2008). However, two meta-analyses have been performed using bipolar 
linkage data sets which showed no overlap in results. Badner and Gershon found 
strongest evidence for susceptibility loci on chromosome 13q and 22q whilst Bennett 
and colleagues for chromosomes 9p21-22, 10q11.2, 14q24-32 and 18p-q (Badner and 
Gershon, 2002; Bennett et al., 2002). What is evident from linkage studies is that there is 
some of overlap in candidate susceptibility loci between bipolar disorder and MDD (for 
example 12q23 a regions which houses the gene ATP2A2 associated with Darier disease 
mentioned above) and bipolar and schizophrenia chromosome regions 18p11, 13q32, 
10p14 and 22q11-13 (Berrettini, 2000). 
 
1.2.2 Case-control association studies 
                    
Population-based case-control association studies involve comparing the frequency of 
polymorphic alleles in a sample of patients with ethnically matched non-symptomatic 
controls. These may be performed as genome-wide scans (Genome–Wide Association 
Study or GWAS) where the positions of the susceptibility loci or causal variants are 
unknown; as candidate gene studies over small genomic regions; or as a comparison of 
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frequencies of a putative disease variant itself. SNP-tag association studies utilise 
markers, predominately SNPs, as ‘proxies’ for susceptibility variants with the 
underlying assumption that the markers will be in linkage disequilibrium with the nearby 
disease susceptibility alleles. Typically, the minor allele frequencies of chosen marker 
SNPs are above 5%, and hence this approach is not designed to detect susceptibility 
alleles that are rare in the general population.  As linkage disequilibrium blocks extend 
over relatively short genomic distances, SNP-tag association studies give higher 
resolution for mapping than linkage mapping but, for sufficient power to detect and 
confirm the presence of alleles of small effect, large sample sets screened with high-
density markers are needed (Owen et al., 2002; Blackwood and Muir, 2004). 
 
High powered multi-centre SNP-tag GWAS studies of non-psychiatric common 
complex diseases and traits have proved to be highly successful in identifying common 
risk loci (WTCCC, 2007; Kathiresan et al., 2008; Willer et al., 2008). Large 
collaborative studies of schizophrenia and MDD are currently underway although the 
results are still unpublished. Nonetheless, one small-scale and therefore less powered 
GWAS study of schizophrenia conducted by Lencz and colleagues found significant 
association at loci on the X and Y chromosomes (Xp22.32 and Yp11.3) neighbouring 
the CSF2RA gene at the level of genome-wide significance (Lencz et al., 2007). 
Furthermore, four GWAS studies provide suggestive or moderate evidence for 
susceptibility loci on chromosomes 1q32, 7q22.1, 2q32.1 and 12q24.23, although there 
is a lack of apparent correspondence between results (Mah et al., 2006; Kirov et al., 
2008; O'Donovan et al., 2008; Shifman et al., 2008a). Similarly, while there are no 
reports of small scale GWA studies for major depressive disorder per se, a GWAS 
performed for neuroticism (a personality trait that shares genetic determinants with 
major depression and anxiety disorders) indicated suggestive evidence within the 
PDE4D gene on chromosome 5q11.2 (Shifman et al., 2008b).  
 
In contrast, three collaborative SNP-tag GWAS studies have been performed for bipolar 
disorder. The Wellcome Trust Case Consortium (WTCCC, 2007) reported one SNP 
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rs420259, located on 16p12, which reached a level of genome-wide significance  
(WTCCC, 2007). This region, however, does not appear to be a BP linkage hotspot as 
analysed by two major meta-analyses of BP linkage (Badner and Gershon, 2002; 
Segurado et al., 2003). A second GWAS study, conducted by Baum and colleagues, 
obtained a nominal P-value for a marker within DGKH. In addition, several other loci 
showed replicated suggestive association, located within the genes DFNB31, SORCS2, 
NXN, and VGCNL1 (Baum et al., 2008). A meta-analysis of these two studies indicated 
some overlap in the top association signals, the most consistent associations being for 
SNPs in or near to the genes ZIP3, JAM3 and DFNB31 (Baum et al., 2008). A third 
multi-centre study reported genome-wide significant association for SNPs in MYO5B, 
TSPAN8 and EGFR (Sklar et al., 2008). Interestingly, the most consistent association 
found between this study and that of the WTCCC was for a SNP in a voltage-gated 
calcium channel, CACNA1C. The lack of consistent findings from GWA studies of 
schizophrenia and BP in relation to previously reported candidate loci and genes 
suggests either that common susceptibility loci are of modest effect with modest to low 
risk ratios, that genetic heterogeneity may be high, or that rare genetic factors other than 
common variants may play a larger part in the aetiology of these disorders. 
 
Genome-wide association studies have also been reported with newly identified rare 
copy number variants in populations of cases and controls. Three recent studies of 
schizophrenia, using high resolution SNP chip arrays, show intriguing results. First, 
Walsh and colleagues reported a three-fold increase in rare (frequency less than 1%) 
structural variants in cases versus controls. This difference increased to four-fold when 
an independent set of cases of childhood onset schizophrenia were analysed. Moreover, 
there was an excess of CNVs disrupting genes from signalling networks, 
neurodevelopmental pathways including synaptic long-term potentiation, axon guidance 
signalling and glutamate receptor signalling (Walsh et al., 2008). A second multi-centre 
study also reported a 1.15-fold increase in large rare CNVs in patients with 
schizophrenia compared to controls. In addition they found significant association for 2 
novel regions, 1q21.1, 15q13.3 as well as 22q11 - a region previously known to be 
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deleted in individuals with velo-cardio-facial syndrome a condition which is commonly 
associated with schizophrenia (ISC, 2008). These loci were also shown to be nominally 
associated with schizophrenia in a third study (Stefansson et al., 2008).  Taken together, 
these findings strongly support a role for rare high risk structural variants contributing to 
the genetic burden of schizophrenia. 
 
Case-control candidate gene association studies aim to identify risk alleles in or around a 
specific candidate gene. Hundreds of candidate gene studies have been performed for 
schizophrenia, bipolar disorder and MDD, with many findings being reported positive. 
However, confirmation of an association by independent replication is often not 
forthcoming and further evidence, whether genetic, functional or behavioural, is needed 
to confirm candidacy.  
 
1.2.3. Chromosomal abnormalities 
  
Distinct chromosomal rearrangements have been the starting point for identifying causal 
genes in common genetic disorders such as Duchenne Muscular Dystrophy (DMD), 
Wilms tumour, fragile-X syndrome and retinoblastoma (Pickard et al., 2005b). 
Individual inversions and translocations which result in breakpoints that directly disrupt 
gene transcripts enable both a candidate gene and the potential functional mutation sites 
to be rapidly identified and hence have the potential to identify individual gene 
components of pathological pathways or processes underlying disease. Although 
bypassing many of the problems associated with linkage and association studies, a 
number of issues inherent to this approach should be highlighted. Firstly, disruption of a 
gene in only one case does not prove causality and additional validation is needed. This 
can be provided by, for instance: the co-segregation of the mutation event with disease 
within a family; positive linkage or association findings for the breakpoint region; 
mutations detected in other unrelated cases; or neurobiological findings implicating a 
role for the gene in the pathogenesis of the disorder. Secondly, genes lying close to a 
breakpoint may also contribute to the clinical phenotype if their regulatory elements, 
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which control expression, are disrupted (Kleinjan and van Heyningen, 1998). Thirdly, 
novel, and putatively pathogenic, transcripts may be produced from the fusion sequence 
contributed by both chromosomes apposing the breakpoint.  
 
These issues aside, the study of cytogenetic abnormalities has been, and continues to be, 
a highly effective strategy for discovering genes of major effect in neuropsychiatric 
illness. For instance, cytogenetic abnormalities identified in patients with autism 
spectrum disorders (ASD) (estimated to be approximately 3% of cases) have revealed 
new susceptibility genes in which rare causal and risk point-mutations have 
subsequently been detected, e.g. NLGN3, NLGN4, SHANK3, CNTNAP2. These lesions 
consequently implicate pathogenic disturbance of specific biological processes such as 
glutamatergic synapse function (Jamain et al., 2003; Vorstman et al., 2006; Durand et 
al., 2007; Bakkaloglu et al., 2008).  
 
Cytogenetic research in schizophrenia, bipolar and MDD lags behind autism in that far 
fewer discrete chromosomal rearrangements have been identified in cases. Nevertheless, 
a number of disrupted breakpoint genes, e.g. DISC1, PDE4B, NPAS3, GRIA3 and 
GRIK4, have gained strong support for their candidacy and provide some insight into 
putative pathological molecular and biological mechanisms.  
 
Disrupted-in-schizophrenia 1 (DISC1) was originally mapped as a gene disrupted by a 
balanced translocation on chromosome 1q42 (1;11) (q42,1;q14.3) that segregated in a 
large Scottish pedigree with schizophrenia, bipolar disorder and MDD (St Clair et al., 
1990; Millar et al., 2000; Blackwood et al., 2001). Linkage and association findings 
support a role of DISC1 as a common susceptibility gene, and recently high risk ultra-
rare coding variants in DISC1 were associated with schizophrenia with an estimated 
attributable risk of approximately 2% (Porteous et al., 2006; Song et al., 2008). DISC1 
encodes a protein predicted to act as a ‘hub’ protein that connects multiple proteins 
involved in a number of biological processes such as neurodevelopment, cytoskeletal 
function and cAMP signaling. Of interest, the down-regulation of Disc1 leads to 
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accelerated neural integration resulting in aberrant positioning of dentate granule cells 
during the process of adult neurogenesis (Duan et al., 2007).  Furthermore, Disc1 
missense mouse mutants exhibit behaviour that is consistent with depression-like and 
schizophrenia-like phenotypes, and show macroscopic brain abnormalities similar to 
those reported for patients with schizophrenia and to lesser extent bipolar disorder 
(Clapcote et al., 2007). 
 
Phosphodiesterase 4B (PDE4B) was identified as a breakpoint gene in two related 
individuals with psychiatric illness carrying a balanced t(1;16)(p31.2;q21) translocation 
(Millar et al., 2005). Subsequent to this finding, two studies have reported association of 
PDE4B with schizophrenia providing additional genetic support for its involvement in 
psychiatric illness (Pickard et al., 2007; Fatemi et al., 2008). PDE4B is a member of the 
PDE4 family which possesses cAMP hydrolysis activity that is specifically inhibited by 
the antidepressant drug rolipram. Moreover, members of this family are orthologous to 
the Drosophila learning and memory gene dunce, so named because mutations in the 
ortholog cause
 
learning and memory deficits. Intriguingly, PDE4B and DISC1 were 
found to be protein-binding partners that modulate cAMP signaling in subcellular 
compartments (Millar et al., 2005). Hence, functional evidence strongly points to a 
cellular signaling mechanism which when disrupted underlies psychiatric illness. 
 
Neuronal PAS domain protein 3 (NPAS3) was identified as a breakpoint gene disrupted 
in a reciprocal balanced translocation between chromosomes 9 and 14, in a Scottish 
family presenting with schizophrenia and unspecified functional psychosis co-morbid 
with learning disability (Kamnasaran et al., 2003; Pickard et al., 2005a). Single SNP and 
SNP haplotypes within NPAS3 have subsequently been associated with schizophrenia 
and bipolar disorder, and (in a second independent study) with the efficacy of the 
antipsychotic drug iloperidone (Lavedan et al., 2008; Pickard et al., 2008a). Npas3 
knockout mice manifest behavioural and neuroanatomical abnormalities reminiscent of 
schizophrenia, including a reduction of reelin expression in the adult brain and 
hippocampal neurogenesis defects (Erbel-Sieler et al., 2004; Pieper et al., 2005). 
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Glutamate receptor subunit 3 gene (GRIA3) was first identified as disrupted in a female 
with bipolar disorder and learning disability carrying a balanced translocation 
t(X;12)(q24;q15) (Gecz et al., 1999).  A second structural variation, a partial tandem 
duplication of GRIA3 was identified in an individual with autistic behaviour, learning 
disability, and severe psychomotor retardation (Chiyonobu et al., 2007). More recently, 
a single SNP and SNP haplotype within GRIA3 was found to be associated with 
schizophrenia in females (Magri et al., 2008). Furthermore, rhesus monkeys chronically 
treated with the antipsychotic drug clozapine showed a significant increase in GRIA3 
mRNA expression in the dorsolateral prefrontal cortex (O'Connor et al., 2007). GRIA3 
encodes an ionotropic glutamate AMPA subtype receptor involved in mediation of fast 
excitatory neurotransmission in the central nervous system. A gene encoding a second 
type of ionotropic glutamate receptor (GRIK4) has also been found to be broken in a 
chromosomal rearrangement carried in a patient with psychiatric illness, the details of 
which are discussed in section 1.4.3. These findings suggest that glutamatergic synapse 
function, strongly implicated as a pathogenic biological process of ASD, may also, 
through dysfunction of excitatory neurotransmission, play a role in the aetiology of 
schizophrenia and bipolar disorder. 
 
1.3   Aetiological theories of psychiatric illness 
 
1.3.1. Aberrant function of neurotransmitter systems 
 
In the last twenty years standard and atypical antipsychotic drugs have become 
conventional treatments of schizophrenia. However, not all patients respond to acute or 
prolonged treatment and only limited effects are seen in some cases, whilst adverse side 
effects are common with most antipsychotic drugs. Given the need for more effective 
psychotropic agents, along with the observations that neurochemical agonists and 
antagonists particular to a neurotransmitter system produce, exacerbate or reduce disease 
symptoms, much psychopharmacological research has focused on theories of 
dysfunction in neurotransmitter systems  (Cunningham Owens, 2004).  
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The most established neurotransmitter theory, ‘the dopamine hypothesis’, is based upon 
two early observations. First, schizophrenia-like symptoms occur in amphetamine 
abusers due to excessive dopamine release, and second, dopamine type-2 receptors (D2) 
antagonists are effective in the treatment of schizophrenia (Snyder, 1973). Hence the 
theory proposes that pathological over-activity of the dopamine neurotransmitter system 
underlies psychotic symptoms. Reports of increased D2 receptor densities and abnormal 
presynaptic DA metabolism, as shown in PET studies, lend support for the hypothesis 
(Harrison, 1999). However, it is unclear whether dopamine hyperactivity is a cause or 
consequence of disease. As the dopaminergic system reciprocally modulates activity in 
other neurotransmitter systems, in particular glutamate transmission, current views now 
emphasise that dopamine dysregulation may be secondary to glutamatergic 
abnormalities. 
 
Dysfunction within the serotonergic neurotransmission system is also postulated to 
underlie the clinical manifestations of both schizophrenia and depressive disorders. This 
theory is based upon, and consequently supported by, several lines of evidence. First, 
epidemiological and behavioural studies strongly suggest that early life stress (acting 
concurrently with genetic factors) is an environmental precipitating factor to the 
development of psychiatric disorders (Blackwood and Knight, 2007). As serotonin (5-
HT) is a neurochemical known to mediate adaptive and maladaptive responses to 
stressful events, alterations of its function could underlie pathological processes.  
Second, the hallucinogen, lysergic acid diethylamide (LSD) produces psychotomimetic 
effects similar to psychotic states and is an agonist of 5-HT2 receptors (Geyer and 
Vollenweider, 2008). Third, HT2A-receptor antagonism is known to contribute to the 
profile of ‘atypical’ antipsychotic action, and serotonin re-uptake inhibitors (SSRIs) are 
a major class of antidepressants. Finally, decreases in 5-HT1A receptor binding and brain 
5-HT2A re-uptake sites are reported in depressed patients (Fujita et al., 2000).  
 
Genetic studies have produced some evidence that variants in genes encoding proteins 
involved in serotonin-related neurotransmission are associated with bipolar disorder and 
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depression. For example, SLC6A4 a serotonin transporter gene, TPH2 a gene encoding 
for a rate-limiting enzyme for serotonin synthesis, and 5HTR1A and 5HTR2A genes 
encoding serotonin receptor subunits have shown consistent association. Furthermore, a 
functional polymorphism in the promoter region of the serotonin transporter gene 
SLC6A4 was found to moderate the influence of stressful life events on depression 
(Caspi et al., 2003).  However, although association of these genetic variants implies that 
a disturbance of serotonergic neurotransmission is a primary causal deficit, serotonin 
(like dopamine) can also modulate other neurotransmitter systems. Indeed, one 
mechanistic theory of depression is that decreased serotonin activity may ‘allow’ these 
systems to act in abnormal and erratic manner and hence “facets of depression may be 
emergent properties of this dysregulation” (Mandell and Knapp, 1979).  
 
The ‘glutamate hypothesis’ postulating hypoactive excitatory glutamatergic 
neurotransmission has recently become popular based on evidence emerging from 
pharmacological, animal, imaging and genetic studies. Initial observations indicated that 
the NMDA (N-methyl-D-aspartic acid) glutamate receptor antagonists phencyclidine 
(PCP) and ketamine cause transient psychosis resembling symptoms of schizophrenia in 
animals and healthy human volunteers. PCP has since been shown to exacerbate pre-
existing symptoms in schizophrenic patients (Javitt and Zukin, 1991; Olney and Farber, 
1995). More recently a drug, LY2140023, which is a selective agonist for metabotropic 
glutamate receptors, is reported to have effective antipsychotic properties (Patil et al., 
2007). Furthermore, post mortem studies show decreased mRNA encoding for non- 
NMDA glutamate receptor subunits, alterations in glutamate synapse-related proteins 
and  abnormalities in the cytoarchitecture of glutamatergic neurons in the prefrontal 
cortex and hippocampus of individuals with schizophrenia (Konradi and Heckers, 2003; 
Harrison and Weinberger, 2005). Likewise, abnormalities in glutamine and glutamate 
metabolism in the frontal lobe and anterior cingulate of schizophrenic patients as 
compared to controls have been indicated in several studies using imaging analysis 
(Theberge et al., 2002; Ohrmann et al., 2007). 
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In addition, linkage and association studies implicate genes which encode for proteins 
which can influence activity at glutamatergic synapses for both schizophrenia and 
bipolar disorder. Examples include, neuregulin 1 (NRG1) which has been shown to 
regulate expression of glutamate receptors, regulator of G-protein signalling 4 (RGS4) 
which inhibits signalling by the mGlu5 receptor, dysbindin (DTNBP1) located at pre- 
and post-synaptic glutamatergic sites, and G72 a protein that interacts with D-amino acid 
oxidase (DAAO) which is involved in the metabolism of D-serine, an agonist of glycine 
modulatory sites on NMDA subunits (Harrison and Weinberger, 2005).  
 
Moreover, subunits of all four major classes of ionotropic glutamate receptor (NMDA, 
AMPA, kainate and delta) as well as the metabotropic G protein-coupled glutamate 
receptors have been implicated in the genetics of schizophrenia and other psychiatric 
conditions. For example, candidate gene association studies of the NMDA receptor 
subunits GRIN1 and GRIN2B, AMPA receptor subunit GRIA1, kainate receptor 
subunits GRIK2, GRIK3, and glutamate metabotropic receptor subunits GRIM3 and 
GRIM4 report significant association of polymorphisms or haplotypes within these 
genes with psychiatric disorders (Fallin et al., 2005; Shibata et al., 2006; Lang et al., 
2007; Schiffer and Heinemann, 2007). Moreover, in addition to the cytogenetic 
abnormalities disrupting GRIA3 and GRIK4 discussed in section 1.2.3, a translocation 
breakpoint close to GRID2 t(4:20)(q22.2; p12.2) encoding an ionotropic delta subunit 
has been identified in a patient with schizophrenia (Malloy and Pickard, unpublished). 
Similarly, copy number variants have been detected in one case of schizophrenia and 
one case of bipolar disorder over the genomic region housing the kainate receptor 
subunit GRIK3 (Wilson et al., 2006). Such consistent genetic findings strongly implicate 
glutamate transmission malfunction as a causal pathological factor, the consequences of 
which would affect key development processes such as synaptic formation and 
neurogenesis; neuroplasticity mechanisms underlying cognitive processing and 
ultimately the establishment of appropriate synaptic connectivity and brain circuitry. 
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The ‘dopamine’, ‘serotonin’ and ‘glutamate’ theories of neurotransmitter system 
dysfunction, as emphasised above, are unlikely to be exclusive of one another. 
Disturbance in one system may well have a ‘downstream’ effect upon the receptor 
function, circuitry and neurotransmission in other connecting brain regions. An 
interesting and more direct link between the function of different neurotransmitter 
systems has recently been made by Gonzalez-Maeso and colleagues when investigating 
the interaction between the serotonin and metabotropic glutamate receptors (Gonzalez-
Maeso et al., 2008). This group demonstrated that 5-HT2A and mGluR2 interact 
physically and form functional complexes in brain cortex, and that a hallucinogenic drug 
influencing one receptor alters functional activity in the other. They conclude that their 
result are “consistent with the hypothesis that the 5-HT2A–mGluR2 complex integrates 
serotonin and glutamate signaling” and therefore is a functional site potentially involved 
in the altered cortical cognitive processes of schizophrenia. These findings may be the 
start of nascent research indicating that disturbances in physiological interactions 
between a variety of different transmitter receptors underlie the neuropathology of 
psychiatric phenotypes.  
 
1.3.2 Fatty acid hypothesis of schizophrenia  
 
An alternative and less ‘mainstream’ aetiological theory originated from clinical 
observations made in the 1970s of an association between fever and psychotic symptom 
remission, and of a lower rate of rheumatoid arthritis in patients with schizophrenia. This 
led to the formulation of the ‘phospholipid hypothesis of schizophrenia’ which, stated 
simply, proposes that deficits in uptake or excessive breakdown of membrane 
phospholipids are associated with, and putatively contribute to, the pathophysiology of 
schizophrenia (Feldberg, 1976; Horrobin, 1977).  
 
Evidence supporting this theory has come from both clinical and basic studies and 
centres on abnormalities in, or effects of, essential fatty acids (EFAs). The most 
consistent findings reported are depletion of EFAs in tissues of schizophrenic patients 
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(Glen et al., 1994; Yao et al., 1994; Peet et al., 1995; Doris et al., 1998; McNamara et 
al., 2007; McNamara et al., 2008); elevated serum/platelet PLA2 activity in drug-free 
schizophrenics, (Gattaz et al., 1987; Noponen et al., 1993); and reduced phospholipid 
metabolism in patients and young offspring at risk of developing schizophrenia as 
suggested by NMR spectroscopy data (Pettegrew et al., 1993; Stanley et al., 1994; Volz 
et al., 2000). Furthermore, all published studies of the effects of omega-3 fatty acid 
supplementation given to neuroleptic-treated schizophrenic patients have reported 
positive therapeutic effects, see (Fenton et al., 1999) and (Yao et al., 2000) for 
comprehensive reviews.  
 
In recent years a growing body of evidence based on imaging studies, microarray 
analysis, and metabolic and transcriptome investigation of myelin biosynthesis has 
implicated oligodendroglia pathophysiology in psychiatric disorders (Segal et al., 2007; 
Sokolov, 2007; Tkachev et al., 2007).  Consistent with these discoveries are the findings 
that membrane phospholipids and the expression of genes encoding enzymes important 
in sphingolipid metabolism are significantly altered in post mortem brain tissue from 
schizophrenic patients and upregulated in response to antidepressant drugs (Schmitt et 
al., 2004; Narayan et al., 2008). However, in addition to myelination, disruption of lipid 
membrane structures and lipid biosynthetic pathways has the potential to affect many 
important biological processes including intracellular signalling pathways and 
neurotransmitter function.  These processes will be discussed in detail in chapter four in 
relation to evidence that a candidate gene ABCA13 (encoding a putative lipid 









1.4 Introduction to projects 
 
1.4.1 Project 1: Homozygosity mapping in  a nuclear consanguineous family  
 
1.4.1.1 Homozygosity mapping in consanguineous populations  
 
Populations that are genetically isolated or have a high frequency of inbreeding tend to 
show an increased prevalence of recessive disorders. Historically, the study of inbred 
populations has been highly successful in the fine mapping of recessive traits. The effect 
of consanguinity reduces allelic and non-allelic heterogeneity and potentially increases 
linkage disequilibrium and hence the power to detect associations between genetic 
markers and disease (Sheffield et al., 1998). Likewise, mapping homozygous regions in 
affected individuals in consanguineous families is a powerful method of localising 
autosomal recessive genes. This technique, known as homozygosity or autozygosity 
mapping, assumes that affected offspring co-inherit two copies of a disease-related 
chromosomal segment from a common ancestor. Such positional cloning of recessive 
genes in families with rare genetic variants can provide valuable insight into the 
localisation and identity of genetic susceptibility factors involved in common types of 
disease with similar clinical features (Lander and Botstein, 1987). 
 
The more closely related the parents, the greater proportion of their offspring’s genome 
is expected to be homozygous. For example, offspring of first cousin marriages are 
expected to have 1/16 (6.25%) of their genome homozygous, and for second cousins the 
fraction is 1/64 (1.56%) (Wright et al., 1997; Weir et al., 2006). Formally this figure 
representing the proportion of homozygous autosomal genome is known as the 
inbreeding coefficient (F). It can be used to estimate parental relationships and 
highlights additional ancestral inbreeding loops. However, the greater the expected 
homozygosity in offspring, the greater the likelihood of identifying shared homozygous-
by-descent (HBD) intervals in affected siblings which are unrelated to the ‘disease’ 
causing locus. 
 24 
1.4.1.2 Family description  
 
The original family investigated comes from North Punjab, Pakistan - a region where 
consanguineous marriages are frequent. The parents are first cousins and there is 
additional (remote) consanguinity in the ancestral kindred.  The parents themselves have 
no detectable clinical disorders. However, five out of their six children present with 
either schizophrenia, epilepsy or sensori-neural hearing impairment or a combination of 
all three (Figure 1.1). A full clinical description of the family is presented in appendix 1. 
The unusual phenotype in several offspring of a cousin marriage is strongly suggestive 
of a rare, Mendelian recessive disorder, although other forms of inheritance can not be 
dismissed. This family therefore presents with a unique opportunity to identify one or 








Figure 1.1 Diagram of consanguineous pedigree. Open shapes represent non-affected 
individuals. Filled shapes denote siblings with schizophrenia, epilepsy and hearing impairment. 




1.4.1.3 Hereditary hearing impairment, epilepsy and schizophrenia  
 
Hereditary hearing impairment is a highly genetic heterogenous condition subdivided 
into syndromic and non-syndromic forms. 77% of non-syndromic cases show autosomal 
recessive inheritance and commonly give rise to sensori-neural defects (Petit, 1996). 
Approximately 50 loci have been linked to recessive non-syndromic hearing impairment 
NSHI, the majority of which were mapped in large consanguineous pedigrees (Van 
Camp, 2005). Mutations in over twenty genes have subsequently been identified and 
typically cause disruption of the molecular mechanisms that underlie sensory processing 
in hair cells of the cochlea (Piatto et al., 2005; Brown et al., 2008).  
 
Epilepsy can be characterized by partial or generalized seizures depending on the pattern 
and localization of ictal activity within the brain. Further sub-classification of forms into 
specific syndromes involves evaluation of age of onset, clinical and 
electroencephalographic (EEG) features. Both monogenic and polygenic inheritance 
patterns have been described, indicating variation in both genetic factors and mode of 
inheritance. Linkage mapping in pedigrees with monogenic Mendelian epilepsy has 
revealed several causative genes encoding ion channel subunits. Moreover, variants in 
two genes, a T-type calcium channel subunit and GABAA δ-receptor subunit have been 
implicated by electrophysiological studies for some forms of complex epilepsy 
[reviewed by (Mulley et al., 2005)].  
 
Investigating genetic contributions to schizophrenia is complicated by the likely 
presence of variable phenotypic presentation, incomplete penetrance and both locus and 
allelic heterogeneity. Given the uncertainties concerning the mode of inheritance of 
schizophrenia discussed earlier, the study of rare, even singular families may provide 





1.4.1.4 Results of a genome-wide scan using microsatellite markers 
 
The initial work with this family was completed as a twelve-week project contributing to 
my MSc by Research in neuroscience degree awarded 2004. A genome-wide scan using 
microsatellites revealed only one marker, D22S423, on chromosome 22q13 that was 
heterozygous in both parents and the unaffected offspring and homozygous for affected 
offspring in the first family. Fine mapping of the region by means of nineteen additional 
markers revealed two further microsatellites with the same pattern of homozygosity by 
descent (HBD) markers; D22S1178 and D22S1151, located 1.1 Mb and 3.1 Mb 
telomeric to D22S423. Construction of parental haplotypes, illustrated in Fig. 1.2, 
indicated that D22S530 and D22S276 were also homozygous for the ‘disease’ alleles in 
all affected siblings and, importantly, either heterozygous or homozygous with one 
normal derived allele in non-affected parents. Consequently, three candidate regions 
define the boundaries of a 3.3 Mb candidate disease locus (Fig. 1.2). Assuming a 
recessive mode of inheritance, a maximum LOD score of 1.8, at zero recombination 
fraction Ө was calculated for D22S423, D22S1178 and D22S1151.  
 
1.4.1.5 A second and related nuclear family presenting with deafness 
 
The second nuclear family of the same clan was identified with a high incidence of 
deafness (Figure 1.3). In this family, five of the siblings were affected with severe 







Figure 1.2 Constructed haplotypes of microsatellite markers on chromosome 22q13. The 
disease haplotype is boxed. Homozygous-by-descent conforming markers are shaded. Marker 









1.4.2 Project 2: Investigation of a complex chromosomal abnormality and identified 
breakpoint gene ABCA13 
1.4.2.1 The mapping of breakpoint regions 
 
A complex chromosomal rearrangement involving a pericentric inversion of 
chromosome 7 coupled with a translocation event between chromosome 7 and 8 was 
previously identified in a patient with severe and chronic schizophrenia, as illustrated in 
Figures 1.4 and 1.5. Family history or karyotypic information was not available and 
hence it is unknown whether this cytogenetic abnormality is de novo or inherited. BAC 
and YAC Fluorescence in situ Hybridization (FISH) analysis positioned the three 
breakpoints within the regions of 7q21.11, 7p12.3 and 8p23.2. The breakpoint on 8p23.2 
is located within a 4 Mb interval which contains a defensin gene cluster. Copy number 
variants of this cluster exist in the normal population, varying between 2 and 12 copies. 
This may explain the multiple FISH signals on the normal and derived chromosome 8 
that are evident in the patient and which complicate the fine mapping process. 7q21.11 
houses no potential candidate genes, as schematically illustrated in Figure 1.6. In 
contrast, detailed characterization of the breakpoint region on 7p12.1 found BAC, RP11-
12G8, to be broken. This BAC spans a genomic region of 180 kb and is situated in the 
middle of a large gene, ABCA13 (NM_152701, NP_689914.2) and hence indicates that 
ABCA13 is directly disrupted by the chromosomal rearrangement. Unfortunately, 
additional family data or samples are unavailable from the individual with the 
translocation. 
 
Chromosome 7p12.1, the region where ABCA13 is located, is an area as yet not linked to 
psychiatric illness. Thus, to confirm that disruption of ABCA13 is causative of disease, 
further genetic evidence of an association is needed. One method is to perform a case-
control SNP-tag association study. An alternative strategy is to screen highly conserved 
coding regions of ABCA13 for mutations in a population of unrelated karyotypically 
normal schizophrenic cases. This approach has, as an advantage, the potential to identify 
directly both rare and common causative mutations, rather than markers merely in 































Figure 1.5 schematic illustrations of the breakpoint regions on chromosomes 7p12.3, 7q21.11 

































Figure 1.6 Schematic illustration of the identified breakpoint region on chromosomes 7q21.11. 
Arrows denote the breakpoint being either downstream or upstream of FISHED cloned BACs. 

















Figure 1.7 Diagrammatic representation of ABCA13 protein structure. The highly conserved 
function domains, nucleotide binding domains 1 and 2 (NBD’s), transmembrane domain clusters 















1.4.2.2 ABC proteins and disease 
 
ABCA13 is a member of the ATP binding cassette transporter gene super-family (ABC) 
which encode ATP-hydrolysing transmembrane proteins that shuttle a variety of 
allocrites (transported molecules) across cellular membranes. ABC protein genes have 
been divided into 7 sub-families based on amino acid sequence phylogeny (designated 
A-G).  Genetic variations in genes of the ABC super-family cause or contribute to a 
variety of human disorders with Mendelian and complex inheritance. Moreover, 
variations in gene mutations in several of ABC genes lead to multiple distinct clinical 
phenotypes (Dean et al., 2001; Uitto, 2005). In mammalian cells, ABC proteins typically 
exist either as full length transporters consisting of two transmembrane cluster domains 
(TMDs) paired in tandem to two nucleotide binding domains (NBDs) [diagrammatically 
illustrated in figure 1.7], or as half transporters that contain only one TMD and NBD 
which homo - or heterodimerize with other half transporters to function. Distinctive 
features of all ABC proteins are the highly conserved Walker A and B and signature 
motifs and stacking aromatic D, H and Q loops contained within the NBDs which are 
involved in NBD-ATP or intra-NBD protein-protein interaction required for ATP 
hydrolysis (Linton and Higgins, 2007).  
 
The human ABCA subfamily is composed of 12 members, ABCA1-10, ABCA12 and 
ABCA13 subdivided into groups.  One group, ABCA5, A6, A8, A9, and A10, forms a 
gene cluster on human chromosome 17q24 and shares structural similarities not evident 
in other ABC transporters. In addition to the 12 human ABCA proteins, four additional 
proteins (ABCA14 - A17) are expressed in rodents (Chen et al., 2004). Members of the 
human ABCA sub-family are also associated with a diverse range of clinical conditions 
For example: ABCA1 causes Tangier disease and familial hypoalphalipoproteinaemia; 
ABCA1 and 2 are both associated risk factors for Alzheimer’s disease; ABCA3 causes 
respiratory distress syndrome and ABCA4 causes Stargardt disease, retinitis pigmentosa, 
cone rod dystrophy and age-related macular degeneration.  
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Furthermore, ABCA12, which shares the highest amino acid sequence similarity ( 47%) 
to ABCA13, causes two dermatological phenotypes; a severe form known as harlequin 
ichthyosis, and a milder form of the disease termed lamellar ichthyosis type 2  
(Kaminski et al., 2006).  ABCA members, so far functionally characterized, are all 
involved with lipid molecule transportation. Figure 1.8 summarizes the chromosomal, 
putative allocrite transported, function and associated disease for ABCA family 
members. 
 
The functional role of ABCA13 is, as yet, undetermined. However, the presence of a 
conserved C-terminal motif known to be shared among the lipid transporting group and 
also present in ABCA13 suggests that it too is a lipid transporter. ABCA13 is the largest 
ABC transporter gene described to date, approximately 450kb consisting 62 exons and 
encoding for a protein product composed of 5058 amino acids.  One unique feature of 
ABCA13 is an extremely long N-terminal transmembrane and cytoplasmic tail spanning 
more than 3500 amino acids. Indeed, there is some debate whether the N-terminal 
component, relating to exons 1-30, is in fact a separate protein (Prades et al., 2002; 
Albrecht and Viturro, 2007).  Moreoever, RT-PCR detected four alternatively spliced 
transcripts which would result in a loss of either the first N-terminal cytoplasmic-
transmembrane domain, or in alternative C-termini that could potentially encode 
functional transporters (Prades et al., 2002).  
 
Tissue profiling of the major ABCA13 transcripts indicated highest expression in human 
trachea, testis and bone marrow, and cell line expression studies indicate that ABCA13 is 
expressed in leukemia, prostate tumor, and CNS tumour cell lines including 
glioblastoma cells lines derived from human brain oligodendrocytes (Prades et al. 2002). 
In contrast, PCR analysis of mouse tissues detected highest expression of Abca13 in 
submaxillary gland, epididymus, ovary and thymus and lower levels in the brain, eye, 
kidney, heart, skeletal muscle, testis and mouse embryo. Furthermore, analysis of the 
putative murine Abca13 promoter region revealed potential transcription factor binding 




















1FHA, familial hypoalphalipoproteinaemia; ARMD, age-related macular degeneration, SD, stargardt’s 




Figure 1.8 ABCA subfamily members. Chromosomal location, putative function and associated 
diseases are listed. ABCA5, A6, A8, A9, and A10, forms a gene cluster on human chromosome 
17q24. ABCA3, A12, A7, A1, A4, and A2 all transport  lipid species across cellular membranes. 


















































1.4.3 Project 3: GRIK4- a candidate breakpoint gene for psychiatric illness 
 
1.4.3.1 GRIK4 disrupted in a chromosomal re-arrangement  
 
A patient with chronic schizophrenia co-morbid with mild mental retardation was 
identified by cytogenetic analysis as having a karyotype abnormality (46, XX, 
ins(8;11)(q13;q23.3q24.2) inv(2)(p12q32.1) t(2;11)(q21.3;q24.2) der(2)(2qter-
>2q32.1::2p12>2q21.3::11q24.2>11qter)der(11)(11pter>11q23.3::2q21.3>2q32.1::2p12-
>2pter) der(8)(8pter->8q13::11q23.3->11q24.2::8q13->8qter). This chromosome re-
arrangement involves a pericentric chromosome 2 inversion coupled with modified 
translocation events between chromosome 2 and 11, and 11q and 8q, illustrated in figure 
1.9. Clear family history or karyotypic information was not available and hence it is 
unknown whether this cytogenetic abnormality is de novo or inherited. The breakpoint at 
11q23.2 directly disrupts a high affinity kainate ionotropic glutamate receptor subunit 
gene, GRIK4 (NM_014619, NP_055434.2) alternative protein nomenclature KA1).  It is 
hypothesised that the breakpoint positioned between exon 2 and 3 results in the 
truncation of all putative transcripts on the derived chromosome 11, and hence 
haploinsufficiency of GRIK4 protein expression (Pickard et al., 2006).  
 
1.4.3.2 Case-control SNP-tag association and identification of 3’UTR variant 
 
A case-control association study on GRIK4 was performed to assess its contribution to 
psychiatric illness in the karyotypically normal population. Two discrete regions within 
GRIK4 were found to be strongly associated with schizophrenia and bipolar disorder 
(figure 1.10). A 3-SNP haplotype in the centre part of the gene was associated with 
susceptibility to schizophrenia (p=0.0430 s.e.0.0064; OR 1.453, 95% CI 1.182-1.787) 
and two single SNP markers positioned within the 3’ UTR region were associated with a 
protective effect against bipolar disorder (p=0.0190 s.e.0.0043; OR 0.624, 95% CI 
0.485-0.802). Subsequent screening of the 3’UTR region in bipolar protective haplotype 
homozygous carriers revealed a 14bp deletion (ss79314275) in linkage disequilibrium 















Figure 1.9 Diagrammatic illustration of a complex chromosomal re-arrangement identified as 
disrupting GRIK4. The red line denotes the approximate position of GRIK4 (11q23.3) disrupted 






Figure 1.10 Diagrammatic representation of GRIK4: showing the cytogenetic and association 
findings. Figure from Pickard et al., 2006 (Figure 4). 
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This deletion, although not in a coding region of the gene, may affect mRNA 
distribution and regulation and thus have an effect upon the physiological properties of 
kainate receptors (KARs) by perturbing receptor subunit availability. 
 
1.4.3.3 The role of kainate receptors in glutamatergic neurotransmission 
 
Kainate ionotropic glutamate receptors (KARs) subunits are divided into two classes 
based on their structural homology and affinity for [
3
H] kainate. GluR5, (GRIK1) 
GluR6, (GRIK2) GluR7, (GRIK3) are classified as ‘low affinity’ subunits while KA1 
(GRIK4) and KA2 (GRIK5) show high-affinity kainate binding. These subunits form 
transmembrane tetrameric receptor assemblies activated by glutamate and kainate, and 
are present at pre- and post-synaptic locations. However, only GluR5, GluR6 and GluR7 
can form functional homomeric and heteromeric receptors, whereas KA1 and KA2 
participate in heteromeric receptors by partnering any of the GluR5-7 subunits (Pinheiro 
and Mulle, 2006). 
 
The activity of kainate receptors and their precise subcellular localization in synaptic 
domains have been inferred mainly from electrophysiological studies. Kainate receptor 
complexes are thought to function through two forms of signalling, a canonical pathway 
involving ion influx and a noncanonical signalling pathway involving receptor coupling 
to G proteins.  Post-synaptic KARs participate directly in excitatory post-synaptic 
currents (EPSCs) by mediating part of the synaptic current charge. Pre-synaptic KARs 
are implicated in regulating transmitter release through noncanonical signalling 
pathways at both excitatory (glutamatergic) and inhibitory (GABAergic) synapses 
(Lerma, 2006). Moreover, in several populations of neurons, e.g. CA1 pyramidal cells of 
the hippocampus, post-synaptic KARs are reported not to participate directly in 
excitatory neurotransmission, suggesting that they are localised to extrasynaptic domains 
in somato-dendritic compartments (Jaskolski et al., 2005).  
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KAR mediated synaptic transmission is reported to be particularly important for mossy 
fibre long term potentiation (LTP) in the hippocampus and long term depression (LTD) 
in the perirhinal cortex.  In addition, KAR complexes have been implicated to play a role 
in axon navigation and synapse formation during development (Lerma, 2006; Park et al., 
2006). Hence it has become clear that KARs are involved in short term synaptic 
plasticity mechanisms, synaptic integration and long-term modulation of 
neurotransmission, the disruption of which would have profound effects upon 
information processing by neural networks during development and in adulthood.  
 
1.4.3.4 Alterations of kainate receptor subunit expression 
 
Over the last two decades evidence has emerged suggesting down-regulation of kainate 
receptor function in severe psychiatric disorders.  Post mortem studies of mRNA 
transcripts and protein immunoreactivity have consistently reported reduced expression 
of kainate receptor subunits in post mortem brain of patients with schizophrenia or 
bipolar disorder compared to matched controls. The key regions studied, and indeed 
implicated to be of functional relevance to psychiatric illness, are the medial temporal 
lobe, thalamus, anterior cingulate cortex and frontal cortex.  
 
The medial temporal lobe includes a system of anatomically related structures that are 
essential for the integrative processing of cognitive and emotional information and the 
encoding and retrieval of declarative memory. This system consists of the hippocampal 
region (CA subfields, dentate gyrus (DG), and subicular complex) and adjacent, 
anatomically related parahippocampal cortex, which includes the entorhinal and 
perirhinal cortices (Squire and Zola-Morgan, 1991).  Kerwin and colleagues, using the 
technique of quantitative autoradiography, first reported a reduction of kainate subtype 
binding in mossy fibre CA3/4 zone in the left hippocampus, and bilateral losses in 
dentate gyrus and parahippocampal regions in tissue from schizophrenic individuals  
(Kerwin et al., 1990). Subsequent findings suggest that specific subunits are decreased in 
subregions of the hippocampus and parahippocampus. For example, decreases in KA2 
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GluR5, GluR6 mRNA and Glur5, Glur6, and Glur7 protein immunoreactivity in the 
hippocampus were found in patients with schizophrenia (Porter et al., 1997; Benes et al., 
2001; Scarr et al., 2005). Similarly, a reduction in GluR6 mRNA in the entorhinal cortex 
and Glur5 mRNA in the perirhinal cortex has been associated with schizophrenia and 
with schizophrenia, bipolar disorder and MDD respectively (Beneyto et al., 2007).  
 
The thalamus is a structure involved in the modulation, integration and relaying of 
sensory information from the periphery to the cerebral hemispheres (Kandel et al., 
2000). Two studies have investigated kainate receptor subunit levels in the thalamus 
from cases and controls, one reporting positive and the other negative results. Ibrahim 
and co-workers found significantly lower levels of
 
KA2 mRNA within thalamic nuclei 
in
 
schizophrenic patients than in comparison subjects. However, they also reported no
 
significant differences in GluR5, GluR6, GluR7, and KA1 mRNA
 
expression or in 
[3H]kainate binding levels (Ibrahim et al., 2000). In contrast, Dracheva et al. report no 
evidence of altered KA2 and GluR5-6 mRNA levels in thalamic tissue from 
schizophrenic patients (Dracheva et al., 2008).   
 
The anterior cingulate cortex specializes in the processing of emotional stimuli, 
expression of emotional behaviour, mood regulation, organization of higher cognitive 
functions and autonomic response to emotional states (Devinsky et al., 1995). Woo and 
colleagues examined kainate receptor subunits mRNA co-localizing with GAD67 
mRNA, i.e. in GABAergic expressing interneurons, in anterior cingulate cortex tissue 
from control, schizophrenic and bipolar disorder individuals. They found reduced levels 
of GAD67 co-expressed GluR5 mRNA in layer 2 of the cortex for schizophrenia and 
bipolar disorder, but no difference between the groups for GluR6 mRNA (Woo et al., 
2004). 
 
Finally, the frontal cortex, important for higher executive functions, has been 
investigated by several groups all of whom report positive results. Meador-Woodruff et 
al. reported a shift in subunit stoichiometry, with increased expression of GluR7 mRNA 
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and decreased KA2 mRNA associated with schizophrenia (Meador-Woodruff et al., 
2001). In contrast, decreases in GluR7 and KA1 mRNA in the left superior gyrus of 
neuroleptic-free schizophrenic individuals were found by Sokolov (Sokolov, 1998). A 
third study, by Garey and co-workers, found a significant reduction in numerical density 
of neurons immunopositive to GluR6 and GluR7 in the orbitofrontal cortex of chronic 
schizophrenics (Garey et al., 2006) These findings, taken collectively, strongly suggest 
that decreases in kainate receptor subunits in specific brain regions are associated with 
psychiatric phenotypes.  
 
1.4.3.5 KA1 expression    
 
Electrophysiological data indicates that kainate receptors are widely expressed 
throughout the mammalian nervous system. Although the KA2 subunit is reported to be 
ubiquitously expressed, animal studies suggest that KA1 expression is more specific to 
given brain regions and cell types (Porter et al., 1997). Table 1 summarizes the findings 
of expression studies of KA1 mRNA transcripts or protein immunoreactivity performed 
on brain tissue from rodent and human hippocampus, frontal cortex and cerebellum.  Of 




(Represa et al., 1987) 
(Wisden and Seeburg, 1993) 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This thesis outlines the genetic and biological investigation of candidate genomic 
regions and genes implicated in psychiatric illness and co-morbid conditions. The aims 
of the three independent studies presented in this thesis are described below. 
 
Project 1    Homozygosity mapping in two consanguineous families 
 
1. Chapter 3:  To perform high density positional cloning in a consanguineous 
family with schizophrenia and co-morbid conditions and concurrently assess the 
extent of homozygosity in terms of degree of inbreeding.  
2. Chapter 3:  To screen candidate genes for potential causative mutations in HBD 
regions identified.  
3. Chapter 3:  To analyze homozyosity in a second (related) family presenting with 
deafness to establish if there is any overlap in HBD regions in all affected 
individuals from both families. 
 
 
Project 2    Investigation of a complex chromosomal abnormality and the 
identified break-point gene ABCA13 
 
1. Chapter 4: To fine map the exact breakpoint positions of a complex 
chromosomal re-arrangement. 
2. Chapter 4: Gather further evidence that disruption of ABCA13 is putatively 
causative of psychiatric illness by screening highly conserved coding regions of 
ABCA13 for rare risk variants. 
3. Chapter 4:  Analyze known SNPs and newly identified variants to assess 
potential differences in frequency between cases and controls. 
4. Chapter 5:  Determine ABCA13 transcript expression in different cell lines, blood 
and lymphoblastoid cells and expression of ABCA13 protein in human brain. 
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Project 3   GRIK4- a candidate breakpoint gene for psychiatric illness  
 
1. Chapter 6:  Further investigate an association between a variant in the 3’UTR of 
GRIK4 and bipolar disorder. 
2. Chapter 7:  Characterise the expression of KA1 in human brain tissue. 
3. Chapter 8: Investigate the potential consequence of the 3’UTR variant upon 
GRIK4 protein distribution and abundance in human brain by means of a 



















































2. Materials and Methods 
 
2.1 Clinical samples 
 
2.1.1 Case Samples 
 
Subjects were Caucasian individuals contacted through inpatient or outpatient services 
of hospitals in southeast and central Scotland, and Grampian. Samples from southeast 
and central regions, Fife, Borders and Lanarkshire were collected by Douglas 
Blackwood, Walter Muir and Donald McIntyre and other clinical colleagues. Samples 
from Grampian and other parts of Scotland were obtained by David St Clair. Samples 
were collected over a period of more than 15 years. Diagnoses were made according to 
DSM-IV criteria of the American Psychiatric Association (Diagnostic and Statistical 
Manual of Mental Disorders, third edition. Washington DC, (American Psychiatric 
Association, 2004) Phenotyping methods for all patients was through personal interview 
using the ‘Schedule for Affective Disorders and Schizophrenia-Lifetime’ version 
(SADS-L) (Endicott and Spitzer, 1978), supplemented by hospital case notes and 
information provided by medical staff and relations of cases. Diagnosis was reached by 
consensus between two experienced psychiatrists. Patients gave written informed 
consent for the collection of DNA samples for use of genetic studies and studies were 
approved by the Multicentre Research Ethics Committee for Scotland and by local ethics 
committees. 
 
Exclusion criteria for schizophrenia were history of severe head injury, epilepsy, drug or 
alcohol use considered the major cause of psychosis. There was no pre-selection of cases 
based on family history of other phenotypic variables. These patients are a representative 
sample of the total population of patients with a diagnosis of schizophrenia attending 
psychiatric services in south Scotland. For bipolars all the above also applied but the 
inclusion criteria were diagnosis of bipolar 1, bipolar 2 and schizoaffective disorder 
(manic). For MDD inclusion was diagnosis of recurrent major depression. Single cases 
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and minor depression were excluded. Also excluded were patients with depression and a 
first degree relative with Scz or BP. A large cohort was recruited from an affective 
disorders treatment service where most referrals are aged under 25 years so there is a 
bias in the cohort towards early onset recurrent depression. Recruitment was of 





The control population was obtained from several sources. One group of controls were 
recruited through the South of Scotland Blood Transfusion Service and the Grampian 
Blood Transfusion service. Blood donor controls were not screened to exclude 
individuals with a personal or family history of a major psychiatric illness. However, 
blood donors are not accepted if they self reported that they are currently on medication 
or have a history of a chronic illness. A second group of controls were recruited at the 
Edinburgh University Student Health Service. These students were taking part in a study 
of glandular fever epidemiology and again were not screened for personal or family 
history of mental illness. A third group of controls were recruited from hospital staff and 
social networks of the research team.  
 
2.1.3 Lothian Birth Cohort control samples 
 
A fourth group of controls were from the 1936 Lothian Birth Cohort (LBC 1936). 
Subjects of the 1936 Lothian Birth Cohort were recruited for a recent study intended to 
examine influences on cognitive aging between childhood and old age (Deary et al., 
2007). The participants comprised surviving members of the Scottish Mental Survey of 
1947. They underwent medical, cognitive and physical assessment in addition to giving 
blood and filling in personality, quality of life and other psycho-social questionnaires, 
full details of which are reported by (Deary et al., 2007). These individuals were not 
screened for psychiatric illness and no information regarding family history of 
psychiatric illness was obtained. Ethics permission for the original study protocol, which 
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included the examination of candidate ‘cognition’ genes, was obtained from the Multi-
centre Research Ethics Committee for Scotland. 
 
2.1.4 Pakistan families 
 
Recruitment and clinical information pertaining to the two consanguineous families 
from Pakistan was obtained by Muhammad Ayub, an experienced psychiatrist assisted 
by Muhammad Irfan and Farooq Naeem. Fully informed written consent was attained 
from each member of the families. The study was approved by the appropriate UK and 
Pakistani ethics of research committees.  
 
2.1.5 Brain tissue samples 
 
Brain tissue sections used for the genotype/expression correlation study were from 
individuals asymptomatic for psychiatric illness as ascertained by a psychiatrist, Dr 
Douglas Blackwood. 12 genotyped samples were matched for age, gender and cause of 
death by Dr Robert Walker of Edinburgh University MRC Sudden Death Brain and 
Tissue Bank. Paraffin embedded postmortem human coronal sections of the 
hippocampus and parietal frontal cortex were received coded and the study performed 
blinded. The MRC Sudden Death Brain Bank is fully described by (Millar et al., 2007). 
 
 
2.2  Materials 
 
2.2.1 Chemicals and biological products 
 
All general use chemicals, reagents and biological products were from Sigma-Aldrich or 
Invitrogen unless otherwise stated below. Chemical and biological products, kits and 
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Table 2.1 Chemical and biological products used for molecular biological techniques. 
 
























































































PCR product purification 
 




PCR product cloning 
 














RNeasy Mini kit 
 
Qiagen 
   
 
Table 2.2 Kits used for molecular biological techniques. 
 
2.2.3 Solutions, buffers and gel loading dyes 
 
Ampicillin stock solution (10mg/ml) 
Ampicillin sodium salt 
Qs (quantity sufficient) 50ml dsH2O 





Blocking buffer (FISH) 
Marvel skimmed milk                                      
20x SSC 







Blocking buffer (immunoblotting) 
Marvel                                        
PBS                                           








20% Goat serum                                     







0.01M Citric Acid  pH 6.0 
Citric Acid   
Qs1L dsH2O 




Coomassie Brilliant Blue protein stain 
Coomassie stain 
Methanol: Water (1:1 v/v) 






















make fresh and add a few drops of HCL to bring pH to 7.0, 















EDTA solution 0.5M  pH 8.0 
Disodium ethylenediaminetetra acetate 
dsH2O 







30ml ethanol (99.7-100% v/v) to every 100ml dsH2O 
 
70% Ethanol 
70ml ethanol  (99.7-100% v/v) to every 100ml dsH2O  
 
90% Ethanol 
70ml ethanol  (99.7-100% v/v) to every 100ml dsH2O  
 










Hybridisation mix buffer (FISH) 
Deionised formamide  
Dextran Sulphate 50% 
20X SSC.  
Tween 20 








3% Hydrogen Peroxide in Methanol 
30% hydrogen peroxide 
Methanol 






IPTG stock solution (100mM) 
Isopropyl β-D-thiogalactopyranoside 
Qs 10ml dsH2O 





Luria-Bertani broth (LB)  
1% (w:v) Bacto-Tryptone (Difco) 
0.5% (w:v) Bacto-Yeast extrct (Difco) 
0.1% (w:v) NaCl 










Lithium carbonate 0.07M 
Lithium carbonate 





10xNick Translation buffer 
Tris HCl  pH7.5 
MgCl2  
β-mercaptoethanol 








Mounting mix medium (FISH)  
Vectashield 











































Laemmli protein sample buffer (2x) 
Tris (hydroxymethyl)-methylamine (0.5M, pH6.8) 
Glycerol 
SDS (20% solution) 
Bromophenol Blue 
























sodium deoxycholate (10% solution) 
sodium deoxycholate (20% solution) 
1mM EGTA (100mM solution) 












Running Buffer (for Tris-acetate gels) 
































20x SSC solution 
NaCl  
Sodium citrate 















TE pH 8.0 
10mM Tris Cl  pH 7.4 
1mM EDTA     pH 8.0 
 
 
Transfer Buffer  









0.05 Tris-HCL  pH 6.7 
Trizma hydrochloride  
















X-gal stock solution 
5-bromo-4chloro-3-indolyl β-D-galactopyranoside 
dimethylformamide 








2.2.4 Antibodies and pre-immune serum 
 
Non-commercial polyclonal antibodies and pre-immune serum were obtained from 
AFFINITI Research Products Limited and EUROGENTEC, and used at dilutions stated 
in table 2.3. Pre-immune serum was taken prior to immunization. Antibody ABCA13 
870 was raised in rabbit against a peptide from the C-terminus of human ABCA13 (aa 
PQHIKNRFGDGYTVKC), and antibody GRIK4 272 was raised in rabbit against a 
peptide from the C-terminus of human (aa CRSEESLEWEKTTNSSEPE). All antibodies 
were immunoaffinity purified by coupling the immunizing peptide to the appropriate 
sepharose column. The peptide relating to the ABCA13 protein sequence that was used 
to raise the 870 antibody and subsequently used for a peptide blocking assay, was 
manufactured and purified by Invitrogen.  
 











































Abcam plc.  
 
















*Pre-immune serum seq 1 denotes from an animal subsequently injected with ABCA13 PQHIKNRFGDGYTVKC 
 
 





2.2.5 Primers and Microsatellite markers 
 
Genomic sequence information for the genes ABCA13, KCNF1, ATF4, GPR24 
CACNG2, GAPDH and G6PD were obtained from the University College Santa Cruz 
(UCSC) [NCBI Build 35 and 36.1] genome browser. Oligonucleotide primers were 
designed using PRIMER3 [http://workbench.sdsc.edu] (Rozen and Skaletsky, 2000). 
Primers were designed from repeat and SNP-free regions of sequence. Due to a high 
number of repetitive sequences and/or pseudogenes, separate amplification primers and 
sequence primers were utilised when sequencing ATF4 and KCNF1. Specificity of all 
primers was checked by Blast and BLAT analysis 
http://www.ncbi.nlm.nih.gov/Blast.cgi, http://genome.ucsc.edu/cgi-bin/hgBlat. Primer 
sequences and amplification conditions are listed in Table 2.4. PCR Primers were re-
suspended at a concentration of µg/µl in primer mix and stored at -20° C. 
 
Microsatellite markers used for chromosome 7 genotyping were a component of a 
linkage set, ABIPRISM
®
 linkage mapping set, MD10 version 2 (PE Biosystems). These 
were: DS7517, D7S531, D7S493, D7S516, D7S484, D7S519, D7S669, D7S630, 
D7S657, D7S515, D7S846, D7S530, D7S640, D7S684, D7S661, D7S636, and D7S798. 
 
Table 2.4 Primers used for DNA PCR amplification and sequencing 
   
Gene /Exon Primers 5’- 3’ Cycling conditions 
   
ABCA13 Exon 32   95°C 120s 
F CTC CTT CAT GGG TTC CTT CA   95°C 30s, 55°C 30s, 68° 55s   x35  
R TTC TTG CAA TCT CAT GTG GC   68°C 10min, 8° 20 min  
   
ABCA13 Exon 33   95°C 120s 
F CTG AAT TTG CAA GCA AGC AG   95°C 30s, 55°C 30s, 68° 55s   x35  
R AAG CAG ATA TCA GAA AGC CCA   68°C 10min, 8° 20 min  
   
ABCA13 Exon 34   95°C 120s 
F TGA CAC TTC AAG CAT CTC GG   95°C 30s, 55°C 30s, 68° 55s   x35  
R CCA GAC GTC AAG GGT GGT AT   68°C 10min, 8° 20 min  
   
ABCA13 Exon 35   95°C 120s 
F  TGG CCA GTG ATA TTG ACC TTC   95°C 30s, 55°C 30s, 68° 55s   x35  
R  CAC TTG GGA AAC AAA GGC AT   68°C 10min, 8° 20 min  
   
   95°C 120s 
 55 
ABCA13 Exon 37 
F TTGATTTGTGTGCTTCACAGAG   94°C 30s, 54°C 30s,72°C 1min  x32  
R GCCTTTCACCCGTGTCTCTA   72°C 10min  
   
ABCA13 Exon 38   95°C 120s 
F AACCAGGTCAGCAGAAGGTG   94°C 30s, 54°C 30s,72°C 1min  x32  
R AATTCAATGCCTTCCCACAG   72°C 10min  
   
ABCA13 Exon 39   95°C 120s 
F TCACGTGTGTGTAGCATCCA   94°C 30s, 54°C 30s,72°C 1min  x32  
R AAAGGTCAAACACAAAGTAAGCAA   72°C 10min  
   
ABCA13 Exon 40   95°C 120s 
F CCAGGACGCATTTCAATTTT   94°C 30s, 54°C 30s,72°C 1min  x32  
R ACAGAAGGCCTCCACTGAGA   72°C 10min  
   
ABCA13 Exon 43   95°C 120s 
F TAA AGG GGA CAC TCA AGG GA   95°C 30s, 55°C 30s, 68° 55s   x35  
R AGA CAG CCT GAG AGG AGC AA   68°C 10min, 8° 20 min  
   
ABCA13 Exon 50   95°C 120s 
F TTG TGT TCT TCG TCA GGT GC   95°C 30s, 55°C 30s, 68° 55s   x35  
R AGA TGA CCC CTT TTT GTG GA   68°C 10min, 8° 20 min  
   
ABCA13 Exon 51   95°C 120s 
F TCC ACG GCT ACA GAA CTC CT   95°C 30s, 55°C 30s, 68° 55s   x35  
R GTC CCT TGC AGA AGC AAC AT   68°C 10min, 8° 20 min  
   
ABCA13 Exon 52   95°C 120s 
F TGC ATT TTC AGG GAT TCA CC   95°C 30s, 55°C 30s, 68° 55s   x35  
R TCG TCA ATT GTT GCT AAG CC   68°C 10min, 8° 20 min  
   
ABCA13 Exon 53   95°C 120s 
F GGG AAG ACC TGG AAC ACA GA   94°C 30s, 54°C 30s,72°C 1min  x32  
R GGG TGA CTG ACA CCA ATC AA   72°C 10min  
   
ABCA13 Exon 54   95°C 120s 
F AAAGCTGACTGCCCAGAAGT   94°C 30s, 54°C 30s,72°C 1min  x32  
R TGAAGGCTATTTTTGGCTCTG   72°C 10min  
   
ABCA13 Exon 55   95°C 120s 
F CAAACCAGCAAAGTCAACTCA   94°C 30s, 54°C 30s,72°C 1min  x32  
R TTTTCCCCACATCAGAGGAG   72°C 10min  
   
ABCA13 Exon 56   95°C 120s 
F AAACTGCAGTGGACTTGTTATTGA   94°C 30s, 54°C 30s,72°C 1min  x32  
R CATATTAGAAAATCTCTTGCAGGTAA   72°C 10min  
   
ABCA13 Exon 57   95°C 120s 
F CTCCAGCTGCAGAAAACTCC   94°C 30s, 54°C 30s,72°C 1min  x32  
R ATGCTGGCTTATGGCAAAAC   72°C 10min  
   
ABCA13 Exon 58   95°C 120s 
F TGGCTTTGTTGAGCAGAGTG   94°C 30s, 54°C 30s,72°C 1min  x32  
R TCCCTCAGGAAGACCTGAAA   72°C 10min  
   
ABCA13 Exon 59   95°C 120s 
F CTCCAGCTGCAGAAAACTCC   94°C 30s, 54°C 30s,72°C 1min  x32  
R ATGCTGGCTTATGGCAAAAC   72°C 10min  
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ATF4 Amp 1   ELRK  95°C 120s 
F GCCCTGAGCCAATAAGAGC   94°C 60s, 56°C 30s,72°C 2min  x32  
R GGGGCCAAGTGAGTCAGATA   72°C 15min  
   
ATF4 Amp 2   ELRK  95°C 120s 
F TAGGGGCCTCCTACCTTTGT   94°C 60s, 56°C 30s,72°C 2min  x32  
R GATCTTCAGCCTTGGACTGC   72°C 15min  
   
ATF4 Seq 5'UTR   96°C 60s 
F ATCTAGGGCCCTGAGCCAAT   96°C 10s, 50°C 5s, 60°C 4min  x25 
R AAAACTACATCTGTGGGCGG   4°C 10min  
   
ATF4 Seq Exon1 
(1)   
 96°C 60s 
F CGTCCCCATAGAGACGAAGT   96°C 10s, 50°C 5s, 60°C 4min  x25 
R ATCTTGGTTCCTGCCACGTT   4°C 10min  
   
ATF4 Seq Exon1 
(2 )  
 96°C 60s 
F CTTCCCCAGGAGCCCTAC   96°C 10s, 50°C 5s, 60°C 4min  x25 
R TAGATCCCACCAGGACGATG   4°C 10min  
   
ATF4 Seq Exon 2 
1  
  96°C 60s 
F AGGGGCCTCCTACCTTTGTA   96°C 10s, 50°C 5s, 60°C 4min  x25 
R GAGAACACCTGGAGATGGGA   4°C 10min  
   
ATF4 Seq 3'UTR    96°C 60s 
F AAGGAGGAAGACACCCCTTC   96°C 10s, 50°C 5s, 60°C 4min  x25 
R GTTAAGACCAGCTTGGGGTG   4°C 10min  
   
CACNG2 5'   95°C 120s 
F AAGACCGAAGGTTGCATCTC   94°C 30s, 54°C 30s,72°C 1min  x32  
R TCCCACAGCTATGGTCATCA   72°C 10min  
   
CACNG2 Exon 1 TTCTGATCTCAAAAGGCAAGC  95°C 120s 
F GAGGATGTTTGAGGGGATGA   94°C 30s, 54°C 30s,72°C 1min  x32  
R    72°C 10min  
   
CACNG2 Exon 2   95°C 120s 
F GAAGGCAGCGTTTTGAAGTC   94°C 30s, 54°C 30s,72°C 1min  x32  
R GAGACCTGGAGGTCGACTGA   72°C 10min  
   
CACNG2 Exon 3   95°C 120s 
F CTGACGGTGTGCTGGAGTT   94°C 30s, 54°C 30s,72°C 1min  x32  
R GTTGCTACAGGACAGGAGCC   72°C 10min  
   
CACNG2 Exon 4   95°C 120s 
F ATGTCCATCTACACCGCCC   94°C 30s, 54°C 30s,72°C 1min  x32  
R TTTGCTTTTGGAAGGTCTCC   72°C 10min  
   
CACNG2 3'   95°C 120s 
F ACCACCCCCGTATAAAGACC   94°C 30s, 54°C 30s,72°C 1min  x32  
R GGGGGTTAAAGGGAACAGAA   72°C 10min  
   
KCNF1 Amp 1   ELRK  95°C 120s 
F GTGCCTTGCAGAATTTCACC   94°C 30s, 54°C 30s,72°C 2 min  x32  
R TACTCCAGGGTGAACCAGC   72°C 10min  
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KCNF1 Amp 2   ELRK  95°C 120s 
F GTGCTCTCCTTCCTGCTCAT   94°C 30s, 54°C 30s,72°C 2 min  x32  
R GTGCCTGAGCTACTCTTGGG   72°C 10min  
   
KCNF1 Seq 1    96°C 60s 
F GCCTTGCAGAATTTCACCAG   96°C 10s, 50°C 5s, 60°C 4min  x25 
R CCCCACGTTGACGACTATCT   4°C 10min  
   
KCNF1 Seq 2  AGATAGTCGTCAACGTGGGG  96°C 60s 
F AGGGTGAACCAGCCAATG   96°C 10s, 50°C 5s, 60°C 4min  x25 
R    4°C 10min  
   
KCNF1 Seq 2    96°C 60s 
F CTTCCTGCTCATCCTCGTCT   96°C 10s, 50°C 5s, 60°C 4min  x25 
R ACGCGCTGCTTGTTGTAGTA   4°C 10min  
   
KCNF1 Seq 3    96°C 60s 
F TACTACAACAAGCAGCGCGT   96°C 10s, 50°C 5s, 60°C 4min  x25 
R AACCTACAACACGGAGGGTG   4°C 10min  
   
Cloning T7    96°C 60s 
F GTAATACGACTCACTATAG   96°C 10s, 50°C 5s, 60°C 4min  x25 
    4°C 10min  
   
RT-PCR primer 1  ELRK  95°C 120s 
F TGGAGAAATACCTGGGAGGA   94°C 60s, 56°C 30s, 72°C 180s  x32  
R ATGATGGGATTCCCTGATGA   72°C 15min  
   
RT-PCR primer 2  ELRK  95°C 120s 
F AGCAAATGGCTTGCTCAACT   94°C 60s, 56°C 30s, 72°C 180s  x32  
R TCTGGAAAAGGCTGGACATT   72°C 15min  
   
RT-PCR primer3  ELRK  95°C 120s 
F GGATTCTCCATCCTGTCTGC   94°C 60s, 56°C 30s, 72°C 180s  x32  
R GGAATCAATGCCGAAGTTGT   72°C 15min  
   
RT-PCR primer 4  ELRK  95°C 120s 
F CTGGATGAGAACCTGCATCA   94°C 60s, 56°C 30s, 72°C 180s  x32  
R TGGGTGAGAAAAGGGATCTG   72°C 15min  
   
RT-PCR primer 5  ELRK  95°C 120s 
F GTCTCCATTTCCCTGGAGGT   94°C 60s, 56°C 30s, 72°C 180s  x32  
R ACGAAGAGGACTGGCAGCA   72°C 15min  
   
GAPDH  ELRK  95°C 120s 
F CAATGACCCCTTCATTGACC   94°C 60s, 56°C 30s, 72°C 180s  x32  
R TGAGCTTGACAAAGTGGTCG   72°C 15min  
   
G6PD  ELRK  95°C 120s 
F CAACCACATCTCCTCCGTG   94°C 60s, 56°C 30s, 72°C 180s  x32  
R ATCTTGGTGTACAGGGCCTC   72°C 15min  
   
GRIK4 3'UTR  ELRK  95°C 2 mins 
F FAM GTGGGAGAAAACCACCAACA   94°C 45s, 57°C 60s,72°C 45s  x7 
R GGGGGAAATTCAACTGATGAT   94°C 45s, 56°C 60s,72°C 45s  x7 
    94°C 45s, 55°C 60s,72°C 45s  x26 
    72°C 15min  
* ELRK denotes Expand long-range kit was used (Roche) 
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2.2.6 BAC and fosmid clones 
 
Bacterial BAC and fosmid clones were obtained from Human TilePath BAC and fosmid 
set, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, 
Cambridgeshire, CB10 1SA, UK. Clones used are listed in table 2.5 
 
 
Table 2.5 BAC and Fosmid clones used for cytogenetic analysis 
 
 





































































































































































































Genomic DNA was extracted from venous blood using standard methods by either 
former members of the Medical Genetics Section, MMC, Western General Hospital 
(WGH) or more recently the genetics core, Wellcome Trust Clinical Research Facility 
(CRF), WGH. DNA concentration quantification and quality control checks were 
performed previous to my receiving the samples. Samples used for TaqMan assays and 
GRIK4 genotyping were already plated at working stock concentrations of 10ng/ul, and 
stored at the CRF.  
 
2.2.8   Cell lines, Lymphocytes, RNA Blood and mouse brain homogenate 
 
In house cell lines LAN5, SH-SY5Y (human neuroblastoma derived), U373, MOG 
(human glioblastoma derived) and HEK293 (embryonic human kidney) were cultured 
using standard laboratory practice, and the pellets gifted to my studies by Ben Pickard 
and Lorna Maclaren.  RNA from lymphocyte and total blood was provided by Pat 
Malloy. Mouse brain homogenate was donated by Shaun Mackie. 
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2.2.9 Human brain tissue 
 
Hippocampus and frontal cortex human brain tissue and Paraffin embedded post-mortem 
Human brain sections were donated by the Edinburgh University MRC Sudden Death 
Brain Bank (http://www.edinburghbrainbanks.ed.ac.uk/). Histology was performed on 
coronal sections of the hippocampus, amygdala, cerebellum and transverse sections 
through the rostral medulla oblongata at the level of the inferior olivary nucleus. Coronal 
sections from the frontal cortex were taken in a parasagittal plane.  
 
2.3 General Methods 
 
Molecular biology techniques were developed from (Sambrook et al., 1989), unless 
otherwise stated. 
 
2.3.1. Molecular cytogenetics: Fluorescence in situ hybridization (FISH)  
 
Fluorescence in situ hybridization (FISH) is a technique that is used to detect 
chromosomal deletions, translocations and copy number variants by hybridizing 
fluorescently labeled DNA probes to metaphase arrested chromosomes (Trask, 1991). 
This method involves several steps; namely: a mini-prep to isolate bacterial DNA; nick 
translation to tag the DNA with chemically modified deoxynucleotide triphosphates 
(dNTPs); preparation of metaphase chromosomes from lymphocytes and dropping onto 
microscope slides; hybridization of the tagged probes to the chromosomal DNA on the 
slides; and probe detection through fluorescein-labeled conjugated antibodies or 
enzymes. Each step will be described below.  
 
2.3.1.1. Miniprep preparation of Bacterial DNA 
 
A single bacterial colony was used to inoculate 5ml of LB-Broth with the appropriate 
antibiotic added. The cultures was grown overnight at 37°C in a shaker incubator. 2ml of 
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bacterial culture was centrifuged for 5 minutes at 3000rpm. DNA was isolated from the 
pellets using the Qiagen plasmid mini kit. In brief, the pellet was resuspended in 0.3ml 
of P1 solution before adding 0.3ml P2 and incubated for 5 minutes at room temperature. 
Next, 0.3ml of P3 was added and the lysate incubated for 10 minutes on ice before 
centrifugation at 13000rpm for 10 minutes. 
 
 The supernatant was transferred to a new micro-tube, 0.8ml of isopropanol added and 
left on ice for 15 minutes followed by centrifugation at 13000rpm for 15 minutes. The 
supernatant was subsequently removed and 0.5ml of 70% alcohol added to wash the 
pellets before centrifugation at 13000rpm for 5 minutes. The supernatant was again 
removed and the pellets air dried at room temperature. Once the DNA pellets had 
become translucent they were re-suspended in 40µl TE (pH 8.0) and left to sit for one 
hour at room temperature before storage at -20°C. The quality of the DNA was 
determined by agarose gel electrophoresis (section 2.3.2.2).  
 
2.3.1.2. Nick Translation 
 
Nick translation is a procedure used to label bacterial DNA with chemical modified 
nucleotides before the ‘tagged’ probe is hybridized to metaphase chromosomes. The 
method used was as follows. To make a total volume of 20µl of reaction mix, 0.5mM of 
dCTP, dGTP & dATPs; 2.5µl of undiluted biotin-16-dUTP or digoxigenin-11-dUTP; 2µl 
nick translation buffer; 1µl DNA polymerase; 1µl DNase (working solution diluted 
1:600) and 6µl bacterial DNA was added to an micro-tube and incubated for 1.5-2hrs at 
16°C. To separate nick translated DNA from unincorporated nucleotides, 100µl of 
labeled DNA solution is run through nick columns and centrifuged for 4 minutes at 
1800rpm.  
 
2.3.1.3. Preparation of metaphase arrested chromosomes  
 
Metaphase-arrested chromosomes and interphase nuclei for cytogenetic analysis were 
prepared by Pat Malloy. In order to generate metaphase-arrested chromosomes for 
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cytogenetic analysis, 0.8mls of patient blood were cultured for 71hrs in medium 
containing phytohaemagglutinin (Peripheral Blood Medium, Sigma). The short-term 
cultures were treated with colcemid for one hour, followed by a conventional fixing 
procedure. Fixed chromosomes were dropped onto microscope slides and stored for one 




Prior to hybridization, the labeled probes were precipitated and re-suspended to produce 
a more concentrated solution whilst simultaneously Cot-1 and salmon sperm (which act 
a competitive DNA by binding to repetitive sequences within the probes) are added to 
decrease background signal. Quantities used: 15µl Bac DNA or 20µl fosmid DNA; 0.5µl 
salmon sperm (10mg/ml); 8µl and 5µl cot1 for Bac or fosmids respectively; precipitated 
in 2 times total volume of absolute alcohol and dried under vacuum in a rotational-
vacuum-concentrator RVC2-18 (Christ freeze Dryers) for 30 minutes.  Pellets were then 
reconstituted by adding 10µl hybridization mix buffer and left at room temperature for 
an hour. The probes were subsequently denatured by being heated to 70°C in a water 
bath and then transferred to a second water bath set at 37°C for 15 minutes.  
 
Simultaneously to this process, the metaphase-arrested chromosome slides were 
prepared for hybridization. This involved: RNaseA treatment in 200ml of 2xSSC & 2ml 
of 10mg/ml RNaseA at 37°C for 30 minutes, followed by a wash in 200ml 2xSSC and 
dehydration through 70% 90% and 100% ethanol (2 minutes each) and air dried. The 
slides were then pre-warmed by placing them in an oven set at 70°C for 5 minutes; 
denatured in 70°C denaturing solution for 2-3 minutes; quenched in ice cold 70%  
ethanol proceeded by dehydration in the ethanol series (2 minutes each), air dried and 
warmed on a metal tray in a water bath set at 37°C. 10µl of labeled probe was then 
dispensed onto each slide, the slides covered with a 22x32mm coverslips and left 
overnight at 37°C. 
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After incubation overnight, the slides were washed in 50% formamide at 45°C for 2x 7 
minutes. This was proceeded by further washes in 0.1x SSC at 60°C (2 x7 minutes) 
before the slides were transferred into 4 x SSC, 0.0.5% Tween 20 and left at room 
temperature. Simultaneously, fluorochrome-labeled avidin Texas red® DSC (Vector) or 
anti-digoxigenin fluorescein FAB fragments were diluted in blocking buffer (1:500 
avidin; 1:10 anti-DIG) and centrifuged for 7 minutes. 40µl of the avidin or FITC block 
mix was dispensed onto the slides using 22x22mm coverslips and incubated for 30 
minutes at 37°C.  Coverslips were then gently removed and slides washed in 4xSSC, 
0.1% Tween 20 heated to 45°C (3 cycles of 3minutes). Lastly, 40µl of mountant mix 
(0.5ml vectorshield antifade and 10µl DAPI) was applied to 22x50mm coverslips and 
overlaid with slides, blotted, and sealed with Tip Top rubber solution. Slides were stored 




2.3.2.1 Polymerase Chain Reaction 
 
Standard PCR amplification reactions were performed using Invitrogen reagents. 
However, when amplifying long sequences, or if the sequence had a high GC content, 
the Expand long-range PCR kit (Roche) was used. Using Invitrogen reagents, PCR was 
performed with a final volume of 25ųl comprised of: 25-50ng template DNA; 2.5ųl of 
2mM dNTPs; 5µmol primer; 2.5µl 10xPCR Invitrogen amplification Buffer; 7µl 
dsH2O; 0.25U Invitrogen Taq DNA polymerase and either 10µl or 1x enhancer solution. 
Using the Expand long-range PCR kit, a total volume of 16ųl comprised; 25ng template 
DNA; 25mM of each dNTP; 5µmol primer; 1.7µl expand long-range Buffers 2 &3; 
13.3µl dsH2O and, 0.25U Invitrogen Taq DNA polymerase. The amplification was 
carried out on a MJ Research Peltier Thermal Cycler, PTC-255 (MJ Research) using the 





2.3.2.2 Agarose gel electrophoresis 
 
DNA/RNA integrity and PCR reaction efficacy were determined by Agarose gel 
electrophoresis. In general, agarose gels of 2% and 0.8% were used for resolution of 
small (~ 0.2kb-1kb) and large (>1kb) fragments respectively. Agarose gels were 
prepared by heating agarose in 1xTBE buffer. After dissolution of the agarose, SYBR 
SafeTM was added to the gel at a final concentration of 1µl/100ml. Sample and 1kb DNA 
ladder were loaded using orange G loading buffer. Electrophoresis was performed using 
Hybaid Electro-4 gel tanks. The gel was submerged in 1xTBE buffer and a current of 
80-100V was passed through the buffer to allow migration of the DNA through the gel. 
Fragments were visualized using by UV transillumination (Thistle Scientific) and 
images captured using a digital imager, Uvidoc (Uvitec).  
 
2.3.2.3 ExoSAP-IT treatment of PCR products 
 
To remove excess primers and dNTPs, PCR products underwent ExoSAP-ITTM 
treatment. In general, 1-3µl PCR product, 2µl dsH2O and 1µl ExoSAP-IT
TM were 
incubated on a thermal cycler for 60 minutes at 37°C followed by 20 minutes at 80°C.  
 
2.3.2.4 Sequencing PCR  
 
PCR sequencing reactions were performed using BigDye
®
 Terminator Ready Reaction 
Mix v3.1 with 1.2µl BDv3.1, 1µl primer 3.2µM, 1.8µl dsH2O, added to the ExoSAP-IT 
treated PCR products giving a total reaction volume of 10µl. Sequencing reactions were 
performed on a MJ Research Peltier Thermal Cycler using following cycling conditions: 
96°C -1min, 96°C -10s, 50°C -5s 60°C -4 min times 25 cycles; 4°C -10min. 
 
2.3.2.5  Ethanol/EDTA Precipitation and sequence analysis 
 
Following sequencing PCR, products were precipitated in an Ethanol/EDTA solution to 
stabilize extension products and to wash out unincorporated dyes. 2.5µl of 125mM 
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EDTA followed by 30µl 100% absolute ethanol was added to products, mixed and 
incubated for 10 minutes. Products were then centrifuged at 3,000rpm for 30 minutes, 
ethanol removed and a further 30µl 70% ethanol dispensed. The samples were again 
centrifuged for 15 minutes, ethanol removed and products air dried. Samples were run 
on an Applied Biosystems 3730 DNA analyser at the WT-CRF or sequencing 
department at the MRC HGU.   
 
2.3.2.6 Sequence analysis 
 
Sequence chromatograms were aligned using the PhredPhrap software and visualized 
with the Consed program (Gordon et al., 1998) 
(http://www.genome.washington.edu/consed/consed.html) or alternatively using 
Chromas (McCarthy 1998) and Finch TV (Geospiza, INC.) (http://www.geospiza.com). 
Variants were identified by visual inspection of forward and/or reverse sequence traces. 
 
2.3.3 Confirmation of novel variants 
 
Newly identified variants were confirmed by repeat re-sequencing, restriction enzyme 
assays and cloning of PCR product followed by sequencing of cloned DNA. For both 
restriction enzyme assays and cloning of PCR product, PCR products were first purified 
using the QIAquick PCR purification kit as instructed by the supplier. In brief, 150µl of 
buffer BP was added to 30µl PCR product and spun in a QIAquick column at 13,000 
rpm for 30s. The flow-through was discarded and DNA washed using 0.75ml buffer PE 
before being spun again (13,000 rpm for 30s). Flow-through was removed and DNA in 
QIAquick column was centrifuged for an additional 1 minute (13,000 rpm). Finally, 
DNA was eluted by adding 30µl dsH2O followed by centrifugation for one minute 










1 restriction enzyme (New England BioLabs) digest assay was used to confirm 
the variant R4728X. Following PCR product purification, 3µl of 1xNE buffer, 0.3µl 
BSA and 3µl of Taqα1 restriction enzyme and 8.7µl of dsH2O was added to 15µl of PCR 
DNA, incubated at 65°C overnight. DNA fragments were visualized by Agarose gel 
electrophoresis (section 2.3.2.2). 
 
2.3.3.2 Cloning PCR products 
 
The cloning of PCR products was used to confirm the presence of variants giving rise to 
the amino acid substitutions H3609P, S3703R, T4031A and R3604Q. Following 
purification, PCR products were cloned using the Qiagen PCR cloning kit (Qiagen). In 
brief, 1µl of pDrive cloning vector and 5µl ligation master mix was added to 4µl of 
purified PCR DNA gently mixed and incubated at 16°C overnight. Transformation of 
PCR DNA was executed using a heat shock method as follows. 2µl of ligation reaction 
mix was added to 25µl of E-coli competent cells, incubated for 30 minutes, heat shocked 
at 42°C for 30 seconds and left on ice for one minute. Subsequently the ligation 
reaction/competent cell mix was added to 250µl of L-broth growth media already 
warmed to 37°C and left on a shaker to incubate for one hour.  
 
The L-broth medium mix was plated on agar plates treated with chromogenic substrates 
IPTG and X/Gal to determine the efficacy of transformation, - a technique termed 
‘blue/white screening’ (Joung et al., 2000). Agar plates were made by heating agar to 
50°C, adding appropriate antibiotics (1µl/ml of ampicillin [100mg/ml stock]), poured 
into Petri dishes and dried in an oven.  40µl of IPTG (100mM) and X/Gal (40 mg/ml) 
was spread over each plate before the L-broth medium transformation mix was plated 
and left to incubate in an inverted position at 37°C overnight. As approximately half of 
the cloned PCR product colonies should contain the mutant allele, DNA from 10 
colonies of each variant was purified. The white colonies which indicated no production 
of the enzyme β-galactosidase and hence successful incorporation of plasmid DNA were 
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subsequently cultured in L-broth, pelleted and DNA isolated using the GenElute
TM
 
Plasmid Purification kit (Sigma-Aldrich) according to manufacturer’s instructions.   
 
The cloned PCR product DNA was directly sequenced using the Qiagen PCR cloning kit 
T7 promoter primer. The sequencing reaction was performed using the BigDye
®
 
Terminator Ready Reaction Mix v3.1 with a final volume of 10ul comprising of 1µl 
BDv3.1, 1µl primer 3.2µM, 2µl cloned DNA and 6µl dsH2O. Primer details are 
presented in table 2.2.5.1.  Sequencing reactions were performed on a MJ Research 
Peltier Thermal Cycler using following cycling conditions: 96°C -1min, 96°C -10s, 
50°C -5s 60°C -4 min times 25 cycles; 4°C -10min. Following the sequencing reaction, 
products were precipitated in an Ethanol/EDTA solution and run on an Applied 
Biosystems 3730 DNA analyser.  
 
2.3.4 TaqMan assays 
 
TaqMan Assays-by Design were used to determine the frequency of variants in control 
and case populations. Primers employed for the TaqMan assays were designed by ABI 
and listed in Table 2.6. Assays were performed and genotypes called by staff at the WT-




In-house genotyping was performed using the primers listed in table 2.4. It was 
performed under cycling conditions stated in table 2.4 or section 2.3.5.2 and using the 
reagents presented below. Amplification was carried out on a MJ Research Peltier 
Thermal Cycler, PTC-255 (MJ Research), and DNA fragments visualized by Agarose 
gel electrophoresis (section 2.3.2.2). PCR products were run on an Applied Biosystems 
3730 DNA analyser at the WT-CRF or MRC HGU sequencing department. Genotypes 




      
Variant Primer Reporter sequence 
      
   
   
R4728X GGACCAATGGAGACATTCTTGTGTT AAAGCGTCGATAATGT 
 CCCAAACTAATATCTTGCACAGCAA AAAGCGTCAATAATGT 
   
T4031A TGCTTGGACCCAGGTCGTA TCATCTTCACAACCCACC 
 TCACTCAGCGCTTCAGCTT ATCTTCACAGCCCACC 
   
R3604Q TGCTGTGGTAACCTTGGGTTTT TCCCATCATCCGCATAT 
 CAGGCCAGGAAATGGATCACT CTCCCATCATCTGCATAT 
   
H3609P TGTGGTAACCTTGGGTTTTTTCTCT CACTGGATGCACTCC 
 GAACCAGGCCAGGAAATGGAT ACTGGAGGCACTCC 
   
S3704R CAGCTTTCTGCCCTACATAGTTCT TACATAACCAATTAAGTTTTGT 
 TGGGATTTTGTCTTGTTAGATAGATTGCA CATAACCAATTAAGGTTTGT 
   
T4550A CAAGGTCTTAGAATGTATCTGCCATAGAT CAGATATGCAACTCTTCCA 
 CGAACTGGAAAAGATTCTGGACATC ATATGCAGCTCTTCCA 
   
H4262R CCCTCCCCTCAGACTCACA CCCGCTGGTAATGT 
 CGAAATCAAAGGAACAAAAACAACTTACCT CCCGCTGGTAACGT 
   
P4648A CCACAACTTCGGCATTGATTCCTA ATCTCAAAGGGACTCACA 
 CGAAGATCCAGCCCAGAAAGTTC TCTCAAAGGCACTCACA 
   
R4590W GGCCTTTGTACCATGCTCATAAC ATTATGCCCCGGTTGC 
 GTGATGCTACAAAGCTACTGACCTT CATTATGCCCTGGTTGC 
   
P4648A CCACAACTTCGGCATTGATTCCTA ATCTCAAAGGGACTCACA 
 CGAAGATCCAGCCCAGAAAGTTC TCTCAAAGGCACTCACA 
      
 








2.3.5.1 Genotyping GRIK4 3’UTR variant 
 
Genotyping was performed using gDNA from a population of control and bipolar 
disorder samples details of which are given in sections 2.1.1, 2.1.2 and 2.1.3. In addition, 
gDNA extracted from Human brain tissue was genotyped by a second experimenter for 
indel status as part of the GRIK4 genotype/protein expression study. PCR amplification 
reactions were performed using the Expand long-range PCR kit (Roche) with a final 
volume of 16ųl was comprised of: 25ng template DNA; 25mM of each dNTP; 5µmol 
primer; 1.7µl expand long-range Buffer 1; 13.3µl dsH2O and, 0.25U Sigma Taq DNA 
polymerase. Products were diluted 400-fold before separated on the DNA analyzer. 
 
2.3.5.2 Chromosome 7 microsatellites 
 
Amplification reactions were performed using sigma reagents with a final volume of 
16.6ųl comprised of: 50ng template DNA; 1.6µl 2mM dNTP’s; 5µmol primer; 1.6µl 
sigma buffer; 9µl dsH2O and, 0.25µl sigma Taq DNA polymerase. Amplification 
cycling conditions were as follows: 93°C -1 minute; 93°C -20s, 65°C -30s, -1°C per 
cycle, 72°C -1 minute  x 9 times;  93°C -20s, 55°C -30s, 72°C -1 minute x 29 times;  
72°C -10 minutes.  Products were diluted 20-fold before separated on the DNA analyser. 
 
2.3.5.3 Whole genome SNP genotyping 
 
The genome wide scan of two consanguineous Pakistan families employed 5858 
biallelic SNPs typed at Illumina Inc., San Diego, USA using proprietorial bead-array 
technology (Linkage IV panel). Marker spacing was approximately 480Kb (0.6cM) and 
locus success rate 99.2%. SNP data was analysed and checked for potential genotyping 






2.3.6. Reverse-transcriptase PCR  
 
2.3.6.1 RNA preparation 
 
RNA was extracted using RNeasy Mini Kit (Qiagen) as per manufacturer’s instructions. 
In brief, cell line and blood pellets were thawed before adding 600µl RLT buffer 
(containing guanidine-thiocyanate to inactivate RNases hence ensuring purification of 
intact RNA) and homogenized in a QIA shredder spin column (Qiagen) spun for 2 
minutes at 13000 rpm. An equal amount of 70% ETOH was added to the lysate, mixed 
well and applied to an RNeasy mini spin column spun at 10000 rpm for 15 seconds. The 
sample was then washed in 350µl RW1 buffer, spun at 10000 rpm for 15 seconds before 
80µl of DNase1 incubation mix was dispensed directly onto the spin column membrane 
and left at room temperature for 15 minutes. The column was then again washed in RW1 
buffer and 500µl RPE buffer added, spun for two minutes at 10000 rpm. RNA was then 
eluted in 30µl RNase-free water and stored at -70°C.  
 
RNA concentrations and RNA Integrity Number (RIN) values, the proprietary quality 
score for total RNA, and were obtained using the Agilent BioAnalyzer platform. All 
scores were above 9, indicating that the RNA was not degraded and of a high quality.  
 
2.3.6.2 cDNA synthesis 
 
RNA was reverse transcribed to cDNA with First Strand cDNA Kit (Roche) using 
primers oligo-p(dT)15 primer method. This technique produces single stranded RNA 
using AMV reverse transcriptase. The synthesis reactions were performed with a final 
volume of 20µl master mix comprised of: 2µl x10 reaction buffer; 4µl 25mM mgCl2; 2µl 
10mM dNTPs; 2µl oligo-p(dT)15 primer; 1µl RNase inhibitor; 0.8µl AMV reverse 
transcriptase and 8.2µl dsH2O. The reactions were cycled on a thermal cycler (Pelter 
PTC-225) as follows: 25°C -10min, 42°C -10min, 99°C -5min, 4°C -5 min. cDNA was 





To investigate any potential differences in expression of various regions of ABCA13, 
i.e. the possibility ABCA13 encodes for two half transporters, several pairs of primers 
were designed across exons as summarized in table 2.7 below. In addition to cell lines 
(LAN5, SH-SY5Y, U373, MOG, HEK293 and lymphoblastoid), human blood RNA and 
human hippocampus and frontal cortex tissue were tested. PCR amplification was 
conducted using reagents in the Expand Long-range PCR kit (Roche) as described in 
section 2.3.2.1. Primer details and cycling conditions are presented in table 2.4 (section 
2.2.5.). PCR products were visualized by Agarose gel electrophoresis (section 2.3.2.2). 
 
 




Primer 1 - N terminal 
 
18, 179, 20, 21, 22 
 
Large Intracellular loop 
before functional domains 
 
Cell lines, blood  RNA 
 
 
Primer 2 -1st half 
 
25, 26, 27, 28 
 
1st half of protein before 
TMD1 
 
Cell lines, blood  RNA 
 
Primer 3 -2nd half 
 
50, 51, 52, 53 
 
2nd half of protein,  TMD2 
 
 
Cell lines, blood  RNA 
 
Primer 4 - middle short 
 
41, 42, 43, 44, 45, 46, 
 
Middle of protein between 
TMD/NBD1 and TMD/NBD2 
 




Primer 4 - middle long 
 
39, 40, 41, 42, 43 
 
Middle of protein  including 







Table 2.7 RT-PCR primers designed across exons encoding different parts of ABCA13. Exons, 





Immunohistochemistry was performed using an indirect immuno-peroxidase staining 
technique (Nakane and Pierce, 1967). This technique involves a number of steps, 
namely: dewaxing; pretreatments such as the blocking of endogenous activity and 
antigen retrieval to uncover hidden antigenic sites; the blocking of non-specific sites; 
incubation with unlabelled antibody, labeling with a secondary antibody which is 
coupled to the enzyme streptavidin-horseradish peroxidase; and detection through 3, 3’-
Diaminobenzidine (DAB) reactivity. The protocol used, developed from (Harlow and 
Lane, 1998) is detailed in section 2.3.7.1 below. 
 
2.3.7.1 Immunoperoxidase staining 
 
10µm formalin-fixed paraffin embedded sections were placed in a slide rack and 
dewaxed in xylene, rehydrated through a graded alcohol series (70%, 100%) and 
incubated in picric acid for 15 minutes (Sigma-Aldrich). Endogenous peroxidase activity 
was blocked by placing the sections into 0.3% hydrogen peroxide/methanol for 30 
minutes. Antigen retrieval was performed by incubating the sections in a citric acid 
buffer (0.01 M citric acid, pH6.0) and heated in a pressure cooker (BioGenix). Slides 
were then transferred to a shandon sequenza slide rack (Thermo Fisher Scientific).  To 
prevent non-specific binding of the secondary antibody and extraneous binding of 
endogenous avidin-biotin sites, sections were first incubated in 100µl 20% goat serum 
diluted in PBS-Triton-X-100 (PBS with 1% T-X-100) followed by blocking using an 
avidin/biotin blocking kit (Vector Laboratories) according to the manufacture’s 
instructions. 100µl of primary antibody was incubated overnight at 4°C. Following two 
washes in PBS with 1% T-X-100 slides were incubated in 100µl goat anti rabbit 
biotinylated secondary antibody and washed again. 
 
Detection of the biotinylated secondary antibody was performed with the streptavidin-
biotin peroxidase complex kit (DAKO StreptABComplex/HRP Duet) and according to 
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supplier’s instructions. Slides were removed from the Sequenza slide rack and antibody 
signal was detected using DAB coupled to an enhancing solution performed using the 
DAB substrate kit for peroxidase (Vector Laboratories). Sections were counterstained in 
Harris hematoxylin for 20 seconds, dipped in lithium carbonate to turn the tissue blue, 
dehydrated, cleared and mounted using Pertex mounting medium. A negative control (no 
primary antibody or pre-immune serum) and a positive control (staining for GFAP 
expression) were performed every IHC experiment. No signal was seen without addition 
of primary antibody or when incubated with pre-immunised serum. 
 
2.3.8. Antibody specificity assays 
 
To determine the specificity of the antibodies raised against GRIK4 and ABCA13, a 
number of assays were conducted. These were: immunoblotting to demonstrate that the 
antibody binds to a protein of the appropriate size (section 2.3.8.1); the use of pre-
immune antiserum to resolve whether primary antibody immunoreactivity is different 
from non-specific antisera staining (section 2.3.8.2); and, pre-absorption of antibody 




Pre-immune sera and an appropriate peptide with which to perform a pre-absorption 
assay were not available to investigate GRIK4 specificity. Therefore, immunoblotting 
was conducted to verify that the GRIK4 antibody binds to a protein of the same size 
(~107KDa) as GRIK4.  The method used is as follows. 500µl of ice cold RIPA buffer 
was added to SH-SY5Y and U373 cell line pellets, sonicated in a water bath for 10 
minutes (Wolf laboratories ltd), left on a rotator for 20 minutes and centrifuged at 
13000rpm at 4°C for 20 minutes. The supernatant was removed and stored at -70°C until 
use.  
 
Protein gel electrophoresis was performed using 7.5µl and 2.5µl of lysate and 8.4µg/µl 
mouse brain homogenate using NuPAGE Electrophoresis System, as per manufacturer’s 
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instructions (3-8% Nupage Tris-Acetate gel) and stained with Coomassie Brillant Blue 
stain to determine appropriate protein loading concentrations. Gels were dried using 
DryEase Mini-Gel Drying System. Consequently, 9.0µl of SH-SY5Y and U373 lysate 
and 4.5µl of mouse brain homogenate were used for protein gel electrophoresis as 
described above and transferred with X-cell SureLockTM MiniCell (Invitrogen) as per 
manufacturer’s instructions to a PVDF membrane (Hybond-P PVDF Membrane, 
Amersham Biosciences). Ponceau’s stain was used to verify successful protein transfer 
onto PVDF membrane. Following five minutes’ incubation in Ponceau S, membranes 
were destained in dsH2O. The membrane was subsequently incubated in 40ml 10% 
Marvel PBS-Tween 20 at 4°C overnight.  
 
Primary antibody GRIK4 272 was incubated at a concentration detailed in table 2.3 
(section 2.2.4) for one hour, followed by three washes in wash buffer and incubation 
with HRP secondary antibody for 30 minutes. Detection was performed with ECL Plus 
Western Blotting detection system (GE Healthcare) following supplier’s instructions, 
and visualized on X-ray film. 
 
2.3.8.2 Pre-immune antisera assay 
 
Pre-immune serum should bind to proteins within brain tissue in a non-specific manner 
and hence characterize non-specific immunoreactivity.  Prior to use of pre-immune 
serum obtained from the same animal in which ABCA13 780 antibody was raised, 
antisera protein concentration was determined by using BIORAD DC protein Assay as 
outlined in the manufacturer’s guidelines. Using EXCELL, a BSA standard curve was 
generated and a straight line equation was used to calculate protein concentrations. 
Based on an approximation of the primary antibody concentration (~0.2mg/ul), it was 
estimated that the pre-immune serum was circa 50 times more concentrated. The serum 
was titrated by using 1µl diluted in 250µl, 1ml, 2.5ml and 5ml of block (relating to 
dilution factors of 5 times, 25 times, 50 times and 100 times primary antibody 
concentration estimates) and incubated with the brain sections during the IHC protocol 
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instead of primary antibody. The 2.5ml dilution, predicted to be roughly equivalent to 
the estimated antibody concentration used in this technique, produced non-specific 
immunoreactivity which was most similar in concentration to primary antibody 
immunoreactivity. 
 
2.3.8.3 Peptide preabsorption of antibodies 
 
An alternative approach to determine specificity is to pre-absorb a primary antibody 
with the appropriate immunizing peptide which should consequently block any specific 
immunoreactivity. 5µg of peptide per 1µl of primary antibody diluted in 100µl block 
was left to incubate overnight on a rotator at 4°C. Before use, the antibody/peptide 
solution was centrifuged at 8000rpm for 30 minutes. Simultaneously, primary antibody 
with no peptide was taken through the same procedure. 
 
2.4. Image Acquisition 
 
Images were visualized on a Zeiss Axioskop 2 MOT epifluorescence microscope with a 
chroma number 81000 multi-spectral filter set, and 3 lenses of 16x, 40x and 100x 
magnification. The microscope was attached to an ORCA-ER digital camera 
(Hamamatsu Photonics) and images captured using SmartCapture 2 version 3 software 
(Digital Scientific Ltd). FISH prepared slides and immunohistochemistry DAB treated 
brain sections were analyzed following standard microscopy procedures and under 
fluorescence and bright field conditions respectively.  
 
2.4.1. Image capture settings 
 
Images capture settings and image saving formats were standardized across samples. 
However, image capture exposure times were set ‘automatic’, i.e. not manually set at a 
fixed value, which could potentially introduce a bias when assessing protein expression 
semi-quantitatively as pertinent to the aim of chapter 8. To investigate this possibility, 
images from a small subset of IHC samples assessed as having either high or low 
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expression values were recaptured with a set exposure time of 0.01s and re-analyzed for 
neuropil staining using the methodology described in section 2.5.4.1. The expression 
values taken under automatic and fixed conditions were found to be similar, suggesting 
that image capture using the automatic exposure setting would not be a confounding 
factor.  
 
2.5 Data Analysis 
 
The methods employed for data analysis are discussed by chapter below. 
 
2.5.1. Chapter 3 
 
2.5.1.1 Genome-wide analysis of autozygosity 
 
Analysis of homozygous SNPs and tracts across 22 autosomes in each individual was 
performed using PLINK v0.99 (http://pnug.mgh.harvard.edu/~purcell/plink  (Purcell et 
al., 2007) using ‘Runs of homozygosity’ analytical tool set. In addition to identifying 
SNP markers homozygous in each affected member but heterozygous in non-affected 
individuals, the length of autozygous runs and number of tracts were estimated for 
individuals belonging to the first consanguineous family. Inspection of homozygous 
tract lengths was limited to 5 or more consecutive SNPs and low SNP densities in 
centromeric regions were excluded. The length of homozygous regions was taken to be 
from the most proximal to the most distal homozygous SNP and the programme allows 
one heterozygous SNP within this run. Marker positions were based upon NCBI build 
35 physical map and DeCode genetic map.  
 
2.5.1.2 Inbreeding coefficients 
 
Inbreeding coefficients (F) were estimated using FEstim (Leutenegger et al., 2003; 
Leutenegger et al., 2006). MAFs (Minor Allele frequencies) as determined for both the 
Caucasian CEPH (Utah residents with ancestry from Northern and Western Europe) and 
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Asian populations (Japanese and Chinese) were provided by Illumina 
(http://www.illumina.com/). MAF data were not available for the Punjabi population. To 
eliminate the possibility that a dense marker map of 5858 SNPs would lead to an 
overestimation of F due to linkage disequilibrium, three marker maps were evaluated: 
5858 SNPs, intermarker distance ~ 0.6 cM; 1170 SNPs intermarker distance ~3cM; and 
585 SNPs, intermarker distance ~6 cM. The formatting of low density marker files was 
performing by Steven Cass using a perl script programme.  The lower marker density 
maps produced consistently higher inbreeding coefficients, suggesting that LD does not 
contribute to inflated F estimates. Inbreeding coefficients estimated using allele 
frequencies calculated for the Asian population were consistently higher at all marker 
densities than estimates calculated using CEPH population frequencies. Therefore 
inbreeding coefficients presented in table 3.1 (chapter 3.2.2) reflect more conservative 
estimates generated using CEPH allele frequencies. 
 
2.5.2. Chapter 4 
 
2.5.2.1 Haplotype analysis 
 
As discussed in chapter 4, two newly identified rare variants, R4728X and T4031A, 
appear to be carried on a conserved haplotype. To investigate the frequency of these 
haplotypes in the general population, in phase data from five SNPs, rs1526093, 
rs17132289, rs17548783, rs1316349, rs7778411 all positioned within ABCA13 were 
downloaded for 30 CEPH trios from HapMap Phase II build 125 
(http://www.hapmap.org. The frequencies of 4 SNP and 2 SNP haplotypes were 
calculated using haploview version 3.2. program (Barrett et al., 2005) 
(http://www.broad.mit.edu/mpg/haploview/). 
 
2.5.2.2 Amino acid conservation and splice site mutation detection 
 
ABCA13 variants identified as mutated were assessed for species and ABCA sub family 
amino acid conservation. Species conservation data was obtained from the University 
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College Santa Cruz (UCSC) [NCBI Build 35 and 36.1] genome browser. Human 
ABCA13 orthologues were also determined using a blast search against the translated 
sequence database (tblast) via the NCBI website (http://ncbi,nlm.nih.gov/BLAST/). 
Protein sequences for ABCA subfamily members were retrieved directly from the 
swissProt database (Boeckmann et al., 2003) http://www.expasy.ch/sprot/, and multiple 
sequence alignments generated automatically using Clustal X (Thompson et al., 1997) 
http://www.clustal.org/. Potential splice site variants were assessed using Berkeley 
Drosophila Genome Project splice site predication tool (Reese et al., 1997) 
http://www.fruitfly.org/seq_tools/splice.html. 
 
2.5.2.3 Linkage analysis 
 
Non-parametric linkage analysis was conducted by Douglas Blackwood using Merlin 
(Abecasis et al., 2002) to calculate allele sharing between all pairs of affected relatives 
in 15 families. There was complete ascertainment of all families of probands with a 
mutation, i.e. every first and second degree relative obtainable was contacted. However, 
there is still the potential for case family bias in that probands where there was no family 
information available may indeed have no family history of psychiatric illness. 
Moreover, we were unable to follow up control individuals.  
 
The analysis was performed under the following assumption; a broad phenotype model 
that included as cases schizophrenia, bipolar disorder, recurrent and single episode major 
depression, anxiety states and alcoholism. The 15 families carried 9 different variants 
with variable penetrance and allele frequencies. However, linkage analysis was 
conducted assuming a single rare variant with a frequency of 0.001 in all families and 






2.5.3. Chapter 6 
 
2.5.3.1 Testing for deviations from Hardy-Weinberg Equilibrium 
 
The standard χ2 test of independence was used to examine if the observed genotype 
frequencies of the GRIK4 insertion/deletion variant in control samples deviate from 
Hardy Weinberg Equilibrium (HWE). This was performed using the Hardy-Weinberg 
Equilibrium Calculator, http://www.changbioscience.com/genetics/hardy.html.  
 
2.5.4. Chapter 7 
 
2.5.4.1 GRIK4 protein expression correlation analysis 
 
For each of the 12 samples (genotype status: 5 heterozygotes, 6 homozygote insertions 
and 1 homozygote deletion) immunohistochemistry was performed (blind to genotype) 
on three sections of the hippocampus and parietal frontal cortex. Immunopositive 
neuronal and glial cells were manually counted in the molecular layer and granular cell 
layer of the dentate gyrus, alveus, hilus, CA4, CA3 and CA1 of the hippocampus and 
layers 1-6 of the frontal cortex.  
 
DAB immunopositive staining in the nucleus, cell body and processes of neuronal cells 
were all included as ‘neuronal positive cell counts’. However, neuronal cells within a 
given quantified region which labelled positive for cytoplasmic, process or nuclear 
staining concurrently were scored only once. In regions where there was only evident 
dendritic/axonal labelling, i.e. the molecular layer of the hippocampus, each KA1 
positive process was counted separately as it could not be ascertained from which 
neuronal cell each process projected. In the granular cell layer of the dentate gyrus, 
granular cell labelling was predominantly nuclear and hence each KA1 DG positive cell 
was counted separately. Likewise, glial counts were based upon clear cytoplasmic 
labelling and each immunopositive glial cell was counted individually.  
 80 
Immunoreactive positive counts were quantified within circles of 50µm radii (x40 
magnification) or 100µm radii (x16 magnification) using Image J image processing 
program (Rasband, 1997-2007) (Abramoff et al., 2004) http://rsb.info.nih.gov/ij/. Two 
circles were counted in 5-10 captured images randomly selected from each region of 
interest per slide and using a minimum of two slides per individual. Neuronal and glial 
cell positive counts were averaged per region before statistical analysis.  
 
Neuropil immunoreactivity was assessed semi-quantitatively using a colour 
deconvolution technique in Image J (Ruifrok and Johnston, 2001) 
http://imagejdocu.tudor.lu/imagej-documentation-wiki/plugins/colour_deconvolution.  
Immunoreactivity was semi-quantified within two 100µm radius circles from 5-10 
captured images randomly selected from each region of interest per slide using a 
minimum of two slides per individual The built-in stain vector setting used was 
Haematoxylin and DAB (H DAB) and background subtraction with colour correction 
was applied to the images before images processing. An appropriate pixel bin (window 
of pixel intensity) was manually chosen which represented genuine neuropil 
immunoreactivity (70-130 bin out of 255 pixels) and the number of pixels in this bin was 
percentaged over total pixel values. Figure 2.1 illustrates an IHC image analyzed by 
using this colour deconvolution technique. Percentages were averaged for each 
individual and statistics performed on the percentage means when comparing genotype 
groups. 
 
2.6 Gene/protein notation 
 
The notation and abbreviation of genes and proteins cited within this thesis follows 
standard scientific practice. Human transcripts are written in capitals whereas the first 
letter of a rodent transcript is capitalized and the remainder of the gene/protein written in 
lower case. Human and rodent genes and mRNA products are italicized to distinguish 





























Figure 2.1 Illustration of IHC image analyzed by a colour deconvolution technique in Image J. 
The original image was captured on an epifluorescence microscope. The built-in stain vector 
setting and background subtraction with colour deconvolution correction was applied. A third 

















































































































2.7 Pedigree drawing 
 
Pedigrees were drawn using Progeny Desktop Version 5 or Sarah Whittal, a graphics 
illustrator working in the Medical Genetics section, MMC. Standard pedigree symbols 
were used (Bennett et al., 1995). Squares and circles represent males and females 
respectively. Non-affected individuals are shapes not filled. Affected individuals are 
shaded and diagnosis is indicated by different colour shading. Black arrows depict the 




Standard statistics were calculated using Minitab 15 Statistical software or on line 
statistical calculators. For the GRIK4 genotype/expression study, correlations between 
gender, age, post mortem interval (PMI), tissue pH and genotype were investigated 
using the non-parametric Spearman’s rank correlation test. The distribution of mean 
protein expression values (counts and neuropil staining percentages) for all samples 
were tested for normality using the Anderson-Darling test (Anderson and Darling, 
1952). If the distribution were deemed normal, differences between genotype groups 
were tested using one-way ANOVA’s – a parametric test.  
 
However, if the mean population distribution was found not to be normal, the non-
parametric Kruskal-Wallis test was employed. These tests were performed by dividing 
the genotype groups in two ways. First, the homozygote insertion group versus 
heterozygotes alone, and second the homozygote insertion group versus heterozygotes 
plus the one homozygote deletion sample. 
 
To test the difference in frequency of a variant between cases and controls, Fisher’s 
exact test (when cell values were less than 5) and Chi Square test (χ2) were used 
(GraphPad Software (http://www.graphpad.com/quickcalcs/contingency1.cfm). The Chi 
Square test (χ2) was also used to calculate the significance of the burden of all newly 
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identified nonsynonymous variants with a minor allele frequency of less than 0.01. This 
analysis included 32 mutated alleles out of 2646 control chromosomes and 101 mutated 
alleles in 3710 joint case chromosomes. Odds ratios (ORs), the measure of effect size, 















HWE calculator: http://www.changbioscience.com/genetics/hardy.html. 




Repeat Masker: http://repeatmasker.genome.washington.edu/ 
OR calculator: http://www.hutchon.net/ConfidOR.htm. 
SDSC Biology workbench: http://workbench.sdsc.edu/ 
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3.  HOMOZYGOSITY MAPPING IN A FAMILY PRESENTING WITH                         
SCHIZOPHRENIA, EPILEPSY AND HEARING IMPAIRMENT. 
 
 3.1 Preface 
 
Homozygosity mapping was initially performed on family members by means of a low 
density microsatellite genome-wide scan. This led to the fine mapping of a region on 
chr22q13.3 which was found to be homozygous by descent (HBD). We observed the 
occurrence of heterozygosity between the closely spaced HBD regions which may be 
explained either by double recombination events or by mutation of the microsatellite 
markers. To determine which hypothesis was more accurate and to simultaneously fine 





3.2.1 A high density genome-wide SNP scan for linkage 
 
The whole genome SNP data confirmed HBD on chromosome 22q13 with fifteen markers 
covering a region of approximately 12 Mb displaying the HBD pattern. As indicated in 
figure 3.1, the presence of intercalated non-HBD SNP markers gives rise to seven HBD 
candidate regions located between 35 Mb (q12.3) and 47 Mb (q13.3) on chromosome 22. 
Interestingly, the largest interval spanning 3 Mb almost completely overlaps with the 
microsatellite defined intervals, suggesting that mutations within the microsatellites have 
occurred.  
 
This putative disease interval houses a large number of genes and thus the choice of 
which genes to screen for mutations was based on functional candidacy. Activating 
Transcription Factor 4 (ATF4) located on 22q13.1 is a strong candidate gene for 





Figure 3.1  SNP and microsatellite data identifying the locus on chromosome 22q12.3-q13.3. 
HBD conforming markers are shaded, non-HBD intervals are not shaded. Physical distance 
along chromosome is indicated. 
 88 
ATF4 interacts with DISC1, an established susceptibility factor for schizophrenia 
identified by multiple genetic and biological studies (Millar et al., 2000; Morris et al., 
2003). 
 
A second strong candidate, CACNG2, encodes the protein stargazin, an L-type calcium 
channel subunit which also functions as a regulator of post-synaptic membrane targeting 
for AMPA type glutamate receptors. Intronic mutations in CACNG2 result in recessively 
inherited epilepsy and ataxia in stargazer mice. However, the introns are large and the 
exact position of some murine mutations is unknown. Furthermore, polymorphisms 
within human CACNG2 are associated with schizophrenia, and response to the mood 
stablilizer lithium, and aberrations in DNA copy number in clones containing CACNG2 
have been found in individuals with bipolar disorder and schizophrenia (Wilson et al., 
2006; Liu et al., 2008; Silberberg et al., 2008).  
 
A third candidate, GPR24 (alternative nomenclature MCHR1), encodes for a G protein-
coupled receptor which binds melanin-concentrating hormone at the plasma membrane. 
Single SNPs and several specific haplotypes within GPR24 have been significantly 
associated with both SCZ and BP in Scottish and Faeroe Island disease populations 
(Severinsen, 2006; Severinsen et al., 2006a). Animal models of depression and anxiety 
also indicate that GPR24 antagonists produce a profile similar to clinically used 
antidepressants and anxiolytics (Borowsky et al., 2002; Chaki et al., 2005). All three 
candidate genes positioned on chromosome 22q12-3 within HBD intervals were 
screened by sequencing family members in order to identify mutations evident in the 
affected individuals only. No obvious potential functional variants were identified in any 
of the coding and promoter regions. 
 
In addition to chromosome 22, the SNP data revealed a second interval on chromosome 
2p24-25 that was homozygous in all affected family members and heterozygous in 









Figure 3.2 SNP markers identifying the HBD locus on chromosome 2p24.1-p25.3. SNP markers 
homozygous in all affected individuals are shaded black and non-HBD intervals white. 
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This region identified by markers rs730990 to rs1978371 spans a distance of ~5.4 Mb 
(figure 3.2), located 11 Mb proximal from the pter. HBD was undetected in the first scan 
because the microsatellite markers used are not positioned within this region. Candidate 
genes at 2p24.3-25.1 are relatively sparse. One gene of interest based on its function is 
KCNF1, a potassium voltage-gated channel of subfamily F.  
 
Mutations in voltage-gated potassium channel subunits have been found to be 
responsible for both monogenic epilepsies and heritable autosomal recessive syndromes 
such as Jervell and Lange-Nielsen Syndrome in which hearing impairment is a clinical 
feature (Jervell and Lange-Nielsen, 1957; Schwartz et al., 2006). The promoter and 
coding regions of KCNF1 was screened in all family members for mutations or 
functional variants. No such mutations were identified. 
 
3.2.2 Inbreeding coefficients and runs of homozygosity (ROHs) 
 
The inbreeding coefficients calculated using the 5858 SNP density map are presented in 
table 3.1. As expected, F values for the parents (Id 1: 0.136 ± 0.027, Id 2: 0.090 ± 0.021) 
are lower than all siblings (average 0.195 ± 0.025), range 0.16-0.22). In addition, runs of 
homozygosity (ROHs) across the 22 autosomes were analysed for each family member 
(graph 3.1). ROHs involving 5 or more contiguous SNPs approximately 2 Mb in length 
were evaluated and shorter tracts of homozygosity were excluded.  
 
Table 3.1 presents the average, median and ROH range per individual. ROH length 
averages range from 5 Mb to 7 Mb and length median from 2.97 Mb to 4.08 Mb. The 
mother (Id 2) was found to have the shortest tracts, and a trend towards all offspring 
having longer average and median tract lengths than both the parents is apparent. The 
longest homozygous tract for each individual ranged between 40 and 74 Mb, with the 




NOTE- Analysis of homozygous segments was limited to 5 or more contiguous SNP in a tract. Hence, the 
minimum value presented for range represents shortest tract length of 5 contiguous SNP.  
 
Table 3.1 Analysis of homozygosity tract lengths and Inbreeding Coefficients (F) per Individual. 























Graph 3.1 – Graph of homozygous tract lengths (ROHs) for each pedigree member.  ID 1 and 2 
are parents, and siblings 4, 5, 6, 7, and 8 are all affected.  ROHs were limited to 5 or more 














6.52  (SD 9.3) 
 






0.136  (SD 0.027) 
Id 2 5.00  (SD 6.0) 2.97  (IQR 2.1-5.2) 0.5 - 46.6 92 0.090  (SD 0.021) 
Id 3 6.00  (SD 7.4) 3.62  (IQR 2.4-5.6) 0.1 - 39.3 119 0.161  (SD 0.260) 
Id 3 6.52  (SD 9.1) 4.08  (IQR 1.8-6.7) 0.3 - 73.7 112 0.205 (SD 0.027) 
Id 4 6.89  (SD 9.2) 3.49  (IQR 2.4-6.7) 0.1 - 53.8 108 0.186  (SD 0.028) 
Id 5 6.18  (SD 7.9) 3.98  (IQR 2.4-6.0) 0.3 - 60.2 114 0.175  (SD 0.025) 
Id 6 6.72  (SD 8.5) 3.97  (IQR 2.7-6.4) 0.1 - 61.3 106 0.222  (SD 0.029) 
Id 7 7.16  (SD 9.4) 3.76  (IQR 2.3-6.3) 0.1 - 55.0 106 0.222  (SD 0.031) 
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The total number of ROHs per individual (ROH count) ranged between 92 and 114, with 
the parents having lower counts than their children. These data are consistent with the 
estimated F values and indicate increased homozygosity in the offspring owing to 
inbreeding over many generations. 
 
3.2.3 A  genome-wide linkage scan performed on a second related sibship 
 
A second nuclear family of the same inbred clan was identified with a high incidence of 
deafness. We hypothesised that a common disease factor(s) may be responsible for 
recessive hearing loss in both families. A high density genome-wide SNP scan 
performed on the second family revealed five HBD intervals situated on chromosomes 
1p22-1q23, 7q21-q31, 8q12.1-12.3, 12p13.32-31, and 20q13. Table 3.2 lists HBD 
markers, the chromosomal and genomic location of SNPs defining each HBD locus, and 
strong candidate genes housed within HBD regions. These regions, however, do not 
overlap with the HBD loci detected in affected siblings from the first family. 
 
The largest intervals, located on 1p22.2-1q23.1 and 7q21.11-q31.1, are not mass blocks 
of HBD but instead punctuated by intermittent non HBD-conforming markers, as 
illustrated in figures 3.3 and 3.4. Thus the region detected on chromosome 7q21.11-
q31.1 has a total of 13 SNPs within 9 loci covering a region of approximately 25 Mb 
displaying the HBD pattern. A ‘core’ region with the most densely populated HBD 
markers is positioned from 105 Mb to 108 Mb and houses within the HBD loci two 
genes, SLC26A4 and SLC26A5, causally associated with hereditary sensori-neural 
hearing loss (SNHL) (Li et al., 1998; Liu et al., 2003; Yoon et al., 2008).  
 
Likewise, twelve HBD positive markers, located within 8 HBD loci, define the 
boundaries of a broad HBD interval spanning over 65 Mb on chromosome 1p22-1q23. 
Again, a core region would appear to be positioned between 117 Mb and 120 Mb 
although candidate genes are lacking in this region.  
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Table 3.2 HBD regions identified in the second related family. The chromosomal and genomic 































































































































































































































































































Figure 3.3 SNP markers identifying HBD loci on chromosome 7q21.11-q31.1. SNP markers 
homozygous in all affected deaf individuals are shaded black. Non-HBD markers shaded light 
grey denotes more than one SNP between HBD intervals. Non-HBD markers shaded white 
denotes only 1 SNP between HBD markers. Potential candidate genes are shown in black and 


















































































Figure 3.4 SNP markers identifying HBD loci on chromosome 1p22.2-q23.1. SNP markers 
homozygous in all affected deaf individuals are shaded black. Non-HBD markers shaded light 
grey denotes more than one SNP between HBD intervals. Non-HBD markers shaded white 





































Conversely, HBD loci identified on chromosomes 8q12.1-12.3, 12p13.32-31, and 20q13 
are more compact, each consisting of two HBD markers, and span smaller intervals of 




This chapter reports the mapping of two putative loci on chromosome 22q13 and 2p24-
25 for a rare combination of schizophrenia, sensori-neural hearing impairment and 
epilepsy present in five out of six offspring of first cousin parents. A second genome-
wide scan performed on a family belonging to the same kinship and in which five out of 
the seven offspring present with hearing loss, resulted in the mapping of HBD loci on 
chromosomes 1p22.2-1q23.1, 7q21-q31.1, 8q12, 12p13 and 20q13. 
 
The consanguineous parents of the first family have estimated inbreeding coefficients 
higher than expected for offspring of first cousins (6%), while the average value for the 
offspring (19%) is greater than that predicted for double first cousins (12.5%). These 
values, although very high, are still within the range of estimates (5%-20%) reported for 
offspring of first cousin marriages of Pakistani and Arabian descent (Woods et al., 2006) 
and are in keeping with our knowledge that, historically, marriages within this family 
have been restricted to a small group of individuals from a small geographical region.  
 
Detailed analysis of genome-wide ROHs revealed that the longest tracts in the present 
study range between 40 and 73 Mb. In contrast, the maximum ROH length as calculated 
in a high density SNP scan of outbred HapMap populations was found to range between 
2.63 Mb (Chinese population [CHB]) and 17.91 (Japanese population [JPT]) (Gibson et 
al., 2006). Average ROH counts estimated by the authors varied between 4.4 and 8.4 
depending on the outbred population (Gibson et al., 2006). A higher mean value of 35.9 
counts per subject was estimated in a second high density SNP scan of individuals with 
European ancestry (Curtis et al., 2008). In the present study family counts were much 
higher ~100 runs, suggesting more tracts and longer runs of homozygosity consistent 
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with inbreeding effects. However, the measure of a ‘ROH’ differs between the studies 
with the criteria in both the outbred population SNP scans were stricter than in the 
present study (i.e a ROH being 10 or more contiguous SNPs as opposed to 5 contiguous 
SNPs used here). Therefore the counts estimated in the present study may be inflated 
due to the inclusion criteria. 
 
In the aforementioned study of 48 affected individuals with diverse autosomal recessive 
diseases born of first cousin marriages and of Pakistani and Arabian descent, an average 
20 homozygous segments exceeding 3 cM in size and an average tract size of 19.5 cM 
per affected person was estimated (Woods et al., 2004).  The present data yields 
estimates of an average tract size for offspring of ~ 6.58 ± 0.44 Mb and an average tract 
count 111± 5(SEM). Assuming parity between cM and Mb, this would suggest a five-
fold greater number of tracts that are, on average, a fifth of the size of that reported by 
Woods et al.-  a difference which may reflect more remote ancestry through additional 
ancestral inbreeding loops in this family.   
 
In this study we have carried out analysis based on a recessive model assuming this is to 
be a single rare phenotype that includes features of hearing loss, epilepsy and 
schizophrenia. A link between deafness and schizophrenia has been described in the 
literature, particularly in old age (Cooper, 1976). However, it is unlikely that the 
schizophrenia phenotype in the family is a direct result of deafness as the onset is early 
and the symptoms of psychosis are episodic with good recovery between episodes. 
Furthermore, we argue that mutations in one or more genes located in the identified 
HBD regions interact with environmental or other genetic factors, giving rise to the 
variable penetrance/expressivity of clinical features. Nevertheless, other modes of 
inheritance should be considered. For example, dominant inheritance with variable 
penetrance and mitochondrial inheritance which indeed can give rise to phenotypic 
manifestations similar to that of this family (e.g. MELAS and MERRF disorders) 
(Simon and Johns, 1999). However, the existence of inbreeding and the lack of cases 
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identified with the phenotype from the same region in Punjab do not support these 
alternative models. 
 
Deletions and duplications can disturb the expected patterns of marker genotypes within 
pedigrees. A common deleted segment on one chromosome in both parents would result 
in missing genotype data in all siblings that inherit this deletion (i.e. null genotypes). 
Likewise, apparent SNP genotyping failures may indicate commonly inherited 
duplicated regions (Redon et al., 2006). SNP marker analysis did not reveal any single 
SNP or regions of missing data in affected siblings from either family, nor were there 
any Mendelian inconsistencies identified at the resolution of our marker density (~480 
kb). Therefore, although the phenotype is consistent with a contiguous gene syndrome, 
no gross duplications or deletions are evident. 
 
The lack of overlap of HBD regions in affected individuals from both sibships disproves 
our hypothesis that a common disease factor(s) may be responsible for recessive hearing 
loss in both families. However, a similar finding has been reported in the mapping of 
Bardet-Biedl syndrome (BBS) loci investigated in a large extended consanguineous 
Lebanese pedigree. In this family, two loci and subsequently identified disease-causing 
genes corresponding to the same clinical phenotype were found to segregate in different 
branches of the extended family.  The authors concluded that owing to the high 
nonallelic heterogeneity and increased cumulative prevalence of BBS in inbred 
populations (similar to non-syndromic hearing loss), it was unsurprising that mutations 
in two different causal genes were segregating and should, by exemplar, emphasise a 
possible ‘pitfall’ of homozygosity mapping in extended kinships (Laurier et al., 2006). 
 
Another limitation of homozygosity mapping, as for linkage studies of small families, is 
that it detects large disease intervals that may house hundreds of genes. Although fine 
mapping or previous linkage reported in other families may reduce the size of the 
putative interval, the overall aim of such studies, gene identification, is dependent on 
examining functional candidate genes in the region. With regard to hereditary sensori-
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neural hearing loss (SNHL), the recently documented DFNB47 locus is linked to 
autosomal recessive hearing impairment and maps to a 5.3 Mb sized region on 2p24.3-
25.1 (Hassan et al., 2006). Of interest, the maximum LOD score of 4.7 is reported for 
markers D2S1400 and D2S262, both of which are located within our chromosome 2 
HBD region. The two large pedigrees segregating this locus live in Pakistan but are 
geographically distant from the family described and there is no suggestion that the 
families will be related. As in the current study, the candidate gene, KCNF1, was 
screened in affected individuals in these two large kindreds and the results were also 
negative.  
 
A second locus linked to autosomal recessive SNHL maps to 22q13.1.  DFNB28 was 
mapped in a large consanguineous Palestinian family, in addition to smaller 
consanguineous families from Pakistan, Indian and America (Walsh TD, 2000; 
Riazuddin et al., 2006; Shahin et al., 2006). Subsequently, causative mutant alleles have 
been identified in the gene TRIOBP encoding for a protein which has a role in actin 
cytoskeletal organization in cochlear sensory hair cells of the inner ear. The interval 
containing TRIOBP (36.5 Mb) is located between HBD loci identified in the present 
family in a region where SNPs were not typed. Hence, it is possible that this location is 
HBD and that mutant alleles within TRIOBP are carried in affected offspring. 
 
The large regions on 7q21-q31 and 1p22.2-1q23.1 homozygous in affected siblings of 
the second related family presenting with hearing loss also house five autosomal 
recessive SNHL loci. DFNB39 located on 7q11.22-q21.12 was found to segregate in a 
consanguineous family from Pakistan (Wajid et al., 2003). However, as yet no causative 
mutations have been identified. DFNB4, DFNB14, and DFNB17 housed within 7q31.1 
were mapped in consanguineous families from India, Israel and Lebanon (Baldwin et al., 
1995; Greinwald et al., 1998; Li et al., 1998; Mustapha et al., 1998). Mutations in the 
gene SLC26A4 encoding a sodium-independent transporter of chloride and iodide and 
known to cause Pendred syndrome (a congenital sensorineural hearing loss syndrome) 
were reported to segregate in one family but are absent in individuals from other hearing 
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loss pedigrees (Li et al., 1998; Yoon et al., 2008). However, a splice variant in a second 
and neighbouring gene, SLC26A5, which encodes a membrane motor protein of cochlear 
outer hair cells, was found to be responsible for recessive deafness in two unrelated 
families (Liu et al., 2003). As stated earlier these genes, both known to cause hearing 
loss, are positioned within smaller HBD loci on chromosome 7q22. 
 
Likewise, DFNB32 linked to autosomal recessive SNHL maps to 1p13.3-p22.1 and is 
located within the broader HBD region on chromosome chr1 p22.2-q23.1 (Masmoudi et 
al., 2003). Currently the DFNB32 gene has not been identified. Nevertheless, a key 
candidate, KCND3 (encoding a voltage-gated potassium channel) is positioned distal to 
the DFNB32 locus but within two intermittent HBD loci detected in this present family. 
As the other HBD loci identified in this second sibship (8q12, 12p13 and 20q13) do not 
house SNHL-linked loci, chromosome 7q21.1-q31.1. and 1p22.2-q23.1 are the key 
candidate intervals on which to focus re-sequencing efforts with the aim of discovering 
causative mutations associated with recessive hearing loss within this family.  
 
Findings from linkage studies provide strong evidence that a single major gene on 
chromosome 22q12 is responsible for an idiopathic epilepsy syndrome. Familial partial 
epilepsy syndrome with variable loci (FPEVL), an autosomal dominant and clinically 
heterogeneous condition, was initially mapped in two large French-Canadian pedigrees 
to a ~4 Mb interval on chr 22q11-q12 (Xiong et al., 1999). Two preceding studies 
confirmed linkage for FPEVL in Dutch, Spanish and French-Canadian pedigrees 
reporting a combined LOD score of 6.3 for the Spanish and three French-Canadian 
pedigrees (Callenbach et al., 2003) (Berkovic et al., 2004). Of note, members of these 
pedigrees are reported to have psychiatric problems including the diagnosis of paranoid 
schizophrenia. Although not overlapping with the present study’s disease interval on 




Epidemiological and clinical characteristics common to schizophrenia and bipolar 
disorder suggest the two disorders share genetic and non-genetic susceptibility factors 
(Berrettini, 2000). Over the last decade converging evidence from independent studies 
strongly implicates chromosome 22q as a candidate region for susceptibility genes for 
these disorders. Positive findings, as reported in 1999, cluster in a region of 4-5cM on 
22q13.1, an interval mapping directly to our ‘core’ region between markers D22S284 
and D22S270 (Schwab and Wildenauer, 1999). More recent linkage analysis of markers 
on 22q for schizophrenia and bipolar disorder fulfils the criteria of suggestive or 
significant linkage implicating a broad genomic region spanning 22q12.3-q13.3 that 
coincides with the findings of the present study. For example, linkage found at markers 
D22S1161 and D22S922 (P = 0.0081) 22q13.3 for bipolar disorder and D22S279 and 
D22S276 (P =0.0075) 22q13.2 for schizophrenia in pedigrees from the Faroe Islands 
(Jorgensen et al., 2002). DeLisi and coworkers also report a LOD score of 2.0 at marker 
D22S283 (22q12.3) in a genome-wide scan of 382 sib pairs with schizophrenia and 
schizoaffective disorder. Moreover, two studies have found linkage with markers in 
bipolar families in the region of 22q12.3: [D22S277 non parametric score 0.003 and 
D22S278 a Max LOD 3.1] (Kelsoe et al., 2001; DeLisi et al., 2002). 
 
Furthermore, the high incidence of identified deletions located within 22q13.12 to 22qter 
in individuals with similar clinical phenotypes has led to the recognition of a separate 
condition known as ‘chromosome 22q13 deletion syndrome’ (also known as Phelan-
McDermic Syndrome). In addition to the main clinical characteristics, delayed 
development and learning disability, secondary features commonly described are 
behavioural problems including autistic-like traits and seizures (Phelan et al., 2001). 
Consistent with this syndrome are singular reports of individuals with cytogenetic 
abnormalities, e.g. inverted duplications, shown to disrupt intervals along chromosome 
22q13. Of relevance, the main clinical manifestations often described for these 
individuals are severe psychiatric abnormalities (i.e. a diagnosis of BPD, schizophrenia 
or psychosis) and delayed development (Failla et al., 2007; Pramparo et al., 2008).  
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Homozygosity mapping is a technique which has been used successfully to identify 
recessive genetic risk factors for a variety of clinical phenotypes. In a recent study 
performed by Paisan-Ruiz and colleagues, consanguineous families from India and 
Pakistan presenting with recessive dystonia-parkinsonism (which includes psychiatric 
features) were genome-wide screened for shared HBD intervals. Interestingly, 
homozygosity on chromosome 22q13 was found to be shared by affected members from 
three families and consequently mutations in the gene PLA2G6 were identified (Paisan-
Ruiz et al., 2008). The reported shared HBD region overlaps with intermittent HBD 
intervals detected in the present study.  This hints at the possibility that the chr22q13 
region may commonly be homozygous in individuals from the Indian/Pakistan 
population with shared recent ancestry, and that mutated recessive alleles in genes 
harboured within this interval may cause or be risk factor for an assortment of clinical 
disorders. 
 
The screening of the promoter and coding regions of ATF4, GPR24 and CACNG2 did 
not reveal any apparent mutations in affected family members. It is still possible that 
mutations in intronic regulatory regions of these genes underlie this recessive disease. 
Furthermore, several alternative candidate genes for this specific phenotype are located 
on chromosome 22q13. For example, ADSL encodes the protein adenylsuccinate lyase, a 
deficiency in which causes a selectively neuronopathic disorder with psychomotor 
retardation, epilepsy and autistic-like features as leading traits (Race et al., 2000). 
Moreover ADSL, was a second gene along with GPR24, significantly associated with 
both SZ and BPD in Scottish and Faeroe Island disease populations (Severinsen et al., 
2006a; Severinsen et al., 2006b). Mutation screening of these and other promising 
candidate genes within 22q12-3-13.3 and 2p24.3-25.1 may lead to the discovery of 
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4.  INVESTIGATION OF A COMPLEX CHROMOSOMAL ABNORMALITY AND                




A complex chromosomal rearrangement was previously identified in a patient with 
severe and chronic schizophrenia. The three breakpoints were positioned within the 
regions of 7q21.11, 7p12.3 and 8p23. The breakpoint interval on 7q21.11 houses no 
potential candidate genes whereas the locus on 7p12.3 directly disrupts the gene, 
ABCA13. To determine if ABCA13 is the only gene disrupted, and to locate the precise 
breakpoint within ABCA13, the breakpoint regions on chromosomes 8p and 7p were 
further analyzed by Fluorescence in situ Hybridisation (FISH).  
 
4.2 Results  
 
4.2.1 Fine mapping breakpoint regions on chromosome 8p and 7p 
 
Cloned bacterial artificial chromosome (BAC) RP11-18L2 located on 8p23.1 was found 
to translocate to the derived chromosome 7. This indicated that the breakpoint was 
proximal to the defensin gene cluster region (8p23.2) previously suspected as the 
breakpoint locus. Systematic FISH analysis of BACs and fosmids located downstream 
of this area identified BACs RP11-429B7 and RP11-179A8 and fosmid 
G248P87290G10 as giving a signature ‘split hybridization signal’, i.e. translocating to 
the derived 7 as well as remaining on the derived chromosome 8. A FISH image of the 
breakpoint fosmid G248P87290G10 is shown in figure 4.1 These clones indicate that the 
breakpoint region on chromosome 8p23.1 does not directly disrupt any genes. However, 
PPP1R3B (NM_024607) a gene which encodes for a protein phosphatase 1 subunit, and 
THEX1 (NM_153332) encoding a RNA exonuclease, lie approximately 8 kB centomeric 
















Figure 4.1 The breakpoint-spanning fosmid G248P87290G10 on chromosome 8. In the 
individual with the complex cytogenetic abnormality, this breakpoint-spanning fosmid shows 















Figure 4.2 BACs and fosmids used to define the breakpoint on chromosome 8p23.1. The genes 




















Cytogenetic mapping of the region previously identified on chromosome 7p12.3 
indicated that two fosmids were broken, G248P8188G7 and G248P85542D8 
(G248P8188G7 shown in figure 4.3)  Moreover, the breakpoint locus was found to be 
between fosmids G248P82942G4 and G248P87241B7 which would indicate disruption 
of ABCA13 in the vicinity of exons 30 and 31, as illustrated in figure 4.4. This disruption 
is predicted to result in a truncated transcript which is likely to be degraded due to 
nonsense-mediated decay mechanisms. All breakpoint-defining BAC and fosmid clones 






















Figure 4.3 Breakpoint fosmid 188G7 on chromosome 7. Three signals (red fluorescence) are 
detected on the derived chromosomes 7 and 8 and normal 7 in the patient with the cytogenetic 




























Figure 4.4 BACs and fosmids used to define the breakpoint on chromosome 7p12.3. The 
breakpoint is positioned between fosmids G248P82942G4 and G248P87241B7 in the vicinity of 
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4.2.2 Re-sequencing exons of the ABCA13 gene encoding functional domains in cases of 
schizophrenia and controls 
 
The ABCA13 locus has not previously been associated with psychiatric disorders. We 
therefore hypothesized that ABCA13 might make a wider contribution to psychiatric 
illness through rare, moderate- to high-penetrance variants identifiable in the population 
only through direct mutation detection. Nineteen key exons (from a total of 62) encoding 
the two nucleotide binding domains (NBDs), two transmembrane domain clusters 
(TMDs) and a hydrophobic dipping region (HDR) were amplified using genomic DNA 
PCR and then re-sequenced in 100 unrelated cases diagnosed with schizophrenia of both 
sporadic and familial origin. In addition, 100 matched healthy controls were also 
screened to assess the frequency of ultra-rare benign variants in the general population. 
A total of thirty-two new variants were identified, 20 within coding regions and 12 
within flanking intronic sequences as listed in table 4.2.  The majority of novel non-
synonymous variants (resulting in amino acid substitutions and hence having potential 
functional significance) were unique to the case population, whereas synonymous or 
intronic variants not affecting amino acid sequence showed no such bias as indicated in 
table 4.3.  
 
To assess the distribution of potential mutations in both the general population and 
across three major psychiatric illnesses, bespoke TaqMan assays were used to genotype 
selected, highly conserved, non-synonymous coding variants in much larger genomic 
DNA sample cohorts of patients with schizophrenia, bipolar disorder, and major 
depression as well as healthy controls. The case cohorts used was not biased towards 
individuals with a strong family history. Further evidence that these potential rare 
mutations are significantly associated with illness was sought by conducting family 
segregation analysis. Based on these assessments, that is, variant frequency differences 
between cases and controls, co-segregation of variants with illness in extended families 
and evolutionary conservation of the mutated residues; I postulate that nine of these 






















Table 4.2 Novel variants identified from re-sequencing 100 cases with schizophrenia and 100 
healthy controls. The functional domain, genomic location, base and amino acid change, type of 
variant and minor allele frequencies are listed. 
Domain Chr7 location bp Base change AA change Type MAF cases MAF controls
NCBI Build 36.1
TMD1 48,382,318 G→A R3604Q missense A: 0.0050 A: 0.0000
TMD1 48,382,333 A→C H3609P missense C: 0.0050 C: 0.0000
TMD1 48,382,337 A→C P3610P synonymous C: 0.0096 C: 0.0000
TMD1 48,382,337 A→T P3610P synonymous T: 0.0048 T: 0.0037
TMD1 48,382,619 T→G S3704R missense/splice variant G: 0.0050 G: 0.0000
TMD1 48,384,364 C→T intronic T: 0.0095 T: 0.0160
TMD1 48,384,474 A→G intronic G: 0.0045 G: 0.0000
TMD1 48,384,623 T→C intronic C: 0.0048 C: 0.0053
TMD1 48,398,156 G→A intronic A: 0.0523 nd
TMD1 48,398,232 G→C intronic C: 0.0048 nd
NBD1 48,399,292 C→G L3861L synonymous G: 0.0000 G: 0.0052
NBD1 48,399,322 T→C T3871T synonymous C: 0.0000 C: 0.0052
NBD1 48,413,738 C→T intronic T: 0.0092 nd
NBD1 48,420,643 C→T intronic T: 0.1651 T: 0.2067
NBD1 48,420,683 A→G T4031A missense G: 0.0050 G: 0.0000
NBD1 48,420,731 C→G L4047V missense G: 0.0169 G: 0.0104
NBD1 48,420,834 C→G intronic G: 0.1651 G: 0.2067
HDR 48,465,394 T→C P4260P synonymous C: 0.0000 C: 0.0052
HDR 48,465,399 A→G H4262R missense G: 0.0050 G: 0.0000
TMD2 48,518,027 C→T R4454C missense T: 0.0142 T: 0.0156
TMD2 48,518,057 C→A L4464M missense A: 0.0095 A: 0.0208
TMD2 48,526,874 A→G T4550A missense A: 0.0050 A: 0.0000
TMD2 48,526,994 C→T R4590W missense T: 0.0000 T: 0.0050
TMD2 48,527,112 C→G intronic G: 0.0286 G: 0.0161
TMD2 48,530,327 C→G P4648A missense G: 0.0000: G: 0.0050
NBD2 48,534,459 A→G R4707R synonymous G: 0.0500 G: 0.0526
NBD2 48,534,520 C→T R4728X nonsense T: 0.0050 T: 0.000
NBD2 48,538,544 C→T intronic T: 0.0000 T: 0.0153
NBD2 48,538,545 C→T intronic T: 0.0000 T: 0.0052
NBD2 48,597,311 A→G I4841V missense G: 0.0040 G: 0.0000
NBD2 48,597,317 C→T R4843C missense T: 0.0000 T: 0.0050
NBD2 48,604,841 C→A intronic A: 0.0519 A: 0.0789
MAF cases and controls calculated from discovery resequencing data.
Genomic position based on NCBI build 36.1. AA, amino acid; MAF, minor allele frequency; 
NBD, nucleotide binding domain; TMD, transmembrane domain, HDR, hydrophobic dipping region.
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Case specific Shared Control specific
non synonomous 8 3 3
synonomous 1 2 3
Intronic 1 6 2  
Table 4.3 The frequency of novel variants in cases, controls or both populations. A bias in the 
number of novel non-synonymous variants unique to the case population is evident. Data for 














Figure 4.5 Flow chart of findings initiated from the screening of exons encoding the functional 
domains of ABCA13. The chart outlines the strategy and results used to assess potential 
pathogenic nature of variants.  
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Figure 4.5 presents a flow chart as a means to visualise the mutation detection strategy 
and results. The ensuing sections present the results in order of variant class. 
 
4.2.2.1 Analysis of Known SNPs  
 
In addition to the 32 novel variants, thirteen known SNPs were detected in the screened 
case and control populations. As shown in table 4.4, the MAFs estimated for these 
variants range between 0.05 (5%) to 0.47 (47%) in the control population, indicating that 
these variants fall into the class of common polymorphisms. Furthermore, none showed 
a statistically significant difference in genotype or allele frequencies between the case 
and control cohorts. 
 
4.2.2.2 Novel intronic and synonymous variants 
  
Twelve novel intronic variants and six novel synonymous (silent) variants were 
identified from re-sequencing. Five of the 12 intronic variants have MAFs lower than 
1% in the case populations and hence can be classified as rare. Data for the control 
population was not obtained for three intronic variants and 2 variants were found unique 
to controls and 1 unique to cases. The difference in minor allele frequencies (MAF) 
between cases and controls was not found to be significant for the remaining 6 intronic 
variants. Nor was there any evidence supporting that any of these variants may disrupt 
splice motif sequences. 
 
Recent theoretical studies suggest that silent mutations, i.e. synonymous variants, which 
involve the substitution of a common codon for a rare codon, may affect the kinetics of 
translation and hence co-translational folding processes and ultimately efficacy of 
protein function (Karlin and Mrazek, 1996; Supek and Vlahovicek, 2005; Kimchi-
Sarfaty et al., 2007). Of the 6 novel silent mutations detected, four (P3610P, L3861L, 
T3871T, P4260P) were found to be unique to either the case or control populations 
(shown in table 4.2). However, the difference in allele frequencies between cases and 
controls is not statistically significant and none of the base changes introduce a rare 
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codon. Taken together, this evidence would suggest that these synonymous silent 
variants are not pathogenic. 
 
4.2.2.3 Novel non synonymous variants discounted as pathogenic 
 
Three non-synonymous variants located within the second transmembrane domain, were 
identified but subsequently discounted as potentially pathogenic. A non-conservative 
substitution from a highly conserved arginine to cysteine (R4454C) located within a 
loop of the second TMD, was detected in 3 cases and 3 control individuals. Consistent 
with this apparent lack of bias between case and control groups, R4454C was found not 
to segregate with illness in a large family with schizoaffective disorder, bipolar disorder 
and MDD, as shown in figure 4.6. Similarly, two conservative amino acid substitutions, 
L4464M and L4047V, were detected in 2 cases and 4 controls, and 4 cases and 2 
controls, respectively. All three of these variants have an allele frequency above 1% in 
the control population (table 4.2) and are likely neutral polymorphisms.  
 
4.2.2.4 The detection of potentially pathogenic variants. 
 
Eleven non-synonymous variants were detected in the screening phase with MAFs lower 
than 1%. However, two of the eleven variants (P4648A and I4841V) both conservative 
substitutions, are of unknown pathogenic status. P4648A positioned in a transmembrane 
loop of the second TMD, was detected in the heterozygous state in one control 
individual. This residue change is conservative and genotyping larger case and control 
cohorts did not identify any additional carriers. Hence it is likely that P4648A is an 
ultra-rare benign variant. The second variant, I4841V, results in a conservative 
substitution from isoleucine to valine positioned within the second NBD. This variant 
was detected in the heterozygous state in an individual identified as a T4031A carrier 












Table 4.4 Known SNPs detected from the sequencing of case and control populations. The MAF 
calculated for the sequenced case and control cohorts is listed. The final column presents data 
pertaining to control individuals obtained from either the HapMap or Perlegen databases. No 














Figure 4.6 Family pedigree carrying the TMD2 non-synonymous variant R4454C. The T allele is 
the mutant allele and does not segregate with illness. ‘Unknown’ denotes unknown phenotype 
and ‘?’ represents unknown genotype. 
Domain SNP Base change AA change Type MAF seq.cases MAF seq.controls MAF controls†
TMD1 rs1526093 A→G intronic  G  0.176 G  0.158 G  0.132
NBD1 rs17132289 A→T Y3796F nonsynonymous   T  0.047  T  0.073 T   0.083
NBD1 rs7780299 C→T intronic T  0.110 T  0.120 nd
NBD1 rs 6978753 G→A intronic A  0.385 A  0.385 A   0.438
NBD1 rs17548783 C→T A4037A synonymous  C  0.459 T  0.476 C   0.442
TMD2 ENSSNP7713259 A→G intronic G  0.032 G  0.052 nd
TMD2 ENSSNP13252658 G→A K4609K synonymous A  0.032 A  0.052 nd
TMD2 ENSSNP13252659 C→T C4619C synonymous T  0.032 T  0.052 nd
TMD2 rs34364517 A→G intronic G  0.032 G  0.052 nd
 NBD2 rs1316349 G→T intronic T  0.058 T  0.071 T  0.092
 NBD2 rs7778411 G→C intronic C  0.298 C  0.342 C 0.264
 NBD2 rs10243913 G→A intronic A  0.399 nd nd
 NBD2 rs10046546 A→G intronic G  0.316 nd nd
MAF cases and controls calculated from resequencing 100 schizophrenics and controls;  nd = no data;  
† denotes data obtained from either HapMap or Perlegen data bases
Diagnosis = MDD Diagnosis = BP






c/t c/c c/t c/c
c/t c/t
?
Family 1 (R4454C) 
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As the base change for I4841V in exon 57 (NBD2) and for T4031A in exon 40 (NBD1) 
are located within two different LD blocks, these variants are not in high LD with one 
another. I4841V was not found in any other control or case sequenced, and so its status 
as a potential risk variant or benign ultra-rare polymorphism is unknown.  
 
The investigation of the remaining nine non-synonymous variants identified by 
screening has provided evidence that these variants are disease liability factors.  The 
details of the nine variants are provided in table 4.5 and discussed in succession below. 
 
Mutation 1: T4031A 
 
The missense mutation T4031A, a non-conservative change of a phylogenetically 
conserved threonine residue to alanine in the first nucleotide binding domain, was 
identified in the heterozygous state in one individual with schizophrenia. The presence 
of this variant was confirmed by cloning the PCR product followed by sequencing as 
shown in figure 4.7a.  
 
The frequency of the T4031A mutation was determined by genotyping DNA from cases 
of schizophrenia, bipolar disorder and MDD as well as two healthy control groups. A 
total of 1 case with schizophrenia and 3 cases with bipolar disorder in a total case 
population of 2208 samples were found to be heterozygous. In contrast, this variant was 
absent in 2362 control individuals assayed. Therefore the minor allele frequencies 
(MAF) for T4031A is 0.009 combined cases and 0.000 controls resulting in a p-value of 
P=0.052, [or P=0.1 replication data only] (Fisher’s exact test, one-tailed) which 
demonstrates a trend towards significance. An estimation of the strength of the effect of 
a genetic variant on the disease phenotype is often expressed as an odds ratio (OR), i.e. 
the ratio of the odds of manifesting the disease in carriers of the risk allele to the odds of 
manifesting the disease in noncarriers. Due to an absence of this variant in the control 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.7 Sequence traces, amino acid position and conservation and family pedigree of the 
T4031A variant. Trace chromatogram of the heterozygous state as identified from sequencing 
gDNA in a case with schizophrenia (a), and cloned wild-type allele (b) and cloned mutant allele 
(c) resulting from the bacterial cloning and sequencing of the heterozygote PCR products. The 
mutated base is shaded blue. Conservation of the wildtype threonine amino acid across species 
(top) and among closely related ABCA protein family members (d). Previously reported 
pathological ABCA subfamily NBD mutations are shown in red. Family pedigree carrying 
T4031A and indicating possible compound heterozygote effect with I4841V (e). Location of the 
mutated T4031A (red) within the first NBD and neighbouring a conserved H-loop motif (f). 








Nucleotide Binding Domain 1
Signature B motif H - loop motif
(d)
ABCA13 -Human
ABCA3  -NBD1    RTIVLTTHFMDEADLLGDR
ABCA7  -NBD1    RTIIFTTHHLDEAEALSDR
ABCA4 -NBD1    RTIIMSTHHMDEAEALSD





ABCA1 -NBD1    RTIILSTHHMDEADVLGD
ABCA12 -NBD1    RTIILSTHHLDEAEVLSDR











Follow-up family studies led to the identification one small family in which the proband 
is heterozygous for T4031A and another non-synonymous variant I4841V. The 
proband’s mother who is not affected, carries T4031A but not I4841V showing that 
T4031A is not a de novo germ line mutation (figure 4.7e). 
 
T4031A, as indicated in figure 4.7f, is situated immediately adjacent to the highly 
conserved functional H-loop Histidine residue and also in proximity of other functional 
motifs required for direct ATP-binding. Indeed, the H-loop histidine residue (H4032), 
adjacent to T4031 has been referred to as the “linchpin” of ATP hydrolysis in NBDs 
because it is essential for holding together all required parts of a complicated network of 
interactions between ATP, water molecules, Mg
2+
, and amino acids (Zaitseva et al., 
2005). Dinesh Soares evaluated the consequence of the T4031A mutation on protein 
structure and function by means of sequence analysis and a structural model (figure 4.8). 
The results suggested it is likely that the loss of two critical hydrogen bonds by 
substitution from a normally conserved and buried threonine residue to the less bulky 
alanine adjacent to the H-loop His4032, and within a complex network of inter-residue-
bonding interactions, will perturb local structure. Hence, optimal ATPase activity, and 
consequently allocrite translocation is likely to be compromised (Soares personal 
communication).  
 
Mutation 2: R4728X 
 
A nonsense mutation, R4728X, located 19 amino acids before the start of the second 
nucleotide binding domain and within the highly conserved A-loop motif (Aromatic 
residue interacting with the Adenine ring of ATP), was detected in one case with 
schizophrenia (figure 4.9). This variant was confirmed by a restriction digest assay, as 
shown figure 4.8b.   Transcripts containing nonsense mutations are frequently degraded 
through ‘nonsense-mediated decay’ which typically, like the original chromosomal 

















Figure 4.8 The location of T4031 and ATP-binding site on 3D-model. (a) A representation of the 
3D-model, with the side-chains of ATP-binding motifs and mutated residue T4031A (green) 
shown; ATP-signature motifs colour coded and labelled; secondary structure assigned by 
STRIDE. (b) Close-up view of T4031 hydrogen bonds indicated by dashed orange lines. The 
buried side-chain hydroxyl group of T4031 forms a potential “loop-stabilising” hydrogen bond 
with the backbone nitrogen of H4033 and additionally with the catalytic Walker B amino acid 
E4001. The backbone-backbone hydrogen bond between T4031 and L3873 is also shown. 
Other amino acid residues proximal to T4031 (5 Å sphere radius) are also shown and labelled 
(colour code: carbon atoms = green; oxygen atoms = red; nitrogen atoms = blue; hydrogen 
atoms are not shown for clarity). Vicinal functional residues H4032 (H-loop), G3875 (Walker A), 
and E4001 (Walker B) can be seen in this representation.  
 





































Figure 4.9 Sequence trace, restriction digest, position and conservation of R4728X. (a) 
Chromatogram of the heterozygous individual with schizophrenia as identified from sequencing. 
The mutated base is shaded blue. (b) Restriction digest of PCR product confirming the presence 
of the base change. The homozygous wildtype allele is fully cleaved by the taq1 enzyme 
producing a product of 200 and 300 bps (red arrows). In contrast, only one allele of the 
heterozygous mutant DNA is cleaved producing a product of 500bp as well as the 200 and 300 
bps products. (c) Location of the mutated R4728X variant 19 AA before the start of the second 
NBD and within the A-loop motif. Amino acids shown in blue represent the start of the NBD and 
residues coloured green correspond to the highly conserved Walker a motif. (d). ABCA sub-
family and species conservation of the wild-type arginine (shown red) amino acid. The arginine 
residue is highly conserved between orthologues but displays more variability between ABCA 
sub-family members.  
Nucleotide Binding Domain 2
R X RFFQNIIAVQDISLGIPK GECFGLLGVNGAGKST





ABCA13_Homo   KEEKRVFEGRTNGDILVLYNLSKHYRRF-FQNIIAVQDISLGIPKGECFGLLGVNGAGK
ERLRVESGAAEFDLVQLYCLTKTYQLI-HKKIIAVNNISIGIPAGECFGLLGVNGAGKTTIFKMLTGDI
ABCA7_Homo    RERERVVQGATQGDVLVLRNLTKVYRG---QRMPAVDRLCLGIPPGECFGLLGVNGAGKTSTFRMVTGDT 
ABCA4_Homo    EERQRIITGGNKTDILRLHELTKIYPG---TSSPAVDRLCVGVRPGECFGLLGVNGAGKT
ABCA1_Homo    RERQRILDGGGQNDILEIKELTKIYRR---KRKPAVDRICVGIPPGECFGLLGVNGAGKSSTFKMLTGDT
ERQRVLRGDADNDMVKIENLTKVYKSRKIGRILAVDRLCLGVRLGECFGLLGVNGAGKTSTFKMLTGDE
LIIKELSKVYEQ--RVPLLAVDRLSLAVQKGECFGLLGFNGAGKTT
ABCA13_Homo   KEEKRVFEG TNGDILVLYNLSKHY
ABCA12_Homo   
ABCA7_Homo    RE ERVVQGATQGDVLVLRNLTKVY
ABCA4_Homo    EERQRIITGGNKTDILRLHELTKIY
ABCA1_Homo    RERQRILDGGGQNDILEIKELTKIY
ABCA2_Homo    
ABCA3_Homo    
Homo            
Rhesus monkey   KEEMRVFEGR
Chimp           KEEKRVFEGRTNGDILVLYNLSKHY
Rat             KEQMRVLEGRTGGDMLVLCNLSKSY
Mouse           
Cow             KEQVRVLKGRTSGDTLVLYNLSKSY
Horse           KEQLRVLKGRTSGDILVLYNLSKSY
Dog             
Chicken         
KEEKRVFEGRTNGDILVLYNLSKHYRRFFQ-NIIAVQDISLGIPKGECFGLLGVNGAGKSTTFKMLNGE
TSGDILVLYNLSKHYRRSFQ-KIIAVQDISLGIPKGECFGLLGVNGAGKSTTFKMLNGEV
Chimp           KEEKRVFEGRTNGDILVLYNLSKHYRRFFQ-N IAVQDI LGIPKGECFGLLGVNGAGKSTTFKMLNGEV
Rat             KEQMRVLEGRTGGDMLVLCNLSKSYR VCR KTTAVHGI LGISRGECFGLLGVNGAGKSTTFKILNGET
VLEGRTGGDMMVLCNLSKSYRSVFGGKTTAVHGISLGIPRGECFGLLGVNGAGKSTTFKILNGET
Cow             KEQVRVLKGRTSGDTLVLYNLSKSYR FFK-S TAVQDI LGVRRGECFGLLGVNGAGKTTTFKMLTGDL





+/- +/- +/+ +/+
- Taq1     - Taq1
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Indeed, the equivalent amino acid has been shown to be mutated in the ABCC6 gene 
causing pseudoxanthoma elasticum - a multi-organ disorder characterised by ectopic 
mineralisation of connective tissues (Bergen et al., 2007). 
 
In a larger population study of 2193 cases, 4 R4728X heterozygotes were found in cases 
diagnosed with schizophrenia, 1 with schizophrenia co-morbid with mental retardation 
(MR), 4 with bipolar disorder, 2 with MDD.  One control individual in the initial 1327 
control sample group was also found to be a heterozygous carrier. Typing of a second 
control population, composed of 1043 individuals from the 1936 Lothian Birth Cohort, 
identified 4 further carriers. However, neither population of controls had been formally 
screened for psychiatric diagnoses or family history of psychiatric illness and the mental 
health of controls is therefore unknown.  
 
Consequently, the MAF is calculated to be <1% (0.0025 cases; 0.0010 controls), relating 
to an OR of 2.4 (Confidence Interval [CI] 0.8-7.0) and a p-value of P=0.076, (fisher’s 
exact test, one tailed) again indicating a trend in significance. Follow-up studies of 
relatives of carrier cases indicate that R4728X shows clear co-segregation with illness in 
two multiplex families presenting with bipolar disorder and MDD and two small 
families with schizophrenia and MDD (figure 4.10a-d).  
Haplotype background of T4031A and R4728X  
Single nucleotide polymorphisms in the region of T4031A and R4728X were sequenced 
in relatives and probands with these variants. The conserved patterns of nearby SNPs 
observed in the sequence of 4 carriers of T4031A and 20 carriers of R4728X imply that 
the two mutant alleles each arose once on a common (but different) haplotype 
background. This suggests all present-day cases of these two mutations are descended 
from two British/European ancestors. As shown in figure 4.11, the haplotypes cover a 
genomic region which may form one large LD block or two smaller LD blocks relating 






























Figure 4.10 Co-segregation of R4728X with illness in four pedigrees. Arrows denote probands. 
Diamond shapes and numbers within represent the number of non-affected individuals. 






Family 4 (R4728X) Family 3 (R4728X) 
Family 5 (R4728X) Family 6 (R4728X) 































Figure 4.11 Conserved background haplotypes carrying the R4728X and T4031A mutations. (a) 
SNP ID, genomic location and alleles comprising the two background haplotypes. * denotes the 
haplotype carrys the MAF and ‡ indicates the 5 SNPs used for haplotype frequency analysis. (b) 
The frequency of the R4728X or T4031A background haplotypes in the general population 
based on data from 5 SNPs and 3 SNPs respectively (red rectangles). 
(b) 
SNP rs1526093 ‡ rs17132289‡ rs 6978753 T4031A rs17548783‡ rs1316349‡ R4728X rs7778411‡ rs10243913 rs10046546
Location 48,377,763 48,399,261 48,414,116 48,420,683 48,420,703 48,538,589 48,534,458 48,597,191 48,625,307 48,625,315
Allele G* A A* A C* G C* C* G* A
R4728X
Allele A A G G* T G T − − −
T4031A
LD BLOCK 1 LD BLOCK 2
* denotes minor allele








The nonsense mutation is carried on a haplotype spanning the entire sequenced region; 
however, the T4031A is carried on a shorter haplotype spanning only the first LD block. 
To investigate how common these haplotypes are in the general population, in phase 
data from five known SNPs (rs1526093, rs17132289, rs17548783, rs1316349, 
rs7778411) were down loaded for 30 CEPH trios from HapMap Phase II build 125 
(http://www.hapmap.org.). The frequency of the 5 SNP R4728X-carrying haplotype was 
found to be less than 10% in the general population. In contrast, based on data pertaining 
to 3 SNPs only (figure 4.11b), T4031A is carried on a background haplotype far more 
common (~54%).  
 
Mutation 3: R4843C 
 
The third novel variant positioned within the NBDs, R4843C, was initially detected in 
one control individual. This non-conservative amino acid substitution from arginine to 
cysteine, occurs proximal to the signature ABC motif and is highly conserved between 
species (Figure 4.12).  To assess whether this variant was a benign ultra-rare variant, a 
further 1870 cases and 1125 controls samples were genotyped (Table 4.5). Nineteen 
cases, 12 schizophrenia, 5 BP and 2 MDD, and 7 controls were identified and confirmed 
as heterozgotes. The frequency of R4843C is therefore estimated to be 0.005 for cases 
and 0.003 controls, p= 0.13, resulting in an OR of 1.6 (CI 0.7 to 4.0). 
Follow-up studies of proband relatives led to the identification of three small families 
(presented in figure 4.13) and co-segregation with illness was observed in two of the 
three families. In the first family, the mother of the proband has bipolar disorder and the 
proband schizoaffective disorder and both are heterozygous for R4843C. Neither of the 
parents in family 8 is affected. However, the father is a carrier and there is family history 
of suicide on the paternal side. In family 9 the mother of the proband who has bipolar 











Figure 4.12 Sequence trace, amino acid position and conservation of R4843C. (a) Sequence 
chromatogram of heterozygous mutant for R4843C. (b) ABCA subfamily and species 
conservation of the wildtype arginine (shown red) amino acid. The arginine residue is 








Figure 4.13 Small families carrying the R4843C variant. In family 7 the mother and proband are 
both affected and carriers. The parents in family 8 are both not affected, however, the father is a 
carrier and there is family history of suicide on the paternal side. R4843C does not appear to 
segregate in family 9 as both the mother and a sibling are affected but not carriers of R4843C. 
      RRLHLEAHADKPVATYSGGTKRKLSTALALVGKPDILLLDEPSSGMDPCSKRYLWQTIMKEVR
monkey   RRLHLEAHADKPVATYSGGTKRKLSTALALLGKPDILLLDEPSSGMDPCSKRYLWQTIMKEVREGCAAVL
Chimp           RRLHLEAHADKPVATYSGGTKRKLSTALALVGKPDILLLDEPSSGMDPCSKRYLWQTIMKEVREGCAAVL
Rat             RRLHLELHVDKPVATYSGGTRRKLSTALALVGKPDILLLDEPSSGMDPCSKRYLWQTI
Mouse           RRLHLESHVDKPVATYSGGTRRKLSTALALVGKPDILLLDEPSSGMDPCSKRYLWQTITQEVRDGCAAVL
Cow             RRLHLEAHVDKPVATYSGGTKRKLSTALALLGKPDLLLLDEPSSGMDPCSKRHLWEALRKEAEEGCAVVL
Horse           RRLHLEAHVDKLVATYSGGTKRKLSTALALLGKPDLLLLDEPSSGMDPCSKRY
Dog             ERLGLEAHVDQLVATYSGGTRRKLSTALALLGSPDLLLLDEPSSGMDPCSKRHLWRTITQEARRGCAVVL
Chicken         NRLQLNAHADKLVRTYSAGTKRKLSAALALVGKPQILLLDEPSSGMDPCSKRYLWKTILKEVQDGCAAVL
          SLTSGHAIIRTPMGDAVDLSSAGTAGVLIGYCPQQDALDELLTGWEHLYYYCSLRGIPRQCIPEVAGDLI 
nkey   SPTSGHAIIRTPMGDAVDLSSAGTAGVLIGYCPQQDALDELLTGWEHLHYYCSLRGIPRQCIPEVAGDLI 
Chimp           SPTSGHAIIRTPMGDAVDLSSAGAAGVLIGYCPQQDALDELLTGWEHLYYYCSLRGIPRQCIPEVAGDLI 
Rat             PPSSGYATIRTPQGDMVDLASAGKVGVLIGYCPQQDALDELLTGWEHLQYYCRL GIPKQNIPEVAADLV 
e           PPSSGYTVIRTPQGDMVDLASAGKAGILIGYCPQQDALDELLTGWEHLQYYCRLRGIPKQYIPEVAADLV 
Cow             PPSSGHAVVRTPTGEDVNLSLAGAAGIRIGYCPQQDALDELLTGWEHLHYYCCLHGIPKQSIPKVAGDLV 
Horse           PPTSGHAVIRTPMGEDVELSFAGAAGIRIGYCPQQDALDELLTGWEHLDYYCSLRGIPKSCISEVAGDLV 
Dog             PPTSGHAVIRTPAGELLDLGAAGAAGLRIGYCPQQDALDELLTGWEHLDYYCRLRGVPSPSIPQVAGDLV 
Chicken         VPSAGRAVIRTPTGSEMDILSASSEGILIGYCPQQDALDELLTGWEHLYYYCTLRGIPKQNICKVAEDLV 
Homo            R
Rhesus monkey   R
Chimp         R
Rat         R
Mouse         R
Cow         R
Horse         R
Dog         E
Chicken         N
 







ABCA13_Homo   RRLHLEAHADK
ABCA12_Homo   RRLHLMPFKDR
ABC 7_Homo    ARLGLSWYADR
ABCA4_Homo    KSLGLTVYADC
ABCA1_Homo    RKLGLVKYGEK
ABCA2_Homo    EKLELTKYADK
ABCA3_Homo    RGLLLEPHANK
ABCA13_Homo   SLTSGHAIIRTPMGDAVDLSSAGTAGVLIGYCPQQDALDELLTGWEHLYYYCSLRGIPRQCIPEVAGDLI
ABCA12_Homo   IPSSGNILIRNKTGSL
ABCA7_Homo    LASRGEAVLAGHSVA
ABCA4_Homo    TVTSGDATVAGKSI
ABCA1_Homo    TVTRGDAFLNKNSI
ABCA2_Homo    STTGGEAFVNGHSV
ABCA3_Homo    SLTSGDAFVGGHRIS
(b) (a) 
(c) 
Family 7 (R4843C) Family 8 (R4843C) Family 9 (R4843C) 
CIPEGIPRQCIPEVAGDLIRR   CLHLEAHADKPVATYSGGTKRKLST
Nucleotide Binding Domain 2
ABC signature motif
= R4843C carrierDiagnosis = MDDDiagnosis = BP 
unknown
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However, no information is available regarding the father’s phenotype. Multiple genetic 
risk variants may contribute to these clinical phenotypes in addition to R4843C inherited 
from the father. 
Mutation 4: S3704R 
 
The non-conservative amino acid substitution of a serine to arginine (S3704R) located 
within a transmembrane loop of the first TMD, was detected in the heterozygous state in 
one proband from a large family with schizophrenia and MDD (Figure 4.14). 
Genotyping large case-control cohorts revealed no further cases (0/1763 samples) or 
controls (0/1039) to be heterozygous carriers. Moreover, S3704R was found to co-
segregate with illness in this large family, as shown in figure 4.14e. It is clear, however, 
that S3704R does not show full penetrance as several asymptomatic family members 
were found to be heterozygous. 
 
In addition to its amino acid substitution, this mutation introduces a novel cryptic splice 
donor site as assessed using the Berkeley Drosophila Genome Project splice site 
predication tool (http://www.fruitfly.org/seq_tools/splice.html). The introduction of a 
novel donor splice site potentially results in a transcript with a downstream frameshift 
and premature stop codon. Calculated MAFs for S3704R are 0.0003 cases, 0.000 
controls, p= 0.62 (Fisher’s exact test, one tailed), and OR infinity. Hence, S3704R 
displays all the typical features of a rare Mendelian, highly penetrant, deleterious 
mutation. 
 
Mutations 5: H3609P 
 
H3609P positioned within transmembrane loops of the first TMD, was initially 
identified in 3 cases of schizophrenia and one control. This variant involves a non-
conservative amino acid substitution of a highly conserved histidine to proline. A 
sequence chromatogram, amino acid position and conservation for H3609P is presented 

























Figure 4.14 Sequence chromatogram, splice variant sequence, amino acid position, 
conservation and segregation of S3704R with illness in a large pedigree. (a) Sequence 
chromatogram of heterozygous mutant for S3704R. (b) Schematic of novel splice donor site. (c) 
Position of amino acid substitution in the first TMD. Transmembrane domains are coloured 
purple. (d)  ABCA subfamily and species conservation of the wildtype serine (shown red). The 
serine residue is highly conserved between species. (e) Family pedigree in which S3704R co-
segregates with illness. The black dot denotes a S3704R heterozygote. ‘Unknown’ denotes 






NTAALCTSLVYMISFLPYIVLLVLHNQLS   RFVNQTFLCLLSTTAF
Transmembrane Domain Cluster 1 
ABCA13   AIVLKTS
ABCA12   IIILKFG
ABCA7    VLVLKLG
ABCA1    VVILKLG
ABCA4    TIFIMHG
ABCA3    TLLFCVKVKPNVAVLSRSDPSLVLAFLLCFAISTISFSFMVSTFFSKANMAAAFGGFLYFFTYIPYFFVA
ABCA2    TAILKYG
ABCA5    AVIATAS
ABCA8    ALVIRST
ABCA10   ALVITSI
  VL----HNQLSFVNQTFLCLLSTTAFGQGVFFITFLEGQETGIQWNNMYQALE
ABCA12   TV----ENELSYVLKVFMSLLSPTAFSYASQYIARYEEQGIGLQWENMYTSPVQDDTTSFGWLCCLILAD
ABCA7    AW----RDRLPAGGRVAASLLSPVAFGFGCESLALLEEQGEGAQWHNVGTRPT
ABCA1    AW----QDYVGFTLKIFASLLSPVAFGFGCEYFALFEEQGIGVQWDNLFESPVEEDGFNLTTSVSMMLFD
ABCA4    AW----QDRMTAELKKAVSLLSPVAFGFGTEYLVRFEEQGLGLQWSNIGNSPTEGDEFSFLLSMQMMLLD
ABCA3    PR----YNWMTLSQKLCSCLL NVA AMGAQLIGKFE KGM IQWRDLLS VNVDDDFCFGQVLGMLLLD
ABCA2    IREEVAHDKITAFEKCIASLMSTTAFGLGSKYFALYEVAGVGIQWHTFSQSPVEGDDFNLLLAVTMLMVD
BCA5    L-----IESFPKSLVWLFSPFCHCTFVIGIAQVM
ABCA8    ------YRHLPASLEWILSLLSPFAFMLGMAQLLHLDYDLNSNAFPHPSD
ABCA10   ------YRQLPLSLGWVLSLLSPFAFTAGMAQVTHLDNYLSGVIFPDPSG
GIFAHSNTFIVFLFLLDFGMSVVMLSYLLSAFFSQ NT ALCTSLVYMISFLPYIVLL 
MSYLISVFFNNTNI ALIGSL YII FFPFIVLV 
DILPYSHPGVVFLFLAAFAVATVTQSFLLSAFFSR NL AACGGLAYFS YLPYVLCV 
NLLPYSDPSVVFVFLSVFAVVTILQCFLISTLFSR NL AACGGIIYFT YLPYVLCV 
ACSGV YFTLYLPHILCF 
ABCA3    TLLFCVKVKPNVAVLSRSDPSLVLAFLLCFAISTISFSFMVSTFFSK NM AAFGGF Y FTYIPYFFVA 
QVLMHSHVVIIWLFLAVYAVATIMFCFLVSVLYSK KL SACGGIIYFLSYVPYMYVA 
LLFPQSSSIVIFLLFFLYGLSSVFFALMLTPLFKKSKHVGIVEFF TVAFGFIGLMII 
QFIILSGFMVVFSLFLLYGLSLVALAFLMSILVKKSFLTGLVVFL TVFWG LGFTSL 
PIVFHTGFMVIFTLYSLYGLSLIALAFLMSVLIRKPML GLAGFLFTVFWG LGFTVL 
Homo            
Rhesus monkey   AIILKTSGIFAHSNAFIIFLFLLDFGMSVVMLSYLLSAFFNQANTAALCTSLVYMISFLPYIVLLVLHNQ
Chimp           AIVLKTSGIFAHSNTFIVFLFLLDFGMSVVMLSYLLSAFFSQANTAALCTSLVYMI
Dog             AVILKVSGIFAHSNACIVFLFLLDFGVSVVMLSYLLGAFFSRANTAALWASLVYMISFLPYIVLLVLRNQ
Rat             ALILKMSGIFMHSDAFIIFLYLLNFGVSAVMLSYFLSVFFNKANTAALCTSLGYMISFLPYVVLLVLHNQ
Mouse           AVILKMSGIFMHSDAFIIFLYLLDFGVSAVMMSYFLSVFFNQANTAALCTS
Horse           ALILKISGIFAYSNACIVFLFLLDFGVSVIMLSYFLSTFFSQANTAALCTSLVYLISFLPYIVLLVLHNQ
Cow             ALVLKVSGIFTYSSAWIVFLFLLDFAVSVVTLSYLLSALFSRASMAALCSSLLYTASFLPYIVLLVLHDQ
Chicken         AVILKASGIFTYSNGFLIFLFLLDFGVTVIMLSYFLGVFFSSANTA
Homo            LSFVNQTFLCLLSTTAFGQGVFFITFLEGQETGIQWNNMYQALEQGG
monkey   LSFVIQTFLCLLSTTAFGQGVFFITFLEGQETGIQWNNMYQAPEQGG
Chimp           LSFVNQTFLCLLSTTAFGQGVFFITFLEGQETGIQWNNM
Dog             LSVIVQMFLCLLSTTAFGQGVFFVTFLEGQEAGVQWDNLSQPPEQMG
Rat             LSFALQTLLCLLSTTAFGQGVFFITFLEGQEEGIQWGNMYRAPEPGG
Mouse           LSFAIQTLLCLLSTTAFGQGVFFITFLEGQEEGI
Horse           LNVVIQTFLCLLSTTAFGQGVFFITFLEGQEAGIQWNNMYQAPEQAG
Cow             MGATLQTLLCLLSTTAFGQGVFFITFLEGQEAGIQWDNMYQSPEVAG
Chicken         LSFTKQIIMCLLSTTAFGQGVFFITFFEG
AIVLKTSGIFAHSNTFIVFLFLLDFGMSVVMLSYLLSAFFSQANTAALCTSLVYMISFLPYIVLLVL----HNQ 
monkey   AIILKTSGIFAHSNAFIIFLFLLDFGMSVVMLSYLLSAFFNQANTAALCTSLVYMISFLPYIVLLVL----HNQ 
Chimp           AIVLKTSGIFAHSNTFIVFLFLLDFGMSVVMLSYLLSAFFSQANTAALCTSLVYMISFLPYIVLLVL----HNQ 
Dog             AVILKVSGIFAHSNACIVFLFLLDFGVSVVMLSYLLGAFFSRANTAALWASLVYMISFLPYIVLLVL----RNQ 
Rat             ALILKMSGIFMHSDAFIIFLYLLNFGVSAVMLSYFLSVFFNKANTAALCTSLGYMISFLPYVVLLVL----HNQ 
LGYMISFLPYVVLLVL----HNQ 
Horse           ALILKISGIFAYSNACIVFLFLLDFGVSVIMLSYFLSTFFSQANTAALCTSLVYLISFLPYIVLLVL----HNQ 






































Figure 4.15 Sequence chromatogram, amino acid position and conservation of H3609P and 
R3604Q. (a) Sequence chromatogram of heterozygous mutant for H3609P. (b) Sequence 
chromatogram of heterozygous mutant for R3604Q (c) Position of amino acid substitutions in the 
first TMD. Transmembrane domains are coloured purple. (d)  ABCA sub-family and species 
conservation of the wildtype histidine and arginine residues (shown red). Both amino acids are 












         LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEQEIQIEEYMRMMGVHPVIHFLAWFLENMAVLTISSATL
monkey   LFLNNVGFFFPLILMLTWMVSVASMVRKLVYEQEIQIEEYLRMMGVHPMTHFLAWFLENMVVLTVSSAAL
Chimp           LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEQEIQIEEYMRMMGVHPVIHFLAWFLENMAVLTISSATL
g             LFLNNVGFFFPLIMMLTWMVSVASMVRRLVYERQTQIEEYMRMMGVHSTVLFLAWFLENVATLALSSAAL
Rat             LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEREIQIEEYMRIMGLHPVIHFLSWFLENMATLALSSAAL
Mouse           LFLNNVGFFFPLIMMLTWMVAVASMVRKLVYEREIQIEEYMRMMGLHPTIHFLSWFLENMATLALSSA
Horse           LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEREIQIEEYMRMMGVHPTIHFLAWFLENMAMLAISSAAL
Cow             LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEREIQLEEYMRMMGVHPAVHFLAWFLENVAVLTVSSAAL
Chicken         LFLNNIGFFFPLMMMLTWMVSVASMVRKLVYEREIHLEEYMKTMGVHPAIHFFAWFLENVIVL
Homo            LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEQEIQIEEYM
Rhesus monkey   LFLNNVGFFFPLILMLTWMVSVASMVRKLVYEQEIQIEEYL
Chimp           LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEQEIQIEEYM
Dog             LFLNNVGFFFPLIMMLTWMVSVASMVRRLVYERQTQIEEYM
Rat             LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEREIQIEEYM
Mouse           LFLNNVGFFFPLIMMLTWMVAVASMVRKLVYEREIQIEEYM
Horse           LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEREIQIEEYM
Cow             LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEREIQLEEYM
Chicken         LFLNNIGFFFPLMMMLTWMVSVASMVRKLVYEREIHLEEYM
LFLNNVGFFFPLIMMLTWMVSVASMVRKLVYEQEIQIEEYMRMMGVHPVIHFLAWFLENMAVLTISSATL
FLTSVSYSLPIVLMVAWVVFIAAFVKKLVYEKDLRLHEYMKMMGVNSCSHFFAWLIESVGFLLVTIVIL
ABCA7    VFLRVLSRSLPLFLTLAWIYSVTLTVKAVVREKETRLRDTMRAMGLSRAVLWLGWFLSCLGPFLLSAALL
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Genotyping a total of 1707 cases and 1039 controls samples revealed 27 cases and 9 
control individuals were heterozygous and one individual with bipolar disorder 
homozygous for H3609P. Allele frequencies for H3609P in the case population (0.0085) 
and control population (0.0043) shows a statistical significant difference, p=0.048 
(Fisher’s exact test, one tailed), and correspond to an OR of 1.9 (CI 0.9-4.0). 
Furthermore, analysis of nearby SNPs in a limited number of unrelated carriers suggests 
that, like T4031A or R4728X, H3609P may have arisen on a common haplotype 
background (data not shown). 
 
Segregation in eight small families with schizophrenia, bipolar disorder and MDD 
indicated that H3609P was inherited by every case investigated and that H3609P 
displays incomplete penetrance (figure 4.16).  In three multiplex pedigrees more than 
one affected sibling was identified. Three male siblings with schizophrenia (family 11), 
one male sibling with schizophrenia and one female sibling with MDD (family 14) and 
three female siblings, two of which have bipolar disorder and one MDD (family 17) 
were all found to be H3609P heterozygotes. 
 
 The remaining five families consist of two parents and an affected child, in three of 
which both parents are unaffected (families 13, 15, 18). In the fourth single child family 
(family 12) the father has MDD and carries H3609P. In the fifth family (family 16) the 
mother was diagnosed with BP but does not have the variant, whereas the father, with a 
diagnosis of alcoholism, was found to be a carrier. This finding does not indicate a lack 
of H3609P segregation with illness as evident from the other families but could suggest 
that a risk factor associated with bipolar disorder illness from the mother differs from 


































Figure 4.16 Family pedigrees carrying H3609P. The probands are denoted by a black arrow. 
Unknown indicates the phenotype is unknown and a question mark denotes unknown genotype.  
"Other" diagnoses are:  major depression -single episode; minor depression; generalised  
anxiety disorder and alcoholism. Arrows indicate probands.  Unknown denotes unknown 
phenotype and ‘?’ represents unknown genotype. 
?
unknown








Family 11 (H3609P) Family 12 (H3609P) 
?
Family 13 (H3609P) 
Family 14 (H3609P) Family 15 (H3609P) Family 16 (H3609P) 
Family 18 (H3609P) 
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Mutations 6: R3604Q 
 
A third variant positioned within transmembrane loops of first the TMD, R3604Q, was 
initially identified in one patient with schizophrenia (figure 4.15). R3604Q, a non-
conservative substitution of arginine to glutamine, was not found in any additional cases 
(total genotyped 1766) but present in one control out of 1051 sampled. Therefore, the 
difference in allele frequency between cases and controls (cases 0.0003, controls 0.0005) 
was found not to be statistically significant. The proband with schizophrenia initially 
detected with R3604Q belongs to a small family presenting with illness as shown in 
figure (4.17). The father and two siblings with affective disorders schizophrenia were 
found to be R3604Q heterozygotes.  
 
Mutations 7: T4550A 
 
T4550A results in a non-conservative amino acid substitution from threonine to alanine 
(figure 4.18). This variant, positioned within the third transmembrane spanning domain, 
was initially detected in the heterozygous state in one case with schizophrenia. A total of 
1708 cases and 1038 controls were typed, leading to the identification of a further 18 
heterozygous cases and 3 heterozygous controls individuals.  
 
The difference in allele frequencies between the two cohorts (0.0056 cases, 0.0014 
controls) was found to be significant (p=0.013, Fisher’s exact test, one-tailed), 
corresponding to a moderately high OR of 3.8 (CI 1.1-12.7). Furthermore, two small 
pedigrees, one with two affected siblings with schizophrenia, were found to carry 


























Figure 4.17 Family pedigree carrying R3604Q. The proband is denoted by a black arrow. 
"Other" diagnoses are:  major depression - single episode, minor depression, generalised  







































Figure 4.18 Sequence chromatogram, amino acid position, AA conservation and segregation of 
T4550A. (a) Sequence chromatogram of heterozygous mutant for T4550A. (b) ABCA sub-family 
and species conservation of the wildtype threonine residue (shown red). T4550A is less 
conserved between ABCA family members (c) Position of amino acid substitution in the second 
TMD. Transmembrane domains are coloured purple. (c) Two small families identified 
withT4550A. The variant was found to be carried by two siblings with schizophrenia in one small 
family and in one proband with bipolar disorder and two individuals not affected in a second 
family. 
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A second novel variant located within TMD2, R4590W, is also positioned within a 
transmembrane-spanning domain (figure 4.19c). The wild-type arginine is highly 
conserved phylogenetically and in its mutated state substituted by a tryptophan residue 
(figure 4.19b).  R4590W was originally identified in one control individual. Subsequent 
genotyping indicated a total of 17 cases (out of 1946 cases sampled) and 5 controls (out 
of 1071 genotyped) were heterozygous for R4590W. This relates to an OR 1.9 (CI 0.7 to 
5.1). However, the frequency difference, 0.0044 cases and 0.00223 controls, is not 




Finally, another low frequency variant, H4262R, located distal to the hydrophobic 
dipping region (HDR) was found only in one individual with schizophrenia and in an 
unaffected sibling in a total of 1817 cases and 1080 controls (figure 4.20b). This variant 
results in an amino acid change from a highly conserved histidine residue to an arginine 
amino acid, as shown in figure 4.20. While this substitution involves residues from the 
same basic group, arginine is classified as very basic whilst histidine has a relatively 
weak affinity for hydrogen atoms and is only partly positive at neutal pH. Therefore, 
although this variant may potentially perturb tertiary structure, in the absence of further 
data, e.g. strong familial segregation, clear association cannot be confirmed.  
 
The locations of all nine putative pathogenic mutations discussed above are summarised 














Figure 4.19 Sequence chromatogram, amino acid position and conservation of R4590W. (a) 
Sequence chromatogram of heterozygous mutant for R4590W. (b) ABCA subfamily and species 
conservation of the wildtype arginine residue (shown red). (c) Position of amino acid substitution 
















Figure 4.20 Sequence chromatogram, amino acid position and pedigree with H4262R. (a) 
Sequence chromatogram of heterozygous mutant for H4262R. (b) Small pedigree identified with 
two H4262R heterozygotes. (c) Position of amino acid substitution in intracellular loop after the 
hydrophobic dipping region. Residues shown purple indicate membrane dipping region.  
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Figure 4.21 Schematic representation of the functional domains within ABCA13 and the 
locations of the identified putative mutations. The long N-terminal cytoplasmic tail and 3’ C-
terminus are not depicted. The mutations do not appear to cluster in any one functional domain. 
Representation based produced using the TOPO2 protein modeling program (Johns 
S.J.,TOPO2, Transmembrane protein display software, http://www.sacs.ucsf.edu/TOPO2/). 
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4.2.2.5 Further assessment of the pathogenic nature of identified coding variants 
The potential pathological nature of the nine point mutations was suggested by type of 
variant, conservation of mutated residues, differences in allele frequencies between 
cases and controls, and variant segregation in affected family members. Furthermore, the 
consequences on protein structure and function of one variant, T4031A, were predicted 
by means of sequence analysis and a structural modelling.  To assess further the nature 
of the identified amino acid substitutions, Ben Pickard examined eight of the nine 
potential mutations (the R4728X nonsense mutation was omitted), the two additional 
non-synonymous variants with as yet unknown status, and three non-synonymous 
‘potential control’ polymorphisms within ABCA13 using the computational models 
PolyPhen, PMUT and Panther PSEC. These computational tools aim to predict the 
pathological consequences of mutated residues within a protein sequence.  
 
The results showed discrepencies in predications between the models, as indicated in 
table 4.6 (Pickard, B. unpublished observation). However, there was a trend towards the 
control variants (common non-synonymous amino acid changes) being predicted as 
neutral or benign by two of the models and the variants with significant ORs showing 
pathological likelihood. No putative pathogenic variant was predicted to be 
damaging/deleterious by all three models and only one tool (Panther) recognised the 
significance of the T4031A substitution, although this tool over-estimated the 
pathological nature of the control variants. An important consideration for future studies 
is to clarify the functional outcome of the identified putative pathogenic variants using 
direct biochemical or functional assays. 
 
4.2.2.6 Cases carrying multiple rare risk variants 
 
A total of 6 cases were found to be compound heterozygotes for two risk variants (listed 
in table 4.7) and a further affected individual biallelic for H3609P. In contrast, all 
controls carriers were found to be monoallelic. Unfortunately, follow-up family studies 











Table 4.6 In silico prediction of the functional/pathological consequences of all 13 newly 
identified non-synonymous variants. Eight of these variants have association/family evidence 
consistent with a role in psychiatric illness, 2 are of unknown status (P4648A and I4841V) and 3 
are putative polymorphisms (L4047V, R4454C, L4464, MAF>1%) and included as negative 
controls. The R4728X nonsense mutation was not included. The red shading in the odds ratio 
column highlights the variants associated with risk. Results are shown for the three in silico 
predictive tools used; Pmut, PolyPhen and Panther, and are colour-coded (grey for moderate 
evidence and red for strong evidence) for predicted pathological consequence. * denotes the 
T4031A variant predicted to be pathogenic by means of structural modelling. Analysis performed 











Table 4.7 Affected individuals identified as being biallelic for risk variants. Six individuals are 
compound heterozygotes and one case homozygous for H3609P. Although the risk status of 
I4841V is unknown, details are included. 
Results from pmut Results from PolyPhen Results from Panther
Variant AA Odds ratios NN output Reliability Prediction
PSIC 
difference Prediction subPSEC  Pdeleterious  
1 T4031A* infinity 0.291 4 NEUTRAL 1.486 BENIGN -6.443 0.969
3 R4843C 1.6 (0.7 - 4.0) 0.901 8 PATHOLOGICAL 2.257 PROBABLY DAMAGING -2.934 0.484
4 S3704R infinity 0.730 4 PATHOLOGICAL 1.613 POSSIBLY DAMAGING No result
5 H3609P 1.9   (0.9 - 4.0) 0.949 8 PATHOLOGICAL 2.734 POSSIBLY DAMAGING -3.320 0.579
6 R3604Q 0.5 (0.03 - 9.5) 0.721 4 PATHOLOGICAL 1.357 BENIGN -4.415 0.805
7 T4550A 3.8  (1.1 - 12.7) 0.328 3 NEUTRAL 1.238 BENIGN -3.013 0.503
8 R4590W 2.4 (0.8 - 7.0) 0.992 9 PATHOLOGICAL 2.257 PROBABLY DAMAGING No result
9 H4262R infinity 0.567 1 PATHOLOGICAL 2.284 PROBABLY DAMAGING -3.123 0.531
P4648A 0.448 1 NEUTRAL 2.100 PROBABLY DAMAGING -3.949 0.721
I4841V 0.056 8 NEUTRAL 0.620 BENIGN -3.114 0.528
L4047V 0.209 5 NEUTRAL 1.017 BENIGN -4.132 0.756
R4454C 0.928 8 PATHOLOGICAL 2.257 PROBABLY DAMAGING -4.460 0.812
L4464M 0.038 9 NEUTRAL 0.792 BENIGN -3.550 0.634
http://mmb2.pcb.ub.es:8080/PMut/ http://genetics.bwh.harvard.edu/pph/ http://www.pantherdb.org/
tools/csnpScoreForm.jsp
Individual Variant 1 Variant 2 Diagnosis
1 T4031A T4550A SCZ
2 T4031A T4550A BP1
3 T4031A I 4841V BP1
4 H3609P R4590W BP1
5 H3609P R4590W BP1
6 H3609P T4550A BP1
7 H3609P H3609P SCZ
SCZ, schizophrenia; BP1, bipolar disorder 1. 
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Intriguingly, these biallelic affected individuals all present with more serious diagnoses 
(bipolar disorder I or schizophrenia) and hence provide support that for the supposition 
that rare variant allelic interactions across ABCA13 potentially increase susceptibility to, 
and severity of, psychiatric illness. 
 
4.2.2.7 Association and linkage analysis 
 
The rarity of these variants makes significant p-values difficult to achieve even in 
sizeable populations. Nevertheless, two risk variants (T4550A and H3609P) show 
significant individual genotype p-values and two (T4031A and R4728X) demonstrate a 
trend towards significance.  However, to avoid a potential bias in estimates of the effect 
size, p-values for individual variants were also calculated for the frequency data derived 
from the secondary ‘replication’ TaqMan genotyping stage alone, i.e. the sequencing 
discovery sample numbers were excluded. Table S1, appendix 2, presents these 
corrected p-values for all cases per variants as well as p-values calculated for each 
variant for Scz, BP and MDD separately.  
 
The Chi Square test (χ2) was used to calculate the collective significance of the burden 
of all newly identified nonsynonymous variants with a minor allele frequency of less 
than 0.01. Total numbers included 31 mutated alleles in 12175 control individuals and 
101 mutated alleles in 16739 joint case individuals, giving a significant global p-value of  
<0.0001 (1 tailed, sequencing and TaqMan genotyping data combined). Moreover, 
excluding the initial discovery sequencing data to ensure an unbiased estimate, the 
global p-value remains significant 0.00026 (corrected TaqMan replication frequency 
data only). This corresponds to an OR of 2.1: 95% CI lower limit 1.5 (TaqMan 
replication frequency data only).  
 
Similarly, using the same inclusion criteria but also including a family carrying a CNV 
located with ABCA13 (discussed in section 4.23), a non-parametric single point linkage 
analysis which estimates identity by descent (IBD) between all pairs of affected relatives 




) (Kong and Cox, 1997). These results indicate significant linkage of 
ABCA13 mutations with psychiatric phenotypes within families. 
 
4.2.2.8 Exploring potential gender effects 
 
Positive associations for schizophrenia and bipolar disorder are commonly reported to be 
gender-specific. To evaluate whether for each of the potentially pathogenic non-
synonymous risk variants there is an obvious over-representation in either gender, the 
percentage of male and female heterozygote carriers was compared to an approximate 
percentage of males and female genotyped. Table 4.8 lists the percentages calculated for 
variants detected in more than one case. Three variants, R4728X, T4550A and R4843C, 
indicate a potential bias in gender, although the scope for interpretation of data from 
such small numbers is limited. R4728X was identified in 4 male cases and 7 female 
cases even though the percentage of affected males typed (55%) were higher than 
females (45%). Conversely, T4550A and R4843C show a potential over-representation 
of male cases carriers to females cases (14 male, 5 female). This may be explained, in 
part, by a larger percentage of male cases successfully typed (T4550A 59.5% vs 50.5%; 
R4843C 55.2% vs 44.8%). 
 
4.2.3 The identification of a CNV within ABCA13 
 
Further evidence lending support for the ABCA13 locus harboring rare pathogenic 
variants comes from the identification of a copy number variant (CNV) showing 
segregation in a large pedigree with schizophrenia and MDD, presented in figure 4.22. 
This CNV was detected in a whole genome CNV screen of schizophrenia cases and 
controls. Using a custom oligo array (Agilent technologies) with 34036 probes covering 
1.5 Mb spanning ABCA13, an 11kb intronic hemizygous deletion positioned between 
exons 55 and 56 within ABCA13 was confirmed to be present in 7 out of 11 family 
members (Tam et al., unpublished data). One family member diagnosed with MDD who 
does not carry this variant is therefore presumed a phenocopy. We postulate that this rare 

























Table 4.8 Comparison of percentage of males and females carrying risk variants. The mean 
percentage of males and females on case and control plates successfully genotyped are listed 
as a comparison.  Variants are listed only if more than one case was detected. Bracketed 
numbers are the total number of cases identified for each variant. 
Variant female (N) % males (N) %
T4031A
case carriers (1) 25 (3) 75
control carriers 0 0
total genotyped cases 45.3 54.7
total genotyped controls* 35.8 64.2
R4728X
case carriers ( 7) 63.6 (4) 36.3
control carriers (3) 60 (2) 40
total genotyped cases 45.0 55.0
total genotyped controls* 35.8 64.2
H3609P
case carriers (12) 42.9 (16) 57.1
control carriers (6) 66.6 (3) 33.3
genotyped cases plates 40.5 59.5
control plates 35.8 64.2
T4550A 
case carriers (5) 26.3 (14) 73.6
control carriers (1) 33.3 (2) 66.6
genotyped cases plates 40.5 59.5
control plates 35.8 64.2
total 38.9 61.1
R4590W  
case carriers (8) 47.1 (9) 52.9
control carriers (2) 40 (3) 60
genotyped cases plates 44.8 55.2
control plates 35.8 64.2
R4843C  
case carriers (5) 26.3 (14) 73.6
control carriers (3) 42.9 (4) 57.1
genotyped cases plates 44.8 55.2
control plates 35.8 64.2












Figure 4.22 Pedigree of family carrying the 11 kb intronic CNV deletion. Heterozygote carriers 
are marked with the black dot. Unknown genotype and phenotype are denoted by a question 
mark and unknown respectively. "Other" diagnoses are:  major depression - single episode, 







Figure 4.23 Schematic illustration of fosmid clones used to investigate a possible deletion in an 
individual with schizophrenia. The exons sequenced encoding the functional domains are 

















Family 23 (CNV)  
 143 
4.2.4 An affected individual homozygous for rare alleles 
 
An individual with schizophrenia screened for mutations within exons 32-40, 43 and 42-
59 was found to be homozygous for all known and new SNPs detected. Moreover, this 
individual was found to be homozygous for three rare alleles (MAF <0.05), suggesting a 
possible deletion on one chromosome along this sequence. To clarify whether this 
individual carried a deletion, FISH was performed using fosmids located within 
ABCA13 in addition to two BACs outside of the ABCA13 locus, and on interphase nuclei 
from control individuals as well as the case. Figure 4.23 schematically illustrates the 
location of the BAC/fosmid clones hybridized in relation to sequenced regions. 
Two fluorescent signals were consistently detected for all ABCA13 clones and control 
BACs as shown in figure 4.24. However, for the adjacent fosmids G248P85917G11 and 
G248P87497D6 there appeared to be a reduced signal on one chromosome 7, suggestive 
of a small deletion. Further analysis using material from control individuals also 
indicated this reduced signal, suggesting signal variation to be inherent to the fosmids 
clones rather than a reduction in chromosomal material specific to the case. DNA from 
this affected individual was further analysed for deletions using the custom oligo array 
(agilent technologies) described above and performed at Sanger. No evidence was found 
for copy number variants (CNVs) over the ABCA13 locus, indicating that a deletion is 
not the cause of homozygosity in this individual. 
Extended tracts of homozygosity may reflect the phenomenon of uniparental disomy 
(UPD) in which a child inherits two copies of a chromosome or chromosome segments 
from one parent. To investigate whether this individual may have UPD, microsatellite 
markers positioned along chromosome 7 were genotyped. The case was found to be 
homozygous for 5 (inter-dispersed) markers and heterozygous for 13 markers including 
the marker D7S519 nearest to ABCA13, shown in figure 4.25. In concert, these data 
disprove the hypothesis that homozygosity for variants located within ABCA13 evident 
in this one individual arises from a deletion or UPD. Nonetheless, this individual may be 












Figure 4.24 Interphase nuclei hybridized with fosmid and BAC DNA in an individual with 
schizophrenia and a potential deletion. Control BACs located outside ABCA13 (a & b), fosmids 








Figure 4.25 Microsatellite marker genotyping on chromosome 7 in an individual with 
schizophrenia. Homozygous markers shaded red, heterozygous markers not filled. The locations 
of the microsatellites and ABCA13 are depicted schematically along the chromosome. 
Fos 2093A10






















































































































































































































































































































































































This chapter reports the fine mapping of a cytogenetic abnormality resulting in the 
disruption of the ABCA13 gene in an individual with chronic schizophrenia and the 
identification of rare coding sequence variants positioned within ABCA13 as a cause of 
schizophrenia, bipolar disorder and major depressive disorder. The findings indicate 
both association of rare variants with disease in the population and linkage of these 
variants within families. Further, the investigation of an affected individual displaying 
homozygosity over the ABCA13 locus led to the conclusion that a deletion within this 
region and UPD of chromosome 7 were not causative factors associated with the clinical 
phenotype. 
 
4.3.1 Cytogenetics and the chromosome 7 region in disease 
 
The identified breakpoint region on chromosome 8p23.1 did not directly disrupt any 
annotated transcripts but was in close proximity to two genes, PPP1R3B which encodes 
a protein phosphatase 1 subunit, and THEX1 which encodes a RNA exonuclease. Protein 
phosphatase-1 proteins have a diverse range of functions in mammalian cells. PPP1R3B, 
a serine/threonine-specific phosphoprotein phosphatase regulatory sub-unit, however, 
targets PP1 to glycogen synthase. Thus it regulates and is necessary for PP1 glycogen 
metabolism (Ceulemans et al., 2002). Moreover, PPP1R3B is expressed ubiquitously 
including in astrocytes at glutamatergic synapses in the brain. Consequently it may play 
an important role in an activity-dependent metabolic ‘tagging’ process – a signaling 
mechanism hypothesized to be important for synaptic plasticity mechanisms (Pellerin 
and Magistretti, 1994). The close proximity of the breakpoint, which could disrupt 
regulatory mechanisms controlling PPP1R3B expression, in conjunction with the 
functional role of this sub-unit in the brain, suggests that PPP1R3B should not be 
dismissed as potentially contributing to the pathology of disease. 
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Cytogenetic analysis of the breakpoint interval on chromosome 7p12.1 indicated that 
ABCA13 was disrupted in the vicinity of exons 30 and 31. The resulting mutated protein 
is predicted to be truncated by approximately 50% of its normal sequence and to lose 
both pairs of functional domains. Even if the extremely long N-terminal cytoplasmic tail 
were a separate transcript product as suggested, the promoter regulatory motifs and 
initial exon(s) adjacent to the functional domains, which are necessary for translation of 
a functional transporter, would be absent from the disrupted protein product. 
Furthermore, it is possible that if ABCA13 were to encode for two half transporter 
transcripts, the second distal transporter might still be transcribed. However, 
unpublished data indicate that only a ‘full transporter’ ABCA13 transcript encoding for 
two transmembrane clusters and NBDs are expressed in mouse and human brain tissue 
(investigated in chapter 5; R. Cannon, personal correspondence). The position of the 
breakpoint is therefore likely to result in lack of functional protein product from the 
disrupted allele and thus is consistent with the hypothesis of haploinsufficiency, i.e. 
insufficient gene product for normal cellular function, underlying the clinical outcome.  
 
Chromosome 7 is a hot-spot for chromosomal abnormalities associated with autistic 
spectrum disorders (ASD). Breakpoint sites along chromosome 7, reported for ASD and 
other clinical phenotypes, are predominately clustered on the long q-arm (Scherer et al., 
2003; Vorstman et al., 2006). Nonetheless, two cases with ASD are reported to have 
cytogenetic abnormalities in the region of 7p12. Wolpert and colleagues describe an 
affected individual with a 20Mb duplication spanning 7p11-p14 (Wolpert et al., 2001). 
In contrast, a reciprocal inversion on chromosome 7 with the p-arm breakpoint identified 
at 7p12 was detected in a second case of ASD (Warburton et al., 2000; Vorstman et al., 
2006). As far as the author can ascertain, both these abnormalities include, or are very 
close to, the ABCA13 locus, and hence they provide some additional evidence of 
potential region-specific dosage effects leading to neuropsychiatric conditions. As yet, 
other than the individual described in the present chapter, no further cases of cytogenic 
disruptions in this interval in individuals schizophrenia, bipolar disorder or MDD have 
been reported.  
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4.3.2 Linking cytogenetics and rare variants: lessons from autism spectrum disorder 
 
Ultra-rare causal and risk variants detected within candidate genes originally identified 
by chromosomal disruptions, e.g. NLGN3, NLGN4, SHANK3, and CNTNAP2, have 
previously been reported for neuropsychiatric disorders. In recent years, research into 
the genetics of ASD has led to the identification of inherited and de novo mutations in 
genes implicated in specific common biological processes. For example, a de novo 
frameshift mutation and an inherited missense mutation within the genes NLGN4 and 
NLGN3 respectively were detected in two pairs of brothers with Autism or Aspergers 
syndrome (Jamain et al., 2003). In a large family with mental retardation, Autism or 
Aspergers syndrome, a 2 base pair deletion resulting in a premature stop codon within 
NLGN4 was found to segregate with all three disorders (Laumonnier et al., 2004). 
Moreover, a single base pair deletion in CNTNAP2 was found in every affected 
individuals from a large Amish pedigree with cortical dysplasia–focal epilepsy (CDFE) 
syndrome - a heterogeneous condition characterized by intractable seizures and autism 
(Strauss et al., 2006). These rare deleterious variants were all found in the homozygous 
state in affected individuals, supporting a recessive, highly penetrant causal nature.  
 
In two candidate, and cytogenetically disrupted ASD genes, SHANK3 and CNTNAP2, 
rare variants were detected in the heterozygous state. In a first resequencing study of 
SHANK3, nine inherited missense mutations, one de novo missense mutation and two de 
novo CNVs were identified as unique to the case population (Moessner et al., 2007). A 
second screen, performed on different case and control cohorts, revealed seven rare 
inherited missense mutations detected in ASD cases only (Durand et al., 2007). 
Furthermore, 13 highly conserved missense mutations (8 predicted deleterious) within 
CNTNAP2 were found unique to individual or multiple cases and at an allele frequency 
lower than 0.00025 (1/4000) (Bakkaloglu et al., 2008). Four of the non-synonymous 
variants reported for CNTNAP2 were identified in pedigrees with more than one affected 
individual and three of these showed segregation with ASD in the affected first-degree 
relatives. Of interest, these variants show not only inheritance from unaffected parents 
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but incomplete penetrance, i.e. carried in non-affected relatives. Moreover, although the 
collective rate of these variants was up to two-fold higher in cases compared to controls, 
owing to their rarity the difference in frequencies did not achieve a statistical threshold 
for an association.  
 
The fact that such heterozygous rare risk variants were identified in the same gene 
(CNTNAP2) found to be disrupted in cases with cytogenetic abnormalities and in which 
a deleterious homozygous frameshift mutation segregates in a large affected pedigree 
indicates that multiple types of causal/risk variants within one gene can contribute to the 
pathogenesis of a disease (Fernandez et al., 2004; Strauss et al., 2006; Bakkaloglu et al., 
2008). These studies also highlight that both private mutations and inherited rare risk 
variants evident in more than one case result in a spectrum of neurobehavioural 
phenotypes. This phenotypic heterogeneity in conjunction with variable expressivity, is 
postulated to be due to the expression of mutations being modulated by other protective 
or liability alleles or non-genetic factors (Laumonnier et al., 2004).  
 
4.3.3 Rare variants in psychiatric illness 
 
With respect to schizophrenia and bipolar disorder, putatively pathological ultra-rare 
non-synonymous variants have been reported in DISC1 (Disrupted in Schizophrenia-1), 
PCM1 (pericentriolar material 1 protein)  and in genes known to cause Wolfram 
syndrome (WS) and Darier disease (DD), two diseases frequently co-morbid with mood 
disorders (Kato, 2001; Song et al., 2008). DISC1, a breakpoint gene disrupted in large 
Scottish family with schizophrenia, bipolar disorder and MDD, is emerging as the best 
supported candidate gene for schizophrenia. An initial mutation detection study of 
DISC1 identified a four nucleotide C-terminal frame-shift deletion predicted to encode a 
protein truncation near the C-terminus. This mutation was present in two affected 
siblings presenting with schizophrenia and schizoaffective disorder and their 
asymptomatic father, but not carried by two siblings with MDD and one sib with 
schizotypal disorder (Sachs et al., 2005).  However, a subsequent re-sequencing study by 
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Green and co-workers did not find this mutation in 655 schizophrenia cases but did find 
it in two of 694 blood donor controls without known history of psychiatric diseases 
(Green et al., 2006). 
 
A third screen of DISC1 using 288 cases with schizophrenia and 288 controls was 
performed by Song and colleagues (Song et al., 2008). Seven heterozygous missense 
variants were found unique to the case population, 1 variant detected only in control 
individual and 6 variants found in both cases and controls. Subsequent genotyping of a 
larger control population revealed 5 missense mutations remained unique to the case 
cohort (three non-conservative AA substitutions, 2 moderately conserved between 
species and 1 found in more than one case) and a further 2 variants had a significant 
difference in frequencies between cases and controls. Unfortunately, the relatives of 
probands were not investigated, and hence whether these variants are inherited or 
segregate with disease is as yet unknown.  
 
Pericentriolar material 1 protein (PCM1), a protein binding partner of DISC1, was 
screened for rare mutations in 32 individuals with schizophrenia and 219 white control 
samples. One novel rare nonsense mutation was detected in the heterozygous state in an 
individual with schizophrenia and absent in the control population. This null mutation 
was subsequently found to be carried by the proband’s affected mother and one sibling 
with schizoaffective disorder but not carried in seven unaffected members of the 
maternal and paternal sibship (Kamiya et al., 2008). 
 
Darier's disease (DD) is a rare autosomal dominantly inherited dermatological disease 
frequently accompanied by neurological disorders such as mild mental retardation, 
epilepsy and psychiatric illness. The mutated gene, ATP2A2, identified as causing 
Darier's disease maps to 12q23−q24.1 and encodes a sarcoplasmic/endoplasmic 
reticulum calcium pump that plays a role in intracellular calcium signalling (Sakuntabhai 
et al., 1999).  The screening of ATP2A2 in cases with neuropsychiatric phenotypes with 
and without DD has produced mixed results. For example, a screen of the gene in 19 
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probands with DD, ten of which presented with neuropsychiatric symptoms, detected 17 
different coding variants and missense mutations. Intriguingly, the mutations, identified 
in the patients with neuropsychiatric features, showed non-random clustering in the 3’ 
half of the gene (Jacobsen et al., 1999). In contrast, a second screen of DD cases with 
neuropsychiatric phenotypes did not find an association between a specific class and 
differential spread of mutations in DD cases with neuropsychiatric features, and 
resequencing ATP2A2 in a cohort of bipolar cases failed to identify any non-
synonymous variants (Ruiz-Perez et al., 1999; Jacobsen et al., 2001). These latter 
findings are in accordance with results from pedigree analysis of DD families showing 
incomplete co-segregation of bipolar disorder and Darrier’s disease (Green et al., 2005). 
Together, this would suggest that mutations within ATP2A2 on their own are insufficient 
to confer major risk for psychiatric illness, but supports instead that the DD locus is in 
linkage disequilibrum with, as yet unidentified, highly penetrant autosomal dominant 
risk factors.  
 
Wolfram syndrome (WFS1) is a rare autosomal recessive neurodegenerative disorder 
characterized by the presence of diabetes mellitus and optic atrophy, although additional 
symptoms such as sensori-neural hearing impairment and psychiatric features are 
reported to be common in WFS1 patients. The WFS1 gene encodes a glycoprotein 
predominately localized in the endoplasmic reticulum whose function is currently 
unknown (Takeda et al., 2001). Homozygous deleterious mutations (usually null 
mutations and unique to a family) within WFS1 give rise to clinically heterogeneous 
WFSL phenotype. However, heterozygous carriers in WFS1 families are 26-fold more 
likely to require psychiatric hospitalization for major depression than non-carriers (Swift 
et al., 1998; Swift and Swift, 2005). Mutation detection studies in patients with 
psychiatric disorders have led to the identification of over 20 rare missense mutations, 
although the causality of some of these variants is hard to interpret as several of studies 
did not include control samples. Furthermore, case control studies of three common 
coding variants indicate a significant association with suicide attempts and completions 
(Crawford et al., 2002; Adolfo Sequeira, 2003). The private nature of most of the 
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identified mutations suggests that multiple but very rare variants within WFS1 may be 
major risk factors for MDD and other psychiatric disorders. 
 
4.3.4 The nature of the ABCA13 rare variants discovered: penetrance issues, variable 
expressivity, and mutation effects 
 
In the present study, 9 putative pathogenic coding mutations within highly conserved 
functional regions of ABCA13 were identified. Follow-up studies did not find evidence 
for any mutation being de novo but showed segregation for 5 of the variants, R4728X, 
S3704R, H3609P, R3604Q and T4550A, within 15 families with severe psychiatric 
conditions. Moreover, segregation analysis indicated incomplete penetrance of variants, 
a finding anticipated from the lack of concordance in monozygotic twins and consistent 
with previous rare variant studies of complex neuropsychiatic diseases discussed above. 
It is worthy of note however, that some second generation members of pedigrees may be 
too young to express a disease phenotype and that this might be a contributing factor to a 
proportion of the variable expressivity.  
 
The occurrence of the same mutations in individuals with phenotypes across the 
psychiatric spectrum supports an overlap of aetiologies for these disorders consistent 
with previous findings. For example, the phenotypic heterogeneity caused by a single 
mutation within ASD candidate genes (discussed above) and a single cytogenetic lesion 
disrupting DISC1 in a large multiplex family (Blackwood et al., 2001). However, 
numerous candidate gene SNP-tag studies have reported the association of a SNP or 
haplotype with one specific psychiatric diagnosis. For example, different common 
haplotypes or variants within the genes NPAS3 and GRIK4 are associated with both 
bipolar and schizophrenia (Pickard et al., 2005a; Pickard et al., 2006). Collectively, 
these findings, would suggest that multiple genetic mechanisms in conjunction with 
environmental factors may differentially influence liability to develop a clinical 
phenotype.   
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Rare variants in other ABCA sub-family members give rise to variable phenotypes.  For 
the majority of cases, and unlike the present findings, different mutations within the 
same gene results in distinct clinical diseases. For instance, loss of function mutations in 
ABCA12 carried in the homozygous or as compound heterozygous state cause a severe 
form of a keratinization disorder known as harlequin ichthyosis, whereas  homozygous 
and heterozygous missense mutations located in the first NBD result in a milder form of 
the disorder- lamellar ichthyosis type 2  (Kaminski et al., 2006). Similar to ABCA12, 
homozygous and compound heterozygote mutations in ABCA1 result in Tangier disease, 
(TD) a severe form of HDL deficiency while rare heterozygous alleles cause low levels 
of high-density lipoprotein cholesterol (HDL-C) a factor which contributes to 
developing coronary artery disease (Bodzioch et al., 1999; Brooks-Wilson et al., 1999; 
Slatter et al., 2008). Furthermore, mutation analysis suggests that where they occur may 
determine the type of clinical presentation. For example, clusters of mutations localized 
within the first extracellular domain and the C-terminus are associated with a 
cardiovascular phenotype, whereas mutations which cluster near to or within the first 
NBD frequently coincide with splenomegaly (Kaminski et al., 2006). 
 
In a third ABCA member, ABCA4, sequence variations cause a variety of degenerative 
retinal dystrophies, e.g. Stargardt disease (STGD), cone-rod dystrophy type 3 (CRD3), 
retinitis pigmentosa type 19 (RP19) and age-related macular degeneration (AMD), 
which vary in clinical severity. Again, there appears to be a broad correlation between 
class of mutation(s) and severity of retinal disease which has led to the formulation of 
the ‘residual activity model’ in which the level of residual ABCA4 protein 
activity/function is hypothesized to determine clinical phenotype (van Driel et al., 1998; 
Rozet et al., 1999). However, the complexity of the genotype/phenotype correlation is 
also illustrated by the observation that a small number of the same rare homozygous and 
complex alleles (compound heterozygote) have been identified in patients with different 
phenotypes (Allikmets, 2000; Kitiratschky et al., 2008).  
 
 153 
These findings suggest that the distribution of variants, class of mutation and allele 
status, i.e. heterozygote, compound heterozygote or homozygote, in mutated ABCA sub-
family members all may be factors influencing disease expression. The spread of rare 
variants detected in the current screen of ABCA13 does not show any clear clustering of 
mutations. As the majority of these variants were found in individuals presenting with 
schizophrenia, bipolar disorder or MDD, there is no evidence supporting that mutation 
location influences clinical expression. However, as only exons encoding the functional 
domains were screened it is still possible that a distribution bias in variant type, which 
may correlate to variable disease presentation, exists.  
 
Missense mutations can give rise to dominant negative effects through an altered gene 
product that interferes with the wild type protein function. The location of the identified 
missense mutations within the encoded ABCA13 protein suggests that pathology can 
result either from inactivation of the nucleotide binding domains or through the 
modification of the properties of the channel. In contrast, null mutations, such as a 
truncated protein resultant from premature stop codon or cytogenetic disruption are 
predicted to cause illness through either haploinsufficiency owing to ‘nonsense-mediated 
decay’ of the truncated allele’s transcript or a gain-of-function effect whereby the 
truncated protein product gains a new and abnormal function. The present results 
suggest that both the missense mutations and the potentially ‘null’ nonsense and splice 
variant mutations contribute to all three clinical phenotypes and therefore there is no 
apparent effect of class of mutation or functional mechanism on clinical outcome. 
Furthermore, it is as yet unclear from the data whether severe, null homozygous 
mutations within ABCA13 cause either a lethal or clinically distinct severe phenotype.  
Previously identified heterozygous null alleles have not always been found to be 
causally related to disease. For instance, a splice variant within the gene ciliary 
neurotrophic factor (CNTF) predicted to result in a truncated protein has been reported 
not to be associated with a variety of neurological and psychiatric disorders (Takahashi 
et al., 1994; Van Vught et al., 2007). However, their findings differ from the present 
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results in two important ways. First, the CNTF null allele was originally identified in the 
homozygous state in 4 out of 151 controls and 5 out of 240 neurological disease subjects 
and hence had a higher frequency in the control population than cases.  Second, the null 
allele occurs in more than 2% of the general population and so may be classified as a 
polymorphism rather than rare variant. The CNTF null allele also highlights that 
mutation effects are protein-specific and dependent on the disrupted function of the gene 
product with specific cells. 
Premature termination codons
 
introduced by random mutation may not always terminate 
at the optimal efficiencies expected of naturally occurring stop codons. Examples exist 
whereby the translation of a significant proportion of the growing polypeptide chain 
continues beyond the termination codon – a process known as read-through (Fox, 1987). 
In mammalian genes there is some evidence that the translation termination signal might 
be influenced by its context and more specifically by the bases following the nonsense 
codon (McCaughan et al., 1995). This observation has been proposed as one explanation 
as to why nonsense mutations located in a conserved region of the cystic fibrosis 
transmembrane conductance regulator (CFTR/ABCC7) are phenotypically less severe 
(Fearon et al., 1994). Using in vitro and in vivo studies of termination signals in 
mammalian systems, McCaughan and co-workers (1995) found that efficiency of 
termination was biased by the fourth and fifth base immediately adjacent to UAG. Their 
data suggested that UAGC was a relatively weak termination signal, as is the sequence 
introduced by the nonsense mutation within ABCA13. However, signal effectiveness was 
found to be greatly increased if the fifth base were G. As the ABCA13 nonsense 
mutation is followed by the bases CG, we would predict that termination does occur 
with some efficiency.  
Furthermore, a consequence of read-through at an opal (UGA) stop codon is the 
insertion of a selenocysteine amino acid into the polypeptide chain (Lee et al., 1989). 
The ABCA13 nonsense mutation is located within a highly conserved A-loop motif 
(Aromatic residue interacting with the Adenine ring of ATP) of the second NBD, and the 
mutated arginine residue is immediately adjacent to the aromatic residue tyrosine which 
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interacts with the adenosine ring of ATP (Ambudkar et al., 2006). If read-through were 
to occur, the substitution of the arginine for an inserted selenocysteine may well have an 
effect on local chemistry, thereby disrupting ATP-binding. 
Taken together, these observations suggest that the R4728X nonsense mutation should 
have a significant effect on ABCA13 function either through null or loss of function 
mechanisms. However, the detection of R4728X in 5 control individuals, suggests that 
the associated estimated risk is more in line with a less penetrant ‘risk’ missense 
mutation. One explanation for this discrepancy may be that the R4728X mutation is 
sufficient to contribute to risk alone whereas some of the missense mutations identified 
may contribute to risk in an additive manner as discussed below. This suggestion would 
also be consistent with the evident familial segregation of R4728X with illness, which is 
less prominent (as would be expected if two or more risk variants needed to be 
transmitted together) for the missense mutations.  
4.3.5 Interacting variants in psychiatric illness 
 
In the current study nine mutations were found in the heterozygous state consistent with 
a model of dominant inheritance. The majority of cases identified were heterozygotes, 
but one affected individual was found to be a homozygous for the missense mutation 
H3609P. Whether this individual belongs to a family where consanguinity has occurred, 
i.e. a state in which there is higher likelihood of recessive risk alleles being inherited, is 
unfortunately at present unknown.   
 
What is unique to this study and thus far not described in schizophrenia, bipolar or MDD 
research, is the identification of cases carrying more than one putative risk variant, e.g. 
compound heterozygotes, and the fact that these individuals present with more severe 
phenotypes. From this observation we can hypothesis two important issues. One, 
interactions between rare risk variants across a gene may be a common mechanism 
which, in an additive manner, contributes to susceptibility to psychiatric illness. 
Evidence supporting multiplicative allele interaction comes from a candidate gene study 
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of NPAS3 in which several common risk-increasing and protective haplotypes were 
identified with clear frequency differences between the bipolar/schizophrenia case and 
healthy control cohorts. These were shown to interact with each other, dictating the net 
genetic risk of psychiatric illness (Pickard et al., 2008a). Two, the additive effects of 
multiple rare risk alleles may also result in a more severe clinical outcome and hence 
may increase penetrance, i.e. the presence of non-affected carriers evident in affected 
families. In this model, similar to findings for the other ABCA family proteins described 
above, the severity of the clinical phenotype would correlate with genetic load. 
 
4.3.6. Odds ratio estimates for common and rare variants 
 
Odds ratios calculated for common and rare variants known to contribute to complex 
diseases such as breast cancer and colorectal cancer are suggested to have different 
distributions. For common variants ORs are usually below 2 and based on observations 
from a range of recent publications cited by Bodmer and Bonilla, have an estimated 
mean OR of 1.36. In contrast, for rare variants most have ORs above 2 with a mean 
estimated as 3.74 (Bodmer and Bonilla, 2008). The observed ORs in the current study 
range between 0.5 to infinity, and, excluding variants unique to cases or found in one 
case and control only, have a mean OR of 2.32. Moreover, two variants, T4550A (OR 
3.8 CI 1.1-12.7) and R4728X (OR 2.4 CI 0.8-7.0) have ORs above 2, and a further three 
variants, H3609P (OR 1.9 CI 0.9-4.0), R4590W (OR 1.9 CI 0.7 to 5.1)) and R4843C 
(OR 1.6 CI 0.7 to 4.0), with values between 1.6-1.9.  
 
Using the calculated ORs and associated IC intervals as an estimate of penetrance may 
explain in part why some mutations, e.g R4728X, provide more evidence of concordant 
segregation within families as opposed to variants with lower ORs. However, in contrast 
to the view as argued by Bodmer and Bonilla, that owing to low penetrance, rare risk 
variants do not give rise to a familial concentration of cases – the present findings 
indicate that the penetrance of some rare variants must be sufficiently high (0.5) to show 
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familial concentration that is similar to standard mendelian segregation (Bodmer and 
Bonilla, 2008).   
 
4.3.7. How do the findings fit with current models of complex genetic disease? 
 
Rare sequence variants are known to have an important role in the multifactorial 
inheritance of common diseases such as breast cancer, colorectal cancer (CRC) and 
Alzheimer’s disease. Using these diseases as a model of the contribution of rare variants 
to complex disease, it has become clear that the term ‘rare variant’ covers two categories 
of mutation. First, the classical rare deleterious familial mutations are analogous to the 
type of mutation detected for Mendelian diseases. These mutations are predominately 
null private mutations, show strong familial aggregation have high penetrance and very 
low frequencies (>0.1). The second type of variant, as reviewed by Bodmer and Bonilla, 
have a higher frequency in the case population (0.1% to 2-3%) and ORs of 2 or above; 
are carried in one or more affected individuals but do not show familial concentration, 
i.e. are sporadic in nature, and in the majority are missense mutations of unknown 
clinical significance (Bodmer and Bonilla, 2008). It is important to note that both types 
of rare variant would not be detected by whole-genome studies and are suggested to be 
population-specific, both properties having important consequences for confirmatory 
candidate gene studies.  
 
Although the present data does not fit exactly into the two classes described for these 
diseases (e.g. MAFs calculated are all <0.5% and clear familial segregation for R4728X 
which has an OR of 2.4) there is evidence supporting some dichotomy. For instance, 
S3704R conforms to the first class of null, private mutation, with high penetrance 
apparent from familial segregation and a very low estimated frequency. Conversely, the 
missense mutations H3609P, T4550A and R4590W show characteristics more typical 
for the second class of rare variant: for example, being detected in controls and having 
moderate ORs, less familial concentration and higher observed frequencies.  Thus these 
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data are the first to lend support to a genetic architecture of psychiatric disorders 
comparable to other common, genetically complex and heterogeneous diseases.  
 
Genes identified as rare variant contributors are commonly discussed in terms of their 
mutation load. Owing to the rarity of these variants, a global or combined p-value is 
typically reported as evidence of association. In the present study the summation effects 
of all coding risk variants resulted in a global p-value of 0.000025.  However, mutation 
detection studies of major genes for other complex disorders, for example 
BRCA1/BRCA2 and breast cancer, have subsequently led to the identification of 
hundreds of different rare pathogenic mutations (Walsh et al., 2006). Therefore, it is 
plausible that the re-sequencing of additional ABCA13 exons may result in the detection 
of further mutations and hence indicate increased association of ABCA13 with disease 
risk. 
 
Furthermore, as indicated by SNP-tagging association studies of DISC1, rare variant 
genes may also harbour common, small-effect, modulating risk alleles (Hennah et al., 
2008). Indeed, in a case-control GWA study of bipolar individuals, a common SNP 
located within ABCA13, was in the top 500 most significant associations (Blackwood et 
al., personnal communication) It is possible, therefore, that the potential collective effect 
of rare ABCA13 mutations and common variants may explain a considerable proportion 
of psychiatric illness.  
 
The current results strongly support the rare variant hypothesis of complex common 
diseases and implicate ABCA13 as a gene of large effect. With the advancement of re-
sequencing technologies, comprehensive mutation detection studies of ABCA13 and 
other appropriately selected candidate genes will reveal the extent to which rare 
mutations contribute to psychiatric illness. Concurrently, the discovery of rare highly 
penetrant variants may enable the development of preventative disease screening in 
addition to providing insight into biological pathways critical to disease development. 
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4.3.8. The function of ABCA13 and its potential involvement in biological processes 
 
All ABCA proteins functionally characterized to date are known to shuttle lipid 
molecules across cellular membranes (Albrecht and Viturro, 2007). The presence in 
ABCA13 of a conserved C-terminal motif known to be shared among the lipid 
transporting group adds weight to its likely role in this process (Fitzgerald et al., 2004). 
Over a 1000 different lipid species exist in eukaryotic cells and, in addition to being 
structural components of cellular membranes, different species have key roles in 
processes such vesicular trafficking, signal transduction and transcriptional regulation 
(D'Angelo et al., 2008; van Meer et al., 2008).  While the precise substrate/allocrite for 
the ABCA13 transporter remains to be identified biochemically, abnormalities in lipid 
metabolism have been strongly implicated as a potential underlying pathology in 
psychiatric illnesses, as discussed in chapter 1.  
 
Lipid metabolism and movement of specific lipid species to appropriate cellular 
compartments is a highly regulated mechanism which, when disrupted in a global or 
local manner, could impact on a number of diverse biological processes. The most 
plausible of these processes to underlie psychiatric phenotypes are defects in 
intracellular signalling pathways, oxidative stress, synaptic function and myelination. In 
recent years, polyunsaturated fats and complex lipids such as arachidonic acid and 
sphingolipids have received attention owing to their role as second messengers in 
proliferation, differentiation, apoptosis, and inflammation. For example, as a second 
messenger, arachidonic acid (AA) can act as a retrograde signal modulating LTP, or 
activate protein kinase C (PKC) which in turn is able to interact with the NMDA 
receptors suggesting a role in neuronal excitability and neuroplasticity (Williams et al., 
1989). Similarly, inositol phospholipids are involved in the intracellular second 
messenger inositol-1, 4,5-triphosphate (IP3) and diacylglycerol (DAG) pathways which 
are endogenous activators of PKC (Lenox and Wang, 2003). Interestingly both IP3 and 
DAG are hypothesized to be downstream components of a signaling pathway directly 
affected by lithium, an anti-manic agent used to treat bipolar patients (Quiroz et al., 
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2004). Furthermore, both lithium and a second mood-stabilising drug, valproic acid, are 
reported to have their therapeutic effects via decreased AA turnover (Chang et al., 1996; 
Chang et al., 2001). 
 
Oxidative stress is a pathological process whereby an excessive increase in reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) by mitochondrial 
dysfunction can cause cell death and tissue damage. A number of publications have 
implicated free radicals and oxidative stress in schizophrenia pathology (Yao et al 2005). 
Sphingolipids such as ceramide have been shown to play an important role in receptor 
mediated signal cascades but also in the generation of ROS and RNS through regulation 
of antioxidant enzymes (Won and Singh, 2006). In parallel, ROS and RNS regulate 
sphingolipid metabolism through regulating enzymes responsible for their metabolism. 
Hence, sphingolipid metabolism and redox homeostasis are regulated in a bidirectional 
manner which when disrupted may cause a pathological state.  
 
The proper composition of cellular membranes is critical for the normal function and 
compartmentalization of ion channels and synaptic receptors. Ion channel activity has 
been shown to be modulated by direct interaction with membrane lipids. For instance, 
phosphatidylinositol 4,5-bisphosphate (PIP2) serves as an obligate cofactor of inward 
rectifying (Kir) potassium channel activity (Tucker and Baukrowitz, 2008). Moreover, 
membrane-protein interaction between the negatively charged phosphate group in 
membrane lipid molecules and voltage-gated potassium channels is essential for channel 
activation (Schmidt et al., 2006). 
 
Neurotransmitter receptors are predominately concentrated and precisely localized in 
specific microdomains within the neuronal membrane called lipid rafts (Simons and 
Ikonen, 1997). These cholesterol- and sphingolipid-enriched microdomains are proposed 
to act as an assembly for clusters of receptors and components of receptor-activated 
signalling cascades. Disruption of lipid rafts through, for example, the depletion and 
enrichment of cholesterol decreases optimal neurotransmitter agonist potency at GABA 
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and nicotinic acetylcholine (nACh) receptors, whilst the integrity of the lipid rafts appear 
to be also necessary for the maintenance of normal synaptic morphology and dendritic 
spine density (Sooksawate and Simmonds, 2001; Hering et al., 2003). Furthermore, in 
vivo and ex vivo studies indicate endogenous neuronal cholesterol biosynthesis, turnover 
and transport impair hippocampal paired pulse facilitation (PPF) and LTP and hence has 
a significant effect on synaptic plasticity. As cholesterol is also known to bind directly to 
a number of transmembrane ion channels, enzymes and receptors, it is as yet unclear 
whether such modulated synaptic function is a result of direct interaction or indirect 
disturbance of lipid raft composition (Haines, 2001).   
 
Antidepressants and antipsychotic drugs are also reported to affect receptor function at 
lipid raft micro-domains. For example, the antidepressants
 
desipramine, fluoxetine, and 
reboxetine and the antipsychotics
 
fluphenazine, haloperidol, and clozapine were found to 
co-localize with the ligand-gated serotonin 5-HT3 receptors in raft-like domains. The 
concentrations
 
of these psychopharmacological drugs within the domain was strongly
 
associated with the inhibitory potency against serotonin-induced
 
cation currents 
(Eisensamer et al., 2005). Moreover, treatment with the antidepressants desipramine and 
fluoxetine has been shown to result in the movement of G s out of lipid rafts and into a 
closer association with adenylyl cyclase and thus thereby potentially modulating cAMP 
signaling cascades (Donati and Rasenick, 2005). Taken together, these findings indicate 
that antidepressants and antipsychotics might exert some of their therapeutic efficacy by 
altering a component of the membrane that is associated with lipid rafts. 
 
A third body of research supports a link between fatty acids and neurotransmitter 
function. Animal and clinical studies suggest that fatty acid supplementation mediates its 
therapeutic effects through modulation of the serotonin (5-HT)2 receptor complex. For 
example, omega-3 fatty acid enhances the 5-HT responsivity as measured by the 
magnitude of 5-HT amplification on ADP-induced platelet aggregation (Yao et al 2004). 
Using a rodent model, omega-3 fatty acid and omega-6 fatty acid supplementation has 
been shown to alter 5-HT receptor and transporter binding and implicated to modulate 
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the biogenic amine metabolism (Hibbeln and Salem, 1995; Farkas et al., 2002). 
Likewise, fatty acid deficient diets differentially affect dopamine D2 receptor binding 
and significantly decrease dopamine concentrations (Hibbeln and Salem, 1995; Zimmer 
et al., 2000). Although the molecular mechanisms underlying these effects are currently 
unknown, these observations suggest that the fatty acid supplementation consistently 
shown to ameliorate the clinical symptoms of psychiatric disorders may be mediating its 
therapeutic effect via modulation of neurotransmitter function. 
 
Finally, myelination-the formation of a myelin sheath around the axons of neurons, is 
essential for the fast propagation of action potentials and the maintenance of axonal 
integrity. The myelin sheath is a specialised, lipid-rich domain of the glial cell plasma 
membrane, synthesised by oligodendrocytes in the CNS. This cellular membrane is 
composed of a specific subset of lipids and proteins the assembly of which is tightly 
regulated in time and place (Simons and Trotter, 2007). Molecular abnormalities of 
myelin and consequential white matter deficits are an attractive candidate pathological 
process for schizophrenia. Reduced levels of the major structural phospholipids of 
myelin have been found in several regions of the brain in schizophrenic patients. 
Moreover, microarray analysis and transcriptomic investigation indicate down regulation 
of oligodendroglia and myelin biosynthesis genes associated with psychiatric disorders 
(Schmitt et al., 2004; Segal et al., 2007; Smesny et al., 2007; Sokolov, 2007; Tkachev et 
al., 2007). 
 
The timescale of myelination, beginning prenatally and with full maturation occurring 
during adolescence and early adulthood, is consistent with the neurodevelopmental 
profile of schizophrenia, whilst a global impairment in white matter activity is in 
keeping with the disconnection hypothesis of schizophrenia which posits a failure in 
“the integration of functionally specialized systems”. It is therefore not inconceivable 
that a deficit in specific lipid species may underlie abnormalities impacting upon the 
process of myelination either alone, or in conjunction with, disruption of other biological 
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processes and that these pathological abnormalities contribute to the expression of 
psychiatric illness. 
 
Many pertinent questions regarding ABCA13 cellular function remain currently 
unanswered. Important future considerations should include the analysis of lipid species 
translocated and ABCA13 subcellular localization and cellular distribution in brain. 
Furthermore, the elucidation of putative protein binding partners may reveal ABCA13’s 
involvement in local cellular pathways or biological systems; and thus suggest new 
directions for research in the quest to find rationally based treatments and preventative 
strategies for some of the most common and disabling psychiatric disorders. 
 
To conclude, the identification of multiple rare coding mutations among unrelated cases 
and found to segregate in pedigrees provides both biological evidence and 
epidemiological support for the causal role of ABCA13 in psychiatric disease. These 
discoveries also present significant novel insight into the genetic architecture of 
psychiatric disorders consistent with molecular models and previous findings of other 
complex diseases. Furthermore, ABCA13’s candidacy provides not only a starting point 
for further examination of pathological pathways and processes but opens up exciting 
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Chapter 4 presented data providing strong evidence supporting the hypothesis that 
ABCA13 is a highly penetrant risk factor for psychiatric illness. However, the exact 
function of ABCA13, its role in biological pathways and expression in human brain are 
still unknown. With an aim to explore these issues, the expression profile of ABCA13 
transcripts in cell lines and human tissue and ABCA13 protein subcellular localization 




5.2.1 RT- PCR of human ABCA13 in cell lines and brain tissue 
 
Pairs of oligonucleotide primers were designed across exons encoding for the large N-
terminal transmembrane domain, first transmembrane domain cluster, middle of protein 
between TMD/NBD1 and TMD/NBD2, and second transmembrane domain cluster 
depicted in figure 5.1a. The spread of primer pairs across the gene would identify any 
potential disparities in expression across the gene – an important consideration as other 
members of the ABC gene family can exist in different splice forms or can even produce 
transcripts encoding just ‘half’ of the gene.  
 
RT-PCR was performed on cDNA derived from two human neuroblastoid cell lines 
LAN5 and SH-SY5Y, two human glioblastoma cell lines U373 and MOG, an embryonic 
human kidney cell line HEK293 human lymphocytes and human blood RNA. In 
addition, cDNA from post-mortem human hippocampus and frontal cortex was analysed 
for expression of a short and long transcript located within the middle of the protein. 
 
ABCA13 was found to be expressed only in the glioblastoma U373 cell line across all 































Figure 5.1 Human ABCA13 expression in cell lines and human tissue.  (a) Schematic 
representation of ABCA13 showing regions examined by RT-PCR. (b) ABCA13 mRNA transcript 
expression assessed in cell lines, lymphocytes and human blood. GAPDH was used as a 
positive control. (c) ABCA13 mRNA transcript expression in post-mortem tissue from the 
hippocampus and frontal cortex. ABCA13 expression in the U373 cell line and G6PD expression 



























































































There was no evidence for differential region-specific gene expression which could arise 
on account of the existence of multiple isoforms. ABCA13 was shown not to be 
expressed in human blood or lymphocytes. Unfortunately, this means that future studies 
potentially investigating reduced expression of ABCA13 RNA or protein in cases 
identified with mutations cannot be performed. However, ABCA13 mRNA transcripts 
were found to be expressed in human hippocampus and frontal cortex tissue, indicating 
that ABCA13 is a brain-expressed gene. 
 
5.2.2 IHC analysis of ABCA13 in human post mortem brain sections 
 
The RT-PCR expression profiling technique has the limitation that expression in specific 
cell types and subcellular domains within human brain regions can not be resolved. To 
further examine further the distribution of ABCA13 protein in brain, IHC was performed 
using transverse sections of the rostral medulla oblongata and coronal sections of the 
human frontal cortex and hippocampus. ABCA13 expression was analysed using a 
rabbit anti-human affinity purified polyclonal antibody (ABCA13 870) raised against a 
C-terminal amino acid sequence not homologous with any of the cloned proteins 
belonging to the ABC family.  
 
A negative control (absence of primary antibody) and a positive control (primary 
antibody Glial Fibrillary Acidic Protein [GFAP] – an astrocyte marker) were performed 
on every IHC run. Omission of a primary antibody resulted in tissue sections without 
any visible DAB reaction product, indicating that the protocol used did not result in any 
non-specific background signal. 
 
In all nuclei of the medulla oblongata, e.g. lateral vestibular nucleus, inferior olivary 
nucleus, hypoglossal nucleus and dorsal motor nucleus of the vagus, ABCA13 870 
immunoreactivity was observed in glia cells and large neurons, localized primarily to the 
cell cytoplasm, shown in figure 5.2. It is possible that a similar pattern of staining might 
be observed if an antibody does not bind specifically to protein peptide sequence. To 
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assess the specificity of the ABCA13 870 antibody, IHC was performed using pre-
immune serum taken from the animal prior to immunization. This pre-immune serum 
should bind to proteins within brain tissue in a non-specific manner, and hence 
characterize non-specific immunoreactivity.  
 
Immunoreactivity for ABCA13 870 was found to differ from non-specific reactivity for 
the corresponding antiserum. For example, as indicated in figure 5.2b and d, pre-
immune serum reactivity was evident in the nuclei of cells and prominent within the 
white matter tracts of the medial lemniscus. In contrast, ABCA13 870 reactivity was 
frequently observed to be absent from the nuclei of large neurons and within white 
matter tracts, shown in figure 5.2a and c. ABCA13 870 reactivity, however, was seen in 
cells interspersed between the tracts of white matter. 
 
ABCA13 870 reactivity was consistently found in neuronal and glial cells in all layers of 
the frontal cortex. As indicated in figures 5.3a, b and 5.4a, reactivity was predominately 
restricted to the cytoplasm and in some cells immuno-positive staining was clearly 
observed to be localized to the endoplasmic reticulum. Furthermore, in the white matter 
underlying the neocortex grey matter, ABCA13 870 reactivity was seen in all types of 
glial cells, i.e. astrocytes, oligodendrocytes and microglia, as shown in figure 5.3b. 
 
In the hippocampus ABCA13 870 immunoreactivity was evident in the cytoplasm of 
large mossy fibre neurons and smaller polymorphic cells within the hilus, and pyramidal 
cells of the CA4, CA3, CA2 and CA1 subfields (figure 5.5c). Moreover, prominent 
cytoplasmic staining was observed in the granule cells of the granule cell layer (GCL) of 
the dentate gyrus, shown in figure 5.5a.  
 
A second antibody specificity test – the pre-absorption of the ABCA13 870 antibody 
with the immunizing peptide prior to IHC - was conducted using sections of the 























Figure 5.2 ABCA13 870 antibody and corresponding pre-immune antiserum immunoreactivity in 
the medulla oblongata. (a) ABCA13 870 antibody reactivity in the dorsal motor nucleus of the 
vagus. (b) Pre-immune antiserum reactivity in inferior olivary nucleus. ABCA13 870 reactivity (c) 
and pre-immune antiserum reactivity (d) in white matter tract of the medial lemniscus. ABCA13 
870 reactivity was however observed in cells interspersed between the white matter tracts 
Yellow stars indicate large neurons in which reactivity is absent from cell nuclei. Yellow arrows 
show DAB stained non-specific reactivity in nuclei of neurons. Images captured at 160 
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Figure 5.3 High magnification images of ABCA13 870 antibody reactivity in layers 2 and 6 and 
the underlying white matter of the frontal cortex.  ABCA13 870 antibody reactivity in layer 2 (a) 
and layer 6 merging into the underlying white matter (b). Yellow arrows indicated DAB stained 

















Figure 5.4 High magnification images of ABCA13 870 antibody and corresponding pre-immune 
antiserum immunoreactivity in layer 3 of the frontal cortex.  (a)  ABCA13 870 antibody immuno-
postive staining appears to localize to the cell cytoplasm. (b) pre-immune serum reactivity 
apparent in the cytoplasm and nucleus of neurons. Images captured at 400 magnification. The 









































Figure 5.5 ABCA13 870 antibody and corresponding pre-immune antiserum immunoreactivity in 
the dentate gyrus and hilus of the hippocampus.  (a) High magnification image of ABCA13 870 
reactivity in the GCL of the DG and (b) ABCA13 870 blocked with pre-absorbed peptide in the 
DG. (c) ABCA13 870 reactivity in the hilus of the hippocampus and (d) after blocking with pre-
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This control assay should block specific immunoreactivity for ABCA13 and hence an 
absence of DAB reactivity would indicate primary antibody specificity.  
 
Immuno-positive staining in the granule cells of the dentate gyrus was found to be 
almost completely absent following peptide pre-absorption (shown in figure 5.5b) 
suggesting that ABCA13 870 immunoreactivity within the granule cells represents 
genuine ABCA13 expression. Indeed, this finding is consistent with IHC data 
investigating abca13 expression in mouse brain (R. Cannon, North Carolina Research 
Triangle, USA; personal communication). However, reduced immuno-positive ABCA13 
870 staining in the large mossy fiber neurons in the hilus and pyramidal cells of the CA 
regions was still observed after peptide incubation, shown in figure 5.5d. This would 
suggest that in addition to what appears to be to specific ABCA13 immunoreactivity in 
the granule cells, the ABCA13 870 antibody also cross-reacts with additional epitopes 
resulting in non-specific binding in these regions.  
 
As the peptide pre-absorption control condition was not conducted prior to ABCA13 
870 IHC in other brain sections, it is unclear whether the ABCA13 870 
immunoreactivity observed and described above is indeed specific, i.e. indicative of real 
ABCA13 expression, or unspecific binding. Future experiments, including this control 
peptide pre-absorbtion control condition performed in other brain region sections and 
examining the immunoreactivity profile of additional human ABCA13 antibodies, will 




This chapter describes the investigation of ABCA13 mRNA and protein expression in 
cell lines, human blood and brain tissue. RT-PCR assays indicated ABCA13 to be 
expressed in one human-derived oligodendrocyte/astrocytoma cell line and post-mortem 
frontal cortex and hippocampus brain tissue. IHC performed using a polyclonal antibody 
which was assayed for ABCA13 protein specificity by means of two control conditions, 
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suggested that ABCA13 is localized to the cytoplasm of granule cells of the dentate 
gyrus. However, these experiments also indicated that the ABCA13 870 antibody binds 
to non-specific epitopes making the interpretation of ABCA13 expression difficult to 
determine. 
 
5.3.1 ABCA13 expression in human and mouse tissues 
 
Human expression studies 
 
One previous study has investigated ABCA13 mRNA expression in human derived cell 
lines and tissues. Prades and colleagues performed tissue profiling (which included 
multiple tissues from different brain regions including the hippocampus and frontal 
cortex) of all major transcripts which encode for the six predicted isoforms of human 
ABCA13. They found that expression of transcripts one and two, the full length isoform 
and an isoform which includes the functional domains but is missing the long N terminal 
tail, was highest in human trachea, testis and bone marrow. The remaining four 
transcripts were undetected in any tested tissues, and transcript expression was absent in 
brain (Prades et al., 2002). These results contrast with the present data, which indicated 
that in the two brain regions assayed – the hippocampus and frontal cortex - ABCA13 
mRNA is expressed.  
 
In the same study Prades and coworkers also examined by means of real time PCR 
ABCA13 expression in a panel of tumor cell lines. They report that expression was 
detected highest in one leukemia (SR), one prostrate (DU-145) and three CNS tumor cell 
lines (SNB-19, U251, SF-539) (Prades et al., 2002). One of these CNS tumor cell lines, 
U251, is suggested to be derived from the U373 human glioblastoma cell line, which 
was tested and found to express ABCA13 in the present study. However, the present 
findings also indicated that in this glioblastoma cell line, transcripts relating to different 
regions of ABCA13 were all consistently expressed. This finding supports the notion 
that, like all other ABCA sub-family members, ABCA13 encodes for a full transporter 
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and not two half transporters – an issue which has important consequences for the 
functional interpretation of potential pathogenic mutations. 
 
The aforementioned study did not test transcript expression in human blood or 
lympohctyes extracted from blood. To perform functional assays assessing the potential 
consequences of mutations using samples taken from mutation carriers, ABCA13 is 
needed to be expressed in the sampled tissues. Unfortunately, the current results did not 
detect any expression in human blood and lymphocytes, the easiest tissue to obtain from 




One study conducted by Barros et al., (2003) has comprehensively investigated Abca13 
mRNA distribution in mouse tissues. Expression was reported to be highest in the 
submaxillary gland, epididymus, ovary, and thymus, however Abca13 was also detected 
in brain, eye, liver, lung, heart, skeletal muscle, pancreas, kidney, thyroid, bone marrow, 
spleen, testis, prostrate, uterus and mouse embryo at lower levels, suggesting that 
Abca13 is widely expressed (Barros et al., 2003). As discussed by the authors, the 
ubiquitous expression of Abca13 is also observed with ABCA1 - a gene/protein that 
when mutated is known to cause HDL-deficiency syndromes. Expression studies of 
Abca1 have reported a lack of consistency between high levels of mRNA expression and 
corresponding protein expression. This has led to the suggestion that, like many ABC 
transporters, post-transcriptional modulation is a likely mechanism regulating ABCA1 
protein expression. Indeed, although inconsistencies between Abca13 mRNA and 
protein expression have not yet been investigated, post-transcriptional modification has 
also been suggested as an important mechanism potentially regulating Abca13 protein 
expression (Barros et al., 2003). 
 
More recent unpublished research, performed by individuals in the same group, has used 
fluorescent IHC to examine Abca13 expression in mouse brain. They report that among 
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other regions of the brain, Abca13 is highly expressed in neurons of the locus ceruleus in 
the brain stem and granule cells of the dentate gyrus. Furthermore, high resolution 
analysis clearly indicates Abca13 to be localized to the cytoplasm and predominately in 
a subcellular domain corresponding to the golgi apparatus or endoplasmic reticulum 
(Cannon et al., personal communication). 
 
These observations are consistent with the current results and highlight that ABCA13 is 
potentially expressed in a region in which new neurons are generated throughout 
adulthood.  This process known as adult neurogenesis, and its link to psychiatric illness, 
is discussed in some detail in chapters 7 and 8. However, it is interesting to note and 
relevant to the current findings that in a recent study a biomarker of neural stem and 
progenitor cells (NPCs) located within the dentate gyrus and which give rise to newly 
generated mature cells was identified as a complex mixture of saturated and/or
 
mono-
unsaturated fatty acids and related compounds (Manganas et al., 2007). As yet, the 
functional
 
relevance of these lipid molecules for the control of proliferation
 
and 
differentiation of NPCs remains to be elucidated. However, as ABCA13 putatively 
transports one or more lipid species across membranes, its expression within granule 
cells of the dentate gyrus leaves open the interesting possibility that disruption of 
ABCA13 function may have a detrimental affect upon neurogenesis.  
 
5.3.2 Expression profile and function of other ABCA sub-family members 
 
Most ABC transporters belonging to the ABCA sub-class are reported to be expressed in 
a broad spectrum of tissues. However, their individual expression profiles, cellular 
localisation and consequential specific function within lipid secretory pathways 
influence why, when such genes are mutated, a diverse range of phenotypic diseases are 
caused. For example, mutations within ABCA4 give rise to retinal diseases including 
Stargardt disease, cone-rod dystrophy, retinitis pigmentosa and age-related macular 
degeneration. The ABCA4 protein is highly expressed within the outer segment disk 
membrane of rod and cone photoreceptors located within the retina. It is proposed to act 
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as an outwardly directed flippase transporting a chromophore of the visual pigment 
rhodopsin (all-trans retinaldehyde), and hence its activity is likely to be involved in the 
recycling of all-trans retinal released from the photobleached rhodopsin during the 
retinoid cycle (Wenzel et al., 2007).  
 
In contrast, genetic defects in ABCA12 cause two hereditary dermatological 
keratinization disorders, harlequin ichthyosis and lamellar ichthyosis type 2. ABCA12 is 
expressed in many tissues but within the keratinocytes of the upper epidermal layers of 
human skin it is localised to the membranes of secretory intracellular lipid storage 
organelles called lamellar granules. Abnormal localisation of glucoceramide within 
cultured keratinocytes from harlequin ichthyosis patients suggests that ABCA12 is 
involved in the intracellular translocation of spingolipids within the lamellar granules 
during the process of kerotinocyte differentiation (Kaminski et al., 2006). 
 
ABCA1 and ABCA2 are both highly expressed in brain, are implicated in brain lipid 
homeostasis and have been linked to neurodegenerative diseases of the brain. ABCA1 is 
expressed in multiple brain cell types albeit with significant cell and region expression 
differences. Evidence from rodent studies suggests that Abca1 plays a significant role in 
the lipidation and homestatic concentrations of apoE and in addition, may be a principal 
modulator of neurotoxic amyloid-β peptide production and amyloid desposition - 
histological symptoms of Altheimer’s disease (AD) (Hirsch-Reinshagen et al., 2004; 
Kim et al., 2008). Conversely ABCA2 is reported to be expressed almost exclusively in 
oligodendrocytes within human brain matter and located within oligodendrocytes at the 
subcellular membranes of the endolysomal compartment and Golgi apparatus. ABCA2 
is therefore postulated to have a role in intracellular lipid trafficking and may be 
important in the regulation of neural sphingolipid transport (Hirsch-Reinshagen et al., 
2004; Kim et al., 2008). However, like ABCA1, ABCA2 has been indicated by genetic 
and biological studies to be linked to the pathology of AD as well as temporal lobe 
epilepsy (Mace et al., 2005; Arion et al., 2006).  
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Several ABCA transporters are known to be expressed in multiple cellular membranes. 
For instance ABCA1 is reported to be localised to the plasma membrane, golgi 
apparatus and lysosomal membranes in a variety of cell types, ABCA3 to the plasma 
membrane, lamellar bodies and lysosomes of alveolar pneumocytes, and ABCA5 to the 
golgi apparatus and lyosmomes within leydig cells of the testis (Wenzel et al., 2007). 
Differential subcellular localisation and hence the potential to influence distinct lipid 
pathways in different cells and tissues may explain how mutations in one transporter 
may give rise to various, phenotypically distinct, clinical disorders, e.g. ABCA1 is 
causally linked to Tangiers disease as well as being implicated to have a role in AD.  
 
The unpublished findings by Cannon et al. indicate Abca13 is localised to the ER in 
spinal neurons in mice. The endoplasmic reticulum is the main cellular compartment of 
lipid synthesis suggesting that ABCA13 many be involved in the transport and hence 
appropriate delivery of lipid molecules to other organelles/membranes. However, 
ABCA13, like ABCA1, may be expressed in different compartments in various cell 
types. Future experiments investigating ABCA13 subcellular distribution in a variety of 
tissue may provide more insight into its functional involvement in lipid secretory 
pathways and potential propensity to cause disease.  
 
Another characteristic of ABC proteins is that they do not appear act in isolation but 
instead are postulated to function as components of multi-unit complexes (Buechler et 
al., 2002; Munehira et al., 2004). Given the general broad range of tissues that express 
ABCA proteins it is likely that tissue-specific interacting partners might define a larger 
spectrum of biological activities associated with each transporter. Furthermore, in 
conjunction with differential subcellular distribution, cell-specific interaction with other 
proteins might also be a major factor influencing disease expression.   
 
The evidence presented in this chapter, that ABCA13 is expressed in human brain, is 
just the beginning of our understanding of the potential function of ABCA13 and 
consequential psychiatric disease molecular pathology. Future research involving 
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conditional gene targeting, IHC co-localisation studies and protein binding assays may 
provide much needed insight into the potential tissue-specific roles, specific lipid species 
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6.   A CASE-CONTROL ASSOCIATION STUDY OF A VARIANT WITHIN THE 




In a tagging SNP case-control association study, a haplotype located within 3’UTR 
GRIK4 was found to be negatively associated with bipolar disorder (Pickard et al., 
2006). Subsequent screening of the 3’UTR region in bipolar protective haplotype 





A case-control association study of the insertion/deletion (indel) variant was performed 
by genotyping 356 individuals diagnosed with bipolar disorder and 286 healthy control 
individuals.  A significant difference between the groups was found (p=0.00000273 
genotype, p=0.00000019 allele), as indicated in table 6.1a. No significant deviation from 
Hardy-Weinberg Equilibrium (HWE) was evident in the control population. However, 
deviation from HWE was found for the bipolar disorder samples, consistent with other 
findings reporting strong association in a disease group. The corresponding Odds Ratios 
(ORs) of 2.16 (95% confidence interval [CI]: 1.61-2.90) insertion allele and 0.46 
deletion allele (95% CI: 0.34-0.62) could equally be interpreted to support the 
hypothesis that the insertion is a risk variant or, alternatively, that the deletion has a 
protective effect. However, as the deletion allele is rarer than the insertion allele (del 
frequency 0.24 controls, 0.13 cases; ins frequency 0.76 controls, 0.87 cases) and the 
original SNP association study showed association for a protective rather than risk 
haplotype, we prefer to describe the finding as a protective effect (figure 6.1). Moreover, 
as both genotype and allele p-values calculated in the present study are more significant 
than the Expectation Maximisation (EM) predicted haplotype p-values calculated in the 
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original SNP association study, this suggests that the indel is either in higher LD with 
the causal variant or is the actual variant itself. 
 
Due to a significant overlap in samples typed for both the initial SNP association and the 
initial indel study, a replication study on an independent Scottish cohort of 376 controls 
and 274 bipolar disorder cases was performed by B. Pickard (Pickard et al., 2008b). 
Consistent with the findings above, a significant negative association for both deletion 
genotype (p=0.0166) and allele (p=0.0107) was shown (table 6.1b). However, although 
the frequency of the deletion allele was found to be similar between studies for controls 
(0.23), it was present at a slightly higher frequency in bipolar disorder cases (0.17). 
Hence, the calculated OR for the deletion allele is less pronounced OR0.69 (95% CI: 
0.52-0.92) than in the first study.  
 
Combining the two data sets results in an OR of 0.47 (95%CI: 0.36-0.62) for 
heterozygotes and an OR of 0.33 (95%CI: 0.18-0.58) for homozygous deletion 
individuals (table 6.2). The increased protection (reflected by a lower OR) for 
homozygotes suggests that the protective effect is additive or dose-dependent and 
implies that the underlying ‘protective’ mechanism may be transcript regulation, 
resulting in an increase in mRNA or protein expression. 
Deletions in the 3’UTR region are postulated to affect RNA secondary structures which 
consequently may determine mRNA stability (Chen et al., 2006). Russell Hamilton and 
IIan Davis modeled RNA secondary structures across species predicted for the insertion 
and deletion alleles to establish whether the RNA sequence variation is functionally 
important. They concluded that the INS and DEL containing RNAs produce two distinct 
populations of secondary structures which potentially have functional consequences 
(Pickard et al., 2008b).  
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a)
Control Bipolar Total 
Genotype
DEL/DEL 20 11 31
DEL/INS 95 67 162
INS/INS 171 278 449
p=0.00000273
Allele
DEL 135 89 224
INS 437 623 1060
p=0.00000019
Freq. allele del 0.24 0.13
    
b)
Control Bipolar Total 
Genotype
DEL/DEL 25 6 31
DEL/INS 121 81 202
INS/INS 230 274 417
p=0.0166
Allele
DEL 171 93 264
INS 581 455 1036
p=0.0107
Freq. allele del 0.23 0.17
 
 
Table 6.1 Insertion/deletion genotyping results from individuals diagnosed with bipolar disorder 
and unaffected controls in the original study a) and replication study b). Chi-square derived p-
values and the frequency of the deletion allele are shown. 
 
 
Control Bipolar Total 
Genotype
DEL/DEL 45 17 62
DEL/INS 216 148 364
INS/INS 401 465 886
Total 662 630 1292
p=0.00000043
Allele
DEL 306 182 488
INS 1018 1078 2096
Total 1324 1260 2584
p=0.00000002
Freq. allele del 0.23 0.14
 
 
Table 6.2 The combined data set from the original and replication association study. Chi-square 
derived p-values and the frequency of the deletion allele are shown. 
 185 
To explore the potential effect of mRNA regulation on transcript expression, Ben 
Pickard examined mRNA allelic expression using a PCR-based assay in two cells lines 
and post-mortem hippocampal and cerebral cortical tissue from heterozygous individuals 
with no history of psychiatric illness. 
 
His results indicated that in cDNA from naturally heterozygous neuroblastoma cell line 
(SHSY-5Y), and human embryonic kidney HEK293 cell line transfected with GFP-
GRIK4 fusion expression constructs, there was a marked predominance of the deletion 
allele mRNA indicating its increased relative abundance. This over-representation of the 
deletion-carrying transcript (calculated to be approximately 40% above the insertion 
allele) was also found in human hippocampal tissue, although frontal cortex tissue did 
not show the same clear bias (figure 6.2). The finding that GRIK4 mRNA transcripts 
carrying the deletion are relatively more abundant supports the hypothesis that the 
genetic protective effect is mediated through increased kainate receptor expression. 
6.3 Discussion 
 
This chapter reports a highly significant association between a deletion in the 3’UTR 
variant of GRIK4 and protection against bipolar disorder. Further evidence in the form 
of RNA secondary structure analysis of the insertion and deletion alleles and mRNA 
allelic expression studies indicating increased over-representation of the deletion-
carrying transcript provide some support that protection afforded by the deletion may 
result from mRNA regulation. 
 
In the field of common disease genetics there has been some debate as to whether some 
positive associations found in case-control studies may result from population 
stratification effects (Cardon and Palmer, 2003; Freedman et al., 2004). The term 
population stratification pertains to differences in allele frequencies between cases and 
controls attributable to diversity in background population rather than association of 
genes with disease. 
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Figure 6.1 Alignment of GRIK4 3’UTR deletion/insertion in human, chimp, macaque and mouse.                
Figure taken from Pickard at al., 2008 (figure 1). 
   
 
Figure 6.2  Relative expression levels of the deletion and insertion GRIK4 alleles as determined 
by a fluorescently labelled PCR reaction. a) Representative examples from the PCR assay. b) 
Proportions of the insertion and deletion forms in SHSY-5Y genomic DNA (n=3), cDNA samples 
from SHSY-5Y (two separate RT primers, n=6), pre-transfection insertion/deletion expression 
plasmid mix (assay replicated 3 times), cDNA from HEK293 cells transfected with the 
insertion/deletion expression plasmid mix (two separate RT primers, n=5) and cDNA from 
heterozygote control human hippocampus (3 samples) and cortex (5 samples). Error bars 
indicate the standard error of the mean. Figure taken from Pickard et al., 2008, figure 2. 
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In the current study, the case-control cohorts consisted of cases and controls from North 
East and South East Scotland, a stable population which shows little evidence of 
stratification (WTCCC, 2007). Moreover, this cohort has been extensively genotyped in 
case-control studies of candidate genes producing both negative and positive results, 
suggesting a lack of cohort-dependent frequency bias. 
 
It is a common observation that the odds ratio of a disease variant is usually 
overestimated in the study that first reports the association (Lohmueller et al., 2003). 
This bias, known as the ‘winner’s curse’, relates to the power of the initial test for 
association, i.e. low powered studies of a variant of genuine but low to moderate 
association results in an effect size that is biased upwards (Zollner and Pritchard, 2007). 
The estimated effect size for the deletion allele in the present study was indeed found to 
be slightly higher in the initial study than replication study (ORs 0.46 versus 0.69). 
However, a significant difference between cases and controls was still ascertained in the 
replication study, so providing independent support that carriers of the deletion allele 
have a reduced chance of developing bipolar disorder. 
 
In addition to the original SNP association study performed in our lab, two further case-
control studies of GRIK4 have been conducted. Shibata and colleagues typed 24 
common SNPs across GRIK4 in 100 unrelated Japanese individuals with schizophrenia 
and a hundred control subjects. They found no evidence for an association with either 
single markers or two SNP haplotypes (Shibata et al., 2006).  Likewise, Li et al. typed 5 
SNPs, including the three originally found to be associated with schizophrenia in the 
Scottish population, in 288 cases of schizophrenia and controls from the Chinese 
population. Again, single SNP and haplotype analysis revealed no statistically 
significant association  (Li et al., 2008). These findings, which contrast with the present 
results, may be explained by number of factors. First, the study by Shibata and 
coworkers was of a modest size and may not have had the power to detect risk effects 
associated with an OR of 1.5 (0.65). Second, the 5 SNPs investigated by Li and 
colleagues may not be in LD with the protective haplotype and therefore do not ‘tag’ the 
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indel variant. Third, the cases investigated in both studies had a diagnosis of 
schizophrenia and not bipolar disorder. Finally, the prevalence of the protective 
haplotype (composed of rs513548, rs2282586 and rs1944522) which tags the indel 
variant was analyzed using phased HapMap data for European, African and Asian 
populations. The results indicate that the haplotype is very rare in the Asian population 
(Eur: 0.22, Afr.: 0.17, Asi.:0.02), and hence a significant association in the Japanese and 
Chinese populations would not be expected (B. Pickard, unpublished observation). 
 
The current findings from European population based genome-wide case-control SNP 
scans of bipolar disorder have also failed to identify GRIK4 as a risk-susceptibility gene. 
One explanation for this disparity is that the SNPs typed on the arrays actually fail to tag 
the indel variant. For example, the 500K affymetrix chip used in the Wellcome Trust 
Case Consortium (WTCCC, 2007) scan has only one SNP (rs2282586) of the original 
associated protective haplotype, and this SNP in isolation showed only moderate 
significance in the original Scottish study. Future case-control studies of GRIK4, 
whether investigating the associated indel directly or the 3 SNP haplotype in proxy with 
the variant, are needed to confirm the present findings and to assess further the 
prevalence of the indel variant in non-Asian populations. 
 
Further evidence supporting GRIK4 candidacy in mental illness comes from 
pharmacogenetic research. The Sequenced Treatment Alternatives to Relieve Depression 
(STAR*D) clinical trial investigated associations between genetic variation in 68 
candidate genes (chosen for their role in major neurotransmitter systems or potential 
pharmacological pathways) and outcome of antidepressant treatment  (Paddock et al., 
2007). Using a two phase study design, 768 markers were initially typed in a discovery 
cohort composed of 1,199 individuals diagnosed with major depressive episodes and 
treated for 14 weeks with the selective serotonin reuptake inhibitor (SSRI) citalopram. 
The second wave genotyping was conducted using a cohort of 617 treated patients with 
depression and a comparison group of 634 unmediated controls. Two markers located 
within the HTR2A gene (encoding a serotonin receptor) and GRIK4 were found to 
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exceed nominal significance for association with treatment response or remission in each 
phase (illustrated in figure 6.3).  Interestingly, the associated SNP (rs1954787) 
positioned within the first intron of GRIK4 is a component of the extended haplotype 
associated with schizophrenia in the original Scottish SNP case-control study. However 
this SNP, located in the proximal portion of GRIK4, is not in strong linkage 
disequilibrium with the associated bipolar haplotype or indel variant.  
 
To determine the nature of the observed association, Paddock and colleagues analyzed 
GRIK4 marker frequencies in cases and comparison controls. This revealed that only 
non-responders (to treatment) differed significantly from healthy controls and that 
significant differences in frequencies existed for 12 markers which span an interval in 
the distal portion of GRIK4 covering several LD blocks (figure 6.3).  
 
Moreover, multiple regression analysis of the same genotype data set performed by Laje 
et al. (unpublished observation) also revealed that a co-morbid condition, anxious 
depression, showed independent associations with GRIK4 (Paddock et al., 2007). 
Whether some of these multiple independent associations are driven by the indel variant 
is as yet unknown. However, these results strongly imply that multiple, common variants 
in GRIK4 may have functional consequences relevant to psychiatric illness.  
 
The 3’untranslated region of mRNA is recognized as having an essential role in the 
posttranscriptional regulation of gene expression. Unlike 5’UTR mRNA sequences 
which contain highly conserved translational regulatory elements, the 3’UTR sequence 
has less evolutionary constraints. Hence 3’UTR sequence variation is postulated to be 
responsible for determining time- and location-specific processes such as nuclear 
transport, polyadenylation, subcellular targeting, and translation efficacy, as well as 

























Figure 6.3 Schematic representations of multiple positive associations of GRIK4 with 
antidepressant treatment and with schizophrenia and bipolar disorder. Blue diamonds represent 
12 independent significant marker associations found for cases of MDD non-responsive to 
citalopram, as reported by the STAR*D study. Positive association of extended (green 
bracketed lines) and core (green filled rectangles) with schizophrenia and bipolar disorder, as 
reported by Pickard et al., 2006, are also indicated. The position of the protective indel (red 
diamond) is shown. The negative log10 values of the respective p values are plotted on the y 
axis.  Physical positions based on UCSC 2006, dbSNP build129 and GRIK4 gene structure is 




























































































































































































































































The associated 14bp indel in GRIK4 is positioned in an interval termed the upstream 
sequence (USS) located between the translational termination codon and the upstream 
core polyadenylation signal. Regulatory motifs and mRNA secondary structures in this 
region can affect transcript stability through adenylate/uridylate-rich element (ARE)-
mediated mRNA decay, interaction with trans-acting factors, and by cleavage site 
protection. The indel region does not contain AU-Rich elements (AREs) and so this 
process is unlikely to contribute to the functional mechanism. This region is however 
AG-rich, a feature linked to an increased likelihood of single-stranded RNA 
conformation. Indeed, the consensus structure of the insertion sequence indicates that 
several regions exist as single strands including a single-stranded region comprising an 
internal loop, and thus these sites are potential targets for protein factor or miRNA 
binding (Pickard et al., 2008b).  
 
One well documented example of mRNA stabilization resulting from trans-acting 
proteins binding to cis-acting elements is that of iron-responsive elements (IRE’s) found 
in genes involved in iron metabolism. IREs form a single-stranded stem loop structure 
with which iron regulatory proteins (IRPs) associate. When cellular iron levels are low, 
IRP binds the mRNA and stabilizes it by shielding it from cleavage (Grzybowska et al., 
2001). Future biochemical experiments investigating the identification of putative 
factors differentially interacting with GRIK4 insertion and deletion sequences may 
provide more insight into the mechanism by which the indel exerts its effects. 
 
A variant in the 3’UTR region of GRIK2 encoding the kainate receptor subunit GLUR6 
has also been associated with disease. Huntington’s disease (HD), a neurodegenerative 
disorder, is caused by an expanded CAG trinucleotide repeat that lengthens a 
polyglutamine tract near the amino terminus of the huntingtin  protein (HTT) 
(Macdonald, 1993). However, multiple reports of an association between a trinucleotide 
repeat polymorphism (16TAA) in the 3’UTR of GRIK2 and age at neurologic onset in 
HD strongly indicates that GRIK2/GLUR6 acts as a modifier of HD pathogenesis. 
Furthermore, a screen of GRIK2 in individuals who possess the 16TAA polymorphism 
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and displayed early onset HD, failed to identify coding variants or an ancestral 
haplotype in LD with the 3’UTR polymorphism. This suggests that the 3’UTR allele is 
itself responsible for the modifier effect (Zeng et al., 2006). The functional mechanisms 
of this modifier allele have yet to be elucidated. Nonetheless, post-transcriptional mRNA 
editing of kainate receptor subunits GLUR5 and GLUR6 at specific TMD sites are 
known to have a functional impact on receptor channel currents (Lerma et al., 2001).   
 
We propose that the associated GRIK4 deletion has its effect through mRNA stability, 
and hence may influence KA1 protein abundance either globally or in specific 
subcellular locations, i.e. neuronal dendrites.  Consequently, this may potentially shift 
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7. Characterisation of KA1 expression in human brain 
 
7.1 Preface 
The previous chapter discussed the identification of a deletion in the 3’UTR of 
GRIK4/KA1 as a protective factor for bipolar disorder. This associated GRIK4 variant is 
hypothesized to exert its effect through mRNA stability and hence may influence KA1 
protein abundance either globally or in specific subcellular locations. To investigate this 
issue, KA1 protein expression was first characterized in regions of the human brain 
commonly reported to be involved in the expression of psychiatric illness. 
 
7.2 Results 
 7.2.1 Antiserum specificity  
 
The current study examined KA1 protein expression in human post-mortem brain using 
sections of the frontal cortex, cerebellum, amygdala hippocampus and parahippocampal 
regions provided by the Edinburgh University MRC Sudden Death Brain and Tissue 
Bank. KA1 expression was determined using an affinity-purified antibody 272, raised in 
rabbit against a human C-terminal amino acid sequence not homologous with any of the 
other cloned subunits belonging to the kainate receptor family.  
 
To assess whether this antibody binds to a protein species of similar molecular weight as 
human KA1, immunoblotting was performed. Western blot analysis using the 272 
antiserum showed two major immunoreactive bands of approximately 105 kDa and 210 
kDa in human glioblastoma cell line U373 and human neuroblastoma cell line SH-SY5Y 
as well as one faint band (~ 105 kDa) in a protein lysate from homogenised mouse brain 
(figure 7.1). The molecular mass of the 105 kDa corresponds closely with that predicted 
from the cloned cDNA sequence (Werner et al., 1991), and hence provides evidence that 












Figure 7.1 KA1 detection in human cell lines and mouse brain. The peptide used for 
immunization (rKA1) shares no homology with the C-terminus of other members of the kainate 
receptor subunit/binding protein families. Protein lysates were prepared from human hU373 and 
hSH-SY5Y cell lines as well as mouse brain protein homogenate (mHom). Two immunoreactive 
bands of approximately 105 kDa and 210 kDa were detected, with the 105kDa molecular 
species consistent with the size predicted from the cloned cDNA. Numbers on the left represent 















Figure 7.2 KA1 protein expression in layer 1 of the frontal cortex. Images captured at low x160 
magnification (a) and at high x400 magnification (b). Arrows indicate the brown DAB 


























The presence of a second band may be due to dimerization of the protein, as no other 
KA1 isoforms are known to exist; or alternatively, may represent a mature glycosylated 
form as previously described (Darstein et al., 2003).  
7.2.2 Frontal cortex  
 
Histology was performed using coronal sections taken in a parasagittal plane of the 
frontal cortex. A negative control (absence of primary antibody) and a positive control 
(primary antibody Glial Fibrillary Acidic Protein [GFAP] – an astrocyte marker) were 
performed on every IHC run. Omission of a primary antibody resulted in tissue sections 
without any visible DAB reaction product. Conversely, the use of α-GFAP as a positive 
control demonstrated that the IHC protocol was fully optimized, and facilitated the 
identification of glial cells, primarily astrocytes, within specific tissue regions.   
 
The cerebral cortex is typically composed of six cell layers numbered from the outer 
surface of the cortex (pia mater) to the underlying white matter. In layers 2-6 the 
principal neuronal cells are excitatory and release glutamate as their primary 
neurotransmitter. Layer 1 of the frontal cortex is an acellular neuronal layer 
predominately composed of glial cells, dendrites and axons of cells located in deeper 
layers and white matter corticocortical fibers. KA1 immunoreactivity was evident in all 
three kinds of glial cell types, i.e. astrocytes, oligodentrocytes and microglia, and in 
between the cells in axonal/dendritic processes, shown in figure 7.2. 
 
KA1 DAB staining was also found in the cell bodies of glial cells and small neuronal 
spherical cells (including granular cells) as well as dendritic processes in layers 2 and 4, 
(also know as the superficial and deep molecular layers), shown in figure 7.3.  KA1 
immunoreactivity in processes was more prevalent in layer 4, which may reflect the fact 
that layer 4, unlike layer 2, has interneurons that are excitatory and glutamatergic. 
Similarly, immunoreactivity in layer 3 was most prominent in glia and the processes of 
pyramidal shaped neurons. However, some neurons also showed cytoplasmic and 
















Figure 7.3  KA1 protein immunoreactivity in layers 2 and 4 of the frontal cortex. Glial cells, small 
spherical neuronal cells (which are likely to include granular cells), and dendrites express KA1 in 
layer 2 (a) and layer 4 (b).  Yellow arrows in (a) indicate immunoreactive positive granular cells 
















Figure 7.4  KA1 protein immunoreactivity in layers 3 and 5 of the frontal cortex. Neuronal and 
glial cells express KA1 in layer 3 (a) and layers 5 (b). Yellow arrows in indicate immunoreactive 
positive pyramidal cells and dendritic/axonal arborizations. The black bar represents 50µm. 
a b 




This pattern of staining was also found in layer 5, which is comprised of large pyramidal 
shaped neurons, and layer 6 – a multiform layer composed of a heterogeneous variety of 
neurons (shown in figures 7.4b and 7.5). In addition, glial cells of the white matter 
underlying the neocortex show strong KA1 and GFAP antibody reactivity, demonstrated 
in figure 7.6. The KA1 Immuno-positive signal was strongest in the cell bodies of glial 
cells and dendritic connections between cell bodies. 
 
7.2.3 Cerebellum  
The cerebellar cortex is divided histologically into three layers: the outer molecular 
layer, purkinje cell layer and inner granular cell layer (GCL). This three layer structure 
consists of 5 primary types of neurons: excitatory granular cells and inhibitory stellate, 
basket, purkinje and golgi cells. In addition to these neuronal cell types, a discrete 
population of radial glial cells (Bergmann cells) located within or near the purkinje cell 
layer, are hypothesized to be potential stem cells. Afferent axons which terminate in the 
cerebellar cortex synapse upon either excitatory mossy fiber terminals in the granular 
layer or climbing fibre connections located in close proximity to the purkinje cells.  
KA1 immunoreactivity was identified in three primary regions of the cerebellar cortex: 
punctate staining the granular cell layer, purkinje cell layer and sparse dendritic 
processes in the molecular layer. The immunoreactivity found in the granular cell layer 
is evident as sporadic circular clusters/blobs (10-20µm) located within the superficial 
portion of the layer, as shown in figures 7.7 and 7.8. This staining is consistent with the 
location of golgi cell axon terminals. However, only a proportion of putative golgi cells 
show this strongly immuno-positive signal. Interestingly, this specific expression pattern 
has also been described for GluR5 (a kainate receptor subunit which can form a 
functional channel with KA1) and mGluR2/3 (metabotropic glutamate receptor subunits) 
and is in accordance with the suggestion that golgi cells can be segregated into two 
groups based on the presence or absence of glutamate receptors (Ohishi et al., 1994; 
















Figure 7.5  KA1 protein immunoreactivity in layer 6 of the frontal cortex. (a) Image captured at 
low x160 magnification, and (b) at high x400 magnification. Immunopositve staining is 
















Figure 7.6  Protein immunoreactivity for KA1 and GFAP in the white matter underlying the 
neocortex. Immuno-positive staining for KA1 (a) and for GFAP (b). Yellow stars indicate 
immunoreactivity for large glial cells, likely to be astrocytes and oligodendrocytes. Yellow arrows 






































Figure 7.7  Protein immunoreactivity for KA1 in the cerebellar cortex. Images captured at low 
x100 magnification (a), and at a higher x160 magnification (b). Yellow stars point to strong 
immuno-reactive staining in the superficial portion of the granular layer. Yellow arrows indicate 
staining in cells which putatively may be Bergmann glia. The black bar represents 50µm. (g, 
























































Figure 7.8 High magnification images of KA1 protein immunoreactivity in the cerebellum. (a)  
High magnification image showing KA1 staining in the superficial granular layer (yellow stars) 
and dendrites in the molecular layer (arrow). (b) Image demonstrating strong KA1 
immunoreactivity in the granular layer, consistent with golgi cell staining. The black bar 












A proportion of the purkinje cells showed weak to moderate cytoplasmic 
immunoreactivity, indicated in figure 7.7.b. Strong but sporadic immuno-positive 
staining was however observed in small cells and dendrites positioned in close proximity 
to the purkinje cells, shown in figures 7.7b and 7.8. Immuno-positive staining for GFAP, 
a marker of astrocytes, indicates that these cells may be Bergmann glia (figure 7.9). 
Furthermore, dendritic arborizations in the purkinje cell layer and superficial molecular 
layer may be dendrites of the Bergmann glia or processes of golgi cells and purkinje 
cells. 
 
7.2.4  Amygdala  
 
The amygdala, a component of the limbic system, is a mass of subcortical grey matter 
involved in the processing of emotive experience. It is comprised of multiple nuclei 
surrounded by cortex which has a characteristic six layer structure analogous to the 
neocortex. KA1 immunoreactivity was observed as weak cytoplasmic staining in large 
neurons within nuclei. However, there was no evidence for axonal/dendritic KA1 
expression in these cells. Immunoreactivity was more prominent within the cytoplasm of 
large neurons within layers 3, 5 and 6 of the cortex, as shown in figure 7.10. Moreover, 
the staining of glial cells, i.e. astrocytes, oligodendrocytes and microglia, was similar to 
that observed in frontal cortex and cerebellum tissue. 
 
7.2.5 The hippocampal formation 
 
7.2.5.1 The hippocampus  
The hippocampal formation is a group of cytoarchitectonically distinct adjoining regions 
including the hippocampus, dentate gyrus (DG) and parahippocampal areas such as 
subiculum, entorhinal and perirhinal cortices. These regions, in concert with other limbic 
structures, are intrinsically involved in cognitive processes such as memory formation, 
















Figure 7.9  Protein immunoreactivity for GFAP in the cerebellar cortex. Images captured at low 
x16 magnification (a) and at high x400 magnification (b). Yellow stars indicate brown 
immunoreactivity for GFAP in Bergmann glial cells located in close proximity to the large purkinje 
















Figure 7.10  Protein KA1 immunoreactivity in cortical layers surrounding deeper nuclei of the 
amygdala in (a) Layer 3 of the amygadala cortex, and (b) large neurons of layer 5 or 6.  Yellow 



















Within the hippocampus proper, the main subdivisions are the Cornu ammonis (CA) 
fields (CA1, CA2, CA3 and CA4), and the alveus – a layer composed of white 
myelinated fibers which borders the lateral ventricle. The major afferent pathway to the 
hippocampus is the perforant path. The axons of the perforant path arise principally in 
the superficial layers of the entorhinal cortex and project to the granule cells of the 
dentate gyrus and pyramidal cells of the CA1 and CA3. Likewise, the axons of the 
granule cells within the DG extend via the hilus to CA3 pyramidal cells, forming a 
second main pathway - the mossy fibre pathway. In turn the pyramidal cells of the CA3 
are the source of major input to the CA1 (the Schaffer collateral pathway). Collectively 
these three pathways have been termed the ‘trisynaptic circuit’ and represent a major 
portion of the functional circuitry of the hippocampal formation, as schematically 
illustrated in figure 7.11. 
 
KA1 immunoreactivity was observed in the dendritic processes of the granule cells 
located within the inner and outer molecular layer (stratum moleculare) of the dentate 
gyrus (presented in figure 7.12a).  Strong but sporadic staining was evident in the DG 
granule cell nuclei and dendrites, with no obvious variation in regional distribution. 
However, as shown in figure 7.13a, weaker and more diffuse cytoplasmic staining was 
also observed in a proportion of the granule cells. Immunoreactivity for GFAP, a marker 
of astrocytes, indicated that astrocytes are located within the granule cell layer (GCL) as 
well as clustering along the GCL inner border, the subgranular zone, adjoining the hilus 
(figure 7.12b). As the size and shape of these glial cells are similar to granule cells, it is 
possible that some immuno-positive KA1 cells within the DG are in fact astrocytes. 
 
The hilus, the inner region of the dentate gyrus, is a polymorphic cell region composed 
of small neurons, glial cells and large mossy fibre neurons which synapse with granule 
cell axons and CA3 pyramidal cells. Strong KA1 immunoreactivity was observed in the 
































Figure 7.11 Schematic illustration of the hippocampal formation and major pathway circuitry. (a)  
Structure and cyto-architecture of the hippocampus and DG. Figure adapted from (McCaffery et 
al., 2006) figure 1. (b) Diagram of a human tissue section illustrating the strata in the CA fields. 
Diagram adapted from Talbot et al. 2004, figure 4A. (c) Schematic illustration of CA3 strata. 
Figure adapted from (Jaskolski et al., 2005), figure 2.  DG, dentate gyrus; h, hilus; m, stratum 
lacunosum-moleculare; o, stratum oriens; oml, outer molecular layer; p, stratum pyramidal; PrS, 









































Figure 7.12  KA1 and GFAP protein immunoreactivity in the molecular layer and GCL of the 
dentate gyrus. (a) KA1 expression in dendrites within the molecular layer (stratum moleculare).  
(b) GFAP expression in the DG hilus, GCL and molecular layer. Yellow stars indicate the 
clustering of astrocytes in the inner layer of the GCL. The black bar represents 50µm. Iml, inner 















































Figure 7.13  KA1 expression in the granular cell layer of the dentate gyrus. Image captured at 
low x160 magnification (a), and at high x400 magnification (b).  Staining is evident in the 
nucleus, cell body and processes of the granule cells. The black bar represents 50µm. (gcl 










Strong reactivity was also observed in neuropil (unmyelinated synaptic processes and 
terminals interspersed between neurons) in an area consistent with it being mossy fibre 
connections (figure 7.14). In addition, and similar to other brain regions, glial cells 
showed a strong immuno-positive signal.  
 
The CA4 field starts within the hilus and curves outwardly until adjoining the CA3 
region in the hippocampus proper, indicated in figure 7.11. KA1 immunoreactive 
expression was observed in the neuropil surrounding the principal cell of this region (the 
large pyramidal cells) as well as weak cytoplasmic staining within the pyramidal cells 
themselves (figure 7.14b).  
 
This pattern of expression is retained within the CA3 and CA2 fields. The strongest and 
most diffuse immuno-positive signal was observed in the neuropil among pyramidal 
cells and the stratum lucidum (l) of the CA3 field, a region in which mossy fibre cells 
synapse with the apical dendrites of CA3 pyramidal cells (figure 7.15a). Moderate signal 
localised to the cytoplasm of pyramidal cells provides support for the hypothesis that 
KA1 is expressed post-synaptically in neurons as well as pre-synaptically in mossy fibre 
cells. Immunoreactivity was also evident in the processes of CA3 pyramidal cells 
located in the stratum radiatum.  In addition, the observed punctate dendritic expression 
in the stratum oriens (CA3 pyramidal basal dendrites) suggests that KA1 may also be 
present at CA3 to CA3 associational, and CA3 to CA1 Schaffer collateral, connections. 
KA1 immunoreactivity in the CA2 region, although consistent with the CA3 expression 
pattern, was more punctate and less pronounced, as shown in figure 7.15b. 
 
Weak staining in the cell bodies of a small number of CA1 pyramidal cells was also 
observed. Stronger immunoreactive signal was evident in processes either between the 
pyramidal cells in the pyramidal stratum or throughout the stratum radiatum of the CA1 




































Figure 7.14  KA1 expression in the DG hilus and CA4 region. (a) Low magnification of KA1 
expression in the hilus. The large immuno-positive cell is a mossy fibre neuron and the brown 
background staining is reactivity for neuropil. (b) Low magnification image of KA1 neuropil 








































Figure 7.15  KA1 expression in the CA3 and CA2 fields. KA1 immunoreactivity in strata oriens, 
pyramidial and radiatum of CA3 (a) and CA2 (b).  The strongest signal was observed in the 
stratum lucidum of the CA3 region. The black bar represents 50µm. l, stratum lucidum; o, 









































Figure 7.16  KA1 immunoreactivity in the CA1 field. KA1 immunoreactivity in stratum pyramidial 
(a), and stratum radiatum (b). Signal was most pronounced in processes of the stratum 










Punctate signal corresponding to KA1 expression in processes and glial cells was 
evident in the stratum lacunosum-moleculare adjoining the stratum radiatum (figure 
7.16b). However, in contrast to the CA3/2 regions no immuno-positive staining was 
observed in the stratum oriens. 
 
The alveus is a layer of white fibres, predominately mossy fibres, covering the 
ventricular surface of the hippocampus. It is comprised of white matter tracts and glial 
cells such as astroctyes, oligodenrocytes and microglia and the processes of neurons 
located in deeper layers. KA1 immunoreactivity was prominent in glial cells of all sizes, 
dendritic processes as well as in regions between the cells which may represent KA1 
expression in the fibres of white matter (shown in figure 7.17 a). 
 
7.2.5.2 Parahippocampal regions 
 
The parahippocampal regions, composed of the subiculum, presubiculum, 
postsubiculum, entorhinal and perirhinal cortices, are located adjacent to the 
hippocampus. The pyramidal cell layer architecture of the CA1 field continues into 
subiculum which in turn adjoins to the pre- and post- subiculum pyramidal layers.  
Prominent KA1 immunoreactivity was observed in dendrites/processes within the 
pyramidal layer in the subiculum (figure 7.17b) and to a lesser extent in the pre- and 
post- subiculum regions.  
 
The cytoarchitecture of the entorhinal cortex (EC) and perirhinal cortex closely 
resembles the frontal cortex, i.e. being divided into 6 distinct cellular layers. However, 
unlike the neocortex, the internal granular layer (layer IV) is absent in the EC and 
instead there is an acellular or plexiform layer (lamina dissecans) (Amaral and Lavenex, 
2007). KA1 immunoreactivity was observed in glial and neuronal cells in all layers of 

















Figure 7.17 KA1 immunoreactivity in the alveus of the hippocampus and subiculum. Low 
magnification images of KA1 immunoreactivity in the alveus (a) and pyramidal layer of the 
subiculum (b). Immunoreactivity in the alveus is prominent in glial cells and in regions between 
the cells whereas in the subiculum KA1 expression is predominately localized to neuronal 
















Figure 7.18  KA1 immunoreactivity in layers 1and 2 of the entorhinal cortex. KA1  expression in 
the acellular layer 1 (a), and granular layer 2 (b), of the entorhinal cortex. The black bar 











The immuno-positive signal in layer 1 of the EC was found to be localized to glial cells 
and regions, putatively processes, between the glia cells (figure 7.18a). Layer 2 is 
populated by excitatory medium to large-sized stellate cells and small pyramidal cells, 
both of which project to the dentate gyrus and CA3. The population of pyramidal cells is 
reported to be grouped in clusters (cell islands) (Kumar and Buckmaster, 2006; Amaral 
and Lavenex, 2007).  Strong but sporadic cell body and dendritic immunoreactivity was 
observed in cells of a size which may be either satellite cells or pyramidal cells, as 
shown in figure 7.18b. However, as there was no evident clustering of the immuno-
positive cells, this would suggest that it is the stellate cells that strongly express KA1.  
 
The most numerous neurons in layer 3 are the excitatory pyramidal cells. However this 
layer also contains other cell types of various sizes and shapes. Strong KA1 
immunoreactivity was seen in a number of pyramidal cells, smaller spherical neurons 
and processes between cells (figure 7. 19a).  Layer 4 was not clearly discernible in the 
EC. Nonetheless, as large and small glial cells were stained immuno-positive throughout 
the EC, this would suggest that glial cells located within layer 4 also express KA1. 
 
Layer 5 is populated by pyramidal cells, small circular cells and fusiform neurons. In 
contrast, layer 6 is reported to contain a wide variety of neuronal cell types. The 
immunoreactive pattern observed was similar in both layers - namely, sporadic staining 
in the cell body and nuclei of large neurons and smaller spherical cells. Furthermore, a 
mesh of dendritic processes surrounding the neuronal cells was prominent for KA1 
reactivity, evident in figure 7.19b 
 
The 6 cellular bands of the perirhinal cortex are composed of cell populations suggested 
to be comparable to the neocortex.  Glial cells and subtypes of neurons in each layer of 
the perirhinal cortex showed positive KA1 immunoreactivity. Similar to the staining 
pattern observed in layer 1 of the neocortex, EC and the alveus, glial cells and processes 

















Figure 7.19  KA1 immunoreactivity in layers 3 and 5 and 6 of the entorhinal cortex. KA1 
expression in layer 3 (a) and layers 5 and 6 (b) of the entorhinal cortex. Glial cells, the cell 
















Figure 7.20  KA1 immunoreactivity in layers 1 and 2 of the perirhinal cortex. KA1 expression in 








Very strong, distinct reactivity was observed in the granular cell bodies and processes in 
layer 2, and strong, sporadic staining of spherical shaped cells and axons/dendrites in 
layer 3 (figure 7.20b and figure 7.21a). In layer 4 of the perirhinal cortex, like layer 2, 
the cell bodies of some spherical cells, consistent in shape and size of granular cells, and 
intercalated processes were found to express KA1, as shown in figure 7.21b. Weak 
cytoplasmic staining of large pyramidal cells and strong staining in smaller neurons was 
observed in layers 5 and 6. Furthermore, similar to layers 5 and 6 in the EC, a mesh of 
immuno-positive dendritic processes surrounding the cell bodies was observed, shown in 




This chapter describes the characterization of KA1 protein expression in paraffin-
embedded post mortem brain tissue using a novel polyclonal antibody specific to a 
carboxy-terminus epitope of the KA1 subunit. KA1 was found to be expressed in glia 
and specific populations of neuronal cells in all layers of the frontal, entorihinal and 
perirhinal cortices. In the cerebellum, distinct sporadic immuno-positive staining was 
observed in the superficial portion of the granular layer and in small cells, putatively 
Bergmann glia, located in the vicinity of the purkinje neurons. Strong KA1 expression 
was seen in hippocampus CA3/CA2 pyramidal dendritic neuropil, the processes in the 
CA1 strata, neuropil of the CA4 region, polymorph cells including glia and mossy fibre 
neurons of the hilus, and cell body and processes of granular cells in the dentate gyrus. 
Within these regions, KA1 expression was most prominent in axonal/dendritic processes 
consistent with localisation to synaptic terminals. 
 
7.3.1 Previous reports of KA1 expression in murine and human brain  
 
Nine studies have previously examined KA1 mRNA or protein expression in the frontal 
cortex, cerebellum and hippocampus formation, in human and murine brain. 

































Figure 7.21 KA1 immunoreactivity in layers 3, 4, 5 and 6 of the perirhinal cortex.  KA1  
expression in layer 3 (a), layer 4 (b), layers 5 and 6 (c and d), of the perirhinal cortex. The 
cellular composition and hence boundary is difficult to differentiate between layers 5 and 6. 
Immunoreactivity was consistently observed in glial cells, the cell bodies and processes of 
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The ensuing sub-sections will discuss similarities and discrepancies in expression 
profiles between the current and previous findings and highlight novel discoveries 
specific to this study. 
7.3.1.1 Frontal cortex 
Five studies have investigated KA1 gene expression in the neocortex of murine brain. 
Using a polyclonal antibody, Darstein and colleagues reported Ka1 protein expression in 
neurons scattered throughout layers two and five of mouse cerebral cortex (Darstein et 
al., 2003). In double Ka1-Cre/lacZ indicator adult transgenic mice, Ka1-Cre 
immunoreactivity was also observed in layer two and the anterior parts of layers five and 
six of the cerebral cortex (Kask et al., 2000). Similarly, Weak Ka1 mRNA expression 
was also reported in layers two, five and six in rat brain (Werner et al., 1991; Wisden 
and Seeburg, 1993). Interestingly, this latter study also describes KA1 expression 
extending into the white matter of the corpus callosum located below the cortical grey 
matter. A higher resolution examination performed using a Ka1 specific antiserum in rat 
brain, describes distinct staining in a subset of layer 5 pyramidal neurons and their apical 
dendrites, as well as lightly stained cells in layers 2, 3 and 4 of the cerebral cortex. 
Double immuno-fluorescence labeling for KA1 and GABA showed that a subpopulation 
of GABAergic interneurons in layers 2 and 4 (superficial and deep granular layers) were 
also Ka1 expressing (Fogarty et al., 2000). 
In human brain KA1 mRNA expression has been reported in all cortical laminae of the 
prefrontal cortex (Meador-Woodruff et al., 2001; Scarr et al., 2005). However, both 
these studies were of low resolution and gave no details of specific KA1 expressing cell 
types. In the current study, and consistent with the mRNA studies, KA1 was found to be 
expressed in all cortical layers. The strongest signal from cell somata was in sub-
populations of spherical cells in layers 2 and 4. The majority of these strongly 
expressing KA1 cells are consistent in shape and size with granular cells. As double 
labeling was not performed, it is unclear whether the same cells express GABA. 
However, kainate receptors have been reported both to modulate GABA release at 
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presynaptic sites and to regulate neuronal GABA receptor expression (Braga et al., 
2003; Payne et al., 2008). 
In the present study weak cytoplasmic labeling of pyramidal neurons and strong 
localized axonic/dendritic staining in layers 3 and 5 was clearly observed. These results 
contrast with the findings by Fogarty and co-workers who describe very distinctive 
labeling of pyramidal cell somata and apical dendrites which extend into the superficial 
layers of the rat cortex. This disparity in KA1 immunoreactivity may be due to 
differences in antibody specificity, in KA1 expression between species or in different 
cerebral cortical regions. 
The current data represent the first description of diffuse KA1 expression in dendritic 
processes throughout the cortical layers and within the cell bodies of large and small 
glial cells in the grey matter layers (including acellular layer) and underlying white 
matter. Kainate receptors have previously been reported to be present in 
oligodendrocytes, astrocytes and microglia, where they are postulated to be important 
for mediating glutamate excitoxicity (Matute et al., 2001; Verkhratsky and Kirchhoff, 
2007). Moreover, non-synaptic release of glutamate from astrocytes is thought to 
constitute a potential source of glutamate to activate extrasynaptic kainate receptors (Liu 
et al., 2004).  Thus, the present data raise a number of intriguing questions such as: what 
is the predominant function of KARs in glia cells; and how, when expression is 
perturbed, may this contribute to pathological states? 
7.3.1.2  Cerebellum 
Only three murine studies have reported a consistent signal for KA1 expression in the 
cerebellar cortex. In mouse sections, Ka1 immunoreactivity was observed in cerebellar 
purkinje cell bodies and their dendritic arborizations but not in the granule layer or in 
molecular layer interneurons (Darstein et al., 2003). This pattern of expression was also 
described in the rat brain by Wilsden and Seeburg (1993).  In contrast, Fogarty and 
colleagues report Ka1 expression in a subset of cells and radial fibres within the 
molecular layer, in addition to strong Ka1 immunoreactivity in purkinje cell somata and 
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their dendritic arborizations in rat cerebellum. Double immuno-fluorescence labeling for 
KA1 and GFAP (a marker of astrocytes) suggested that the radial fibres observed in the 
molecular layer were Bergmann glia. However the cell bodies of the Bergmann glia 
were not found to be immuno-positive (Fogarty et al., 2000).  
In the current study distinct immunoreactivity was observed in sporadic clusters located 
within the superficial portion of the granular layer. This pattern of staining, although not 
previously described for KA1, has been reported for GluR5 and mGluR2/3 (Ohishi et 
al., 1994; Lerma et al., 2001). The shape, size and position of these clusters is accordant 
with excitatory GABAergic golgi cells. Double immuno-fluorescence analysis using 
antibodies for mGluR2/3 and GABA performed by Ohishi and colleagues, confirmed 
that these putative cell bodies/signal clusters show GABA immunoreactivity. Although 
the functional consequences of KA1 receptor subunit expression within or in close 
proximity to (putative) golgi cells remains to be clarified, this finding again supports the 
hypothesis that kainate receptor activity may influence GABAergic transmission and 
hence, within the cerebellum, contribute to information processing and integration via 
feedback mechanisms.  
The present results also indicated weak cytoplasmic KA1 expression within purkinje 
neurons, consistent with previous findings from mouse and rat expression studies. In 
addition, diffuse immuno positive staining was observed in small spherical cells within 
the granular and purkinje layers and sparser staining in dendrites positioned within the 
molecular layer, both in close proximity to purkinje cells. Immunoreactivity for GFAP 
indicated that the position of the spherical cells is consistent with the location of 
Bergmann glia. However, the sparse dendritic signal may be the processes of either 
purkinje or Bergman glia cells. These results contrast with the findings from Fogarty and 
co-workers which describe strong and diffuse Ka1 expression in a subset of cells and 
radial glial fibres within the molecular layer in rat brain (Fogarty et al., 2000). However, 
the fact that KA1 may be expressed in a population of cells in the cerebellum suggested 
to have a neural stem cell phenotype is an interesting discovery which parallels findings 
for other brain regions (discussed in section 7.3.1.4).   
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7.3.1.3 Amygdala 
There has been only one study of KA1 expression in the amygdaloid complex. In the rat 
brain, Ka1 mRNA was found to be absent as examined by low resolution in situ 
hybridization (Werner et al., 1991). Nevertheless, electrophysiological experiments 
suggest an involvement of kainate receptors in synaptic transmission (Bleakman, 1999). 
The current findings indicate weak KA1 expression in the cell bodies of large neurons 
located within amygdala nuclei, and strong immunoreactivity in glia cells in both grey 
and white matter. Staining in processes was noticeably absent as compared to other brain 
regions, which could be explained, in part, by the reduced quality of tissue sections. 
7.3.1.4 Hippocampus 
The distribution of Ka1 mRNA and protein, as reported in the mouse and rat 
hippocampal formation, is comparable to the current findings. For example, Ka1 
expression was found in all CA regions of the hippocampus with the most prominent 
expression in the CA3 subfield and DG granule cells (Wisden and Seeburg, 1993; Porter 
et al., 1997; Fogarty et al., 2000; Darstein et al., 2003). One disparity between previous 
findings and the present data was observed in a study using KA1-Cre/lacZ adult 
transgenic mice. KA1-Cre immunoreactivity was described as absent in the somata and 
dendrites of DG granule cells and cell bodies of CA3 pyramidal neurons (Kask et al., 
2000). As these results also conflict with other rodent Ka1 expression studies, it is 
unlikely that this inconsistency is due to differential expression between species but may 
be the result of aberrant transgene expression pattern or altered intracellular Cre 
distribution.   
 
Three In situ hybridization studies investigating KA1 mRNA expression in the human 
hippocampus have been conducted. Wisden and Seeburg observed KA1 expression in all 
pyramidal cells and found substantially elevated levels in CA3 pyramidal neurons 
(Wisden and Seeburg, 1993). Whereas Porter and co-workers report that KA1 was 
detected in the dentate gyrus and CA3 region (Porter et al., 1997). Similarly, Beneyto 
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and co-workers observed KA1 in all regions examined but, like the two aforementioned 
studies, did not describe in detail specific strata or KA1 expressing cell types (Beneyto 
et al., 2007).  
 
Consistent with these findings, the present study demonstrated strong distinct KA1 
expression in the dendrites (mossy fibre inputs) located within the stratum lucidum and 
more sporadic dendritic staining in the stratum radiatum of the CA3 field. The 
ultrastructural localization of KA1 in these mossy fibre synapses, i.e localization on pre- 
or post-synaptic sites, has been a matter of some debate. Fogarty et al. (2000) 
investigated this question by using electron microscopy (EM) on pre-embedded, Ka1 
immunostained rat brain sections of the CA3 subfield. They showed that labeling was 
present in dendritic structures that were post-synaptic to axon terminals within the 
stratum radiatum. They also report that mossy fibre terminals (pre-synaptic) and the 
post- synaptic dendritic spines within the stratum lucidum were devoid of label.  
 
In contrast, Darstein and co-workers performed immunogold EM on hippocampal mouse 
sections stained for Ka1. They reported immunogold labeling on pre-synaptic, mossy 
fibre boutons, and to a lesser degree, postsynaptic spines within the stratum lucidum. 
Furthermore, labeling with 5nm 2 gold particles, which gives an increased spatial 
resolution, indicated a major KA1 peak in distribution on the presynaptic membrane and 
a smaller peak of distribution near to the post-synaptic membrane in both synaptic and 
extrasynaptic zones (Darstein et al., 2003). Unfortunately, the resolution of 
immunostaining in the current study is too low to determine ultrastructure localization. 
However, KA1 was shown to be clearly expressed in both CA3 pyramidal cells and 
mossy fibre neurons. 
 
In the current study, weak KA1 staining of pyramidal neurons and stronger labeling of 
processes with the pyramidal cell layer and throughout the stratum radiatum of the CA1 
subfield was observed. The stratum radiatum within the CA1 is described as the 
suprapyramidal region in which CA3 to CA1 Schaffer collateral afferent connections are 
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located. This region is also rich in a variety of inhibitory interneurons such as basket and 
radial trilaminar cells. Administration of kainate (KA), the agonist of this receptor type, 
has been reported to cause a reduction in GABAergic inhibition in CA1 pyramidal 
neurons as revealed by a decrease of evoked GABAergic IPSCs. Whether this inhibitory 
effect is mediated by presynaptic KARs localized on GABAergic terminals on CA1 
pyramidal cells is still a matter of debate (Lerma, 2003). However, administration of KA 
in submicromolar concentrations produces the opposite effect, i.e. an increase in 
spontaneous GABAergic IPSCs, and this GABAergic facilitation has been proposed to 
occur through the activation of somatodendritic KARs located on interneurons (Vincent 
and Mulle, 2008).  Again, double labeling experiments using KA1 and neurotransmitter 
specific marker antibodies, might reveal the class of cell in which KA1 is expressed 
within the strata of the CA1 subfield. 
 
The present results also clearly indicate that KA1 is expressed in all regions of the 
mossy fibre pathway, i.e. apical dendrites, somata and axons of the granular cells, mossy 
fibre neurons in the hilus, mossy fibre terminals in the CA3 field and mossy fibre white 
matter tracts in the alveus. Of particular interest is the evident KA1 distribution within 
the granule cells and along the subgranular zone (SGZ) in the dentate gyrus. It is in this 
specific region that adult neurogenesis occurs, i.e. the generation of new neurons in the 
adult brain. Granule neurons are generated throughout life from two populations of 
neural progenitor cells located within the DG which can be identified according to their 
specific morphologies and expression of sets of molecular markers.  
 
Type 1 progenitor cells have radial processes spanning the granule cell layer and express 
nestin, SOX2 (Sry-related HMG box transcription factor) and GFAP (Zhao et al., 2008). 
In the current study, immunohistochemistry performed using a GFAP specific antibody 
on hippocampal sections indicated that there may be some positional overlap in GFAP 
and KA1 expressing cells. Type 2 progenitor cells have short processes, do not express 
GFAP but are SOX2-positive.  A recent study has shown that a single, type 2 progenitor 
cell can give rise to both a neuron and glial cells, i.e. these cells have stem cell 
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properties (Suh et al., 2007). The distribution of KA1 in cells at the SGZ raises the 
intriguing possibility that KA1 is expressed in one or both types of neural progenitor cell 
and is in line with finding that KA1 is potentially expressed in Bergmann glia – a stem 
cell population in the cerebellum.  Important future considerations should include co-
localisation studies of KA1 and neurogenesis/stem cell specific molecular markers 
within human hippocampal and cerebellum sections.  
 
The proliferation and differentiation of neural progenitor granule cells are both processes 
which may result in aberrant neurogenesis when disrupted. However, equally important 
is the migration and functional integration of the newly-born granule neurons into the 
mossy fibre circuitry. Recent evidence suggests that during development KARs may be 
involved in axon navigation. For example, filopodial motility is reported to be 
differentially regulated by kainate receptors in hippocampal mossy fibres in the 
developing neonatal mouse brain (Tashiro et al., 2003). Furthermore, similar to the 
process of synaptogenesis during development, synapse formation and activity 
dependent re-modelling of synapses are critical factors determining appropriate 
functional connectivity. Indeed, the specialized synapses of mossy fibres (known as 
‘thorny excrescences’) are described to have numerous morphological types of terminal, 
and this morphological variation has been proposed to reflect different maturational 
stages of connections formed by newly generated granule cells (Gould, 2007). The 
expression profile of KA1, in conjunction with its functional role at mossy fibre 
terminals, leaves open the possibility that KA1 (within a KAR complex) may play a part 
in the migration and synaptic integration of newly generated neurons. Future research 
exploring this exciting avenue, for example histological and electrophysiological 
investigation of Ka1 transgenic mice, might provide further insight into these 





7.3.1.5 Parahippocampal regions 
 
Two studies have examined KA1 mRNA expression within regions of the 
parahippocampus in sections of rat and human tissue. KA1/Ka1 was detected at a 
moderate level in both the subiculum and EC (Wisden and Seeburg, 1993; Beneyto et 
al., 2007). Furthermore, human KA1 was found to be distributed throughout all 6 layers 
of the perirhinal cortex, consistent with the present results (Beneyto et al., 2007). As yet 
the cellular organization of the perirhinal cortex and consequential direct afferents to 
other hippocampal regions has not been fully characterized (Liu and Bilkey, 1998). 
However, the current findings indicated prominent KA1 immunoreactivity in cells 
within layer 2 of the EC, a region which is known to provide a direct input (the perforant 
path projection) to the CA1 and CA3 subfields as well as the dentate gyrus.  
7.3.2 Discrepancies between studies: advantages and disadvantages of IHC 
 
The disparity in reports of KA1 expression evident in previous studies and compared to 
the current findings may reflect a difference in species-specific expression. In addition, 
there may be subtle differences between KA1 mRNA and protein localization. 
Nevertheless, discrepancies might also arise on account of the technique used to 
examine KA1 expression profile. For example, in situ hybridization and quantitative 
autoradiography are techniques which have a low spatial resolution and a high 
background signal which may make weaker sporadic cell staining difficult to interpret. 
An advantage of IHC is that labeling is of a higher resolution, enabling localized cell 
and subcellular distribution to be determined. Conversely, a disadvantage to IHC is the 
possibility that the KA1 antibody cross reacts to structurally similar epitopes such as 
different isoforms or other KAR subunits. This may be one explanation as to why the 
IHC study by Fogarty et al., (2000) report differences in expression both to, other studies 
performed using rat brain and to the current findings. However, an additional control 
test, not performed in this study, would be to pre-absorb the KA1 primary antibody with 
the appropriate (unique) immunizing peptide, which should consequently block any 
specific immunoreactivity. 
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7.3.3 Expression patterns of kainate receptor subunits in the brain 
 
Kainate receptors are tetrameric combinations of five subunits (GluR5-7, KA1, KA2) of 
which only GluR5-7 can form functional homomeric cationic channels. The auxillary 
subunits, KA1 and KA2 must co-assemble with the principal subunits for functional 
expression on the plasma membrane. Within the brain, KAR subunit composition is 
suggested to be highly heterogeneous, with different combinations giving rise to native 
kainate receptors that have distinct physiological and pharmacological properties 
(Jaskolski et al., 2005). All receptor subunits are expressed widely throughout the adult 
central nervous system and show distinct overlapping patterns of mRNA and protein 
expression. To add to the complexity of KAR subunit distribution, GluR5-7 undergo 
alternative splicing and/or mRNA editing and these iosforms may also be differentially 
distributed in cell populations and subcellular sites.  
 
KA2, GluR6 and GluR7 are described as having a widespread pattern of distribution in 
human brain tissue (Porter et al., 1997; Chittajallu et al., 1999). In contrast, it is 
suggested that GluR5 shows a more limited expression profile. In the present study, the 
most comprehensive investigation of KA1 mRNA or protein distribution in human 
brain, KA1 was indicated to be expressed in both glia and subsets of neuronal cells in 
every brain region examined. 
 
All five subunits are reported to be present in layers 2-5 in human frontal and entorhinal 
cortices.  KA1 and GluR7 were found to be expressed at the highest levels in the frontal 
cortex and similarly KA1, KA2 and GluR7 highest in the EC (Meador-Woodruff et al., 
2001; Scarr et al., 2005; Beneyto et al., 2007). In the cerebellum KA2 and GluR6 are 
strongly expressed throughout the granular cell layer but are absent in the purkinje cells 
or the molecular layer, whereas GluR7 mRNA is expressed in some cells in the 
molecular layer (putatively stellate/basket cells) as well as at low levels in purkinje and 
granule cells. The expression patterns of GluR5 and KA1 show some overlap, e.g. 
purkinje cells and sporadic labeling in a specific subgroup of cells (putatively golgi 
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cells) located within the superficial portion granular cell layer. This would suggest that 
in these particular cells KA1 assembles with GluR5 to form a functional receptor.  
 
The heterogeneous nature of kainate receptor subunit composition is also apparent in the 
human hippocampus at both a cellular and subcellular level. KA1, KA2, and GluR6 
mRNA are all reported to be expressed in pyramidal cells within the CA1 and CA3 
subfields and granule cells of the dentate gyrus (Porter et al., 1997). However, 
electrophysiological studies in conjunction with in situ histology examination suggests 
that, unlike KA1, GluR6 and KA2 are predominately localized to the post synaptic site 
at mossy fibre contacts in the CA3 stratium lucidum (Pinheiro and Mulle, 2008). GluR5 
and GluR7 subunits have an even more distinct regional pattern. GluR5 is expressed in 
the CA1 and CA3 but not in the dentate gyrus. In contrast, GluR7 is expressed in the 
dentate gyrus and at low levels in cells within the stratium oriens and CA3 subfield 
(Porter et al., 1997). Figure 7.22 summarizes the current findings for KA1 and 
schematically illustrates distribution of GluR5-7 and KA2 in the hippocampal formation. 
7.3.4 The function of KARs and KA1 
 
As introduced in section 1.4.3.3 of chapter 1, kainate receptors are involved in short 
term synaptic plasticity mechanisms, synaptic integration and long-term modulation of 
neurotransmission. KARs located at post-synaptic sites directly mediate excitatory 
transmission, while pre-synaptic KARs typically modulate neurotransmitter release 
through noncanonical signalling pathways (Lerma, 2006). Furthermore, activation of 
kainate receptors is reported to produce bi-directional modulation of both excitatory and 
inhibitory transmission, i.e. low to moderate activation enhances transmission, whereas 
stronger activation inhibits transmission (Huettner, 2003).  
 
These diverse functions require the appropriate subcellular localization of native KARs 
(comprised of particular subunits) within specific functional domains of neurons (see 






















Figure 7.22 Schematic representation summarizing KAR subunit expression in the hippocampus 
and dentate gyrus. Figure adapted from Vincent and Mulle, 2008, figure 1. The distribution of 
KA1, as determined in the present study, is shown (KA1 coloured red). Differences in ultra-







However, it is not yet known if it is the assembly of specific combinations of subunits 
which determines subcellular localization.  
 
KAR mediated synaptic function is reported to be particularly important for 
hippocampal mossy fibre - CA3 (MF-CA3) long-term potentiation and normal synaptic 
plasticity. Plasticity mechanisms at these synapses are fundamentally different from 
other regions. For example, induction of mossy fibre LTP is independent of NMDA 
activation and is expressed presynaptically (Harris and Cotman, 1986; Nicoll and 
Schmitz, 2005). 
 
The use of transgenic mice has begun to provide some insight into which receptor 
subunits are involved in the different functions of kainate receptors in this region. 
Contractor and colleagues investigated the electrophysiological properties at MF-CA3 
synapses in KA1 knockout and Ka1/Ka2 double knockout mice. They found that paired 
pulse and frequency facilitation in these mice was normal, suggesting that an absence of 
KA1, or both subunits, does not alter presynaptic kainate function. However, mossy 
fibre LTP was found to be impaired in Ka1/Ka2 double KO mice. Furthermore, in Ka1
-/-
  
mice, EPSCKA was not observed with normal high synaptic stimulation but could be 
observed using a train of high frequency stimuli. This suggested that the distribution of 
post-synaptic KARs is localised to the peri-synaptic regions and hence is abnormal in 
Ka1
-/-
 mice. Together these results led the authors to hypothesise that Ka1 and Ka2 
together control functional surface expression of KARs and Ka1 controls synaptic 
localization at MF-CA3 synapses (A. Contractor, Personal communication). 
 
From the distribution profile of KA1 in the human hippocampal formation presented in 
this chapter, it is evident that KA1 is expressed in regions involved in neuronal 
processing within all three pathways forming the trisynaptic circuit- the major route of 
information transfer commonly considered to underlie memory consolidation. It is 
possible therefore, that alterations in KA1 expression not only have a significant effect 
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upon CA-MF transmission, as discussed above, but could also influence information 
processing within other regions of the hippocampal circuitry. This in turn may have 
physiological consequences on network activity outside of the hippocampus, which 
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8. A genotype expression correlation study of KA1 in human brain 
 
8.1 Preface 
The previous two chapters described the identification of an insertion/deletion (indel) in 
the 3’UTR of GRIK4/KA1 as a protective factor for bipolar disorder, and the subsequent 
characterization of KA1 protein expression in human brain sections. As we have shown 
that GRIK4 mRNA transcripts carrying the deletion are relatively more abundant, we 
hypothesise this variant may also result in differential protein distribution and 
abundance. To that end, this chapter reports the results of a genotype/protein correlation 
using brain tissue from individuals asymptomatic for psychiatric illness genotyped for 
the associated 3’UTR deletion variant. 
 
8.2 Results 
 8.2.1 Quantification of KA1 expression  
Brain tissue donated from the Edinburgh University Human brain bank was genotyped 
for the ins/del variant. Five heterozygote indels, 6 homozygote insertions and 1 
homozygote deletion were matched for age, gender and cause of death. Details 
pertaining to these samples and the demographic profile of each genotype group are 
presented in tables 8.1 and 8.2.  Paraffin embedded post mortem human coronal sections 
of the hippocampus and parietal frontal cortex were received coded and the study 
performed blinded. 
In the hippocampus, areas analyzed were the molecular layer and granular cell layer of 
the dentate gyrus, alveus, hilus, CA4, CA3 and CA1 subfields. In the frontal cortex, 
immunopositive cell counts in layers 1- 4 were analysed separately. Due to the difficulty 
in distinguishing between layers 5 and 6, these strata were classified as one region. 
Immunopositive axons/processes, neuronal and glial counts were quantified within 
circles of 100µm radii taken from 5-10 images randomly selected from each region of 











Table 8.1 Details of individual samples used for the genotype correlation study. Gender, age, 
post mortem interval (PMI), pH, genotype and cause of death listed. (DEL/DEL), homozygous 









Table 8.2 Genotype Group Demographics. Mean age, gender ratio, mean post mortem interval 
(PMI) and mean brain pH listed for each genotype group. The number of samples in each group 
is listed in brackets. 
Case 
Identifier Gender Age PMI (h) Brain pH
 
Genotype Cause of Death
SD004/06 F 52 64 6.40 DEL/DEL Acute myocardial infarct 
SD006/06 M 40 48 6.20 INS/INS Acute myocardial infarct
SD007/05 M 37 92 nd INS/DEL Acute myocardial infarction
SD014/05 F 59 48 nd INS/DEL Subarachnoid haemorrhage
SD016/06 M 25 92 6.60 INS/INS Internal bleeding. Rupture of thoracic aorta (RTA)
SD019/05 F 51 115 6.30 INS/INS Hypertensive heart disease & cirrhosis
SD019/06 M 20 37 5.55 INS/DEL Hyperglycaemic coma
SD021/05 F 48 50 6.50 INS/INS Pulmonary thromboembolism
SD022/06 M 53 51 6.30 INS/INS Acute myocardial infarct
SD025/05 M 28 39 7.50 INS/DEL Suspension by a ligature
SD036/05 M 50 61 7.30 INS/DEL GI haemorrhage & liver failure
SD041/05 M 24 51 6.30 INS/INS Fatal poisoning with alcohol
hom del (n =1) het (n =5) hom ins (n =6)
Mean age: yr (range) 52 38.3  (20-59) 40.2  (24-53) 
Gender ratio: male/female 0/1 4/1 4/2
Mean PMI: hr (range) 64 55.4 (37-92) 67.8 (50-115)
Mean Brain pH 6.4 6.8 6.4
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Immunopositive glial cells, i.e. astrocytes, oligodendrocytes and microglia, were 
examined separately from neuronal counts in the hilus, CA4, CA3 and CA1 of the 
hippocampus and layers 3 and 5 of the frontal cortex. Neuronal positive counts included 
immunopositive labelled processes as well as cell somata and nuclei. Neuropil staining 
in the hilus, CA4 and CA3 subfields was assessed semi-quantitatively using a colour 
deconvolution technique in Image J (Ruifrok and Johnston, 2001). Details of this 
method are presented in chapter 2, section 2.5.4.1. 
8.2.2 Genotype/protein correlation in the hippocampus   
 
The mean hippocampal cell counts and neuropil percentages calculated for each sample 
are presented in table 8.3. One sample (SD016/06 genotyped homozygous insertion) had 
to be excluded from the analysis of all hippocampal regions owing to torn tissue 
sections. Data for a second sample (SD014/05 genotyped heterozygous) was also not 
obtained for the CA4, CA3, CA1 sub-regions on account of poor tissue quality. The 
mean cell counts and neuropil percentages per genotype group are listed in table 8.4.  
 
A summary of the P and F values associated with hippocampal cell count and neuropil 
immunoreactivity percentage differences between the groups is provided in table 8.5. A 
significant difference in immunoreactive cell counts between the homozygous insertion 
(hom ins) group and heterozygous/homozygous deletion (het/hom del) or heterozygous 
(het) groups was found in the direction predicted for the granular cell layer of the dentate 
gyrus (het + hom del vs hom ins, F = 25.07, [1,10], P = 0.0005; het vs hom ins, F = 
25.51, [1,10], P = 0.0005) , and CA3 pyramidal cells (het + hom del vs hom ins, F = 
6.35, [1,9], P = 0.018; het vs hom ins, F = 11.93, [1,9], P = 0.0055) [one way ANOVA, 
one tailed], shown in table 8.5 and graph 8.1 a and b). Moreover, comparison of 
homozygous insertion versus heterozygotes alone genotypes indicated a trend in 
increased protein expression in heterozygotes in CA3 dendritic neuropil (H = 2.16, P = 
0.07), CA4 pyramidial cells (F = 2.26, [1,8], P = 0.09), CA1 pyramidal cells (F = 2.16, 
[1,8], P = 0.09), and immunoreactivity in the alveus (F = 2.19, [1,8], P = 0.09), [one 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 8.4 Hippocampal cell count and neuropil percentage means per genotype group. Values 
are shown for homozygous insertion group (Hom insertion), heterozygous and homozygous 
deletion group, Heterozygous group (het) and homozygous group (hom deletion). Red values 










Table 8.5 P and F values associated with hippocampal cell counts and neuropil 
immunoreactivity percentages. * denotes non parametric analysis. Red values indicate 
significance or a trend towards significance. Parametric tests performed, one-way ANOVA (one-
tailed) and non-parametric, Kruskal-Wallis (one-tailed). 
Hom insertion (n =6) Het + hom del (n= 6) Het  (n= 5) Hom deletion (n =1)
Mean SEM Mean SEM Mean SEM Mean SEM
Molecular layer neuronal 6.08 1.69 8.62 2.15 9.44 2.43 4.50 0.56
Molecular layer glia 8.30 1.35 9.62 0.99 9.34 1.16 11.00 1.16
Dentate gyrus granule cells 4.69 0.43 8.09 0.50 8.28 0.57 7.10 0.93
Alveus 10.42 1.96 13.36 1.31 14.23 1.32 9.9 1.03
Hilus neuronal 8.78 1.81 12.40 2.56 13.52 2.82 6.8 0.78
Hilus glia 11.52 1.92 12.47 2.14 11.56 2.38 17.00 1.50
Hilus Neuropil abundance 2.70 1.07 4.94 1.28 5.12 1.55 4.06 1.49
CA4 neuronal 11.16 2.16 15.82 3.99 17.16 3.59 10.50 1.09
CA4 glia 13.02 1.58 12.22 2.37 12.17 2.59 12.40 1.31
CA4 Neuropil abundance 3.11 1.16 6.65 2.55 7.40 3.11 3.64 1.68
CA3 neuronal 9.95 1.72 18.34 2.60 20.35 2.34 10.30 0.89
CA3 glia 13.42 1.20 14.94 2.51 15.45 3.12 12.92 0.98
CA3 Neuropil abundance 3.05 0.47 9.49 3.69 11.36 4.11 2.04 0.13
CA1 neuronal 8.42 1.80 11.22 1.19 11.93 1.27 8.40 0.72
CA1 glia 8.38 1.02 9.05 0.80 8.68 0.92 10.50 1.08
het + hom del vs hom ins het  vs hom ins
P value F  value P value F  value
Molecular layer neuronal 0.20 0.81 0.14 1.29
Molecular layer glia 0.22 0.65 0.29 0.34
Dentate gyrus granule cells 0.00050 25.07 0.00050 25.51
Alveus 0.13 1.47 0.09 2.19
Hilus neuronal 0.15 1.23 0.10 2.00
Hilus glia 0.38 0.11 0.50 0.00
Hilus Neuropil abundance 0.11 1.72 0.12 1.66
CA4 neuronal 0.13 1.54 0.09 2.26
CA4 glia 0.40 0.07 0.41 0.06
CA4 Neuropil abundance 0.13* 0.16*
CA3 neuronal 0.018 6.35 0.0055 11.93
CA3 glia 0.31 0.26 0.28 0.37
CA3 Neuropil abundance 0.17* 0.07*
CA1 neuronal 0.12 1.59 0.09 2.16



















Graph 8.1 Genotype effect on mean cell counts and neuropil abundance in the hippocampus.  
Granule layer cell in the dentate gyrus; (b) CA3 pyramidal layer; (c) CA3 dendritic neuropil; (d) 
Alveus. Red dot indicates the homozygous deletion individual. Red line indicates the mean of 
each group. Het, heterozygous group; het & hom, heterozygous group plus the one homozygous 
deletion individual; hom ins, homozygous insertion group. Differences between genotype groups 
for the DG cell layer, CA3 pyramidal cells and alveus regions were tested using one-way 
ANOVAs – a parametric test. A non-parametric, Kruskal-Wallis (one-tailed) test was employed 






Het & hom del vs hom ins  P= 0.018
Het vs hom ins P= 0.0055
CA3 Dendritic Neuropil
Het & hom del vs hom ins  P= 0.17
Het vs hom ins P= 0.07
Alveus
Het & hom del vs hom ins  P= 0.13
Het vs hom ins P= 0.09
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Figure S1, appendix 3 provides an example of increased KA1 expression in the CA3 
region evident in a heterozygous carrier as compared to homozygous insertion carrier.  
 
All neuronal cell counts and neuropil abundance percentage means were found to be 
higher in the deletion allele groups than the homozygous insertion group, shown in table 
8.4. Table 8.6 and graph 8.2 summarise the percentage increase in KA1 expression 
associated with the deletion groups in quantified neuronal and glial cell regions. The 
mean of means for all neuronal regions analysed together indicates a 75% and 92% 
increase in the het/hom group and het group, respectively. This analysis includes values 
calculated for the alveus region as dendritic processes as well as glial cells were counted. 
In contrast, counts of just glial cells in the molecular layer, hilus, CA4, CA3 and CA1 
were found to be similar between groups. Consequently, the mean increase in KA1 
expression associated with the deletion allele groups for glial count regions was found to 
be low (7.4 het/hom and 5.0 het). 
 
The individual P values calculated for the differences between groups in each region, 
presented in table 8.5 and discussed above, were not corrected for multiple testing. 
However, assuming a more conservative level of significance (α = 0.01), the genotype 
effect observed for the granule cell layer in the dentate gyrus and pyramidal cells in the 
CA3 still remain significant. Owing to the small numbers analysed in each neuronal 
region - making reaching statistical significance hard to reach - the observed percentage 
increase in all neuronal count regions strongly suggests that a genotype effect is 
predominant in neuronal associated expression. 
 
Analysis of confounding variables was assessed by the non-parametric Spearman’s rank 
correlation test. Table 8.7 presents the Pearson correlation coefficient P-values (two 
tailed) calculated for genotype, gender, age, PMI, pH and hippocampal counts. No 
correlation was found between genotype, gender, PMI and pH. However, a significant 
correlation was indicated between gender and age. As the groups were matched for age 














Table 8.6 Percentage increase in KA1 expression calculated for the deletion groups relative to 















Graph 8.2 The deletion allele increases KA1 immunoreactivity in neuronal cells in the 
hippocampus. Red dashed lines indicate the mean of neuronal and glial cell regions in the two 
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% ins hom vs het + hom % ins hom vs het
Neuronal 
Molecular layer neuronal 41.78 55.26
Dentate gyrus granule cells 72.49 76.55
Hilus neuronal 41.23 53.99
Hilus Neuropil abundance 83.33 89.63
CA4 neuronal 41.75 53.76
CA4 Neuropil abundance 113.83 137.94
CA3 neuronal 84.32 104.52
CA3 Neuropil abundance 211.14 272.45
CA1 neuronal 33.25 41.69
Alveus* 28.21 36.56
All regions neuronal mean % increase 75.13 92.24
Glial
Molecular layer glia 15.90 12.53
Hilus glia 8.25 0.03
CA4 glia -6.22 -6.53
CA3 glia 11.40 15.12
CA1 glia 7.88 3.58
All regions glial cell mean % increase 7.44 4.95















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Four region-specific KA1 counts were also found to be significantly correlated with 
either gender or tissue pH. Cell counts in the alveus were significantly correlated with 
gender (P =0.03), and CA3 neuronal cell counts (P =0.003), CA4 and CA3 neuropil 
percentages (P =0.04, P =0.004) with tissue pH. Both the alveus and CA3 neuropil 
quantified regions showed a trend in significance between genotype groups. However, as 
genotype was found not to correlate with gender or pH, it is improbable that these 
differences in counts are due to gender and pH as confounding variables. 
8.2.3 Genotype/protein correlation in the frontal cortex  
 
Mean frontal cortex cell counts calculated for each sample are presented in table 8.8. 
One sample, SD019/05 genotyped homozygous insertion, was excluded from the 
analysis of layers 3 - 6 owing to the poor quality of tissue sections. The mean cell counts 
for all strata per genotype group are listed in table 8.9.  
 
P and F values calculated for cell count differences between the groups are summarized 
in table 8.10. A significant difference in immunoreactive cell counts between the 
homozygous insertion (hom ins) group and heterozygous/homozygous deletion (het/hom 
del) or heterozygous (het) groups was found in the direction predicted for layer 1 
(het/hom del vs hom ins, H = 5.77, P = 0.0058; het vs hom ins, H = 4.80, P = 0.014) 
[nonparametric Kruskal-Wallis Test, one tailed], shown in graph 8.3a).  
 
A significant difference between the groups was found also for layer 2 heterozygote 
group versus homozygous insertion (F = 3.49, [1,9], P = 0.047, one way ANOVA one 
tailed) which showed only a trend in significance when comparing the 
heterozygous/homozygous deletion group with the insertion group (F = 3.14, [1,10], P = 
0.054 one way ANOVA one tailed) indicated in graph 8.3b. Furthermore, a trend 
towards significance was also observed for layer 4 (het/hom del vs hom ins, F = 2.97, 















Table 8.8 Frontal cortex cell count means per individual sample. Standard errors are presented. 









Table 8.9 Frontal cortex cell count means per genotype group. * denotes non-parametric 
analysis. Red values indicate significance or a trend. Values are shown for homozygous 
insertion group (Hom insertion), heterozygous and homozygous deletion group, Heterozygous 
group (het) and homozygous group (hom deletion). Red values indicate a significance difference 
between groups or a trend towards significance. 
Hom insertion Het + hom del Heterzygous only Homozygous del
Mean SEM Mean SEM Mean SEM Mean SEM
Layer 1 19.94 2.10 29.49 3.73 29.30 4.57 30.41 2.17
Layer 2 23.82 5.20 37.44 5.65 39.25 6.56 28.40 3.20
Layer 3 neuronal 11.00 2.06 13.58 2.12 14.39 2.40 9.56 0.71
Layer 3 glia 18.73 1.59 19.02 1.56 18.10 1.55 23.63 1.72
Layer 4 10.74 2.47 16.85 2.76 17.01 3.05 16.08 1.38
Layers 5 & 6 neuronal 12.48 2.52 14.28 1.89 14.75 2.21 11.88 0.91
Layer 5 & 6  glia 20.57 1.94 23.18 1.47 22.69 1.70 25.63 1.90
Sample    Layer 1    layer 2      layer 3 
neuronal
Layer 3 glia Layer 4  Layers 5 & 6 
neuronal
Layers 5 & 6 
glia
SD025/05 19.8 ± 1.5 21.8  ± 1.6 5.9 ± 0.5 17.3 ± 1.8 8.7 ± 0.8 6.7 ± 0.5 21.1 ± 1.2
SD022/06 14.2  ± 1.2 11.7  ± 1.0 4.5 ± 0.4 15.5 ± 1.3 3.5 ± 0.4 4.0 ± 0.3 13.9  ± 1.0
SD041/05 20.5 ± 1.5 16.0 ± 1.1 11.6 ± 0.9 16.7 ± 1.3 8.5 ± 0.7 12.9 ± 1.0 20.5 ± 1.5
SD019/05 18.1  ± 1.4 16.9 ± 1.2 nd nd nd nd nd
SD016/06 19.5 ± 1.4 20.9 ± 1.6 7.4 ± 0.5 18.2 ± 1.3 10.5 ± 0.9 10.5 ± 0.8 21.8 ± 1.5
SD036/05 30.9 ± 2.3 50.8 ± 3.7 16.8 ± 1.2 19.3 ±  1.3 19.1 ±  1.3 17.9 ± 1.3 27.8 ±  2.0
SD004/06 30.4 ± 2.1 28.4 ± 2.2 9.6 ± 0.7 23.6 ± 1.7 16.1 ± 1.4 11.9 ± 0.9 25.6 ± 1.9
SD006/06 29.5 ± 2.4 45.9 ± 3.6 15.2 ± 1.1 24.7 ± 1.7 18.6 ± 1.3 18.2 ± 1.2 26.0 ± 1.9
SD021/05 17.9 ± 1.4 31.6 ± 2.2 16.3 ± 1.3 18.5 ± 1.4 12.5 ± 0.9 16.9 ± 1.2 20.6 ± 1.5
SD019/06 21.0 ± 1.5 34.9 ± 2.4 13.0 ± 1.0 12.7 ± 1.0 13.6 ± 1.2 14.1 ± 1.1 18.3 ± 1.4
SD014/05 29.6 ± 2.3 31.2 ± 2.3 16.1 ± 1.2 19.3 ± 1.5 16.4 ± 1.3 15.5 ± 1.1 20.9 ± 1.4








Table 8.10 P and F values associated calculated for frontal cortex cell counts. * denotes non-
parametric analysis. Red values indicate significance or a trend towards significance. Parametric 











Graph 8.3 Genotype effect on mean cell counts in the frontal cortex. Genotype effects found for 
(a) layer 1 and (b) layer 2. Red dot indicates the homozygous deletion individual. Red line 
indicates the mean of each group.  Het, heterozygous group; het & hom, heterozygous group 
plus the one homozygous deletion individual; hom ins, homozygous insertion group. . 
Differences between genotype groups for layer 1 mean counts were tested using one-way 
ANOVAs – a parametric test. A non-parametric, Kruskal-Wallis (one-tailed) test was performed 
for layer 2 mean counts . 
Layer 1 
Het & hom del vs hom ins  P= 0.008
Het vs hom ins P= 0.014
Layer 2 
Het & hom del vs hom ins  P= 0.054
Het vs hom ins P= 0.047
het + hom del vs hom ins het  vs hom ins
P value F  value P value F  value
Layer 1 0.008* 0.014*
Layer 2 0.054 3.14 0.047 3.49
Layer 3 neuronal 0.21 0.69 0.17 1.06
Layer 3 glia 0.45 0.02 0.39 0.08
Layer 4 0.06 2.97 0.07 2.55
Layers 5&6  neuronal 0.29 0.34 0.26 0.46
Layer 5 &6  glia 0.15 1.19 0.22 0.68
a b 
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Consistent with the results for the hippocampus, all neuronal cell counts means were 
found to be higher in the deletion allele groups than the homozygous insertion group, as 
shown in table 8.9. A summary of the percentage increase in KA1 expression associated 
with the deletion groups estimated separately for neuronal and glial cell regions is 
presented in table 8.11 and graph 8.4. The mean for all neuronal regions analysed 
together indicates a 40% and 44% increase in the het/hom group and het group, 
respectively. This analysis included values calculated for layer 1 as immuno-positive 
dendritic processes were counted in addition to glial cells. Again similar to the 
hippocampus, counts of immunopositive glial cells in layers 3 and 5/6 were observed to 
be similar between groups and the mean increase in KA1 expression associated with the 
deletion allele groups for glial count regions was found to be low (7% het/hom and 3% 
het group alone). 
 
Table 8.10 presents the Pearson correlation coefficient P-values (two tailed) calculated 
for genotype, gender, age, PMI, pH and frontal cortex counts. No correlation was found 




This chapter reports the findings of a genotype expression correlation investigating the 
candidate gene GRIK4. A significant correlation was found for DG granule and CA3 
pyramidal cells in the hippocampus and layer 1 immunoreactivity in the frontal cortex. 
Neuronal and neuropil expression in all regions quantified was observed to be higher in 
the deletion groups than the insertion group, showing a mean 75-92% increase in 
expression in the hippocampus and 40-43% increase in the frontal cortex. Collectively, 
these findings were found to be consistent with our hypothesis that this deletion variant 
exerts a protective effect against bipolar disorder through increased KA1 protein 
















Table 8.11 Mean percentage increase in frontal cortex KA1 expression estimated for the 


















Graph 8.4 The deletion allele increases KA1 immunoreactivity in neuronal cells in the frontal 
cortex. Red dashed lines indicate the mean of neuronal and glial cell regions in the two deletion 
allele groups 
% ins hom vs het + hom % ins hom vs het
Neuronal 
Layer 1* 47.89 46.94
Layer 2 x16 57.18 64.78
Layer 3 neuronal 23.45 30.81
Layer 4 x40 56.89 58.38
Layers 5 & 6 neuronal 14.42 18.19
All regions neuronal mean % increase 39.97 43.82
Glial
Layer 3 glia 1.55 -3.63
Layer 5 & 6  glia 12.68 10.3
All regions glial mean % increase 7.12 3.34









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.3.1. Abnormalities in KAR subunit expression in individuals with psychiatric illness 
 
As discussed in chapter 1, a number of studies have reported abnormal kainate receptor 
(KAR) subunit expression in the hippocampus, parahippocampus and frontal cortex 
regions in cases of psychiatric illness. However, unlike the current study which assessed 
a genotype-specific effect in tissue from asymptomatic control subjects, these previous 
investigations compared expression in post mortem brains of individuals with 
schizophrenia and affective disorders with comparison control groups. With respect to 
the hippocampus, Kerwin and colleagues using the technique of quantitative 
autoradiography, first reported a reduction of kainate subtype binding in mossy fibre 
CA3/4 zone in the left hippocampus, and bilateral losses in dentate gyrus and 
parahippocampal regions in tissue from schizophrenic individuals  (Kerwin et al., 1990). 
Those regions indicated to have reduced KA binding are consistent with the areas found 
in the current study to show lower KA1 expression in the insertion group. However, the 
technique used by Kerwin et al. localizes KA receptor binding and hence does not 
provide any information concerning specific KAR subunits.  
 
Three studies have subsequently examined alterations in specific KAR subunit 
expression in the hippocampal formation of healthy controls and cases. Porter and 
coworkers found reduced KA2 and GluR6 mRNA expression in the dentate gyrus 
granule cells and CA2/3 subfield in brains. Unfortunately, KA1 expression was not 
considered abundant enough to quantify differences between cases and controls. A 
second study reported a 30-35% reduction in the density of GluR5,6,7 immunoreactivity 
in dendrites found in both stratum radiatum and stratum moleculare of sectors CA3 and 
CA2, as well as proximal and middle portions of CA1 in schizophrenic brain. 
Nonetheless, no difference was found between control and the bipolar disorder group 
and the dentate gyrus was not examined (Benes et al., 2001).  
 
In contrast, Beneyto and colleagues analyzed mRNA transcript expression of all five 
KAR subunits in the hippocampus and parahippocampal regions in tissue from 
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individuals with schizophrenia, bipolar disorder and MDD. They report a significant 
reduction in GluR6 in the entorhinal cortex (EC) in bipolar disorder individuals and a 
significant decrease in GluR5 expression in the perirhinal cortex associated with all 
three psychiatric phenotypes. Alterations in KAR subunit expression was not observed 
in the hippocampus, and KA1 expression did not differ significantly between the groups 
(Beneyto et al., 2007).  
 
In the frontal cortex four papers report changes in KAR subunit transcript expression 
associated with schizophrenia. Meador-Woodruff et al. reported a shift in subunit 
stoichiometry, with increased expression of GluR7 mRNA and decreased KA2 mRNA 
in both infragranular and supragranular layers of the prefrontal cortex (Meador-
Woodruff et al., 2001).  Furthermore, Garey and co-workers, found a significant 
reduction in numerical density of neurons immunopositive to GluR6 and GluR7 in 
layers 2-6 of the orbitofrontal cortex of chronic schizophrenics, whereas Scar and 
colleagues observed a significant decrease in GluR5 expression in all layers of the 
frontal cortex but no changes in GluR6, GluR7, KA1 and KA2 (Scarr et al., 2005; Garey 
et al., 2006).  Conversely, decreases in both GluR7 and KA1 mRNA in the left superior 
gyrus of neuroleptic-free schizophrenic individuals were found by Sokolov. This study 
quantified expression by performing RT-PCR assays, and so alterations in laminae 
distribution, i.e. concordant with the present findings, were not investigated.  
Interestingly, Sokolov also reported a negative correlation between the subunit mRNA 
and time without neuroleptic medication before death suggesting that kainate receptor 
subunit mRNAs decline rapidly after drug withdrawal (Sokolov, 1998).  
 
These findings led to a number of observations pertinent to the current results. First, a 
potential confound to most of these post mortem studies is the possible effects of past 
antipsychotic exposure. Indeed, animal studies have suggested that KAR subunit 
transcripts are altered after chronic antipsychotic treatment – a finding which provides 
additional evidence for a link between KAR function and psychiatric illness (Meador-
Woodruff et al., 1996; Schmitt et al., 2003). The present study avoided this potential 
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confound by analyzing expression in asymptomatic individuals naive to antipsychotic 
medication.  
 
Second, various assessments of frontal cortex KAR subunit expression associated with 
psychiatric illness have led to inconsistent results. It is possible that these discrepancies 
may be due to different neocortical areas examined, to different techniques used to 
quantify expression in laminae, potential confounding variables such as antipsychotic 
exposure, or alternatively sub region-specific changes in subunit expression.  
 
A third observation is that all studies reporting alterations in KAR subunit expression in 
the hippocampus consistently found decreases in subunit abundance. This would suggest 
that a reduction in specific subunits which may result in an ‘unfavorable’ shift in kainate 
receptor subunit composition (at least in the hippocampus) might be the underlying 
mechanism giving rise to illness. Such a hypothesis is in accordance with the current 
results – namely a decrease in KA1 expression found for the insertion genotype is 
positively associated with bipolar disorder. Furthermore, unlike the previous studies in 
which groups were based on genotype rather than phenotype status, the present study 
provides a direct link between a causal factor, i.e. genetic risk factor, subunit expression 
differences and a psychiatric disorder. Future examination of identified genetic risk 
variants in other KAR subunits and subunit expression abundance in postmortem brain 
tissue may provide further insight into underlying factors contributing to the findings of 
previous positive reports.  
8.3.2 Genotype-specific KA1 increases in neuronal cells, dendrites and neuropil 
In the current study a difference between the deletion allele and insertion groups in two 
regions, the granule cell layer in the dentate gyrus and CA3 hippocampal pyramidal 
cells, remains statistically significant after assuming a more conservative level of 
significance (α = 0.01). An intrinsic limitation to this study is the small number of 
individuals examined, especially when samples cannot be included in some sub-regions 
owing to torn tissue sections. This makes statistical significance difficult to achieve and 
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hence complicates the interpretation of apparent, but not statistically significant, 
quantified differences in expression counts. However, the data clearly indicate that for 
all neuronal associated expression, i.e. neuronal cell soma, processes and dendrite, but 
not glial cells, in both the hippocampus and frontal cortex the deletion allele groups had 
higher immunopositive counts than the insertion group. 
The fact that this effect was not evident for glial cell regions suggests two possible 
explanations. First, the deletion allele increases KA1 mRNA abundance globally, but in 
glial cells there is an opposing mechanism leading to increased KA1 degradation. Such a 
mechanism might be the availability of GluR5-7 subunits with which KA1 forms 
functional and stable kainate receptors. A second possibility is that KA1 longevity is 
increased in specific subcellular locations, e.g. neuronal processes/dendrites. Such a 
localised cellular effect might be influenced by factors such as synaptic activity within 
neuronal pathways (Steward and Wallace, 1995). 
In addition to neuronal soma and processes, KA1 expression was also found to show a 
genotype-specific increase in CA3/4 neuropil abundance. This finding is worth 
considering in the context of the ‘reduced neuropil hypothesis’ of schizophrenia 
forwarded by (Selemon et al., 1995). The theory, based on morphometric analysis of the 
prefrontal cortex and quantitative studies of neuronal densities in brains from 
schizophrenic patients, proposes that disturbances in cognitive functioning in 
schizophrenia may be mediated by a process which involves atrophy of neuronal 
processes, giving rise to deficits in neuronal connections (Selemon and Goldman-Rakic, 
1999). Although in the current study absolute levels of neuropil were not quantified, the 
results are consistent with the hypothesis that altered expression of a protein involved in 
plasticity processes at neuronal connections (neuropil) may give rise to abnormalities in 




8.3.3 Genotype/KA1 expression in DG and link to neurogenesis 
A striking KA1 expression genotype effect was found for the granule cell layer in the 
dentate gyrus. As discussed in chapter 7, it is in this region that adult hippocampal 
neurogenesis occurs resulting in the functional integration of new born neurons within 
the mossy fibre pathway. Adult hippocampal neurogenesis has been consistently shown 
to be increased under conditions known to ameliorate psychiatric symptoms, e.g. 
administration of antidepressants, mood stabilizers and cognitive enhancers, and 
conversely decreased under states of stress, a precipitating factor for psychiatric illnesses 
(Scharfman and Hen, 2007). Consequently, this has led to adult neurogenesis being 
considered a factor in the pathogenesis and course of mood disorders and schizophrenia.  
 
The most compelling evidence supporting this hypothesis is that the blockade of 
hippocampal neurogenesis inhibits the therapeutic-like effects of most physical and 
chemical anti-depressant treatments, and antidepressants increase the level of several 
growth factors, e.g. brain derived growth factor (BDNF) and vascular endothelial growth 
factor EGV, which themselves have pro-neurogenic properties (Krishnan and Nestler, 
2008). However, the dependence of behavioral effects of antidepressants on adult 
neurogenesis is also known to be influenced by factors such as species, genotype, the 
nature of antidepressants, and the type of behavioural paradigms assessed (Zhao et al., 
2008). Consequently, this has led to the speculation that antidepressants may exert their 
behavioural effects through both neurogenesis-dependent and neurogenesis-independent 
pathways, and that neurogenesis-dependent processes are likely to be influenced by 
hippocampal network activity (Sahay and Hen, 2007). 
 
The biological investigation of DISC1 and NPAS3, two candidate genes for 
schizophrenia, provides further support for aberrant neurogenesis contributing to 
hippocampal aspects of psychiatric disease. For example, DISC1-deficient cells in the 
subventricular zone exhibit an increase in neuritic sprouting and neuronal migration 
resulting in aberrant morphological development, mis-positioning of new dentate 
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granule cells as well as defects in axonal targeting and development of mossy fibre 
synaptic outputs (Duan et al., 2007; Faulkner et al., 2008). In contrast, NPAS3 knockout 
mice display a marked attenuation in adult hippocampal neural precursor cell 
proliferation (Pieper et al., 2005).  
 
The significant correlation between the protective allele within GRIK4 for bipolar 
disorder and increased immunopostive counts in the DG granule cell layer and CA3 
pyramidal/mossy fibre CA3 terminals, hint at the possibility that the protective effect 
may be through an adult hippocampal neurogenesis related mechanism. Although further 
research is needed to investigate the role of KA1 in adult neurogenesis, the present 
results add to the emerging evidence that hippocampal neurogenesis might be a 
‘biological convergent point’ upstream of primary genetic defects in the pathogenesis of 
psychiatric illnesses.  
8.3.4 Stress, psychiatric illness and a role for KA1 
Epidemiological and behavioural studies strongly suggest that environmental stress 
(acting concurrently with genetic factors) is an environmental precipitating factor to the 
development of psychiatric disorders. During stressful situations and episodes of high 
arousal, the hypothalamic-pituitary-adrenal (HPA) axis becomes activated, resulting in, 
among other physiological processes, corticosterone/glucocorticoid (GC) release from 
the adrenal cortex into the circulatory system. The surprising discovery that 
glucocorticoid receptors are highly expressed in the rodent hippocampus and possibly at 
lower levels in the frontal cortex, has led to the conjecture that the hippocampus and 
frontal cortex might regulate aspects of the HPA axis (McEwen, 1980; Sarrieau et al., 
1986; Sanchez et al., 2000). 
Extensive studies using both acute and chronic stress/steroid protocols have revealed 
that corticosteroids can inhibit postnatal and adult DG granule cell proliferation. 
Elevation of corticosterone (glucocorticoid) levels by the activated hypothalamic-
pituitary-adrenal axis is the main mechanism for stress-mediated suppression of 
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newborn granule cell proliferation. In addition, moderate durations of stress and high 
GC exposure in rats and tree shrews cause reversible atrophy of apical dentrites of CA3 
pyramidal cells and dentate gyrus neurons and alterations in synaptic terminal structure 
(Magarinos and McEwen, 1995; Magarinos et al., 1996; McEwen and Magarinos, 1997).   
McEwen argues that short-term structural plasticity (dendritic pruning in CA3) and 
inhibition of neurogenesis are both examples of adaptive ‘protective’ mechanisms that 
could reduce the impact of glutamate and glucocorticoids in causing more permanent 
damage to the hippocampus (McEwen, 1999). What is pertinent to the current research 
is that KA1 activity, through pre-synaptic mechanisms at mossy fibre terminals, is 
postulated to be critical to the process of reversible atrophy of CA3 apical dendrites 
(McEwen, personal communication). Although this research is still in its infancy, this 
intriguing finding links KA1 function to the physiological processes activated during 
chronic stressful states and mechanisms by which the hippocampus adapts to short term 
disturbances. It is exciting therefore, that the current findings - showing association 
between bipolar disorder (characterized by episodes of depression and elevated mood 
states) and alterations in KA1 expression at the same critical hippocampal regions - are 
complimentary to McEwen’s research implicating KA1 as a potential mood disorder 
factor. 
8.3.5 Differential KA1 expression and neural circuits 
Neurodevelopmental disorders are hypothesized to be caused by neuronal dysfunction.  
One theory forwarded by Ramocki and Zoghbi, posits that neuropsychiatric phenotypes 
arise owing to failure of neuronal homeostasis (Ramocki and Zoghbi, 2008). Neurons 
are dynamic entities which must constantly adapt to changing external and internal 
stimuli through, for example, the remodeling and pruning of synaptic connections. 
Neuron-specific changes resultant from aberrant alterations in protein function or 
expression, are likely to affect neuronal networks.   
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Ramocki and Zoghbi argue that neurons within affected networks must make 
homeostatic responses to establish or re-establish “a proper balance of excitation and 
inhibition” (Ramocki and Zoghbi, 2008). Consistent with this concept is the model 
proposed by Sudhof (2008) to explain the physiological consequences of mutations in 
neuroligins and neurexins associated with autism spectrum disorders (ASD) (Sudhof, 
2008). Neuroligins and neurexins are trans-synaptic cell-adhesion molecules that 
mediate essential signaling between presynaptic and postsynaptic domains. Sudhof 
proposes that these proteins are involved in shaping synaptic efficacy and plasticity and 
hence can alter the balance between excitatory and inhibitory neurotransmission in a 
subset of neural circuits. Consequently, mutations within neuroligins and neurexins are 
postulated to result in disturbance of neural network function (Sudhof, 2008). 
The distribution of KA1 and its role in synaptic plasticity makes it a key functional 
candidate for influencing pathway dynamics. It is therefore unsurprising and in total 
concordance with a ‘neuronal homeostasis’ hypothesis that the present findings revealed 
an increase in KA1 correlated with the protective allele in all neuronal regions 
examined. Alterations in KA1 expression might be a mechanism which contributes to 
changes in synaptic strength and hence might modify the relative contribution of 
different synapses and shape the properties of the tri-synaptic pathway or circuitry 
within the frontal cortex. In turn, cognitive processing associated with circuit activity 
within these structures could be altered or indeed impaired.  
The hippocampus and frontal cortex do not function in isolation from other brain 
regions. Information flow within interconnecting circuits modulates the processing and 
function of these structures which consequently underlie the expression of complex 
behaviour. For example, reciprocal processing within the amygdala and hippocampus 
mediates the affective component of context-dependent memory formation. Such 
processing, when disrupted, is hypothesized to be linked to symptoms of post- traumatic 
stress disorder (PTSD) as well as other affective disorders (Nadel and Jacobs, 1996).  
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Although only the frontal cortex and hippocampus were examined in the present study, 
it is possible that the KA1 genotype effect may influence expression and potential 
plasticity processes in different brain regions. Consequently, this could influence 
transmission within diffuse series of neural networks interlinking multiple brain 
structures, and thus give rise to abberant facets of cognition and behaviour. Functional 
imaging studies investigating a GRIK4 genotype effect on cognition are currently 
underway and may provide more insight into region-specific or global deficits in 
processing.  
 
The present results also raise the possibility that pharmacologically mediated increases 
in kainate receptor activity, mirroring the protective deletion's effect on expression and 
potentially circuit activity, might present a therapeutic opportunity for bipolar disorder 
and other psychiatric illnesses. However, kainate receptor agonists are known to 
compromise neuronal viability by impeding structural and functional integrity, i.e. they 
are excitotoxic to neuronal and glial cells (Michaelis, 1998; Konradi and Heckers, 2003).  
Therefore, a more practical strategy aimed at facilitating kainate receptor function would 
be the use of drugs that inhibit kainate receptor desensitization. For example, the lectin 
Concanavalin A (ConA) blocks desensitization in all native as well as cloned KA 
subtypes by inhibiting conformational changes within the receptor-protein complex 
(Bunch and Krogsgaard 2008). The development of ConA and other related 
pharmacological agents which effectuate changes in plasticity mechanisms might lead to 
important drug discoveries in the treatment of psychiatric diseases. 
 
The findings presented in chapters 6, 7 and 8 are unique in that they provide a direct link 
between a protective genetic variant, alterations in RNA/protein expression and a 
potential model of the physiological consequences on synaptic and network activity. 
This body of research not only provides strong support for the glutamate hypothesis of 
schizophrenia and mood disorders, but also - as GRIK4 is likely to be one of many risk 
factors which may converge in common endpoints- sets a precedent for what might be 
expected to be discovered for other candidate risk factors. Furthermore, this model does 
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not exclude the possibility of involvement of interacting physiological systems, e.g. 
HPA axis, and disturbances in other neurotransmitter systems acting concurrently upon, 
or down stream from, a primary glutamate synaptic defect.  Further research examining 
the molecular determinants of pathways involved in KA1 function, i.e. a potential role in 
neurogenesis, GC receptor activation at mossy fiber terminals, and synaptic modulation 
of pathway dynamics, may provide significant insight into common disrupted processes 























































9.  GENERAL DISCUSSION 
 
9.1 Review of projects 
 
This thesis has presented research utilizing two powerful genetic approaches in order to 
identify and subsequently examine, genetically and biologically, candidate genes for 
psychiatric disease. The first approach (project 1), employing positional mapping in two 
consanguineous families which presented with a high incidence of disease, aimed to 
identify recessive loci and putative risk variants. The second approach involved the 
genetic and biological investigation of the candidate genes, ABCA13 and GRIK4 
(projects 2 and 3), identified as directly disrupted in patients with schizophrenia who 
carry complex chromosomal rearrangements.  
 
In this chapter, I will first review very briefly the major findings of each project. This 
will serve as the background for the subsequent discussion centred on critical questions 
debated in the field of psychiatric genetics, i.e. the issues of phenotypic heterogeneity, 
potential risk allele interaction, rare versus common risk variants, protective alleles, and 
mode of genetic mutations. These questions, and the insight provided by the findings of 
the thesis are of central importance in efforts to comprehend the composition of genetic 
risk in the population and thus provide a strong starting point for biological 
investigations into pathophysiological processes of psychiatric disease. 
 
In the first project, homozygosity mapping was initially performed in a consanguineous 
family in which five out of six offspring present with schizophrenia, epilepsy or sensori-
neural hearing impairment either singly or in combination. Two HBD loci were detected 
on chromosomes 22q13 and 2p24-25, regions previously implicated to harbour 
susceptibility factors for psychiatric illness, or hearing loss, respectively. Unfortunately, 
the sequencing of strong candidate genes within these HBD loci failed to identify any 
potential causal coding variants.  
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Homozygosity mapping was subsequently performed in a second, related family with a 
high incidence of deafness as a means to identify common loci of shared ancestry 
putatively housing recessive genes for hearing loss.  Five HBD loci were identified on 
chromosomes 1p22.2-1q23.1, 7q21-q31.1, 8q12, 12p13 and 20q13. There was 
nonetheless, no evident overlap of the HBD intervals detected in the two families 
suggesting that the underlying causative genetic factors segregating within the two 
related families are not the same. These identified HBD loci do, however, overlap with 
non-syndromic deafness loci two of which house known deafness genes.  
 
The primary aim of the second project was to provide additional evidence that the 
breakpoint gene ABCA13 is a liability factor for schizophrenia. The fine mapping of the 
breakpoint regions interrupted by a cytogenetic abnormality carried by a patient with 
schizophrenia indicated that ABCA13 is the only gene directly disrupted. The sequencing 
of exons encoding the highly conserved functional domains commonly mutated in other 
ABCA sub-family members led to the identification of eight potentially pathogenic, 
ultra-rare coding variants. Follow-up family and case-control association studies 
indicated that these variants collectively are strongly associated with increased risk for 
schizophrenia, bipolar disorder and major depression and show linkage with illness in 
families. Expression studies indicated that ABCA13 mRNA is expressed in the human 
hippocampus and frontal cortex and that ABCA13 protein is expressed in the granule 
cells of the dentate gyrus.  
 
The third project involved the investigation of the candidate gene, GRIK4, initially 
identified through disruption by a chromosomal abnormality in a patient with severe 
schizophrenia and mild learning disability. A haplotype within GRIK4 was previously 
identified as associated with bipolar disorder. A case-control association study of a 
common indel variant located in the 3’UTR of GRIK4 and in LD with the associated 
haplotype, suggested the deletion allele to be a causal factor exerting a protective effect 
against bipolar disorder. KA1, the glutamate receptor sub-unit protein encoded by 
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GRIK4, was found to be expressed in all layers of the human frontal and entorhinal 
cortices, in the superficial portion of the granular layer and in small cells in the vicinity 
of purkinje neurons within the cerebellum and at regions involved in neuronal 
processing within all three pathways forming the trisynaptic circuit within the human 
hippocampus. A subsequent genotype/protein expression correlation study indicated that 
KA1 expression within the hippocampus and frontal cortex was significantly increased 
in subjects carrying the protective deletion allele.  
 
9.2 What do the findings tell us about the genetic architecture of psychiatric 
illness? 
 
Genetic risk variants and phenotypic heterogeneity  
 
Research into Mendelian disease genes has shown that lesions in one gene can cause 
several phenotypic traits, i.e. can have a pleiotropic effect, or conversely mutation of 
several genes, the effects of which converge on commonly disrupted biological 
processes, can give rise to one clinical phenotype. For example, mutations within 
ABCA4 give rise to a variety of retinal dystrophies, as discussed in chapters 4 and 5, and 
multiple genes are known to cause sensori-neural deafness, as discussed in chapter 3. 
Both models of gene action have been postulated for common complex disease, and 
evidence indicates that both theories are relevant to psychiatric illnesses (Dean, 2003; 
Ramocki and Zoghbi, 2008).  
 
The present findings provide strong evidence that two genes, ABCA13 and GRIK4, 
contribute to liability of developing bipolar disorder, and hence add support for a model 
that more than one gene may be an etiological factor for a psychiatric phenotype. There 
are, however, intriguing differences between the findings of the two present studies. 
Although research suggests that GRIK4 may also contribute to risk for schizophrenia 
(indicated by the chromosomal abnormality and additional associated haplotypes and 
SNPs discussed in chapter 6), the present results indicate the protective effect afforded 
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by the common indel variant (and associated haplotype in LD with the variant) per se is 
specific to bipolar disorder (Pickard et al., 2005a; Paddock et al., 2007).  
 
In contrast, multiple rare variants within ABCA13 were identified in individuals with 
schizophrenia, bipolar disorder or MDD. Thus the ABCA13 data support the supposition 
that one gene and indeed one allele may increase risk for three diagnoses of psychiatric 
disease. This phenomenon has previously been described for a cytogenetic lesion 
disrupting DISC1 which segregates with disease in a pedigree with multiple psychiatric 
conditions (St Clair et al., 1990; Blackwood et al., 2001). However, the ABCA13 data 
suggest that in addition to a major structural mutation which putatively results in a 
haploinsuffiency, point mutations with potentially less severe consequences on protein 
function may also contribute to variable clinical phenotypes.  
 
Multiplicative variant interaction 
 
Considerable evidence from animal and human studies suggests that multiple risk genes 
or alleles are required for the expression of some Mendelian disease such as 
Waardenburg syndrome and Bardet-Biedl Syndrome (Dean, 2003). Genetic research of 
breast cancer, a common complex disease, also indicates that multiplicative interaction 
between rare high penetrant alleles or low penetrant common variants, both in the same 
or different susceptibility gene, can exist and may give rise to different phenotypes 
(Stratton and Rahman, 2008). 
 
Within the field of psychiatric genetics, evidence supporting a model of additive allelic 
interaction has come from studies of common, low penetrance associated SNPs or 
haplotypes (Pickard et al., 2005a; Baum et al., 2008). The ABCA13 findings are the first 
data to suggest that interactions between ultra-rare moderate penetrance risk variants 
across a gene may be a mechanism which, in an additive manner, contributes to 
susceptibility to psychiatric illness, and that such additive effects may also be a 
contributory factor to the severity of clinical outcome. Hence these findings not only set 
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a precedent for what may be revealed from future studies of candidate genes but also 
indicate that the mode of gene action underlying psychiatric illness may be similar to 
other common complex disorders. 
 
Rare versus common alleles 
 
A third issue, historically debated in the field of psychiatric genetics, is the contribution 
of rare and common alleles to disease risk. The results reported in this thesis provide 
support both the ‘common disease - common allele’ hypothesis (associated GRIK4 indel 
variant) and ‘common disease - rare allele hypothesis’ (ABCA13 rare variants). However 
the data also provide additional information which extends our current understanding of 
variant classes.  
 
First, the ABCA13 results suggest that there are two types of rare variant - moderate 
penetrance rare coding variants with ORs of 1.6-3.8 and high penetrance, potentially null 
private mutations which show strong familial aggregation. Again, these findings are 
consistent with genetic models of other complex diseases such as breast cancer and 
Alzheimer’s disease.  
 
Second, common risk variants as identified by GWAS and SNP tag case-control 
association studies are reported to have low odds ratios of 1.5 or less. However, the 
combined GRIK4 indel association data resulted in an OR of 0.47 for heterozygotes 
(equivalent to ~ 2 fold risk) is lower, i.e. has a greater effect, than previously predicted 
for a common allele.  
 
Third, a GWAS scan identified a SNP within ABCA13 as being in the top 200 SNPs 
associated with bipolar disorder. This opens the possibility that, similar to DISC1, a 
candidate gene of major effect, ABCA13 may harbour both rare high penetrance and 
common low risk alleles. As yet, GRIK4, like many other ‘common allele’ candidate 
genes, has not been comprehensively screened for rare variants. Forthcoming re-
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sequencing efforts focused on these genes will provide crucial insight into the frequency 




In addition to the identification of rare susceptibility alleles, the findings of this thesis 
also provide strong support for the existence of protective alleles. To the author’s 
knowledge, the GRIK4 indel variant is the first actual ‘causal’ protective variant reported 
for a psychiatric condition. Rare coding variants identified in only control individuals  
within candidate genes of major effect, e.g. P4648A in ABCA13, have the potential also 
to be protective.  However, owing to the difficulties associated with distinguishing 
between a benign ultra-rare variant and potential protective allele and the interpretation 
of pedigree segregation, modeling and functional studies are needed to verify the 
protective nature of such a candidate variant. Therefore, many unresolved issues 
regarding the genetics of protective variants remain,  
such as the typical frequencies of alleles and whether the magnitude of protective  
effects is similar to that of risk variants. 
 
Types of mutations 
 
The study of other diseases implicates multiple molecular mechanisms by which genetic 
changes may lead to human disease. Common risk variants as identified by GWAS or 
SNP-tag case-control studies are often located within non-coding regions. This has led to 
the supposition that common risk alleles are likely to have to have a regulatory effect 
upon transcript expression. We hypothesized that the common non-coding indel located 
in the 3’UTR of GRIK4 would have a regulatory effect through differential mRNA 
stability altering GRIK4 mRNA abundance. The results of RNA and protein indel 
expression studies presented in this thesis support our hypothesis.  
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In contrast, cytogenetic lesions which directly disrupt a gene and null point mutations, as 
identified within ABCA13, are thought to result in a state of haploinsufficiency owing to 
‘nonsense-mediated decay’, i.e. produce reduced gene dosage effects. Moreover, 
missense mutations are predicted to have a direct effect on protein activity either by 
increasing or reducing the protein’s functional efficacy, as suggested by the structural 
modeling of T4031A ABCA13 variant. The findings of projects 2 and 3 therefore 
provide compelling evidence that a variety of mutation ‘types’ contribute to the 
expression of psychiatric phenotypes. Bioinformatic, genetic and biological research 
may further uncover how the consequences of such mutations alter normal gene 
transcript function and hence lead to a disruption of biological pathways. 
 
9.3 Future research 
 
With the development of new technologies, the genetic study of psychiatric disease is 
more assessable than ever before. The strategy used to study the candidacy of ABCA13 
has been shown to be highly effective in identifying rare risk variants. Re-sequencing 
efforts using high throughput, cost efficient platforms such as the Solexa (Illumina), 
SOLID
TM
 (Applied Biosystems) and 454 Life Science
TM
 (Roche Applied Science) will 
be invaluable for the comprehensive screening for rare variants of candidate genes either 
located within mapped loci or previously implicated as pathological. Furthermore, re-
sequencing will be necessary to verify whether detected rare variants are specific to a 
geographic population or indeed to phenotypic groups. As with the present study, this 
approach should be followed by case-control association studies and pedigree analysis of 
the any identified coding variants. In parallel, the use of large scale, high throughput 
whole genome SNP or oligo array chips will aid the identification of rare and/or 
associated CNVs, whilst follow-up case-control studies using Multiplex Amplicon 
Quantification (MAQ), qPCR, or cytogenetic assays will provide further information 
into the contribution to disease risk of rare and common structural variants. 
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As more genetic risk variants are identified, it will crucial that the functional 
consequences of mutated alleles are comprehensively explored. Computational modeling 
and functional analysis will be necessary for predicting the causal genetic mechanism 
and underlying mode pathology. The biological examination of candidate genes is also a 
vital step in understanding common disrupted biological mechanisms. The discussion 
section of each results chapter has already highlighted future experiments which would 
naturally continue from my studies and which might provide support for, or disprove, 
speculated theories. Such experiments should include co-localisation studies of 
candidate genes with synaptic and cell population markers, and the molecular 
investigation of complexes and physical interactors, thereby giving further insight into 
functionally relevant molecular pathways.  
 
Animal models of psychiatric illness, candidate gene targeted knock out mice and the 
use of pharmacological interventions, are other areas of research which have been and 
may prove particularly productive. For instance, as discussed in chapter 8, using an 
animal model of stress/depression, KA1 was shown to be critical for the process of 
reversible atrophy of CA3 apical dendrites within the mossy fibre pathway and hence 
implicated as a contributing factor in pathophysiological processes. This line of research, 
complementary to our own findings, may subsequently reveal important aspects of 
plasticity, circuit and systems related disease mechanisms. Furthermore, the recent 
generation of GRIK4/Ka1 and Abca13 KO mice strains provide an opportunity for 
histological, neuroanatomical and phenotypic examination and may prove valuable for 
the development of pharmacological agents.  
 
An alternative and complementary strategy for investigating potential 
pathophysiological processes is to employ a top down approach. The study of 
endophenotypes, e.g. brain structure and activity, cognition and neurophysiology in 
affected and asymptomatic relatives of probands who carry identified risk factors, will 
further our knowledge of the effects of high-risk genotypes on phenotypic features. 
Moreover, such human studies may reveal significant differences, or indeed aspects of 
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commonality, between risk genotypes, and thus highlight variation or convergence of 
underlying biological processes. Consequently, the standard definitions of psychiatric 
disease may evolve as diagnostic categories are adapted to reflect genetic and 
pathophysiological aetiology, the outcome of which may bring new opportunities for 
personalized medicine. 
 
 9.4 Concluding remarks 
 
The ultimate ambition of genetic studies is the development of effective treatments or 
preventative strategies by furthering our understanding of the aetiology of disease. This 
thesis has contributed to this goal through the genetic and biological investigation of 
candidate genes for psychiatric and neurological disorders. The findings of all three 
projects, mapped HBD loci, the identification of rare variants within ABCA13 and the 
association of common protective allele located within GRIK4 with increased protein 
expression in human brain tissue, offer significant potential for future research and 






















Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin--rapid analysis of 
dense genetic maps using sparse gene flow trees. Nat Genet 30:97-101. 
Abramoff MD, Magelhaes PJ, Ram SJ (2004) Image Processing with Image J. 
Biophotonics International 11:36-42. 
Adolfo Sequeira (2003) Wolfram syndrome and suicide: Evidence for a role of WFS1 in 
suicidal and impulsive behavior. American Journal of Medical Genetics Part B: 
Neuropsychiatric Genetics 119B:108-113. 
Albrecht C, Viturro E (2007) The ABCA subfamily--gene and protein structures, 
functions and associated hereditary diseases. Pflugers Arch 453:581-589. 
Allikmets R (2000) Simple and complex ABCR: genetic predisposition to retinal 
disease. Am J Hum Genet 67:793-799. 
Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo 
G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess 
V, Lepine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-
Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-
Salvany A, Ferrer M, Joo SS, Martinez-Alonso M, Matschinger H, Mazzi F, 
Morgan Z, Morosini P, Palacin C, Romera B, Taub N, Vollebergh WA (2004) 
Prevalence of mental disorders in Europe: results from the European Study of the 
Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 
Suppl:21-27. 
Amaral D, Lavenex P (2007) Hippocampal Neuroanatomy. In: The Hippocampus Book 
(Anderson P, Morris R, Amaral D, Bliss T, O’Keefe J, eds). Oxford: Oxford 
University Press. 
Ambudkar SV, Kim IW, Xia D, Sauna ZE (2006) The A-loop, a novel conserved 
aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is 
critical for ATP binding. FEBS Lett 580:1049-1055. 
American Psychiatric Association (2004) Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition Edition. Washington DC: American Psychiatric 
Association. 
Anderson TW, Darling DA (1952) Asymptotic theory of certain "goodness-of-fit" 
criteria based on stochastic processes  
Annals of Mathematical Statistics 23:193–212. . 
Arion D, Sabatini M, Unger T, Pastor J, Alonso-Nanclares L, Ballesteros-Yanez I, 
Garcia Sola R, Munoz A, Mirnics K, DeFelipe J (2006) Correlation of 
transcriptome profile with electrical activity in temporal lobe epilepsy. Neurobiol 
Dis 22:374-387. 
Badner JA, Gershon ES (2002) Meta-analysis of whole-genome linkage scans of bipolar 
disorder and schizophrenia. Mol Psychiatry 7:405-411. 
Bakkaloglu B, O'Roak BJ, Louvi A, Gupta AR, Abelson JF, Morgan TM, Chawarska K, 
Klin A, Ercan-Sencicek AG, Stillman AA, Tanriover G, Abrahams BS, Duvall 
JA, Robbins EM, Geschwind DH, Biederer T, Gunel M, Lifton RP, State MW 
 270 
(2008) Molecular cytogenetic analysis and resequencing of contactin associated 
protein-like 2 in autism spectrum disorders. Am J Hum Genet 82:165-173. 
Baldwin CT, Weiss S, Farrer LA, De Stefano AL, Adair R, Franklyn B, Kidd KK, 
Korostishevsky M, Bonne-Tamir B (1995) Linkage of congenital, recessive 
deafness (DFNB4) to chromosome 7q31 and evidence for genetic heterogeneity 
in the Middle Eastern Druze population. Hum Mol Genet 4:1637-1642. 
Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of 
LD and haplotype maps. Bioinformatics 21:263-265. 
Barros SA, Tennant RW, Cannon RE (2003) Molecular structure and characterization of 
a novel murine ABC transporter, Abca13. Gene 307:191-200. 
Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, Schulze TG, 
Cichon S, Rietschel M, Nothen MM, Georgi A, Schumacher J, Schwarz M, 
Abou Jamra R, Hofels S, Propping P, Satagopan J, Detera-Wadleigh SD, Hardy 
J, McMahon FJ (2008) A genome-wide association study implicates 
diacylglycerol kinase eta (DGKH) and several other genes in the etiology of 
bipolar disorder. Mol Psychiatry 13:197-207. 
Benes FM, Todtenkopf MS, Kostoulakos P (2001) GluR5,6,7 subunit immunoreactivity 
on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic 
depressives. Hippocampus 11:482-491. 
Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH 
(2007) Abnormal glutamate receptor expression in the medial temporal lobe in 
schizophrenia and mood disorders. Neuropsychopharmacology 32:1888-1902. 
Bennett P, Segurado R, Jones I, Bort S, McCandless F, Lambert D, Heron J, Comerford 
C, Middle F, Corvin A, Pelios G, Kirov G, Larsen B, Mulcahy T, Williams N, 
O'Connell R, O'Mahony E, Payne A, Owen M, Holmans P, Craddock N, Gill M 
(2002) The Wellcome trust UK-Irish bipolar affective disorder sibling-pair 
genome screen: first stage report. Mol Psychiatry 7:189-200. 
Bennett RL, Steinhaus KA, Uhrich SB, O'Sullivan CK, Resta RG, Lochner-Doyle D, 
Markel DS, Vincent V, Hamanishi J (1995) Recommendations for standardized 
human pedigree nomenclature. Pedigree Standardization Task Force of the 
National Society of Genetic Counselors. Am J Hum Genet 56:745-752. 
Bergen AA, Plomp AS, Hu X, de Jong PT, Gorgels TG (2007) ABCC6 and 
pseudoxanthoma elasticum. Pflugers Arch 453:685-691. 
Berkovic SF, Serratosa JM, Phillips HA, Xiong L, Andermann E, Diaz-Otero F, Gomez-
Garre P, Martin M, Fernandez-Bullido Y, Andermann F, Lopes-Cendes I, 
Dubeau F, Desbiens R, Scheffer IE, Wallace RH, Mulley JC, Pandolfo M (2004) 
Familial Partial Epilepsy with Variable Foci: Clinical Features and Linkage to 
Chromosome 22q12. Epilepsia 45:1054-1060. 
Berrettini WH (2000) Are schizophrenic and bipolar disorders related? A review of 
family and molecular studies. Biol Psychiatry 48:531-538. 
Blackwood DH, Knight HM (2007) Genetic Predispositions to Stressful Conditions. In: 
Encyclopedia of Stress, Second Edition Edition (Fink G, ed), pp 141-145. . 
Oxford: Academic Press. 
Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ (2001) 
Schizophrenia and affective disorders--cosegregation with a translocation at 
 271 
chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 
findings in a family. Am J Hum Genet 69:428-433. 
Blackwood DHR, Muir WJ (2004) Genetics in relation to psychiatry. In: Companion to 
Psychiatric Studies, Seventh edition Edition. U.K.: Churchill Livingstone. 
Bleakman D (1999) Kainate receptor pharmacology and physiology. Cell Mol Life Sci 
56:558-566. 
Bodmer W, Bonilla C (2008) Common and rare variants in multifactorial susceptibility 
to common diseases. Nat Genet 40:695-701. 
Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, 
Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, 
Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G (1999) The gene 
encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat 
Genet 22:347-351. 
Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, Gasteiger E, Martin 
MJ, Michoud K, O'Donovan C, Phan I, Pilbout S, Schneider M (2003) The 
SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. 
Nucleic Acids Res 31:365-370. 
Borowsky B, Durkin MM, Ogozalek K, Marzabadi MR, DeLeon J, Lagu B, Heurich R, 
Lichtblau H, Shaposhnik Z, Daniewska I, Blackburn TP, Branchek TA, Gerald 
C, Vaysse PJ, Forray C (2002) Antidepressant, anxiolytic and anorectic effects of 
a melanin-concentrating hormone-1 receptor antagonist. Nat Med 8:825-830. 
Braga MF, Aroniadou-Anderjaska V, Xie J, Li H (2003) Bidirectional modulation of 
GABA release by presynaptic glutamate receptor 5 kainate receptors in the 
basolateral amygdala. J Neurosci 23:442-452. 
Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, 
Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, 
Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale 
D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Genest J, Jr., 
Hayden MR (1999) Mutations in ABC1 in Tangier disease and familial high-
density lipoprotein deficiency. Nat Genet 22:336-345. 
Brown SD, Hardisty-Hughes RE, Mburu P (2008) Quiet as a mouse: dissecting the 
molecular and genetic basis of hearing. Nat Rev Genet 9:277-290. 
Buechler C, Boettcher A, Bared SM, Probst MC, Schmitz G (2002) The 
carboxyterminus of the ATP-binding cassette transporter A1 interacts with a 
beta2-syntrophin/utrophin complex. Biochem Biophys Res Commun 293:759-
765. 
Callenbach PMC, van den Maagdenberg AMJM, Hottenga JJ, van den Boogerd EH, de 
Coo RFM, Lindhout D, Frants RR, Sandkuijl LA, Brouwer OF (2003) Familial 
Partial Epilepsy with Variable Foci in a Dutch Family: Clinical Characteristics 
and Confirmation of Linkage to Chromosome 22q. Epilepsia 44:1298-1305. 
Camp NJ, Lowry MR, Richards RL, Plenk AM, Carter C, Hensel CH, Abkevich V, 
Skolnick MH, Shattuck D, Rowe KG, Hughes DC, Cannon-Albright LA (2005) 
Genome-wide linkage analyses of extended Utah pedigrees identifies loci that 
influence recurrent, early-onset major depression and anxiety disorders. Am J 
Med Genet B Neuropsychiatr Genet 135B:85-93. 
 272 
Cardno AG, Gottesman, II (2000) Twin studies of schizophrenia: from bow-and-arrow 
concordances to star wars Mx and functional genomics. Am J Med Genet 97:12-
17. 
Cardon LR, Palmer LJ (2003) Population stratification and spurious allelic association. 
Lancet 361:598-604. 
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, 
Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: 
moderation by a polymorphism in the 5-HTT gene. Science 301:386-389. 
Ceulemans H, Stalmans W, Bollen M (2002) Regulator-driven functional diversification 
of protein phosphatase-1 in eukaryotic evolution. Bioessays 24:371-381. 
Chaki S, Funakoshi T, Hirota-Okuno S, Nishiguchi M, Shimazaki T, Iijima M, Grottick 
AJ, Kanuma K, Omodera K, Sekiguchi Y, Okuyama S, Tran TA, Semple G, 
Thomsen W (2005) Anxiolytic- and antidepressant-like profile of ATC0065 and 
ATC0175: nonpeptidic and orally active melanin-concentrating hormone 
receptor 1 antagonists. J Pharmacol Exp Ther 313:831-839. 
Chakravarti A (1999) Population genetics--making sense out of sequence. Nat Genet 
21:56-60. 
Chang MC, Grange E, Rabin O, Bell JM, Allen DD, Rapoport SI (1996) Lithium 
decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett 
220:171-174. 
Chang MC, Contreras MA, Rosenberger TA, Rintala JJ, Bell JM, Rapoport SI (2001) 
Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in 
brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 
77:796-803. 
Chen JM, Ferec C, Cooper DN (2006) A systematic analysis of disease-associated 
variants in the 3' regulatory regions of human protein-coding genes II: the 
importance of mRNA secondary structure in assessing the functionality of 3' 
UTR variants. Hum Genet 120:301-333. 
Chen ZQ, Annilo T, Shulenin S, Dean M (2004) Three ATP-binding cassette transporter 
genes, Abca14, Abca15, and Abca16, form a cluster on mouse Chromosome 
7F3. Mamm Genome 15:335-343. 
Chittajallu R, Braithwaite SP, Clarke VR, Henley JM (1999) Kainate receptors: 
subunits, synaptic localization and function. Trends Pharmacol Sci 20:26-35. 
Chiyonobu T, Hayashi S, Kobayashi K, Morimoto M, Miyanomae Y, Nishimura A, 
Nishimoto A, Ito C, Imoto I, Sugimoto T, Jia Z, Inazawa J, Toda T (2007) Partial 
tandem duplication of GRIA3 in a male with mental retardation. Am J Med 
Genet A 143A:1448-1455. 
Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble 
K, Uchiyama M, Sakuraba Y, Kaneda H, Shiroishi T, Houslay MD, Henkelman 
RM, Sled JG, Gondo Y, Porteous DJ, Roder JC (2007) Behavioral phenotypes of 
Disc1 missense mutations in mice. Neuron 54:387-402. 
Conne B, Stutz A, Vassalli JD (2000) The 3' untranslated region of messenger RNA: A 
molecular 'hotspot' for pathology? Nat Med 6:637-641. 
Cooper AF (1976) Deafness and psychiatric illness. Br J Psychiatry 129:216-226. 
 273 
Craddock N, Jones I (2001) Molecular genetics of bipolar disorder. Br J Psychiatry 
178:S128-133. 
Craddock N, O'Donovan MC, Owen MJ (2005) The genetics of schizophrenia and 
bipolar disorder: dissecting psychosis. J Med Genet 42:193-204. 
Crawford J, Zielinski MA, Fisher LJ, Sutherland GR, Goldney RD (2002) Is there a 
relationship between Wolfram syndrome carrier status and suicide? Am J Med 
Genet 114:343-346. 
Cunningham Owens DG (2004) Clinical psychopharmacology. In: Companion to 
Psychiatric Studies, Seventh edition Edition (Johnstone E, Lawrie S M, Sharpe 
M, Freeman CPL ed). UK: Churchill  Livingstone. 
Curtis D, Vine AE, Knight J (2008) Study of regions of extended homozygosity 
provides a powerful method to explore haplotype structure of human 
populations. Ann Hum Genet 72:261-278. 
D'Angelo G, Vicinanza M, De Matteis MA (2008) Lipid-transfer proteins in 
biosynthetic pathways. Curr Opin Cell Biol 20:360-370. 
Darstein M, Petralia RS, Swanson GT, Wenthold RJ, Heinemann SF (2003) Distribution 
of kainate receptor subunits at hippocampal mossy fiber synapses. J Neurosci 
23:8013-8019. 
Dean M (2003) Approaches to identify genes for complex human diseases: lessons from 
Mendelian disorders. Hum Mutat 22:261-274. 
Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) 
transporter superfamily. Genome Res 11:1156-1166. 
Deary IJ, Gow AJ, Taylor MD, Corley J, Brett C, Wilson V, Campbell H, Whalley LJ, 
Visscher PM, Porteous DJ, Starr JM (2007) The Lothian Birth Cohort 1936: a 
study to examine influences on cognitive ageing from age 11 to age 70 and 
beyond. BMC Geriatr 7:28. 
DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW, Wellman N, Loftus 
J, Nanthakumar B, Razi K, Stewart J, Comazzi M, Vita A, Heffner T, 
Sherrington R (2002) A Genome-Wide Scan for Linkage to Chromosomal 
Regions in 382 Sibling Pairs With Schizophrenia or Schizoaffective Disorder. 
            American Journal of Psychiatry 159:803-812. 
Devinsky O, Morrell MJ, Vogt BA (1995) Contributions of anterior cingulate cortex to 
behaviour. Brain 118 ( Pt 1):279-306. 
Di Rienzo A (2006) Population genetics models of common diseases. Curr Opin Genet 
Dev 16:630-636. 
Donati RJ, Rasenick MM (2005) Chronic antidepressant treatment prevents 
accumulation of gsalpha in cholesterol-rich, cytoskeletal-associated, plasma 
membrane domains (lipid rafts). Neuropsychopharmacology 30:1238-1245. 
Doris AB, Wahle K, MacDonald A, Morris S, Coffey I, Muir W, Blackwood D (1998) 
Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia. 
Schizophr Res 31:185-196. 
Dracheva S, Byne W, Chin B, Haroutunian V (2008) Ionotropic glutamate receptor 
mRNA expression in the human thalamus: absence of change in schizophrenia. 
Brain Res 1214:23-34. 
 274 
Duan X, Chang JH, Ge S, KFaulkner RL, Kim JY, Kitabatake Y, Liu XB, Yang CH, 
Jorden JD, Ma DK, Liu CY, Ganesan S, Cheng HJ, Ming GL, Lu B, Song H 
(2007) Disrupted-In-Schizophrenia 1 Regulates Integration of Newly Generated 
Neurons in the Adult Brain. 130:1146-1158. 
Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren 
G, Rastam M, Gillberg IC, Anckarsater H, Sponheim E, Goubran-Botros H, 
Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Roge B, 
Heron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T (2007) Mutations in 
the gene encoding the synaptic scaffolding protein SHANK3 are associated with 
autism spectrum disorders. Nat Genet 39:25-27. 
Eisensamer B, Uhr M, Meyr S, Gimpl G, Deiml T, Rammes G, Lambert JJ, 
Zieglgansberger W, Holsboer F, Rupprecht R (2005) Antidepressants and 
antipsychotic drugs colocalize with 5-HT3 receptors in raft-like domains. J 
Neurosci 25:10198-10206. 
Endicott J, Spitzer RL (1978) A diagnostic interview: the schedule for affective 
disorders and schizophrenia. Arch Gen Psychiatry 35:837-844. 
Erbel-Sieler C, Dudley C, Zhou Y, Wu X, Estill SJ, Han T, Diaz-Arrastia R, Brunskill 
EW, Potter SS, McKnight SL (2004) Behavioral and regulatory abnormalities in 
mice deficient in the NPAS1 and NPAS3 transcription factors. Proc Natl Acad 
Sci U S A 101:13648-13653. 
Failla P, Romano C, Alberti A, Vasta A, Buono S, Castiglia L, Luciano D, Di Benedetto 
D, Fichera M, Galesi O (2007) Schizophrenia in a patient with subtelomeric 
duplication of chromosome 22q. Clin Genet 71:599-601. 
Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA, 
Steel G, Nestadt G, Liang KY, Huganir RL, Valle D, Pulver AE (2005) Bipolar I 
disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 
candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 
77:918-936. 
Farkas E, de Wilde MC, Kiliaan AJ, Meijer J, Keijser JN, Luiten PG (2002) Dietary 
long chain PUFAs differentially affect hippocampal muscarinic 1 and 
serotonergic 1A receptors in experimental cerebral hypoperfusion. Brain Res 
954:32-41. 
Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S, Fan YT, Paciga 
SA, Conti M, Menniti FS (2008) PDE4B polymorphisms and decreased PDE4B 
expression are associated with schizophrenia. Schizophr Res 101:36-49. 
Faulkner RL, Jang MH, Liu XB, Duan X, Sailor KA, Kim JY, Ge S, Jones EG, Ming 
GL, Song H, Cheng HJ (2008) Development of hippocampal mossy fiber 
synaptic outputs by new neurons in the adult brain. Proc Natl Acad Sci U S A 
105:14157-14162. 
Fearon K, McClendon V, Bonetti B, Bedwell DM (1994) Premature translation 
termination mutations are efficiently suppressed in a highly conserved region of 
yeast Ste6p, a member of the ATP-binding cassette (ABC) transporter family. J 
Biol Chem 269:17802-17808. 
Feldberg W (1976) Possible association of schizophrenia with a disturbance in 
prostaglandin metabolism: a physiological hypothesis. Psychol Med 6:359-369. 
 275 
Fenton WS, Hibbeln J, Knable M (1999) Essential fatty acids, lipid membrane 
abnormalities, and the diagnosis and treatment of schizophrenia. Biological 
Psychiatry 47:8-21. 
Fernandez T, Morgan T, Davis N, Klin A, Morris A, Farhi A, Lifton RP, State MW 
(2004) Disruption of contactin 4 (CNTN4) results in developmental delay and 
other features of 3p deletion syndrome. Am J Hum Genet 74:1286-1293. 
Fitzgerald ML, Okuhira K, Short GF, 3rd, Manning JJ, Bell SA, Freeman MW (2004) 
ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA 
motif that is required for its cholesterol efflux and ApoA-I binding activities. J 
Biol Chem 279:48477-48485. 
Fogarty DJ, Perez-Cerda F, Matute C (2000) KA1-like kainate receptor subunit 
immunoreactivity in neurons and glia using a novel anti-peptide antibody. Brain 
Res Mol Brain Res 81:164-176. 
Fox TD (1987) Natural variation in the genetic code. Annu Rev Genet 21:67-91. 
Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel 
SB, Topol EJ, Smoller JW, Pato CN, Pato MT, Petryshen TL, Kolonel LN, 
Lander ES, Sklar P, Henderson B, Hirschhorn JN, Altshuler D (2004) Assessing 
the impact of population stratification on genetic association studies. Nat Genet 
36:388-393. 
Fujita M, Charney DS, Innis RB (2000) Imaging serotonergic neurotransmission in 
depression: hippocampal pathophysiology may mirror global brain alterations. 
Biol Psychiatry 48:801-812. 
Garey LJ, Von Bussmann KA, Hirsch SR (2006) Decreased numerical density of kainate 
receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics. 
Exp Brain Res 173:234-242. 
Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PK (1987) Increased plasma 
phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic 
therapy. Biol Psychiatry 22:421-426. 
Gecz J, Barnett S, Liu J, Hollway G, Donnelly A, Eyre H, Eshkevari HS, Baltazar R, 
Grunn A, Nagaraja R, Gilliam C, Peltonen L, Sutherland GR, Baron M, Mulley 
JC (1999) Characterization of the human glutamate receptor subunit 3 gene 
(GRIA3), a candidate for bipolar disorder and nonspecific X-linked mental 
retardation. Genomics 62:356-368. 
Gelder M, Harrison P, Cowen P (2006) Shorter Oxford Textbook of Psychiatry, 5th 
edition Edition. Oxford: Oxford University Press. 
Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding 
psychoses. Trends Pharmacol Sci. 
Gibson J, Morton NE, Collins A (2006) Extended tracts of homozygosity in outbred 
human populations. Hum Mol Genet 15:789-795. 
Glen AI, Glen EM, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, Ellis K, 
Skinner FS (1994) A red cell membrane abnormality in a subgroup of 
schizophrenic patients: evidence for two diseases. Schizophr Res 12:53-61. 
Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou 
M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, 
 276 
Sealfon SC (2008) Identification of a serotonin/glutamate receptor complex 
implicated in psychosis. Nature 452:93-97. 
Gordon D, Abajian C, Green P (1998) Consed: a graphical tool for sequence finishing. 
Genome Res 8:195-202. 
Gottesman II (1991) Schizophrenia genesis: the origins of madness. New York: 
Freeman. 
Gould E (2007) Structural Plasticity In: The Hippocampus Book (Anderson P, Morris R, 
Amaral D, Bliss T, O’Keefe J, eds), pp 321-342. Oxford: Oxford University 
Press. 
Green E, Elvidge G, Jacobsen N, Glaser B, Jones I, O'Donovan MC, Kirov G, Owen 
MJ, Craddock N (2005) Localization of bipolar susceptibility locus by molecular 
genetic analysis of the chromosome 12q23-q24 region in two pedigrees with 
bipolar disorder and Darier's disease. Am J Psychiatry 162:35-42. 
Green EK, Norton N, Peirce T, Grozeva D, Kirov G, Owen MJ, O'Donovan MC, 
Craddock N (2006) Evidence that a DISC1 frame-shift deletion associated with 
psychosis in a single family may not be a pathogenic mutation. Mol Psychiatry 
11:798-799. 
Greinwald JH, Jr., Wayne S, Chen AH, Scott DA, Zbar RI, Kraft ML, Prasad S, Ramesh 
A, Coucke P, Srisailapathy CR, Lovett M, Van Camp G, Smith RJ (1998) 
Localization of a novel gene for nonsyndromic hearing loss (DFNB17) to 
chromosome region 7q31. Am J Med Genet 78:107-113. 
Grzybowska EA, Wilczynska A, Siedlecki JA (2001) Regulatory functions of 3'UTRs. 
Biochem Biophys Res Commun 288:291-295. 
Haines TH (2001) Do sterols reduce proton and sodium leaks through lipid bilayers? 
Prog Lipid Res 40:299-324. 
Harlow E, Lane D (1998) Antibodies A Laboratory Manual. New York: Cold Spring 
Harbour Laboratory Press. 
Harris EW, Cotman CW (1986) Long-term potentiation of guinea pig mossy fiber 
responses is not blocked by N-methyl D-aspartate antagonists. Neurosci Lett 
70:132-137. 
Harrison PJ (1999) The neuropathology of schizophrenia. A critical review of the data 
and their interpretation. Brain 122 ( Pt 4):593-624. 
Harrison PJ, Weinberger DR (2005) Schizophrenia genes, gene expression, and 
neuropathology: on the matter of their convergence. Mol Psychiatry 10:40-68; 
image 45. 
Hassan MJ, Santos RL, Rafiq MA, Chahrour MH, Pham TL, Wajid M, Hijab N, 
Wambangco M, Lee K, Ansar M, Yan K, Ahmad W, Leal SM (2006) A novel 
autosomal recessive non-syndromic hearing impairment locus (DFNB47) maps 
to chromosome 2p25.1-p24.3. Hum Genet 118:605-610. 
Hennah W, Thomson P, McQuillin A, Bass N, Loukola A, Anjorin A, Blackwood D, 
Curtis D, Deary IJ, Harris SE, Isometsa ET, Lawrence J, Lonnqvist J, Muir W, 
Palotie A, Partonen T, Paunio T, Pylkko E, Robinson M, Soronen P, Suominen 
K, Suvisaari J, Thirumalai S, Clair DS, Gurling H, Peltonen L, Porteous D 
(2008) DISC1 association, heterogeneity and interplay in schizophrenia and 
bipolar disorder. Mol Psychiatry. 
 277 
Hering H, Lin CC, Sheng M (2003) Lipid rafts in the maintenance of synapses, dendritic 
spines, and surface AMPA receptor stability. J Neurosci 23:3262-3271. 
Hibbeln JR, Salem N, Jr. (1995) Dietary polyunsaturated fatty acids and depression: 
when cholesterol does not satisfy. Am J Clin Nutr 62:1-9. 
Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley 
GH, Cohn JS, Hayden MR, Wellington CL (2004) Deficiency of ABCA1 
impairs apolipoprotein E metabolism in brain. J Biol Chem 279:41197-41207. 
Horrobin DF (1977) Schizophrenia as a prostaglandin deficiency disease. Lancet 1:936-
937. 
Huettner JE (2003) Kainate receptors and synaptic transmission. Prog Neurobiol 70:387-
407. 
Ibrahim HM, Hogg AJ, Jr., Healy DJ, Haroutunian V, Davis KL, Meador-Woodruff JH 
(2000) Ionotropic glutamate receptor binding and subunit mRNA expression in 
thalamic nuclei in schizophrenia. Am J Psychiatry 157:1811-1823. 
ISC ISC (2008) Rare chromosomal deletions and duplications increase risk of 
schizophrenia. Nature 455:237-241. 
Jacobsen NJ, Lyons I, Hoogendoorn B, Burge S, Kwok PY, O'Donovan MC, Craddock 
N, Owen MJ (1999) ATP2A2 mutations in Darier's disease and their relationship 
to neuropsychiatric phenotypes. Hum Mol Genet 8:1631-1636. 
Jacobsen NJ, Franks EK, Elvidge G, Jones I, McCandless F, O'Donovan MC, Owen MJ, 
Craddock N (2001) Exclusion of the Darier's disease gene, ATP2A2, as a 
common susceptibility gene for bipolar disorder. Mol Psychiatry 6:92-97. 
Jamain S, Quach H, Betancur C, Rastam M, Colineaux C, Gillberg IC, Soderstrom H, 
Giros B, Leboyer M, Gillberg C, Bourgeron T (2003) Mutations of the X-linked 
genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat 
Genet 34:27-29. 
Jaskolski F, Coussen F, Mulle C (2005) Subcellular localization and trafficking of 
kainate receptors. Trends Pharmacol Sci 26:20-26. 
Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of 
schizophrenia. Am J Psychiatry 148:1301-1308. 
Jervell A, Lange-Nielsen F (1957) Congenital deaf-mutism, functional heart disease 
with prolongation of the Q-T interval and sudden death. Am Heart J 54:59-68. 
Jorgensen TH, Borglum AD, Mors O, Wang AG, Pinaud M, Flint TJ, Dahl HA, Vang 
M, Kruse TA, Ewald H (2002) Search for common haplotypes on chromosome 
22q in patients with schizophrenia or bipolar disorder from the Faroe Islands. 
Am J Med Genet 114:245-252. 
Kaminski WE, Piehler A, Wenzel JJ (2006) ABC A-subfamily transporters: structure, 
function and disease. Biochim Biophys Acta 1762:510-524. 
Kamiya A, Tan PL, Kubo K, Engelhard C, Ishizuka K, Kubo A, Tsukita S, Pulver AE, 
Nakajima K, Cascella NG, Katsanis N, Sawa A (2008) Recruitment of PCM1 to 
the centrosome by the cooperative action of DISC1 and BBS4: a candidate for 
psychiatric illnesses. Arch Gen Psychiatry 65:996-1006. 
Kamnasaran D, Muir WJ, Ferguson-Smith MA, Cox DW (2003) Disruption of the 
neuronal PAS3 gene in a family affected with schizophrenia. J Med Genet 
40:325-332. 
 278 
Kandel ER, Schwartz JH, Jessell TM (2000) Principles of Neural Science, fourth 
Edition. New York McGraw-Hill Health Professions Division  
Karlin S, Mrazek J (1996) What drives codon choices in human genes? J Mol Biol 
262:459-472. 
Kask K, Jerecic J, Zamanillo D, Wilbertz J, Sprengel R, Seeburg PH (2000) 
Developmental profile of kainate receptor subunit KA1 revealed by Cre 
expression in YAC transgenic mice. Brain Res 876:55-61. 
Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos 
C, Voight BF, Havulinna AS, Wahlstrand B, Hedner T, Corella D, Tai ES, 
Ordovas JM, Berglund G, Vartiainen E, Jousilahti P, Hedblad B, Taskinen MR, 
Newton-Cheh C, Salomaa V, Peltonen L, Groop L, Altshuler DM, Orho-
Melander M (2008) Six new loci associated with blood low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat 
Genet 40:189-197. 
Kato T (2001) Molecular genetics of bipolar disorder. Neurosci Res 40:105-113. 
Kelsoe JR, Spence MA, Loetscher E, Foguet M, Sadovnick AD, Remick RA, Flodman 
P, Khristich J, Mroczkowski-Parker Z, Brown JL, Masser D, Ungerleider S, 
Rapaport MH, Wishart WL, Luebbert H (2001) A genome survey indicates a 
possible susceptibility locus for bipolar disorder on chromosome 22. Proc Natl 
Acad Sci U S A 98:585-590. 
Kendler KS (2000) Schizophrenia genetics. In: Kaplan and Sadock's comprehensive 
textbook of psychiatry (Sadock BJ, Sadock VA, eds), pp p1147-1159. 
Philadelphia: Lippincott, Williams & Wilkins. 
Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ (1993) A longitudinal twin 
study of personality and major depression in women. Arch Gen Psychiatry 
50:853-862. 
Kendler KS, Ochs AL, Gorman AM, Hewitt JK, Ross DE, Mirsky AF (1991) The 
structure of schizotypy: a pilot multitrait twin study. Psychiatry Res 36:19-36. 
Kerwin R, Patel S, Meldrum B (1990) Quantitative autoradiographic analysis of 
glutamate binding sites in the hippocampal formation in normal and 
schizophrenic brain post mortem. Neuroscience 39:25-32. 
Kessler RC, Davis CG, Kendler KS (1997) Childhood adversity and adult psychiatric 
disorder in the US National Comorbidity Survey. Psychol Med 27:1101-1119. 
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen 
HU, Kendler KS (1994) Lifetime and 12-month prevalence of DSM-III-R 
psychiatric disorders in the United States. Results from the National Comorbidity 
Survey. Arch Gen Psychiatry 51:8-19. 
Kim WS, Weickert CS, Garner B (2008) Role of ATP-binding cassette transporters in 
brain lipid transport and neurological disease. J Neurochem 104:1145-1166. 
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, 
Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes 
substrate specificity. Science 315:525-528. 
Kirov G, Zaharieva I, Georgieva L, Moskvina V, Nikolov I, Cichon S, Hillmer A, 
Toncheva D, Owen MJ, O'Donovan MC (2008) A genome-wide association 
study in 574 schizophrenia trios using DNA pooling. Mol Psychiatry. 
 279 
Kitiratschky VB, Grau T, Bernd A, Zrenner E, Jagle H, Renner AB, Kellner U, Rudolph 
G, Jacobson SG, Cideciyan AV, Schaich S, Kohl S, Wissinger B (2008) ABCA4 
gene analysis in patients with autosomal recessive cone and cone rod 
dystrophies. Eur J Hum Genet 16:812-819. 
Kleinjan DJ, van Heyningen V (1998) Position effect in human genetic disease. Hum 
Mol Genet 7:1611-1618. 
Kong A, Cox NJ (1997) Allele-sharing models: LOD scores and accurate linkage tests. 
Am J Hum Genet 61:1179-1188. 
Konradi C, Heckers S (2003) Molecular aspects of glutamate dysregulation: implications 
for schizophrenia and its treatment. Pharmacol Ther 97:153-179. 
Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 
455:894-902. 
Kumar SS, Buckmaster PS (2006) Hyperexcitability, interneurons, and loss of 
GABAergic synapses in entorhinal cortex in a model of temporal lobe epilepsy. J 
Neurosci 26:4613-4623. 
Lander ES, Botstein D (1987) Homozygosity mapping: a way to map human recessive 
traits with the DNA of inbred children. Science 236:1567-1570. 
Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J (2007) Molecular 
mechanisms of schizophrenia. Cell Physiol Biochem 20:687-702. 
Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Raynaud 
M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Ropers HH, 
Hamel BC, Andres C, Barthelemy C, Moraine C, Briault S (2004) X-linked 
mental retardation and autism are associated with a mutation in the NLGN4 
gene, a member of the neuroligin family. Am J Hum Genet 74:552-557. 
Laurier V, Stoetzel C, Muller J, Thibault C, Corbani S, Jalkh N, Salem N, Chouery E, 
Poch O, Licaire S, Danse JM, Amati-Bonneau P, Bonneau D, Megarbane A, 
Mandel JL, Dollfus H (2006) Pitfalls of homozygosity mapping: an extended 
consanguineous Bardet-Biedl syndrome family with two mutant genes (BBS2, 
BBS10), three mutations, but no triallelism. Eur J Hum Genet 14:1195-1203. 
Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson 
A, Wolfgang CD, Polymeropoulos MH (2008) Association of the NPAS3 gene 
and five other loci with response to the antipsychotic iloperidone identified in a 
whole genome association study. Mol Psychiatry. 
Lee BJ, Worland PJ, Davis JN, Stadtman TC, Hatfield DL (1989) Identification of a 
selenocysteyl-tRNA(Ser) in mammalian cells that recognizes the nonsense 
codon, UGA. J Biol Chem 264:9724-9727. 
Lencz T, Morgan TV, Athanasiou M, Dain B, Reed CR, Kane JM, Kucherlapati R, 
Malhotra AK (2007) Converging evidence for a pseudoautosomal cytokine 
receptor gene locus in schizophrenia. Mol Psychiatry 12:572-580. 
Lenox RH, Wang L (2003) Molecular basis of lithium action: integration of lithium-
responsive signaling and gene expression networks. Mol Psychiatry 8:135-144. 
Lerma J (2003) Roles and rules of kainate receptors in synaptic transmission. Nat Rev 
Neurosci 4:481-495. 
Lerma J (2006) Kainate receptor physiology. Curr Opin Pharmacol 6:89-97. 
 280 
Lerma J, Paternain AV, Rodriguez-Moreno A, Lopez-Garcia JC (2001) Molecular 
physiology of kainate receptors. Physiol Rev 81:971-998. 
Leutenegger AL, Prum B, Genin E, Verny C, Lemainque A, Clerget-Darpoux F, 
Thompson EA (2003) Estimation of the inbreeding coefficient through use of 
genomic data. Am J Hum Genet 73:516-523. 
Leutenegger AL, Labalme A, Genin E, Toutain A, Steichen E, Clerget-Darpoux F, 
Edery P (2006) Using genomic inbreeding coefficient estimates for 
homozygosity mapping of rare recessive traits: application to Taybi-Linder 
syndrome. Am J Hum Genet 79:62-66. 
Levinson DF (2006) The genetics of depression: a review. Biol Psychiatry 60:84-92. 
Lewis CM, Levinson DF, Wise LH, DeLisi LE, Straub RE, Hovatta I, Williams NM, 
Schwab SG, Pulver AE, Faraone SV, Brzustowicz LM, Kaufmann CA, Garver 
DL, Gurling HM, Lindholm E, Coon H, Moises HW, Byerley W, Shaw SH, 
Mesen A, Sherrington R, O'Neill FA, Walsh D, Kendler KS, Ekelund J, Paunio 
T, Lonnqvist J, Peltonen L, O'Donovan MC, Owen MJ, Wildenauer DB, Maier 
W, Nestadt G, Blouin JL, Antonarakis SE, Mowry BJ, Silverman JM, Crowe RR, 
Cloninger CR, Tsuang MT, Malaspina D, Harkavy-Friedman JM, Svrakic DM, 
Bassett AS, Holcomb J, Kalsi G, McQuillin A, Brynjolfson J, Sigmundsson T, 
Petursson H, Jazin E, Zoega T, Helgason T (2003) Genome scan meta-analysis 
of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 
73:34-48. 
Li XC, Everett LA, Lalwani AK, Desmukh D, Friedman TB, Green ED, Wilcox ER 
(1998) A mutation in PDS causes non-syndromic recessive deafness. Nat Genet 
18:215-217. 
Li Z, He Z, Tang W, Tang R, Huang K, Xu Z, Xu Y, Li L, Li X, Feng G, He L, Shi Y 
(2008) No genetic association between polymorphisms in the kainate-type 
glutamate receptor gene, GRIK4, and schizophrenia in the Chinese population. 
Prog Neuropsychopharmacol Biol Psychiatry 32:876-880. 
Liddle PF (1987) The symptoms of chronic schizophrenia. A re-examination of the 
positive-negative dichotomy. Br J Psychiatry 151:145-151. 
Linton KJ, Higgins CF (2007) Structure and function of ABC transporters: the ATP 
switch provides flexible control. Pflugers Arch 453:555-567. 
Liu P, Bilkey DK (1998) Is there a direct projection from perirhinal cortex to the 
hippocampus? Hippocampus 8:424-425. 
Liu QS, Xu Q, Arcuino G, Kang J, Nedergaard M (2004) Astrocyte-mediated activation 
of neuronal kainate receptors. Proc Natl Acad Sci U S A 101:3172-3177. 
Liu XZ, Ouyang XM, Xia XJ, Zheng J, Pandya A, Li F, Du LL, Welch KO, Petit C, 
Smith RJ, Webb BT, Yan D, Arnos KS, Corey D, Dallos P, Nance WE, Chen ZY 
(2003) Prestin, a cochlear motor protein, is defective in non-syndromic hearing 
loss. Hum Mol Genet 12:1155-1162. 
Liu YL, Fann CS, Liu CM, Chen WJ, Wu JY, Hung SI, Chen CH, Jou YS, Liu SK, 
Hwang TJ, Hsieh MH, Chang CC, Yang WC, Lin JJ, Chou FH, Faraone SV, 
Tsuang MT, Hwu HG (2008) RASD2, MYH9, and CACNG2 Genes at 
Chromosome 22q12 Associated with the Subgroup of Schizophrenia with Non-
Deficit in Sustained Attention and Executive Function. Biol Psychiatry. 
 281 
Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN (2003) Meta-analysis of 
genetic association studies supports a contribution of common variants to 
susceptibility to common disease. Nat Genet 33:177-182. 
Macdonald ME, C.M. Ambrose, M.P. Duyao, R.H. Myers, C. Lin, L. Srinidhi, G. 
Barnes, S.A. Taylor, M. James, N. Groot, H. Macfarlane, B. Jenkins, M.A. 
Anderson, N.S. Wexler, J.F. Gusella, G.P. Bates, S. Baxendale, H. Hummerich, 
S. Kirby, M. North, S. Youngman, R. Mott, G. Zehetner, Z. Sedlacek, A. 
Poustka, A.M. Frischauf, H. Lehrach, A.J. Buckler, D. Church, L. 
Doucettestamm, M.C. Odonovan, L. Ribaramirez, M. Shah, V.P. Stanton, S.A. 
Strobel, K.M. Draths, J.L. Wales, P. Dervan, D.E. Housman, M. Altherr, R. 
Shiang, L. Thompson, T. Fielder, J.J. Wasmuth, D. Tagle, J. Valdes, L. Elmer, 
M. Allard, L. Castilla, M. Swaroop, K. Blanchard, F.S. Collins, R. Snell, T. 
Holloway, K. Gillespie, N. Datson, D. Shaw and P.S. Harper (1993) A novel 
gene containing a trinucleotide repeat that is expanded and unstable on 
Huntington's disease chromosomes. Cell 72:971-983. 
Mace S, Cousin E, Ricard S, Genin E, Spanakis E, Lafargue-Soubigou C, Genin B, 
Fournel R, Roche S, Haussy G, Massey F, Soubigou S, Brefort G, Benoit P, 
Brice A, Campion D, Hollis M, Pradier L, Benavides J, Deleuze JF (2005) 
ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. 
Neurobiol Dis 18:119-125. 
Magarinos AM, McEwen BS (1995) Stress-induced atrophy of apical dendrites of 
hippocampal CA3c neurons: involvement of glucocorticoid secretion and 
excitatory amino acid receptors. Neuroscience 69:89-98. 
Magarinos AM, McEwen BS, Flugge G, Fuchs E (1996) Chronic psychosocial stress 
causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in 
subordinate tree shrews. J Neurosci 16:3534-3540. 
Magri C, Gardella R, Valsecchi P, Barlati SD, Guizzetti L, Imperadori L, Bonvicini C, 
Tura GB, Gennarelli M, Sacchetti E, Barlati S (2008) Study on GRIA2, GRIA3 
and GRIA4 genes highlights a positive association between schizophrenia and 
GRIA3 in female patients. Am J Med Genet B Neuropsychiatr Genet 147B:745-
753. 
Mah S, Nelson MR, Delisi LE, Reneland RH, Markward N, James MR, Nyholt DR, 
Hayward N, Handoko H, Mowry B, Kammerer S, Braun A (2006) Identification 
of the semaphorin receptor PLXNA2 as a candidate for susceptibility to 
schizophrenia. Mol Psychiatry 11:471-478. 
Mandell A, Knapp S (1979) Asymmetry and mood, emergent properties of serotonin 
regulation. Archives of general psychiatry 36:909-916. 
Manganas LN, Zhang X, Li Y, Hazel RD, Smith SD, Wagshul ME, Henn F, Benveniste 
H, Djuric PM, Enikolopov G, Maletic-Savatic M (2007) Magnetic resonance 
spectroscopy identifies neural progenitor cells in the live human brain. Science 
318:980-985. 
Masmoudi S, Tlili A, Majava M, Ghorbel AM, Chardenoux S, Lemainque A, Zina ZB, 
Moala J, Mannikko M, Weil D, Lathrop M, Ala-Kokko L, Drira M, Petit C, 
Ayadi H (2003) Mapping of a new autosomal recessive nonsyndromic hearing 
loss locus (DFNB32) to chromosome 1p13.3-22.1. Eur J Hum Genet 11:185-188. 
 282 
Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez 
MV (2001) The link between excitotoxic oligodendroglial death and 
demyelinating diseases. Trends Neurosci 24:224-230. 
McCaffery P, Zhang J, Crandall JE (2006) Retinoic acid signaling and function in the 
adult hippocampus. J Neurobiol 66:780-791. 
McCaughan KK, Brown CM, Dalphin ME, Berry MJ, Tate WP (1995) Translational 
termination efficiency in mammals is influenced by the base following the stop 
codon. Proc Natl Acad Sci U S A 92:5431-5435. 
McClellan JM, Susser E, King MC (2007) Schizophrenia: a common disease caused by 
multiple rare alleles. Br J Psychiatry 190:194-199. 
McEwen BS (1980) Steroid hormones and the brain: cellular mechanisms underlying 
neural and behavioral plasticity. Psychoneuroendocrinology 5:1-11. 
McEwen BS (1999) Stress and hippocampal plasticity. Annu Rev Neurosci 22:105-122. 
McEwen BS, Magarinos AM (1997) Stress effects on morphology and function of the 
hippocampus. Ann N Y Acad Sci 821:271-284. 
McGuffin P, Owen MJ, Farmer AE (1995) Genetic basis of schizophrenia. Lancet 
346:678-682. 
McGuffin P, Katz R, Watkins S, Rutherford J (1996) A hospital-based twin register of 
the heritability of DSM-IV unipolar depression. Arch Gen Psychiatry 53:129-
136. 
McNamara RK, Jandacek R, Rider T, Tso P, Hahn CG, Richtand NM, Stanford KE 
(2007) Abnormalities in the fatty acid composition of the postmortem 
orbitofrontal cortex of schizophrenic patients: gender differences and partial 
normalization with antipsychotic medications. Schizophr Res 91:37-50. 
McNamara RK, Jandacek R, Rider T, Tso P, Stanford KE, Hahn CG, Richtand NM 
(2008) Deficits in docosahexaenoic acid and associated elevations in the 
metabolism of arachidonic acid and saturated fatty acids in the postmortem 
orbitofrontal cortex of patients with bipolar disorder. Psychiatry Res 160:285-
299. 
Meador-Woodruff JH, Davis KL, Haroutunian V (2001) Abnormal kainate receptor 
expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology 
24:545-552. 
Meador-Woodruff JH, King RE, Damask SP, Bovenkerk KA (1996) Differential 
regulation of hippocampal AMPA and kainate receptor subunit expression by 
haloperidol and clozapine. Mol Psychiatry 1:41-53. 
Michaelis EK (1998) Molecular biology of glutamate receptors in the central nervous 
system and their role in excitotoxicity, oxidative stress and aging. Prog 
Neurobiol 54:369-415. 
Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, Devon 
RS, Clair DM, Muir WJ, Blackwood DH, Porteous DJ (2000) Disruption of two 
novel genes by a translocation co-segregating with schizophrenia. Hum Mol 
Genet 9:1415-1423. 
Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, 
Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, 
Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ 
 283 
(2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that 
regulate cAMP signaling. Science 310:1187-1191. 
Millar T, Walker R, Arango JC, Ironside JW, Harrison DJ, MacIntyre DJ, Blackwood D, 
Smith C, Bell JE (2007) Tissue and organ donation for research in forensic 
pathology: the MRC Sudden Death Brain and Tissue Bank. J Pathol 213:369-
375. 
Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J, Zwaigenbaum L, 
Fernandez B, Roberts W, Szatmari P, Scherer SW (2007) Contribution of 
SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 81:1289-
1297. 
Morris JA, Kandpal G, Ma L, Austin CP (2003) DISC1 (Disrupted-In-Schizophrenia 1) 
is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 
and NUDEL: regulation and loss of interaction with mutation. Hum Mol Genet 
12:1591-1608. 
Mulley JC, Scheffer IE, Harkin LA, Berkovic SF, Dibbens LM (2005) Susceptibility 
genes for complex epilepsy. Hum Mol Genet 14 Spec No. 2:R243-249. 
Munehira Y, Ohnishi T, Kawamoto S, Furuya A, Shitara K, Imamura M, Yokota T, 
Takeda S, Amachi T, Matsuo M, Kioka N, Ueda K (2004) Alpha1-syntrophin 
modulates turnover of ABCA1. J Biol Chem 279:15091-15095. 
Murray CJ, Lopez AD (1996) Evidence-based health policy--lessons from the Global 
Burden of Disease Study. Science 274:740-743. 
Mustapha M, Salem N, Weil D, el-Zir E, Loiselet J, Petit C (1998) Identification of a 
locus on chromosome 7q31, DFNB14, responsible for prelingual sensorineural 
non-syndromic deafness. Eur J Hum Genet 6:548-551. 
Nadel L, Jacobs WJ (1996) The role of the hippocampus in PTSD, panic and phobia In: 
The hippocampus: functions and clinical relevance (Kato N, ed). Amsterdam: 
Elsevier. 
Nakane PK, Pierce J (1967) Enzyme-labeled antibodies: preparations and applications 
for the localisation of antigens. Journal of Histochemistry and Cytochemistry 
14:929-930. 
Narayan S, Head SR, Gilmartin TJ, Dean B, Thomas EA (2008) Evidence for disruption 
of sphingolipid metabolism in schizophrenia. J Neurosci Res. 
Nicoll RA, Schmitz D (2005) Synaptic plasticity at hippocampal mossy fibre synapses. 
Nat Rev Neurosci 6:863-876. 
Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, Wolkin A, Duncan E, 
Rotrosen J (1993) Elevated PLA2 activity in schizophrenics and other 
psychiatric patients. Biol Psychiatry 34:641-649. 
O'Connor JA, Muly EC, Arnold SE, Hemby SE (2007) AMPA receptor subunit and 
splice variant expression in the DLPFC of schizophrenic subjects and rhesus 
monkeys chronically administered antipsychotic drugs. Schizophr Res 90:28-40. 
O'Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, 
Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, 
Spencer CC, Howie B, Leung HT, Hartmann AM, Moller HJ, Morris DW, Shi 
Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, 
Zammit S, Schumacher J, Quinn EM, Schulze TG, Williams NM, Giegling I, 
 284 
Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson 
DF, Gejman PV, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, 
Silverman JM, Byerley WF, Cloninger CR, Cichon S, Nothen MM, Gill M, 
Corvin A, Rujescu D, Kirov G, Owen MJ (2008) Identification of loci associated 
with schizophrenia by genome-wide association and follow-up. Nat Genet. 
Ohishi H, Ogawa-Meguro R, Shigemoto R, Kaneko T, Nakanishi S, Mizuno N (1994) 
Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 
and mGluR3, in rat cerebellar cortex. Neuron 13:55-66. 
Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt 
M, Arolt V, Heindel W, Pfleiderer B (2007) Cognitive impairment and in vivo 
metabolites in first-episode neuroleptic-naive and chronic medicated 
schizophrenic patients: a proton magnetic resonance spectroscopy study. J 
Psychiatr Res 41:625-634. 
Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch 
Gen Psychiatry 52:998-1007. 
Owen MJ, O'Donovan MC, Gottesman II (2002) Schizophrenia. In: Psychiatric genetics 
and genomics (McGuffin P, Owen MJ, Gottesman II, eds). Oxford, OX2 6DP.: 
Oxford University Press,. 
Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ, Lipsky R, Wisniewski 
SR, Manji H, McMahon FJ (2007) Association of GRIK4 with outcome of 
antidepressant treatment in the STAR*D cohort. Am J Psychiatry 164:1181-
1188. 
Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden 
H, Singleton A, Schneider SA (2008) Characterization of PLA2G6 as a locus for 
dystonia-parkinsonism. Ann Neurol. 
Park Y, Jo J, Isaac JT, Cho K (2006) Long-term depression of kainate receptor-mediated 
synaptic transmission. Neuron 49:95-106. 
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, 
Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, 
Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD 
(2007) Activation of mGlu2/3 receptors as a new approach to treat 
schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13:1102-1107. 
Payne HL, Ives JH, Sieghart W, Thompson CL (2008) AMPA and kainate receptors 
mediate mutually exclusive effects on GABA(A) receptor expression in cultured 
mouse cerebellar granule neurones. J Neurochem 104:173-186. 
Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G (1995) Depleted red cell 
membrane essential fatty acids in drug-treated schizophrenic patients. J Psychiatr 
Res 29:227-232. 
Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic 
glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc 
Natl Acad Sci U S A 91:10625-10629. 
Petit C (1996) Genes responsible for human hereditary deafness: symphony of a 
thousand. Nat Genet 14:385-391. 
Pettegrew JW, Keshavan MS, Minshew NJ (1993) 31P nuclear magnetic resonance 
spectroscopy: neurodevelopment and schizophrenia. Schizophr Bull 19:35-53. 
 285 
Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, McDermid H, Shaw SR, 
Claytor J, Willis J, Kelly DP (2001) 22q13 deletion syndrome. Am J Med Genet 
101:91-99. 
Piatto VB, Nascimento EC, Alexandrino F, Oliveira CA, Lopes AC, Sartorato EL, 
Maniglia JV (2005) Molecular genetics of non-syndromic deafness. Rev Bras 
Otorrinolaringol (Engl Ed) 71:216-223. 
Pickard BS, Malloy MP, Porteous DJ, Blackwood DH, Muir WJ (2005a) Disruption of a 
brain transcription factor, NPAS3, is associated with schizophrenia and learning 
disability. Am J Med Genet B Neuropsychiatr Genet 136B:26-32. 
Pickard BS, Millar JK, Porteous DJ, Muir WJ, Blackwood DH (2005b) Cytogenetics 
and gene discovery in psychiatric disorders. Pharmacogenomics J 5:81-88. 
Pickard BS, Thomson PA, Christoforou A, Evans KL, Morris SW, Porteous DJ, 
Blackwood DH, Muir WJ (2007) The PDE4B gene confers sex-specific 
protection against schizophrenia. Psychiatr Genet 17:129-133. 
Pickard BS, Christoforou A, Thomson PA, Fawkes A, Evans KL, Morris SW, Porteous 
DJ, Blackwood DH, Muir WJ (2008a) Interacting haplotypes at the NPAS3 locus 
alter risk of schizophrenia and bipolar disorder. Mol Psychiatry. 
Pickard BS, Malloy MP, Christoforou A, Thomson PA, Evans KL, Morris SW, 
Hampson M, Porteous DJ, Blackwood DH, Muir WJ (2006) Cytogenetic and 
genetic evidence supports a role for the kainate-type glutamate receptor gene, 
GRIK4, in schizophrenia and bipolar disorder. Mol Psychiatry 11:847-857. 
Pickard BS, Knight HM, Hamilton RS, Soares DC, Walker R, Boyd JK, Machell J, 
Maclean A, McGhee KA, Condie A, Porteous DJ, St Clair D, Davis I, 
Blackwood DH, Muir WJ (2008b) A common variant in the 3'UTR of the 
GRIK4 glutamate receptor gene affects transcript abundance and protects against 
bipolar disorder. Proc Natl Acad Sci U S A 105:14940-14945. 
Pieper AA, Wu X, Han TW, Estill SJ, Dang Q, Wu LC, Reece-Fincanon S, Dudley CA, 
Richardson JA, Brat DJ, McKnight SL (2005) The neuronal PAS domain protein 
3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in 
mice. Proc Natl Acad Sci U S A 102:14052-14057. 
Pinheiro P, Mulle C (2006) Kainate receptors. Cell Tissue Res 326:457-482. 
Pinheiro PS, Mulle C (2008) Presynaptic glutamate receptors: physiological functions 
and mechanisms of action. Nat Rev Neurosci 9:423-436. 
Porteous DJ, Thomson P, Brandon NJ, Millar JK (2006) The genetics and biology of 
DISC1--an emerging role in psychosis and cognition. Biol Psychiatry 60:123-
131. 
Porter RH, Eastwood SL, Harrison PJ (1997) Distribution of kainate receptor subunit 
mRNAs in human hippocampus, neocortex and cerebellum, and bilateral 
reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain 
Res 751:217-231. 
Prades C, Arnould I, Annilo T, Shulenin S, Chen ZQ, Orosco L, Triunfol M, Devaud C, 
Maintoux-Larois C, Lafargue C, Lemoine C, Denefle P, Rosier M, Dean M 
(2002) The human ATP binding cassette gene ABCA13, located on chromosome 
7p12.3, encodes a 5058 amino acid protein with an extracellular domain encoded 
in part by a 4.8-kb conserved exon. Cytogenet Genome Res 98:160-168. 
 286 
Pramparo T, de Gregori M, Gimelli S, Ciccone R, Frondizi D, Liehr T, Pellacani S, Masi 
G, Brovedani P, Zuffardi O, Guerrini R (2008) A 7 Mb duplication at 22q13 in a 
girl with bipolar disorder and hippocampal malformation. Am J Med Genet A 
146A:1754-1760. 
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar 
P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome 
association and population-based linkage analyses. Am J Hum Genet 81:559-
575. 
Quiroz JA, Gould TD, Manji HK (2004) Molecular effects of lithium. Mol Interv 4:259-
272. 
Race V, Marie S, Vincent MF, Van den Berghe G (2000) Clinical, biochemical and 
molecular genetic correlations in adenylosuccinate lyase deficiency. Hum Mol 
Genet 9:2159-2165. 
Ramocki MB, Zoghbi HY (2008) Failure of neuronal homeostasis results in common 
neuropsychiatric phenotypes. Nature 455:912-918. 
Rasband WS ( 1997-2007) ImageJ,. National Institutes of Health, Bethesda,  
Maryland, USA, http://rsb.info.nih.gov/ij/,. In. 
Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero 
MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, Gonzalez JR, 
Gratacos M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall 
CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, 
Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Armengol L, 
Conrad DF, Estivill X, Tyler-Smith C, Carter NP, Aburatani H, Lee C, Jones 
KW, Scherer SW, Hurles ME (2006) Global variation in copy number in the 
human genome. Nature 444:444-454. 
Reese MG, Eeckman FH, Kulp D, Haussler D (1997) Improved splice site detection in 
Genie. J Comput Biol 4:311-323. 
Represa A, Tremblay E, Ben-Ari Y (1987) Kainate binding sites in the hippocampal 
mossy fibers: localization and plasticity. Neuroscience 20:739-748. 
Riazuddin S, Khan SN, Ahmed ZM, Ghosh M, Caution K, Nazli S, Kabra M, Zafar AU, 
Chen K, Naz S, Antonellis A, Pavan WJ, Green ED, Wilcox ER, Friedman PL, 
Morell RJ, Riazuddin S, Friedman TB (2006) Mutations in TRIOBP, which 
encodes a putative cytoskeletal-organizing protein, are associated with 
nonsyndromic recessive deafness. Am J Hum Genet 78:137-143. 
Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist 
programmers. Methods Mol Biol 132:365-386. 
Rozet JM, Gerber S, Ghazi I, Perrault I, Ducroq D, Souied E, Cabot A, Dufier JL, 
Munnich A, Kaplan J (1999) Mutations of the retinal specific ATP binding 
transporter gene (ABCR) in a single family segregating both autosomal recessive 
retinitis pigmentosa RP19 and Stargardt disease: evidence of clinical 
heterogeneity at this locus. J Med Genet 36:447-451. 
Ruifrok AC, Johnston DA (2001) Quantification of histochemical staining by color 
deconvolution. Anal Quant Cytol Histol 23:291-299. 
Ruiz-Perez VL, Carter SA, Healy E, Todd C, Rees JL, Steijlen PM, Carmichael AJ, 
Lewis HM, Hohl D, Itin P, Vahlquist A, Gobello T, Mazzanti C, Reggazini R, 
 287 
Nagy G, Munro CS, Strachan T (1999) ATP2A2 mutations in Darier's disease: 
variant cutaneous phenotypes are associated with missense mutations, but 
neuropsychiatric features are independent of mutation class. Hum Mol Genet 
8:1621-1630. 
Sachs NA, Sawa A, Holmes SE, Ross CA, DeLisi LE, Margolis RL (2005) A frameshift 
mutation in Disrupted in Schizophrenia 1 in an American family with 
schizophrenia and schizoaffective disorder. Mol Psychiatry 10:758-764. 
Sahay A, Hen R (2007) Adult hippocampal neurogenesis in depression. Nat Neurosci 
10:1110-1115. 
Sakuntabhai A, Ruiz-Perez V, Carter S, Jacobsen N, Burge S, Monk S, Smith M, Munro 
CS, O'Donovan M, Craddock N, Kucherlapati R, Rees JL, Owen M, Lathrop 
GM, Monaco AP, Strachan T, Hovnanian A (1999) Mutations in ATP2A2, 
encoding a Ca2+ pump, cause Darier disease. Nat Genet 21:271-277. 
Sambrook J, Fritsch, Maniatis T (1989) Molecular Cloning: a laboratory manual. Cold 
Spring Harbor: Cold Spring Harbor Press. 
Sanchez MM, Young LJ, Plotsky PM, Insel TR (2000) Distribution of corticosteroid 
receptors in the rhesus brain: relative absence of glucocorticoid receptors in the 
hippocampal formation. J Neurosci 20:4657-4668. 
Sarrieau A, Dussaillant M, Agid F, Philibert D, Agid Y, Rostene W (1986) 
Autoradiographic localization of glucocorticosteroid and progesterone binding 
sites in the human post-mortem brain. J Steroid Biochem 25:717-721. 
Scarr E, Beneyto M, Meador-Woodruff JH, Deans B (2005) Cortical glutamatergic 
markers in schizophrenia. Neuropsychopharmacology 30:1521-1531. 
Scharfman HE, Hen R (2007) Neuroscience. Is more neurogenesis always better? 
Science 315:336-338. 
Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, 
Carson AR, Parker-Katiraee L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, 
Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos 
CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, 
Lu F, Zeesman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg 
R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, 
Heng HH, Pelicci PG, Lo-Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, 
Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins 
AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, 
Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, 
Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop 
BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek 
E, Oscier DG, Mould SJ, Dohner H, Dohner K, Rommens JM, Vincent JB, 
Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC (2003) Human chromosome 
7: DNA sequence and biology. Science 300:767-772. 
Schiffer HH, Heinemann SF (2007) Association of the human kainate receptor GluR7 
gene (GRIK3) with recurrent major depressive disorder. Am J Med Genet B 
Neuropsychiatr Genet 144B:20-26. 
Schmidt D, Jiang QX, MacKinnon R (2006) Phospholipids and the origin of cationic 
gating charges in voltage sensors. Nature 444:775-779. 
 288 
Schmitt A, May B, Muller B, Jatzko A, Petroianu G, Braus DF, Henn FA (2003) Effects 
of chronic haloperidol and clozapine treatment on AMPA and kainate receptor 
binding in rat brain. Pharmacopsychiatry 36:292-296. 
Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, Gattaz 
WF (2004) Altered thalamic membrane phospholipids in schizophrenia: a 
postmortem study. Biol Psychiatry 56:41-45. 
Schwab SG, Wildenauer DB (1999) Chromosome 22 workshop report. Am J Med Genet 
88:276-278. 
Schwartz PJ, Spazzolini C, Crotti L, Bathen J, Amlie JP, Timothy K, Shkolnikova M, 
Berul CI, Bitner-Glindzicz M, Toivonen L, Horie M, Schulze-Bahr E, Denjoy I 
(2006) The Jervell and Lange-Nielsen syndrome: natural history, molecular 
basis, and clinical outcome. Circulation 113:783-790. 
Segal D, Koschnick JR, Slegers LH, Hof PR (2007) Oligodendrocyte pathophysiology: a 
new view of schizophrenia. Int J Neuropsychopharmacol 10:503-511. 
Segurado R, Detera-Wadleigh SD, Levinson DF, Lewis CM, Gill M, Nurnberger JI, Jr., 
Craddock N, DePaulo JR, Baron M, Gershon ES, Ekholm J, Cichon S, Turecki 
G, Claes S, Kelsoe JR, Schofield PR, Badenhop RF, Morissette J, Coon H, 
Blackwood D, McInnes LA, Foroud T, Edenberg HJ, Reich T, Rice JP, Goate A, 
McInnis MG, McMahon FJ, Badner JA, Goldin LR, Bennett P, Willour VL, 
Zandi PP, Liu J, Gilliam C, Juo SH, Berrettini WH, Yoshikawa T, Peltonen L, 
Lonnqvist J, Nothen MM, Schumacher J, Windemuth C, Rietschel M, Propping 
P, Maier W, Alda M, Grof P, Rouleau GA, Del-Favero J, Van Broeckhoven C, 
Mendlewicz J, Adolfsson R, Spence MA, Luebbert H, Adams LJ, Donald JA, 
Mitchell PB, Barden N, Shink E, Byerley W, Muir W, Visscher PM, Macgregor 
S, Gurling H, Kalsi G, McQuillin A, Escamilla MA, Reus VI, Leon P, Freimer 
NB, Ewald H, Kruse TA, Mors O, Radhakrishna U, Blouin JL, Antonarakis SE, 
Akarsu N (2003) Genome scan meta-analysis of schizophrenia and bipolar 
disorder, part III: Bipolar disorder. Am J Hum Genet 73:49-62. 
Selemon LD, Goldman-Rakic PS (1999) The reduced neuropil hypothesis: a circuit 
based model of schizophrenia. Biol Psychiatry 45:17-25. 
Selemon LD, Rajkowska G, Goldman-Rakic PS (1995) Abnormally high neuronal 
density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 
and occipital area 17. Arch Gen Psychiatry 52:805-818; discussion 819-820. 
Serretti A, Mandelli L (2008) The genetics of bipolar disorder: genome 'hot regions,' 
genes, new potential candidates and future directions. Mol Psychiatry 13:742-
771. 
Severinsen JE, Als TD, Binderup H, Kruse TA, Wang AG, Vang M, Muir WJ, 
Blackwood DH, Mors O, Borglum AD (2006a) Association analyses suggest 
GPR24 as a shared susceptibility gene for bipolar affective disorder and 
schizophrenia. Am J Med Genet B Neuropsychiatr Genet 141:524-533. 
Severinsen JE, Bjarkam CR, Kiaer-Larsen S, Olsen IM, Nielsen MM, Blechingberg J, 
Nielsen AL, Holm IE, Foldager L, Young BD, Muir WJ, Blackwood DH, 
Corydon TJ, Mors O, Borglum AD (2006b) Evidence implicating BRD1 with 
brain development and susceptibility to both schizophrenia and bipolar affective 
disorder. Mol Psychiatry 11:1126-1138. 
 289 
Severinsen JE, Bjarkam, C.R., Olsen, I.M., Nielsen, M.M., Blechingberg, J., Nielsen, 
I.E., Foldager, L., Young, B.D., Muir, W.J., Blackwood, D.H.R., Corydon, T.J., 
Mors, O., Borglum, A.D. (2006) Evidence implicating BRD1 with brain 
develpoment and susceptibilty to both schizophrenia and bipolar affective 
disorder. submitted. 
Shahin H, Walsh T, Sobe T, Abu Sa'ed J, Abu Rayan A, Lynch ED, Lee MK, Avraham 
KB, King MC, Kanaan M (2006) Mutations in a novel isoform of TRIOBP that 
encodes a filamentous-actin binding protein are responsible for DFNB28 
recessive nonsyndromic hearing loss. Am J Hum Genet 78:144-152. 
Sheffield VC, Stone EM, Carmi R (1998) Use of isolated inbred human populations for 
identification of disease genes. Trends in Genetics 14:391-396. 
Shibata H, Aramaki T, Sakai M, Ninomiya H, Tashiro N, Iwata N, Ozaki N, Fukumaki 
Y (2006) Association study of polymorphisms in the GluR7, KA1 and KA2 
kainate receptor genes (GRIK3, GRIK4, GRIK5) with schizophrenia. Psychiatry 
Res 141:39-51. 
Shifman S, Johannesson M, Bronstein M, Chen SX, Collier DA, Craddock NJ, Kendler 
KS, Li T, O'Donovan M, O'Neill FA, Owen MJ, Walsh D, Weinberger DR, Sun 
C, Flint J, Darvasi A (2008a) Genome-wide association identifies a common 
variant in the reelin gene that increases the risk of schizophrenia only in women. 
PLoS Genet 4:e28. 
Shifman S, Bhomra A, Smiley S, Wray NR, James MR, Martin NG, Hettema JM, An 
SS, Neale MC, van den Oord EJ, Kendler KS, Chen X, Boomsma DI, 
Middeldorp CM, Hottenga JJ, Slagboom PE, Flint J (2008b) A whole genome 
association study of neuroticism using DNA pooling. Mol Psychiatry 13:302-
312. 
Silberberg G, Levit A, Collier D, St Clair D, Munro J, Kerwin RW, Tondo L, Floris G, 
Breen G, Navon R (2008) Stargazin involvement with bipolar disorder and 
response to lithium treatment. Pharmacogenet Genomics 18:403-412. 
Simon DK, Johns DR (1999) Mitochondrial Disorders: Clinical and Genetic Features. 
AnnuRev Med 50:111-127. 
Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387:569-572. 
Simons M, Trotter J (2007) Wrapping it up: the cell biology of myelination. Curr Opin 
Neurobiol 17:533-540. 
Sklar P, Smoller JW, Fan J, Ferreira MAR, Perlis RH, Chambert K, Nimgaonkar VL, 
McQueen MB, Faraone SV, Kirby A, de Bakker PIW, Ogdie MN, Thase ME, 
Sachs GS, Todd-Brown K, Gabriel SB, Sougnez C, Gates C, Blumenstiel B, 
Defelice M, Ardlie KG, Franklin J, Muir WJ, McGhee KA, MacIntyre DJ, 
McLean A, VanBeck M, McQuillin A, Bass NJ, Robinson M, Lawrence J, 
Anjorin A, Curtis D, Scolnick EM, Daly MJ, Blackwood DH, Gurling HM, 
Purcell SM (2008) Whole-genome association study of bipolar disorder. 13:558-
569. 
Slatter TL, Jones GT, Williams MJ, van Rij AM, McCormick SP (2008) Novel rare 
mutations and promoter haplotypes in ABCA1 contribute to low-HDL-C levels. 
Clin Genet 73:179-184. 
 290 
Smesny S, Rosburg T, Nenadic I, Fenk KP, Kunstmann S, Rzanny R, Volz HP, Sauer H 
(2007) Metabolic mapping using 2D 31P-MR spectroscopy reveals frontal and 
thalamic metabolic abnormalities in schizophrenia. Neuroimage 35:729-737. 
Smith AL, Weissman MM (1992) Handbook of Affective Disorders, second edition 
Edition. Edinburgh: Churchill Livingstone. 
Snyder SH (1973) Amphetamine Psychosis: A "Model" Schizophrenia Mediated by 
Catecholamines. Am J Psychiatry %R 101176/appiajp130161 130:61-67. 
Sokolov BP (1998) Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate 
receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" 
schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J 
Neurochem 71:2454-2464. 
Sokolov BP (2007) Oligodendroglial abnormalities in schizophrenia, mood disorders 
and substance abuse. Comorbidity, shared traits, or molecular phenocopies? Int J 
Neuropsychopharmacol 10:547-555. 
Song W, Li W, Feng J, Heston LL, Scaringe WA, Sommer SS (2008) Identification of 
high risk DISC1 structural variants with a 2% attributable risk for schizophrenia. 
Biochem Biophys Res Commun 367:700-706. 
Sooksawate T, Simmonds MA (2001) Effects of membrane cholesterol on the sensitivity 
of the GABA(A) receptor to GABA in acutely dissociated rat hippocampal 
neurones. Neuropharmacology 40:178-184. 
Squire LR, Zola-Morgan S (1991) The medial temporal lobe memory system. Science 
253:1380-1386. 
St Clair D, Blackwood D, Muir W, Carothers A, Walker M, Spowart G, Gosden C, 
Evans HJ (1990) Association within a family of a balanced autosomal 
translocation with major mental illness. Lancet 336:13-16. 
Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Morrison-Stewart S, 
Thompson RT (1994) Membrane phospholipid metabolism and schizophrenia: 
an in vivo 31P-MR spectroscopy study. Schizophr Res 13:209-215. 
Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, Fossdal R, 
Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, 
Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson 
D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Bjornsson A, Mattiasdottir S, 
Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Moller HJ, Hartmann A, 
Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, 
Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon E, Di Forti 
M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, 
Muhleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney 
LA, Franke B, Kahn RS, Linszen D, van Os J, Wiersma D, Bruggeman R, Cahn 
W, Germeys I, de Haan L, Krabbendam L, Sabatti C, Freimer NB, Gulcher JR, 
Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff RA, Georgi A, Rietschel 
M, Werge T, Petursson H, Goldstein DB, Nothen MM, Peltonen L, Collier DA, 
St Clair D, Stefansson K (2008) Large recurrent microdeletions associated with 
schizophrenia. Nature. 
Steward O, Wallace CS (1995) mRNA distribution within dendrites: relationship to 
afferent innervation. J Neurobiol 26:447-449. 
 291 
Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. 
Nat Genet 40:17-22. 
Strauss KA, Puffenberger EG, Huentelman MJ, Gottlieb S, Dobrin SE, Parod JM, 
Stephan DA, Morton DH (2006) Recessive symptomatic focal epilepsy and 
mutant contactin-associated protein-like 2. N Engl J Med 354:1370-1377. 
Sudhof TC (2008) Neuroligins and neurexins link synaptic function to cognitive disease. 
Nature 455:903-911. 
Suh H, Consiglio A, Ray J, Sawai T, D'Amour KA, Gage FH (2007) In vivo fate 
analysis reveals the multipotent and self-renewal capacities of Sox2+ neural stem 
cells in the adult hippocampus. Cell Stem Cell 1:515-528. 
Supek F, Vlahovicek K (2005) Comparison of codon usage measures and their 
applicability in prediction of microbial gene expressivity. BMC Bioinformatics 
6:182. 
Swift M, Swift RG (2005) Wolframin mutations and hospitalization for psychiatric 
illness. Mol Psychiatry 10:799-803. 
Swift RG, Polymeropoulos MH, Torres R, Swift M (1998) Predisposition of Wolfram 
syndrome heterozygotes to psychiatric illness. Mol Psychiatry 3:86-91. 
Takahashi R, Yokoji H, Misawa H, Hayashi M, Hu J, Deguchi T (1994) A null mutation 
in the human CNTF gene is not causally related to neurological diseases. Nat 
Genet 7:79-84. 
Takeda K, Inoue H, Tanizawa Y, Matsuzaki Y, Oba J, Watanabe Y, Shinoda K, Oka Y 
(2001) WFS1 (Wolfram syndrome 1) gene product: predominant subcellular 
localization to endoplasmic reticulum in cultured cells and neuronal expression 
in rat brain. Hum Mol Genet 10:477-484. 
Tashiro A, Dunaevsky A, Blazeski R, Mason CA, Yuste R (2003) Bidirectional 
regulation of hippocampal mossy fiber filopodial motility by kainate receptors: a 
two-step model of synaptogenesis. Neuron 38:773-784. 
Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, 
Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC (2002) 
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated 
patients with schizophrenia and healthy volunteers. Am J Psychiatry 159:1944-
1946. 
Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The 
CLUSTAL_X windows interface: flexible strategies for multiple sequence 
alignment aided by quality analysis tools. Nucleic Acids Res 25:4876-4882. 
Tkachev D, Mimmack ML, Huffaker SJ, Ryan M, Bahn S (2007) Further evidence for 
altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J 
Neuropsychopharmacol 10:557-563. 
Trask BJ (1991) Fluorescence in situ hybridization: applications in cytogenetics and 
gene mapping. Trends Genet 7:149-154. 
Tucker SJ, Baukrowitz T (2008) How highly charged anionic lipids bind and regulate 
ion channels. J Gen Physiol 131:431-438. 
Uitto J (2005) The gene family of ABC transporters--novel mutations, new phenotypes. 
Trends Mol Med 11:341-343. 
 292 
Van Camp G, Smith, R., (2005) The Hereditary Hearing Loss Homepage. In. 
URL:http://www.webhost.ua.ac.be/hhh/. 
van Driel MA, Maugeri A, Klevering BJ, Hoyng CB, Cremers FP (1998) ABCR unites 
what ophthalmologists divide(s). Ophthalmic Genet 19:117-122. 
van Meer G, Voelker DR, Feigenson GW (2008) Membrane lipids: where they are and 
how they behave. Nat Rev Mol Cell Biol 9:112-124. 
Van Vught PW, Van Wijk J, Bradley TE, Plasmans D, Jakobs ME, Veldink JH, de Jong 
JM, Van den Berg LH, Baas F (2007) Ciliary neurotrophic factor null alleles are 
not a risk factor for Charcot-Marie-Tooth disease, hereditary neuropathy with 
pressure palsies and amyotrophic lateral sclerosis. Neuromuscul Disord 17:964-
967. 
Verkhratsky A, Kirchhoff F (2007) Glutamate-mediated neuronal-glial transmission. J 
Anat 210:651-660. 
Vincent P, Mulle C (2008) Kainate receptors in epilepsy and excitotoxicity. 
Neuroscience. 
Volz HR, Riehemann S, Maurer I, Smesny S, Sommer M, Rzanny R, Holstein W, 
Czekalla J, Sauer H (2000) Reduced phosphodiesters and high-energy 
phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift 
spectroscopic-imaging study. Biol Psychiatry 47:954-961. 
Vorstman JA, Staal WG, van Daalen E, van Engeland H, Hochstenbach PF, Franke L 
(2006) Identification of novel autism candidate regions through analysis of 
reported cytogenetic abnormalities associated with autism. Mol Psychiatry 11:1, 
18-28. 
Wajid M, Abbasi AA, Ansar M, Pham TL, Yan K, Haque S, Ahmad W, Leal SM (2003) 
DFNB39, a recessive form of sensorineural hearing impairment, maps to 
chromosome 7q11.22-q21.12. Eur J Hum Genet 11:812-815. 
Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, 
Lee MK, Ciernikova S, Foretova L, Soucek P, King MC (2006) Spectrum of 
mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of 
breast cancer. Jama 295:1379-1388. 
Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord 
AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF, Roccanova P, 
Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg T, Merriman B, 
Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, Long R, Chen Z, Davis 
S, Baker C, Eichler EE, Meltzer PS, Nelson SF, Singleton AB, Lee MK, 
Rapoport JL, King MC, Sebat J (2008) Rare structural variants disrupt multiple 
genes in neurodevelopmental pathways in schizophrenia. Science 320:539-543. 
Walsh TD SH, Morrow J, King M-C, Lynch E, Avraham KB, Kanaan M (2000) 
DFNB28, a novel locus for prelingual nonsyndromic autosomal recessive 
hearing loss maps to 22q13 in a large consanguineous Palestinian kindred. In: 
50th Annual Meeting of American Society of Human Genetics Philadelphia. 
Warburton P, Baird G, Chen W, Morris K, Jacobs BW, Hodgson S, Docherty Z (2000) 
Support for linkage of autism and specific language impairment to 7q3 from two 
chromosome rearrangements involving band 7q31. Am J Med Genet 96:228-234. 
 293 
Weir BS, Anderson AD, Hepler AB (2006) Genetic relatedness analysis: modern data 
and new challenges. Nat Rev Genet 7:771-780. 
Weissman MM, Broadhead WE, Olfson M, Sheehan DV, Hoven C, Conolly P, Fireman 
BH, Farber L, Blacklow RS, Higgins ES, Leon AC (1998) A diagnostic aid for 
detecting (DSM-IV) mental disorders in primary care. Gen Hosp Psychiatry 
20:1-11. 
Wenzel JJ, Piehler A, Kaminski WE (2007) ABC A-subclass proteins: gatekeepers of 
cellular phospho- and sphingolipid transport. Front Biosci 12:3177-3193. 
Werner P, Voigt M, Keinanen K, Wisden W, Seeburg PH (1991) Cloning of a putative 
high-affinity kainate receptor expressed predominantly in hippocampal CA3 
cells. Nature 351:742-744. 
WHO (2003) ICD-10 classification of mental and behavioural disorders: clinical 
descriptions and diagnostic guidelines., Second edition Edition. Geneva: World 
Health Organization. 
Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, Heath SC, 
Timpson NJ, Najjar SS, Stringham HM, Strait J, Duren WL, Maschio A, 
Busonero F, Mulas A, Albai G, Swift AJ, Morken MA, Narisu N, Bennett D, 
Parish S, Shen H, Galan P, Meneton P, Hercberg S, Zelenika D, Chen WM, Li Y, 
Scott LJ, Scheet PA, Sundvall J, Watanabe RM, Nagaraja R, Ebrahim S, Lawlor 
DA, Ben-Shlomo Y, Davey-Smith G, Shuldiner AR, Collins R, Bergman RN, 
Uda M, Tuomilehto J, Cao A, Collins FS, Lakatta E, Lathrop GM, Boehnke M, 
Schlessinger D, Mohlke KL, Abecasis GR (2008) Newly identified loci that 
influence lipid concentrations and risk of coronary artery disease. Nat Genet 
40:161-169. 
Williams JH, Errington ML, Lynch MA, Bliss TV (1989) Arachidonic acid induces a 
long-term activity-dependent enhancement of synaptic transmission in the 
hippocampus. Nature 341:739-742. 
Wilson GM, Flibotte S, Chopra V, Melnyk BL, Honer WG, Holt RA (2006) DNA copy-
number analysis in bipolar disorder and schizophrenia reveals aberrations in 
genes involved in glutamate signaling. Hum Mol Genet 15:743-749. 
Wisden W, Seeburg PH (1993) A complex mosaic of high-affinity kainate receptors in 
rat brain. J Neurosci 13:3582-3598. 
Wolpert CM, Donnelly SL, Cuccaro ML, Hedges DJ, Poole CP, Wright HH, Gilbert JR, 
Pericak-Vance MA (2001) De novo partial duplication of chromosome 7p in a 
male with autistic disorder. Am J Med Genet 105:222-225. 
Won JS, Singh I (2006) Sphingolipid signaling and redox regulation. Free Radic Biol 
Med 40:1875-1888. 
Woo TU, Walsh JP, Benes FM (2004) Density of glutamic acid decarboxylase 67 
messenger RNA-containing neurons that express the N-methyl-D-aspartate 
receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and 
bipolar disorder. Arch Gen Psychiatry 61:649-657. 
Woods CG, Valente EM, Bond J, Roberts E (2004) A new method for autozygosity 
mapping using single nucleotide polymorphisms (SNPs) and EXCLUDEAR. 
             J Med Genet 41:e101-. 
 294 
Woods CG, Cox J, Springell K, Hampshire DJ, Mohamed MD, McKibbin M, Stern R, 
Raymond FL, Sandford R, Malik Sharif S, Karbani G, Ahmed M, Bond J, 
Clayton D, Inglehearn CF (2006) Quantification of homozygosity in 
consanguineous individuals with autosomal recessive disease. Am J Hum Genet 
78:889-896. 
Wright AF, Teague PW, Bruford E, Carothers A (1997) Problems in dealing with 
linkage heterogeneity in autosomal recessive forms of retinitis pigmentosa. In: 
Genetic mapping of disease genes (Pawlowitzki IH, Edwards JH, Thompson EA, 
eds), pp 255-272. London. 
WTCCC (2007) Genome-wide association study of 14,000 cases of seven common 
diseases and 3,000 shared controls. Nature 447:661-678. 
Xiong L, Labuda M, Li DS, Hudson TJ, Desbiens R, Patry G, Verret S, Langevin P, 
Mercho S, Seni MH, Scheffer I, Dubeau F, Berkovic SF, Andermann F, 
Andermann E, Pandolfo M (1999) Mapping of a gene determining familial 
partial epilepsy with variable foci to chromosome 22q11-q12. Am J Hum Genet 
65:1698-1710. 
Yao JK, van Kammen DP, Gurklis J (1994) Red blood cell membrane dynamics in 
schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures. 
Schizophr Res 13:227-232. 
Yao JK, Leonard S, Reddy RD (2000) Membrane phospholipid abnormalities in 
postmortem brains from schizophrenic patients. Schizophr Res 42:7-17. 
Yoon JS, Park HJ, Yoo SY, Namkung W, Jo MJ, Koo SK, Park HY, Lee WS, Kim KH, 
Lee MG (2008) Heterogeneity in the processing defect of SLC26A4 mutants. J 
Med Genet 45:411-419. 
Zaitseva J, Jenewein S, Jumpertz T, Holland IB, Schmitt L (2005) H662 is the linchpin 
of ATP hydrolysis in the nucleotide-binding domain of the ABC transporter 
HlyB. Embo J 24:1901-1910. 
Zeng W, Gillis T, Hakky M, Djousse L, Myers RH, MacDonald ME, Gusella JF (2006) 
Genetic analysis of the GRIK2 modifier effect in Huntington's disease. BMC 
Neurosci 7:62. 
Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult 
neurogenesis. Cell 132:645-660. 
Zimmer L, Delion-Vancassel S, Durand G, Guilloteau D, Bodard S, Besnard JC, Chalon 
S (2000) Modification of dopamine neurotransmission in the nucleus accumbens 
of rats deficient in n-3 polyunsaturated fatty acids. J Lipid Res 41:32-40. 
Zollner S, Pritchard JK (2007) Overcoming the winner's curse: estimating penetrance 












Appendix 1: Clinical description of consanguineous family  
 
The family from a small village in North West Punjab where there is a strong tradition 
of marriages between cousins was identified by Mohammed Ayub, an experienced 
psychiatrist who speaks the local language. Clinical information was gathered through 
multiple interviews with all members of the family and inspection of hospital records of 
inpatient admissions. The parents gave no history of still births or miscarriages. Physical 
examination of all members revealed no signs of systemic illness or dysmorphic 
features. Investigations confirmed normal haematology, liver and renal function. 
Computed tomography (CT) brain scans of two affected siblings indicated no structural 
changes and electroencephalography (EEG) showed only minor non-specific alterations 
in the same two individuals. The diagnosis of schizophrenia was made according to 
ICD-10 criteria based on direct interviews using the Schedule of Affective Disorders and 
Schizophrenia, and information from informants and hospital care records. Audiometry 
confirmed sensori-neural hearing impairment. 
 
Cognitive function was assessed by a clinical psychologist and schools were approached 
for information about educational performance. The affected siblings had normal 
physical and cognitive development with normal performance in school until around the 
age of 8 years when they presented with partial complex seizures sometimes leading to 
generalized seizures. At approximately the same age these individuals developed tinnitus 
and sensori-neural hearing loss that became progressively more profound during 
adolescence leading to severe loss of hearing by the age of twenty. Three siblings had 
experienced psychotic episodes by the age of twenty-five years and met ICD 10 criteria 
for schizophrenia. Symptoms included auditory hallucinations and delusions of 
reference and persecution with no affective component. The psychosis is intermittent 
with good recovery between the episodes which have responded well to treatment with 
antipsychotic medication. The oldest sibling, now in late forties, is unaffected. Three of 
 296 
the siblings who are over thirty years old have all three components of the phenotype. 
One of the younger siblings has only impaired hearing and one has epilepsy but neither 
of these siblings who are in their twenties have had symptoms of psychosis although 
they remain at risk of developing symptoms. The oldest of the affected siblings received 
inpatient treatment in a psychiatric unit where she responded to antipsychotic medication 
but later relapsed because of poor compliance. In all of the affected siblings epilepsy has 
responded to carbamazepine. Between episodes of psychosis the social and occupational 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S1 Comparison of KA1 expression in the CA3 field of the hippocampus in a 
heterozygous indel individual (a) and a homozygous insertion individual (b). The strongest signal 
was observed in the stratum lucidum of the CA3 region. The black bar represents 50µm. l, 






Appendix 4: Published Papers 
 
Paper 1: Homozygosity mapping in a family presenting with schizophrenia, epilepsy and 
hearing impairment. 
 
Paper 2: A common variant in the 3'UTR of the GRIK4 glutamate receptor gene affects 
transcript abundance and protects against bipolar disorder. 
 
